drTarget portfolio target-disease associations for cancer DrTarget’s AI-Powered Indication Expansion for Human Tumours

DrTarget’s AI-Driven Insights for Cancer Research

DrTarget has identified 348 target proteins from PubChem screens linked to 2,199 cancer types, leveraging data from Open Targets and other public repositories. Our machine learning models and advanced analytics uncover new therapeutic opportunities by prioritizing high-confidence gene-disease associations.

Our AI-powered approach enables:

✔ Target identification for novel drug discovery
✔ Drug repurposing opportunities for existing therapies
✔ Pathway and biomarker analysis for precision oncology

By integrating AI-driven virtual screening and multi-source validation, we provide actionable insights to accelerate cancer research and therapeutic innovation.

Target-disease associations for several types of cancer.

Check best scored target-disease associations in table:

PubChemAssay	program	diseaseName	assayType	testedCompounds	activeCompounds	associationScore	numberOfEvidences
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	acute myeloid leukemia	targetBased	217959	2390	0.694746124032017	594
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	acute myeloid leukemia	targetBased	359207	1432	0.529206458958698	625
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	acute myeloid leukemia	targetBased	143816	859	0.514639149025548	44
qHTS assay for re-activators of p53 using a Luc reporter	TP53	acute myeloid leukemia	pathwayBased	321427	201	0.820990723759405	3172
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	acute myeloid leukemia	targetBased	54509	528	0.820990723759405	3172
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	acute myeloid leukemia	targetBased	54513	338	0.820990723759405	3172
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	acute myeloid leukemia	targetBased	125394	1890	0.820990723759405	3172
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	acute myeloid leukemia	targetBased	124022	1156	0.820990723759405	3172
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2_inhibitors	acute myeloid leukemia	targetBased	57013	201	0.563380212187245	510
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	acute myeloid leukemia	targetBased	359244	2975	0.718076005186988	918
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	acute myeloid leukemia	targetBased	215667	993	0.830898626678178	3529
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	acute myeloid leukemia	targetBased	218234	1620	0.830898626678178	3529
HCS assay for microtubule stabilizers	TUBB	Hodgkins lymphoma	targetBased	195821	1625	0.651414538506129	246
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	acute myeloid leukemia	targetBased	194628	267	0.549734792816803	69
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	T-cell acute lymphoblastic leukemia	targetBased	359207	1432	0.518323037311425	58
Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3	HDAC3	unspecified peripheral T-cell lymphoma	targetBased	318291	483	0.566224706091656	20
HCS assay for microtubule stabilizers	TUBB	unspecified peripheral T-cell lymphoma	targetBased	195821	1625	0.624986273516276	69
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	acute lymphoblastic leukemia	targetBased	217959	2390	0.671778593539966	457
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	acute lymphoblastic leukemia	targetBased	359207	1432	0.821223780852646	2618
qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS	TXNRD1	acute promyelocytic leukemia	targetBased	386663	3977	0.622116387379182	33
Development of Small Molecule Probes of the Histone Methyltransferase, NSD2 Measured in Biochemical System Using Plate Reader - 7053-01_Inhibitor_SinglePoint_HTS_Activity_Set2	NSD2	acute lymphoblastic leukemia	targetBased	309684	1662	0.503855438557983	70
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	myelodysplastic syndrome	targetBased	143816	859	0.603738282918877	75
qHTS for Inhibitors of TGF-b	TGFB1	myelodysplastic syndrome	pathwayBased	403345	4970	0.629372173160002	108
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	myelodysplastic syndrome	targetBased	359244	2975	0.677763361237735	571
qHTS assay for re-activators of p53 using a Luc reporter	TP53	acute lymphoblastic leukemia	pathwayBased	321427	201	0.655097189866326	1529
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	acute lymphoblastic leukemia	targetBased	54509	528	0.655097189866326	1529
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	acute lymphoblastic leukemia	targetBased	54513	338	0.655097189866326	1529
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	acute lymphoblastic leukemia	targetBased	125394	1890	0.655097189866326	1529
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	acute lymphoblastic leukemia	targetBased	124022	1156	0.655097189866326	1529
qHTS assay for re-activators of p53 using a Luc reporter	TP53	myelodysplastic syndrome	pathwayBased	321427	201	0.533745835566975	780
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	myelodysplastic syndrome	targetBased	54509	528	0.533745835566975	780
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	myelodysplastic syndrome	targetBased	54513	338	0.533745835566975	780
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	myelodysplastic syndrome	targetBased	125394	1890	0.533745835566975	780
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	myelodysplastic syndrome	targetBased	124022	1156	0.533745835566975	780
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	acute lymphoblastic leukemia	targetBased	215667	993	0.551609117000469	1706
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	acute lymphoblastic leukemia	targetBased	218234	1620	0.551609117000469	1706
qHTS assay for re-activators of p53 using a Luc reporter	TP53	chronic lymphocytic leukemia	pathwayBased	321427	201	0.791053421387467	1441
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	chronic lymphocytic leukemia	targetBased	54509	528	0.791053421387467	1441
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	chronic lymphocytic leukemia	targetBased	54513	338	0.791053421387467	1441
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	chronic lymphocytic leukemia	targetBased	125394	1890	0.791053421387467	1441
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	chronic lymphocytic leukemia	targetBased	124022	1156	0.791053421387467	1441
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	chronic lymphocytic leukemia	targetBased	322361	619	0.721306850470058	362
HCS assay for microtubule stabilizers	TUBB	acute lymphoblastic leukemia	targetBased	195821	1625	0.655164699314168	219
qHTS assay for re-activators of p53 using a Luc reporter	TP53	adenocarcinoma	pathwayBased	321427	201	0.557676411022396	7865
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	adenocarcinoma	targetBased	54509	528	0.557676411022396	7865
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	adenocarcinoma	targetBased	54513	338	0.557676411022396	7865
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	adenocarcinoma	targetBased	125394	1890	0.557676411022396	7865
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	adenocarcinoma	targetBased	124022	1156	0.557676411022396	7865
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	adenocarcinoma	targetBased	322361	619	0.718867795822544	302
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	gastric carcinoma	targetBased	322361	619	0.544948834234569	37
qHTS assay for re-activators of p53 using a Luc reporter	TP53	gastric carcinoma	pathwayBased	321427	201	0.557967975359973	759
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	gastric carcinoma	targetBased	54509	528	0.557967975359973	759
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	gastric carcinoma	targetBased	54513	338	0.557967975359973	759
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	gastric carcinoma	targetBased	125394	1890	0.557967975359973	759
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	gastric carcinoma	targetBased	124022	1156	0.557967975359973	759
qHTS for Inhibitors of WRN Helicase	WRN	gastric carcinoma	targetBased	364011	1678	0.524091359604701	8
qHTS assay for re-activators of p53 using a Luc reporter	TP53	breast adenocarcinoma	pathwayBased	321427	201	0.835161405915504	527
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	breast adenocarcinoma	targetBased	54509	528	0.835161405915504	527
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	breast adenocarcinoma	targetBased	54513	338	0.835161405915504	527
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	breast adenocarcinoma	targetBased	125394	1890	0.835161405915504	527
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	breast adenocarcinoma	targetBased	124022	1156	0.835161405915504	527
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	breast adenocarcinoma	targetBased	356517	1139	0.76578869022397	161
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	bladder tumor	targetBased	194628	267	0.55177181402749	130
HCS assay for microtubule stabilizers	TUBB	adenocarcinoma	targetBased	195821	1625	0.590697931637223	315
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	breast adenocarcinoma	pathwayBased	376029	3978	0.536209548600684	198
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	breast adenocarcinoma	targetBased	86095	1442	0.696683621141791	918
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	breast adenocarcinoma	targetBased	86095	1151	0.696683621141791	918
qHTS assay for re-activators of p53 using a Luc reporter	TP53	Ewing sarcoma	pathwayBased	321427	201	0.586304863474545	249
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	Ewing sarcoma	targetBased	54509	528	0.586304863474545	249
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	Ewing sarcoma	targetBased	54513	338	0.586304863474545	249
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	Ewing sarcoma	targetBased	125394	1890	0.586304863474545	249
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	Ewing sarcoma	targetBased	124022	1156	0.586304863474545	249
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2_inhibitors	neoplasm of mature B-cells	targetBased	57013	201	0.553583014844976	351
HCS assay for microtubule stabilizers	TUBB	breast adenocarcinoma	targetBased	195821	1625	0.508319648934431	47
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	adenoma	targetBased	359518	300	0.529784692452108	89
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	adenoma	targetBased	335652	1779	0.529784692452108	89
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	adenoma	targetBased	362274	1056	0.529784692452108	89
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	adenoma	targetBased	336308	6862	0.529784692452108	89
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	adenoma	targetBased	357537	806	0.529784692452108	89
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	adenoma	targetBased	339887	1178	0.529784692452108	89
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	colorectal adenocarcinoma	targetBased	334825	423	0.564864589281233	18
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	colorectal adenocarcinoma	targetBased	337446	1356	0.564864589281233	18
qHTS assay for re-activators of p53 using a Luc reporter	TP53	adenoid cystic carcinoma	pathwayBased	321427	201	0.513954747920079	22
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	adenoid cystic carcinoma	targetBased	54509	528	0.513954747920079	22
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	adenoid cystic carcinoma	targetBased	54513	338	0.513954747920079	22
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	adenoid cystic carcinoma	targetBased	125394	1890	0.513954747920079	22
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	adenoid cystic carcinoma	targetBased	124022	1156	0.513954747920079	22
qHTS assay for re-activators of p53 using a Luc reporter	TP53	colorectal adenocarcinoma	pathwayBased	321427	201	0.746609442237671	429
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	colorectal adenocarcinoma	targetBased	54509	528	0.746609442237671	429
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	colorectal adenocarcinoma	targetBased	54513	338	0.746609442237671	429
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	colorectal adenocarcinoma	targetBased	125394	1890	0.746609442237671	429
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	colorectal adenocarcinoma	targetBased	124022	1156	0.746609442237671	429
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	breast carcinoma	pathwayBased	376029	3978	0.938370121037582	9141
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	breast carcinoma	targetBased	86095	1442	0.852709036989038	5420
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	breast carcinoma	targetBased	86095	1151	0.852709036989038	5420
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	head and neck squamous cell carcinoma	targetBased	334825	423	0.511667802800374	19
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	head and neck squamous cell carcinoma	targetBased	337446	1356	0.511667802800374	19
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay	MAPK1	head and neck squamous cell carcinoma	pathwayBased	70898	707	0.553293708152968	66
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF	MAPK1	head and neck squamous cell carcinoma	pathwayBased	131324	544	0.553293708152968	66
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2_inhibitors	breast carcinoma	targetBased	57013	201	0.530249603412033	201
qHTS assay for re-activators of p53 using a Luc reporter	TP53	adrenal gland pheochromocytoma	pathwayBased	321427	201	0.539378622906823	39
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	adrenal gland pheochromocytoma	targetBased	54509	528	0.539378622906823	39
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	adrenal gland pheochromocytoma	targetBased	54513	338	0.539378622906823	39
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	adrenal gland pheochromocytoma	targetBased	125394	1890	0.539378622906823	39
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	adrenal gland pheochromocytoma	targetBased	124022	1156	0.539378622906823	39
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	colorectal adenocarcinoma	targetBased	356517	1139	0.67820446347352	59
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	colorectal adenocarcinoma	targetBased	322361	619	0.672688746591176	19
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	head and neck squamous cell carcinoma	targetBased	335239	991	0.500992087079442	21
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	head and neck squamous cell carcinoma	targetBased	335239	695	0.500992087079442	21
qHTS for Inhibitors of WRN Helicase	WRN	colorectal adenocarcinoma	targetBased	364011	1678	0.550149135016612	6
Nrf2 qHTS screen for inhibitors	nrf2Inhibitors	head and neck squamous cell carcinoma	targetBased	360873	7438	0.638949556374262	113
qHTS of Nrf2 Activators	Nrf2 activators	head and neck squamous cell carcinoma	pathwayBased	403871	1243	0.638949556374262	113
HTS of Smad transcription factor inhibitors	SMAD3	colorectal adenocarcinoma	targetBased	88033	251	0.658346544341343	17
uHTS identification of Caspase-8 TRAIL sensitizers in a luminesence assay	TNFRSF10B	head and neck squamous cell carcinoma	targetBased	363840	3764	0.517986428422721	40
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	breast carcinoma	targetBased	86095	1114	0.639892659510695	224
qHTS assay for re-activators of p53 using a Luc reporter	TP53	breast carcinoma	pathwayBased	321427	201	0.742846429132578	2349
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	breast carcinoma	targetBased	54509	528	0.742846429132578	2349
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	breast carcinoma	targetBased	54513	338	0.742846429132578	2349
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	breast carcinoma	targetBased	125394	1890	0.742846429132578	2349
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	breast carcinoma	targetBased	124022	1156	0.742846429132578	2349
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	breast carcinoma	targetBased	356517	1139	0.79025743556127	934
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	colorectal adenocarcinoma	pathwayBased	43989	342	0.516313607375484	40
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	breast carcinoma	targetBased	322361	619	0.73759684515586	1997
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac activated mutant	RAC1	head and neck squamous cell carcinoma	targetBased	194629	219	0.559322758217218	35
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac wildtype	RAC1	head and neck squamous cell carcinoma	targetBased	194628	521	0.559322758217218	35
qHTS assay for re-activators of p53 using a Luc reporter	TP53	head and neck squamous cell carcinoma	pathwayBased	321427	201	0.872621428237112	3127
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	head and neck squamous cell carcinoma	targetBased	54509	528	0.872621428237112	3127
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	head and neck squamous cell carcinoma	targetBased	54513	338	0.872621428237112	3127
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	head and neck squamous cell carcinoma	targetBased	125394	1890	0.872621428237112	3127
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	head and neck squamous cell carcinoma	targetBased	124022	1156	0.872621428237112	3127
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	head and neck squamous cell carcinoma	targetBased	193542	587	0.531641034089883	101
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	head and neck squamous cell carcinoma	targetBased	194628	267	0.708595202152874	261
HCS assay for microtubule stabilizers	TUBB	breast carcinoma	targetBased	195821	1625	0.682065381231255	257
HCS assay for microtubule stabilizers	TUBB	head and neck squamous cell carcinoma	targetBased	195821	1625	0.608750307574734	185
qHTS assay for re-activators of p53 using a Luc reporter	TP53	astrocytoma	pathwayBased	321427	201	0.573950587211972	792
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	astrocytoma	targetBased	54509	528	0.573950587211972	792
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	astrocytoma	targetBased	54513	338	0.573950587211972	792
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	astrocytoma	targetBased	125394	1890	0.573950587211972	792
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	astrocytoma	targetBased	124022	1156	0.573950587211972	792
qHTS assay for re-activators of p53 using a Luc reporter	TP53	chromophobe renal cell carcinoma	pathwayBased	321427	201	0.597239078637754	77
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	chromophobe renal cell carcinoma	targetBased	54509	528	0.597239078637754	77
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	chromophobe renal cell carcinoma	targetBased	54513	338	0.597239078637754	77
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	chromophobe renal cell carcinoma	targetBased	125394	1890	0.597239078637754	77
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	chromophobe renal cell carcinoma	targetBased	124022	1156	0.597239078637754	77
Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity	SMARCA4	Burkitts lymphoma	targetBased	344733	7043	0.583982765294942	29
qHTS assay for re-activators of p53 using a Luc reporter	TP53	Burkitts lymphoma	pathwayBased	321427	201	0.58936406559799	275
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	Burkitts lymphoma	targetBased	54509	528	0.58936406559799	275
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	Burkitts lymphoma	targetBased	54513	338	0.58936406559799	275
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	Burkitts lymphoma	targetBased	125394	1890	0.58936406559799	275
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	Burkitts lymphoma	targetBased	124022	1156	0.58936406559799	275
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	chronic myelogenous leukemia	targetBased	217959	2390	0.509598213983665	271
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	chronic myelogenous leukemia	targetBased	359207	1432	0.920783141818354	6490
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	carcinoma	pathwayBased	376029	3978	0.550324090196856	10180
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	cutaneous melanoma	targetBased	334825	423	0.566105204863099	9
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	cutaneous melanoma	targetBased	337446	1356	0.566105204863099	9
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2_inhibitors	cutaneous melanoma	targetBased	57013	201	0.521864485975192	44
Nrf2 qHTS screen for inhibitors	nrf2Inhibitors	hepatocellular carcinoma	targetBased	360873	7438	0.717676555746485	407
qHTS of Nrf2 Activators	Nrf2 activators	hepatocellular carcinoma	pathwayBased	403871	1243	0.717676555746485	407
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac activated mutant	RAC1	cutaneous melanoma	targetBased	194629	219	0.60668394398872	21
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac wildtype	RAC1	cutaneous melanoma	targetBased	194628	521	0.60668394398872	21
qHTS assay for re-activators of p53 using a Luc reporter	TP53	cutaneous melanoma	pathwayBased	321427	201	0.600703099701458	325
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	cutaneous melanoma	targetBased	54509	528	0.600703099701458	325
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	cutaneous melanoma	targetBased	54513	338	0.600703099701458	325
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	cutaneous melanoma	targetBased	125394	1890	0.600703099701458	325
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	cutaneous melanoma	targetBased	124022	1156	0.600703099701458	325
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	carcinoma	targetBased	86095	1114	0.608626082644483	601
qHTS assay for re-activators of p53 using a Luc reporter	TP53	carcinoma	pathwayBased	321427	201	0.624221075469731	20998
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	carcinoma	targetBased	54509	528	0.624221075469731	20998
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	carcinoma	targetBased	54513	338	0.624221075469731	20998
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	carcinoma	targetBased	125394	1890	0.624221075469731	20998
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	carcinoma	targetBased	124022	1156	0.624221075469731	20998
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	carcinoma	targetBased	108286	1415	0.551307642137785	39
HTS for BAP1 Enzyme inhibitors	BAP1_inhibitors	cutaneous melanoma	targetBased	71016	346	0.50942246785541	78
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	cutaneous melanoma	targetBased	193542	587	0.566976009544841	60
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	cutaneous melanoma	targetBased	194628	267	0.573097734825806	104
MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity	MITF	cutaneous melanoma	targetBased	331360	2760	0.783010945534478	722
AlphaScreen-based biochemical high throughput primary assay to identify inhibitors of microphthalmia-associated transcription factor (MITF)	MITF inhibitors	cutaneous melanoma	targetBased	642362	5830	0.783010945534478	722
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	cutaneous melanoma	pathwayBased	43989	342	0.567767359841182	34
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	hepatocellular carcinoma	targetBased	86095	1114	0.570526943027433	87
qHTS assay for re-activators of p53 using a Luc reporter	TP53	hepatocellular carcinoma	pathwayBased	321427	201	0.891165571922842	7068
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	hepatocellular carcinoma	targetBased	54509	528	0.891165571922842	7068
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	hepatocellular carcinoma	targetBased	54513	338	0.891165571922842	7068
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	hepatocellular carcinoma	targetBased	125394	1890	0.891165571922842	7068
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	hepatocellular carcinoma	targetBased	124022	1156	0.891165571922842	7068
HCS assay for microtubule stabilizers	TUBB	carcinoma	targetBased	195821	1625	0.620413702006112	1700
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	hepatocellular carcinoma	targetBased	193542	587	0.875521957433293	1848
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	hepatocellular carcinoma	targetBased	194628	267	0.528549083483217	245
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2_inhibitors	diffuse large B-cell lymphoma	targetBased	57013	201	0.677996101121258	565
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	essential thrombocythemia	targetBased	217959	2390	0.753090144400383	1853
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	diffuse large B-cell lymphoma	targetBased	359244	2975	0.531063254206481	67
qHTS assay for re-activators of p53 using a Luc reporter	TP53	clear cell renal carcinoma	pathwayBased	321427	201	0.510792843766613	21
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	clear cell renal carcinoma	targetBased	54509	528	0.510792843766613	21
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	clear cell renal carcinoma	targetBased	54513	338	0.510792843766613	21
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	clear cell renal carcinoma	targetBased	125394	1890	0.510792843766613	21
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	clear cell renal carcinoma	targetBased	124022	1156	0.510792843766613	21
HTS for BAP1 Enzyme inhibitors	BAP1_inhibitors	clear cell renal carcinoma	targetBased	71016	346	0.687745221766357	15
qHTS assay for re-activators of p53 using a Luc reporter	TP53	diffuse large B-cell lymphoma	pathwayBased	321427	201	0.743259744045603	845
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	diffuse large B-cell lymphoma	targetBased	54509	528	0.743259744045603	845
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	diffuse large B-cell lymphoma	targetBased	54513	338	0.743259744045603	845
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	diffuse large B-cell lymphoma	targetBased	125394	1890	0.743259744045603	845
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	diffuse large B-cell lymphoma	targetBased	124022	1156	0.743259744045603	845
Primary cell-based high throughput screening assay to measure STAT3 activation	STAT3	diffuse large B-cell lymphoma	pathwayBased	194666	1772	0.592602942376381	397
Primary cell-based high throughput screening assay to measure STAT3 inhibition	STAT3	diffuse large B-cell lymphoma	pathwayBased	194666	1722	0.592602942376381	397
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	clear cell renal carcinoma	pathwayBased	43989	342	0.620163172618119	38
HCS assay for microtubule stabilizers	TUBB	diffuse large B-cell lymphoma	targetBased	195821	1625	0.651733669028007	342
Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	follicular thyroid adenoma	targetBased	329153	670	0.540640624407186	22
Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	follicular thyroid adenoma	targetBased	329153	670	0.540640624407186	22
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor	TSHR	follicular thyroid adenoma	targetBased	72026	352	0.540640624407186	22
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293	TSHR	follicular thyroid adenoma	targetBased	72026	1794	0.540640624407186	22
HTS for BAP1 Enzyme inhibitors	BAP1_inhibitors	hepatocellular carcinoma	targetBased	71016	346	0.581453884185817	29
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	follicular thyroid carcinoma	targetBased	194628	267	0.755392732456168	65
Dicer-mediated maturation of pre-microRNA	Dicer_inhibitors	embryonal rhabdomyosarcoma	targetBased	46715	2829	0.769159310314872	123
qHTS assay for re-activators of p53 using a Luc reporter	TP53	gastric adenocarcinoma	pathwayBased	321427	201	0.798791596621054	633
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	gastric adenocarcinoma	targetBased	54509	528	0.798791596621054	633
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	gastric adenocarcinoma	targetBased	54513	338	0.798791596621054	633
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	gastric adenocarcinoma	targetBased	125394	1890	0.798791596621054	633
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	gastric adenocarcinoma	targetBased	124022	1156	0.798791596621054	633
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	gastric adenocarcinoma	targetBased	193542	587	0.575548071830238	88
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	gastric adenocarcinoma	targetBased	194628	267	0.533364555936172	31
qHTS assay for re-activators of p53 using a Luc reporter	TP53	leiomyosarcoma	pathwayBased	321427	201	0.579427927799183	247
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	leiomyosarcoma	targetBased	54509	528	0.579427927799183	247
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	leiomyosarcoma	targetBased	54513	338	0.579427927799183	247
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	leiomyosarcoma	targetBased	125394	1890	0.579427927799183	247
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	leiomyosarcoma	targetBased	124022	1156	0.579427927799183	247
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	leukemia	targetBased	359207	1432	0.718194542732695	3745
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	leukemia	targetBased	335239	991	0.500371196337833	17
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	leukemia	targetBased	335239	695	0.500371196337833	17
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	leukemia	targetBased	359244	2975	0.518197290267351	503
qHTS assay for re-activators of p53 using a Luc reporter	TP53	papillary renal cell carcinoma	pathwayBased	321427	201	0.567761442812016	128
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	papillary renal cell carcinoma	targetBased	54509	528	0.567761442812016	128
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	papillary renal cell carcinoma	targetBased	54513	338	0.567761442812016	128
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	papillary renal cell carcinoma	targetBased	125394	1890	0.567761442812016	128
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	papillary renal cell carcinoma	targetBased	124022	1156	0.567761442812016	128
Primary cell-based high throughput screening assay to measure STAT3 activation	STAT3	leukemia	pathwayBased	194666	1772	0.585207833502101	486
Primary cell-based high throughput screening assay to measure STAT3 inhibition	STAT3	leukemia	pathwayBased	194666	1722	0.585207833502101	486
HCS assay for microtubule stabilizers	TUBB	leukemia	targetBased	195821	1625	0.52960653881427	339
qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM)	BLM_inhibitors	leukemia	targetBased	347933	673	0.572630433777704	14
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	papillary renal cell carcinoma	pathwayBased	43989	342	0.571926902752998	24
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	lung adenocarcinoma	targetBased	336894	489	0.68606434581265	211
qHTS assay for re-activators of p53 using a Luc reporter	TP53	neuroblastoma	pathwayBased	321427	201	0.507751259134717	1059
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	neuroblastoma	targetBased	54509	528	0.507751259134717	1059
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	neuroblastoma	targetBased	54513	338	0.507751259134717	1059
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	neuroblastoma	targetBased	125394	1890	0.507751259134717	1059
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	neuroblastoma	targetBased	124022	1156	0.507751259134717	1059
qHTS assay for re-activators of p53 using a Luc reporter	TP53	glioblastoma multiforme	pathwayBased	321427	201	0.709913256686522	2001
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	glioblastoma multiforme	targetBased	54509	528	0.709913256686522	2001
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	glioblastoma multiforme	targetBased	54513	338	0.709913256686522	2001
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	glioblastoma multiforme	targetBased	125394	1890	0.709913256686522	2001
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	glioblastoma multiforme	targetBased	124022	1156	0.709913256686522	2001
Nrf2 qHTS screen for inhibitors	nrf2Inhibitors	lung adenocarcinoma	targetBased	360873	7438	0.515767117951293	97
qHTS of Nrf2 Activators	Nrf2 activators	lung adenocarcinoma	pathwayBased	403871	1243	0.515767117951293	97
Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity	SMARCA4	lung adenocarcinoma	targetBased	344733	7043	0.636562053600706	51
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	nevus	targetBased	194628	267	0.571671843940988	81
qHTS assay for re-activators of p53 using a Luc reporter	TP53	lung adenocarcinoma	pathwayBased	321427	201	0.834485116926117	1395
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	lung adenocarcinoma	targetBased	54509	528	0.834485116926117	1395
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	lung adenocarcinoma	targetBased	54513	338	0.834485116926117	1395
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	lung adenocarcinoma	targetBased	125394	1890	0.834485116926117	1395
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	lung adenocarcinoma	targetBased	124022	1156	0.834485116926117	1395
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	lung adenocarcinoma	targetBased	322361	619	0.62431172792332	91
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	lung adenocarcinoma	targetBased	193542	587	0.61641044122721	104
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	lung adenocarcinoma	targetBased	194628	267	0.565482845742141	126
qHTS assay for re-activators of p53 using a Luc reporter	TP53	osteosarcoma	pathwayBased	321427	201	0.793475959159254	405
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	osteosarcoma	targetBased	54509	528	0.793475959159254	405
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	osteosarcoma	targetBased	54513	338	0.793475959159254	405
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	osteosarcoma	targetBased	125394	1890	0.793475959159254	405
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	osteosarcoma	targetBased	124022	1156	0.793475959159254	405
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	lymphoma	targetBased	143816	859	0.578691902621926	614
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2_inhibitors	lymphoma	targetBased	57013	201	0.661365156411374	554
qHTS assay for re-activators of p53 using a Luc reporter	TP53	lymphoma	pathwayBased	321427	201	0.692516703724469	2300
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	lymphoma	targetBased	54509	528	0.692516703724469	2300
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	lymphoma	targetBased	54513	338	0.692516703724469	2300
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	lymphoma	targetBased	125394	1890	0.692516703724469	2300
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	lymphoma	targetBased	124022	1156	0.692516703724469	2300
Primary cell-based high throughput screening assay to measure STAT3 activation	STAT3	lymphoma	pathwayBased	194666	1772	0.51373824732454	888
Primary cell-based high throughput screening assay to measure STAT3 inhibition	STAT3	lymphoma	pathwayBased	194666	1722	0.51373824732454	888
HCS assay for microtubule stabilizers	TUBB	lymphoma	targetBased	195821	1625	0.654474277762646	1237
qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM)	BLM_inhibitors	lymphoma	targetBased	347933	673	0.566768728375716	18
HTS for BAP1 Enzyme inhibitors	BAP1_inhibitors	mesothelioma	targetBased	71016	346	0.605356658796186	276
uHTS identification of HIF-2a Inhibitors in a luminesence assay	HIF-2a_inhibitors	renal cell carcinoma	targetBased	363840	2624	0.707437226974782	676
qHTS assay for re-activators of p53 using a Luc reporter	TP53	renal cell carcinoma	pathwayBased	321427	201	0.633336943115504	1152
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	renal cell carcinoma	targetBased	54509	528	0.633336943115504	1152
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	renal cell carcinoma	targetBased	54513	338	0.633336943115504	1152
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	renal cell carcinoma	targetBased	125394	1890	0.633336943115504	1152
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	renal cell carcinoma	targetBased	124022	1156	0.633336943115504	1152
HTS for BAP1 Enzyme inhibitors	BAP1_inhibitors	renal cell carcinoma	targetBased	71016	346	0.581080744195547	138
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	renal cell carcinoma	pathwayBased	43989	342	0.593783534704895	1898
Dicer-mediated maturation of pre-microRNA	Dicer_inhibitors	melanoma	targetBased	46715	2829	0.532731295041119	55
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2_inhibitors	melanoma	targetBased	57013	201	0.536984685004855	430
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac activated mutant	RAC1	melanoma	targetBased	194629	219	0.70849417048193	39
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac wildtype	RAC1	melanoma	targetBased	194628	521	0.70849417048193	39
qHTS assay for re-activators of p53 using a Luc reporter	TP53	prostate adenocarcinoma	pathwayBased	321427	201	0.804334708461005	352
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	prostate adenocarcinoma	targetBased	54509	528	0.804334708461005	352
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	prostate adenocarcinoma	targetBased	54513	338	0.804334708461005	352
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	prostate adenocarcinoma	targetBased	125394	1890	0.804334708461005	352
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	prostate adenocarcinoma	targetBased	124022	1156	0.804334708461005	352
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	prostate adenocarcinoma	targetBased	356517	1139	0.613766243992196	71
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	prostate adenocarcinoma	targetBased	322361	619	0.71034534298668	56
qHTS assay for re-activators of p53 using a Luc reporter	TP53	melanoma	pathwayBased	321427	201	0.727160629242358	2492
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	melanoma	targetBased	54509	528	0.727160629242358	2492
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	melanoma	targetBased	54513	338	0.727160629242358	2492
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	melanoma	targetBased	125394	1890	0.727160629242358	2492
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	melanoma	targetBased	124022	1156	0.727160629242358	2492
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	melanoma	targetBased	356517	1139	0.500221889593926	2582
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	neoplasm	pathwayBased	376029	3978	0.838869652727156	24991
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	prostate adenocarcinoma	targetBased	193542	587	0.731249965361392	63
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	prostate adenocarcinoma	targetBased	194628	267	0.543234231990126	23
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2_inhibitors	sarcoma	targetBased	57013	201	0.57334986414968	191
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	neoplasm	targetBased	334825	423	0.624327417617625	1348
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	neoplasm	targetBased	337446	1356	0.624327417617625	1348
HTS for BAP1 Enzyme inhibitors	BAP1_inhibitors	melanoma	targetBased	71016	346	0.555227813487309	130
qHTS for Inhibitors of WRN Helicase	WRN	melanoma	targetBased	364011	1678	0.54225293911469	19
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	melanoma	targetBased	193542	587	0.707371985908243	295
qHTS assay for re-activators of p53 using a Luc reporter	TP53	sarcoma	pathwayBased	321427	201	0.714640176905728	2314
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	sarcoma	targetBased	54509	528	0.714640176905728	2314
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	sarcoma	targetBased	54513	338	0.714640176905728	2314
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	sarcoma	targetBased	125394	1890	0.714640176905728	2314
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	sarcoma	targetBased	124022	1156	0.714640176905728	2314
HCS assay for microtubule stabilizers	TUBB	prostate adenocarcinoma	targetBased	195821	1625	0.609422103028697	210
HCS assay for microtubule stabilizers	TUBB	sarcoma	targetBased	195821	1625	0.510898490357025	221
MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity	MITF	melanoma	targetBased	331360	2760	0.53648241518688	2725
AlphaScreen-based biochemical high throughput primary assay to identify inhibitors of microphthalmia-associated transcription factor (MITF)	MITF inhibitors	melanoma	targetBased	642362	5830	0.53648241518688	2725
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	neoplasm	targetBased	86095	1442	0.797175874096195	36242
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	neoplasm	targetBased	86095	1151	0.797175874096195	36242
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	neoplasm	targetBased	217959	2390	0.832471458207819	8077
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	neoplasm	targetBased	359207	1432	0.773198977841017	6645
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	neoplasm	targetBased	143816	859	0.546980995818396	895
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2_inhibitors	neoplasm	targetBased	57013	201	0.649002328313517	9186
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	neoplasm	targetBased	335239	991	0.668792435509745	475
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	neoplasm	targetBased	335239	695	0.668792435509745	475
uHTS identification of HIF-2a Inhibitors in a luminesence assay	HIF-2a_inhibitors	neoplasm	targetBased	363840	2624	0.634731505143747	3280
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	squamous cell lung carcinoma	targetBased	336894	489	0.591749999583246	57
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	neoplasm	targetBased	99314	335	0.519243461811769	4416
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	neoplasm	targetBased	196176	782	0.519243461811769	4416
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	neoplasm	targetBased	99314	390	0.519243461811769	4416
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	neoplasm	targetBased	196177	811	0.519243461811769	4416
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	neoplasm	targetBased	196176	670	0.519243461811769	4416
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	neoplasm	targetBased	196177	519	0.519243461811769	4416
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	neoplasm	targetBased	359244	2975	0.657839573780106	4779
qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide	Menin-MLL_inhibitors	neoplasm	targetBased	263421	615	0.510157872963492	4780
Nrf2 qHTS screen for inhibitors	nrf2Inhibitors	squamous cell lung carcinoma	targetBased	360873	7438	0.700426818850629	89
qHTS of Nrf2 Activators	Nrf2 activators	squamous cell lung carcinoma	pathwayBased	403871	1243	0.700426818850629	89
qHTS assay for re-activators of p53 using a Luc reporter	TP53	small cell lung carcinoma	pathwayBased	321427	201	0.743850543799876	1614
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	small cell lung carcinoma	targetBased	54509	528	0.743850543799876	1614
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	small cell lung carcinoma	targetBased	54513	338	0.743850543799876	1614
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	small cell lung carcinoma	targetBased	125394	1890	0.743850543799876	1614
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	small cell lung carcinoma	targetBased	124022	1156	0.743850543799876	1614
qHTS assay for re-activators of p53 using a Luc reporter	TP53	squamous cell lung carcinoma	pathwayBased	321427	201	0.782904796477414	523
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	squamous cell lung carcinoma	targetBased	54509	528	0.782904796477414	523
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	squamous cell lung carcinoma	targetBased	54513	338	0.782904796477414	523
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	squamous cell lung carcinoma	targetBased	125394	1890	0.782904796477414	523
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	squamous cell lung carcinoma	targetBased	124022	1156	0.782904796477414	523
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	squamous cell lung carcinoma	targetBased	194628	267	0.577906415694614	34
HCS assay for microtubule stabilizers	TUBB	squamous cell lung carcinoma	targetBased	195821	1625	0.585836319535447	61
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	neoplasm	targetBased	86095	1114	0.66776754745673	3322
qHTS assay for re-activators of p53 using a Luc reporter	TP53	neoplasm	pathwayBased	321427	201	0.734763617551086	117109
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	neoplasm	targetBased	54509	528	0.734763617551086	117109
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	neoplasm	targetBased	54513	338	0.734763617551086	117109
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	neoplasm	targetBased	125394	1890	0.734763617551086	117109
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	neoplasm	targetBased	124022	1156	0.734763617551086	117109
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	neoplasm	targetBased	356517	1139	0.563185687279908	52761
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	neoplasm	targetBased	359518	300	0.505795193234879	607
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	neoplasm	targetBased	335652	1779	0.505795193234879	607
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	neoplasm	targetBased	362274	1056	0.505795193234879	607
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	neoplasm	targetBased	336308	6862	0.505795193234879	607
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	neoplasm	targetBased	357537	806	0.505795193234879	607
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	neoplasm	targetBased	339887	1178	0.505795193234879	607
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	neoplasm	targetBased	322361	619	0.87594830406283	8058
qHTS assay for re-activators of p53 using a Luc reporter	TP53	squamous cell carcinoma	pathwayBased	321427	201	0.691147782991076	5273
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	squamous cell carcinoma	targetBased	54509	528	0.691147782991076	5273
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	squamous cell carcinoma	targetBased	54513	338	0.691147782991076	5273
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	squamous cell carcinoma	targetBased	125394	1890	0.691147782991076	5273
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	squamous cell carcinoma	targetBased	124022	1156	0.691147782991076	5273
uHTS luminescence assay for the identification of compounds that inhibit NOD2	NOD2	neoplasm	targetBased	292323	1836	0.582604832960078	313
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	neoplasm	targetBased	193542	587	0.655184857451428	8177
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	neoplasm	targetBased	305610	3794	0.591556848961583	113
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	squamous cell carcinoma	targetBased	194628	267	0.561703048438636	329
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	neoplasm	targetBased	339674	2841	0.583703277674933	62
Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3	HDAC3	neoplasm	targetBased	318291	483	0.669681742135009	1140
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	neoplasm	targetBased	194628	267	0.645516132179648	4509
HCS assay for microtubule stabilizers	TUBB	squamous cell carcinoma	targetBased	195821	1625	0.624144915124246	254
HCS assay for microtubule stabilizers	TUBB	neoplasm	targetBased	195821	1625	0.685425205092243	6252
qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS	TXNRD1	neoplasm	targetBased	386663	3977	0.546990287972955	620
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	neoplasm	pathwayBased	43989	342	0.541889017137273	28013
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	ovarian carcinoma	pathwayBased	376029	3978	0.811014153936412	630
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	multiple myeloma	targetBased	359207	1432	0.526059241881704	50
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	multiple myeloma	targetBased	143816	859	0.676525185755556	1089
qHTS assay for re-activators of p53 using a Luc reporter	TP53	ovarian carcinoma	pathwayBased	321427	201	0.564167801515414	1002
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	ovarian carcinoma	targetBased	54509	528	0.564167801515414	1002
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	ovarian carcinoma	targetBased	54513	338	0.564167801515414	1002
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	ovarian carcinoma	targetBased	125394	1890	0.564167801515414	1002
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	ovarian carcinoma	targetBased	124022	1156	0.564167801515414	1002
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	ovarian carcinoma	targetBased	356517	1139	0.661454282948221	250
qHTS assay for re-activators of p53 using a Luc reporter	TP53	multiple myeloma	pathwayBased	321427	201	0.739052515476112	726
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	multiple myeloma	targetBased	54509	528	0.739052515476112	726
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	multiple myeloma	targetBased	54513	338	0.739052515476112	726
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	multiple myeloma	targetBased	125394	1890	0.739052515476112	726
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	multiple myeloma	targetBased	124022	1156	0.739052515476112	726
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	ovarian carcinoma	targetBased	193542	587	0.528561751035599	76
Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3	HDAC3	multiple myeloma	targetBased	318291	483	0.62323885367771	117
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	multiple myeloma	targetBased	194628	267	0.524918664126389	29
HCS assay for microtubule stabilizers	TUBB	multiple myeloma	targetBased	195821	1625	0.624291315565239	141
qHTS assay for re-activators of p53 using a Luc reporter	TP53	anaplastic astrocytoma	pathwayBased	321427	201	0.569608536065496	177
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	anaplastic astrocytoma	targetBased	54509	528	0.569608536065496	177
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	anaplastic astrocytoma	targetBased	54513	338	0.569608536065496	177
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	anaplastic astrocytoma	targetBased	125394	1890	0.569608536065496	177
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	anaplastic astrocytoma	targetBased	124022	1156	0.569608536065496	177
qHTS assay for re-activators of p53 using a Luc reporter	TP53	cervical adenocarcinoma	pathwayBased	321427	201	0.538818108466208	100
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	cervical adenocarcinoma	targetBased	54509	528	0.538818108466208	100
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	cervical adenocarcinoma	targetBased	54513	338	0.538818108466208	100
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	cervical adenocarcinoma	targetBased	125394	1890	0.538818108466208	100
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	cervical adenocarcinoma	targetBased	124022	1156	0.538818108466208	100
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	cervical adenocarcinoma	targetBased	193542	587	0.520077721092215	24
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	cervical adenocarcinoma	targetBased	194628	267	0.522134222563113	17
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	cirrhosis of liver	targetBased	324747	813	0.543359118242622	6
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	cirrhosis of liver	targetBased	339297	1446	0.505376346678683	6
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	lymphoid neoplasm	targetBased	359207	1432	0.681165036449891	1079
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2_inhibitors	lymphoid neoplasm	targetBased	57013	201	0.635028303815862	555
Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity	SMARCA4	lymphoid neoplasm	targetBased	344733	7043	0.515089787821532	44
qHTS assay for re-activators of p53 using a Luc reporter	TP53	lymphoid neoplasm	pathwayBased	321427	201	0.673172901271881	2270
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	lymphoid neoplasm	targetBased	54509	528	0.673172901271881	2270
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	lymphoid neoplasm	targetBased	54513	338	0.673172901271881	2270
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	lymphoid neoplasm	targetBased	125394	1890	0.673172901271881	2270
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	lymphoid neoplasm	targetBased	124022	1156	0.673172901271881	2270
Primary cell-based high throughput screening assay to measure STAT3 activation	STAT3	lymphoid neoplasm	pathwayBased	194666	1772	0.616157212101945	884
Primary cell-based high throughput screening assay to measure STAT3 inhibition	STAT3	lymphoid neoplasm	pathwayBased	194666	1722	0.616157212101945	884
HCS assay for microtubule stabilizers	TUBB	lymphoid neoplasm	targetBased	195821	1625	0.56726113328905	802
qHTS for Inhibitors of Polymerase Kappa	POLK	prostate carcinoma	targetBased	395295	2034	0.599073001448264	42
Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3	HDAC3	Cutaneous T-cell lymphoma	targetBased	318291	483	0.562111104478172	44
qHTS assay for re-activators of p53 using a Luc reporter	TP53	prostate carcinoma	pathwayBased	321427	201	0.598179746256734	442
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	prostate carcinoma	targetBased	54509	528	0.598179746256734	442
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	prostate carcinoma	targetBased	54513	338	0.598179746256734	442
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	prostate carcinoma	targetBased	125394	1890	0.598179746256734	442
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	prostate carcinoma	targetBased	124022	1156	0.598179746256734	442
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	prostate carcinoma	targetBased	356517	1139	0.509965207659139	140
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	prostate carcinoma	targetBased	322361	619	0.648714094744205	50
Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.	BCL2L11_inhibitors	prostate carcinoma	targetBased	325630	216	0.515874114696088	13
qHTS assay for re-activators of p53 using a Luc reporter	TP53	esophageal carcinoma	pathwayBased	321427	201	0.631553488700546	1025
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	esophageal carcinoma	targetBased	54509	528	0.631553488700546	1025
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	esophageal carcinoma	targetBased	54513	338	0.631553488700546	1025
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	esophageal carcinoma	targetBased	125394	1890	0.631553488700546	1025
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	esophageal carcinoma	targetBased	124022	1156	0.631553488700546	1025
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	esophageal carcinoma	targetBased	193542	587	0.531275226876165	65
Dicer-mediated maturation of pre-microRNA	Dicer_inhibitors	rhabdomyosarcoma	targetBased	46715	2829	0.569574565978751	92
qHTS assay for re-activators of p53 using a Luc reporter	TP53	rhabdomyosarcoma	pathwayBased	321427	201	0.688273946449154	275
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	rhabdomyosarcoma	targetBased	54509	528	0.688273946449154	275
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	rhabdomyosarcoma	targetBased	54513	338	0.688273946449154	275
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	rhabdomyosarcoma	targetBased	125394	1890	0.688273946449154	275
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	rhabdomyosarcoma	targetBased	124022	1156	0.688273946449154	275
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	lung carcinoma	targetBased	336894	489	0.533631681825241	335
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	myeloid neoplasm	targetBased	217959	2390	0.545293990265582	4706
Nrf2 qHTS screen for inhibitors	nrf2Inhibitors	lung carcinoma	targetBased	360873	7438	0.536803382389076	198
qHTS of Nrf2 Activators	Nrf2 activators	lung carcinoma	pathwayBased	403871	1243	0.536803382389076	198
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2_inhibitors	myeloid neoplasm	targetBased	57013	201	0.539402074530581	535
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	myeloid neoplasm	targetBased	215667	993	0.552307095351119	1680
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	myeloid neoplasm	targetBased	218234	1620	0.552307095351119	1680
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	chronic myeloproliferative disorder	targetBased	217959	2390	0.509912994147925	5588
qHTS assay for re-activators of p53 using a Luc reporter	TP53	lung carcinoma	pathwayBased	321427	201	0.51063680830263	3214
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	lung carcinoma	targetBased	54509	528	0.51063680830263	3214
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	lung carcinoma	targetBased	54513	338	0.51063680830263	3214
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	lung carcinoma	targetBased	125394	1890	0.51063680830263	3214
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	lung carcinoma	targetBased	124022	1156	0.51063680830263	3214
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	rhabdomyosarcoma	targetBased	194628	267	0.566060561247714	32
Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity	SMARCA4	medulloblastoma	targetBased	344733	7043	0.636851805368641	16
qHTS assay for re-activators of p53 using a Luc reporter	TP53	medulloblastoma	pathwayBased	321427	201	0.623581877783622	55
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	medulloblastoma	targetBased	54509	528	0.623581877783622	55
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	medulloblastoma	targetBased	54513	338	0.623581877783622	55
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	medulloblastoma	targetBased	125394	1890	0.623581877783622	55
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	medulloblastoma	targetBased	124022	1156	0.623581877783622	55
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	polycythemia vera	targetBased	217959	2390	0.838231550055395	1434
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	primary myelofibrosis	targetBased	217959	2390	0.828570613464231	590
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	medulloblastoma	targetBased	193542	587	0.814044525642904	108
Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex	PRKAR1A	endocrine neoplasm	targetBased	343468	285	0.658688749369898	83
qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide	Menin-MLL_inhibitors	endocrine neoplasm	targetBased	263421	615	0.814230692322863	2441
qHTS assay for re-activators of p53 using a Luc reporter	TP53	endocrine neoplasm	pathwayBased	321427	201	0.629328151945855	4684
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	endocrine neoplasm	targetBased	54509	528	0.629328151945855	4684
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	endocrine neoplasm	targetBased	54513	338	0.629328151945855	4684
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	endocrine neoplasm	targetBased	125394	1890	0.629328151945855	4684
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	endocrine neoplasm	targetBased	124022	1156	0.629328151945855	4684
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	pancreatic carcinoma	pathwayBased	376029	3978	0.717108809180929	280
HCS assay for microtubule stabilizers	TUBB	anaplastic large cell lymphoma	targetBased	195821	1625	0.503028356338076	26
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pancreatic carcinoma	pathwayBased	321427	201	0.772563433295667	611
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	pancreatic carcinoma	targetBased	54509	528	0.772563433295667	611
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	pancreatic carcinoma	targetBased	54513	338	0.772563433295667	611
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	pancreatic carcinoma	targetBased	125394	1890	0.772563433295667	611
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	pancreatic carcinoma	targetBased	124022	1156	0.772563433295667	611
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	pancreatic carcinoma	targetBased	322361	619	0.718784932807895	97
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	breast neoplasm	pathwayBased	376029	3978	0.969800044375086	10492
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	breast neoplasm	targetBased	86095	1442	0.835522351213338	6847
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	breast neoplasm	targetBased	86095	1151	0.835522351213338	6847
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	breast neoplasm	targetBased	86095	1114	0.630680665640952	453
qHTS assay for re-activators of p53 using a Luc reporter	TP53	breast neoplasm	pathwayBased	321427	201	0.755353716652497	2799
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	breast neoplasm	targetBased	54509	528	0.755353716652497	2799
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	breast neoplasm	targetBased	54513	338	0.755353716652497	2799
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	breast neoplasm	targetBased	125394	1890	0.755353716652497	2799
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	breast neoplasm	targetBased	124022	1156	0.755353716652497	2799
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	breast neoplasm	targetBased	356517	1139	0.66299167834792	1506
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	breast neoplasm	targetBased	322361	619	0.757177438416621	2227
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	breast neoplasm	targetBased	305610	3794	0.54706759205653	11
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	breast neoplasm	targetBased	339674	2841	0.544285598520276	6
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	breast neoplasm	targetBased	194628	267	0.536580295784799	144
HCS assay for microtubule stabilizers	TUBB	breast neoplasm	targetBased	195821	1625	0.678524544348591	1359
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	breast neoplasm	pathwayBased	43989	342	0.517897767902	729
HCS assay for microtubule stabilizers	TUBB	pancreatic carcinoma	targetBased	195821	1625	0.586465101589641	371
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	non-small cell lung carcinoma	targetBased	336894	489	0.655334675854879	718
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	refractory anemia with excess blasts	targetBased	359244	2975	0.634927526187759	20
qHTS assay for re-activators of p53 using a Luc reporter	TP53	renal carcinoma	pathwayBased	321427	201	0.521275564851696	754
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	renal carcinoma	targetBased	54509	528	0.521275564851696	754
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	renal carcinoma	targetBased	54513	338	0.521275564851696	754
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	renal carcinoma	targetBased	125394	1890	0.521275564851696	754
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	renal carcinoma	targetBased	124022	1156	0.521275564851696	754
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	renal carcinoma	pathwayBased	43989	342	0.590771525813295	872
Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity	SMARCA4	non-small cell lung carcinoma	targetBased	344733	7043	0.648573088621513	308
qHTS assay for re-activators of p53 using a Luc reporter	TP53	non-small cell lung carcinoma	pathwayBased	321427	201	0.709956252910777	4899
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	non-small cell lung carcinoma	targetBased	54509	528	0.709956252910777	4899
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	non-small cell lung carcinoma	targetBased	54513	338	0.709956252910777	4899
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	non-small cell lung carcinoma	targetBased	125394	1890	0.709956252910777	4899
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	non-small cell lung carcinoma	targetBased	124022	1156	0.709956252910777	4899
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	non-small cell lung carcinoma	targetBased	356517	1139	0.510746001221223	4077
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	non-small cell lung carcinoma	targetBased	322361	619	0.560157288727676	289
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	thyroid carcinoma	targetBased	276265	806	0.556084553629844	50
HTS of Smad transcription factor inhibitors	SMAD3	thyroid carcinoma	targetBased	88033	251	0.5522484605199	10
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	non-small cell lung carcinoma	targetBased	193542	587	0.600629550249717	203
HCS assay for microtubule stabilizers	TUBB	non-small cell lung carcinoma	targetBased	195821	1625	0.673534018217188	1970
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	brain neoplasm	targetBased	335239	991	0.516390636682191	6
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	brain neoplasm	targetBased	335239	695	0.516390636682191	6
qHTS assay for re-activators of p53 using a Luc reporter	TP53	brain neoplasm	pathwayBased	321427	201	0.646414536804601	648
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	brain neoplasm	targetBased	54509	528	0.646414536804601	648
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	brain neoplasm	targetBased	54513	338	0.646414536804601	648
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	brain neoplasm	targetBased	125394	1890	0.646414536804601	648
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	brain neoplasm	targetBased	124022	1156	0.646414536804601	648
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	brain neoplasm	targetBased	193542	587	0.52338689289213	78
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	ovarian neoplasm	pathwayBased	376029	3978	0.906277040676126	7663
qHTS assay for re-activators of p53 using a Luc reporter	TP53	ovarian neoplasm	pathwayBased	321427	201	0.800787973060319	1661
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	ovarian neoplasm	targetBased	54509	528	0.800787973060319	1661
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	ovarian neoplasm	targetBased	54513	338	0.800787973060319	1661
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	ovarian neoplasm	targetBased	125394	1890	0.800787973060319	1661
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	ovarian neoplasm	targetBased	124022	1156	0.800787973060319	1661
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	ovarian neoplasm	targetBased	356517	1139	0.518401315696728	245
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	ovarian neoplasm	targetBased	193542	587	0.73592106151764	111
HCS assay for microtubule stabilizers	TUBB	ovarian neoplasm	targetBased	195821	1625	0.578223516620776	256
Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	thyroid neoplasm	targetBased	329153	670	0.667632909500217	246
Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	thyroid neoplasm	targetBased	329153	670	0.667632909500217	246
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor	TSHR	thyroid neoplasm	targetBased	72026	352	0.667632909500217	246
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293	TSHR	thyroid neoplasm	targetBased	72026	1794	0.667632909500217	246
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	thyroid neoplasm	targetBased	194628	267	0.717923499573761	177
Nrf2 qHTS screen for inhibitors	nrf2Inhibitors	uterine neoplasm	targetBased	360873	7438	0.506284165020475	31
qHTS of Nrf2 Activators	Nrf2 activators	uterine neoplasm	pathwayBased	403871	1243	0.506284165020475	31
qHTS assay for re-activators of p53 using a Luc reporter	TP53	uterine neoplasm	pathwayBased	321427	201	0.60477961198684	1095
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	uterine neoplasm	targetBased	54509	528	0.60477961198684	1095
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	uterine neoplasm	targetBased	54513	338	0.60477961198684	1095
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	uterine neoplasm	targetBased	125394	1890	0.60477961198684	1095
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	uterine neoplasm	targetBased	124022	1156	0.60477961198684	1095
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	uterine neoplasm	targetBased	193542	587	0.580345234831025	177
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	uterine neoplasm	pathwayBased	43989	342	0.531396657480323	110
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	colorectal neoplasm	targetBased	334825	423	0.554868394038899	47
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	colorectal neoplasm	targetBased	337446	1356	0.554868394038899	47
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	colorectal neoplasm	targetBased	359207	1432	0.611627732068766	81
Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-gamma1).	PLCG1	angiosarcoma	targetBased	369953	3123	0.524654275968588	7
qHTS assay for re-activators of p53 using a Luc reporter	TP53	angiosarcoma	pathwayBased	321427	201	0.542272992084	75
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	angiosarcoma	targetBased	54509	528	0.542272992084	75
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	angiosarcoma	targetBased	54513	338	0.542272992084	75
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	angiosarcoma	targetBased	125394	1890	0.542272992084	75
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	angiosarcoma	targetBased	124022	1156	0.542272992084	75
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	pancreatic neoplasm	pathwayBased	376029	3978	0.589482433026752	212
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	pancreatic neoplasm	targetBased	334825	423	0.536472991523101	54
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	pancreatic neoplasm	targetBased	337446	1356	0.536472991523101	54
qHTS assay for re-activators of p53 using a Luc reporter	TP53	colorectal neoplasm	pathwayBased	321427	201	0.625072089258988	1870
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	colorectal neoplasm	targetBased	54509	528	0.625072089258988	1870
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	colorectal neoplasm	targetBased	54513	338	0.625072089258988	1870
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	colorectal neoplasm	targetBased	125394	1890	0.625072089258988	1870
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	colorectal neoplasm	targetBased	124022	1156	0.625072089258988	1870
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	colorectal neoplasm	targetBased	356517	1139	0.50059601177339	285
qHTS for Inhibitors of WRN Helicase	WRN	colorectal neoplasm	targetBased	364011	1678	0.513929896480345	19
HTS of Smad transcription factor inhibitors	SMAD3	colorectal neoplasm	targetBased	88033	251	0.544854494739693	43
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	colorectal neoplasm	targetBased	193542	587	0.614843970379271	382
qHTS assay for re-activators of p53 using a Luc reporter	TP53	stomach neoplasm	pathwayBased	321427	201	0.50387992859265	589
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	stomach neoplasm	targetBased	54509	528	0.50387992859265	589
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	stomach neoplasm	targetBased	54513	338	0.50387992859265	589
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	stomach neoplasm	targetBased	125394	1890	0.50387992859265	589
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	stomach neoplasm	targetBased	124022	1156	0.50387992859265	589
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	stomach neoplasm	targetBased	193542	587	0.500764838812246	68
HCS assay for microtubule stabilizers	TUBB	stomach neoplasm	targetBased	195821	1625	0.609719050629167	231
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pancreatic neoplasm	pathwayBased	321427	201	0.808830166678429	1045
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	pancreatic neoplasm	targetBased	54509	528	0.808830166678429	1045
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	pancreatic neoplasm	targetBased	54513	338	0.808830166678429	1045
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	pancreatic neoplasm	targetBased	125394	1890	0.808830166678429	1045
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	pancreatic neoplasm	targetBased	124022	1156	0.808830166678429	1045
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	pancreatic neoplasm	targetBased	322361	619	0.664254622474054	127
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	colorectal neoplasm	pathwayBased	43989	342	0.502617440457158	133
qHTS assay for re-activators of p53 using a Luc reporter	TP53	kidney neoplasm	pathwayBased	321427	201	0.51632178998452	831
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	kidney neoplasm	targetBased	54509	528	0.51632178998452	831
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	kidney neoplasm	targetBased	54513	338	0.51632178998452	831
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	kidney neoplasm	targetBased	125394	1890	0.51632178998452	831
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	kidney neoplasm	targetBased	124022	1156	0.51632178998452	831
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	kidney neoplasm	pathwayBased	43989	342	0.550908270499343	1037
qHTS assay for re-activators of p53 using a Luc reporter	TP53	basal cell carcinoma	pathwayBased	321427	201	0.693049628473067	401
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	basal cell carcinoma	targetBased	54509	528	0.693049628473067	401
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	basal cell carcinoma	targetBased	54513	338	0.693049628473067	401
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	basal cell carcinoma	targetBased	125394	1890	0.693049628473067	401
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	basal cell carcinoma	targetBased	124022	1156	0.693049628473067	401
qHTS assay for re-activators of p53 using a Luc reporter	TP53	colonic neoplasm	pathwayBased	321427	201	0.521265092035978	689
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	colonic neoplasm	targetBased	54509	528	0.521265092035978	689
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	colonic neoplasm	targetBased	54513	338	0.521265092035978	689
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	colonic neoplasm	targetBased	125394	1890	0.521265092035978	689
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	colonic neoplasm	targetBased	124022	1156	0.521265092035978	689
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	colonic neoplasm	targetBased	322361	619	0.59125709347292	27
qHTS assay for re-activators of p53 using a Luc reporter	TP53	carcinoid tumor	pathwayBased	321427	201	0.53134326398704	73
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	carcinoid tumor	targetBased	54509	528	0.53134326398704	73
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	carcinoid tumor	targetBased	54513	338	0.53134326398704	73
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	carcinoid tumor	targetBased	125394	1890	0.53134326398704	73
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	carcinoid tumor	targetBased	124022	1156	0.53134326398704	73
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	lymphoid leukemia	targetBased	359207	1432	0.655837105084316	996
qHTS assay for re-activators of p53 using a Luc reporter	TP53	lymphoid leukemia	pathwayBased	321427	201	0.592682461616264	926
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	lymphoid leukemia	targetBased	54509	528	0.592682461616264	926
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	lymphoid leukemia	targetBased	54513	338	0.592682461616264	926
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	lymphoid leukemia	targetBased	125394	1890	0.592682461616264	926
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	lymphoid leukemia	targetBased	124022	1156	0.592682461616264	926
HCS assay for microtubule stabilizers	TUBB	lymphoid leukemia	targetBased	195821	1625	0.584126459536702	130
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	myeloproliferative disorder	targetBased	217959	2390	0.861829240204984	5324
HCS assay for microtubule stabilizers	TUBB	upper aerodigestive tract neoplasm	targetBased	195821	1625	0.578977454387374	45
qHTS assay for re-activators of p53 using a Luc reporter	TP53	nasopharyngeal neoplasm	pathwayBased	321427	201	0.699511170028026	49
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	nasopharyngeal neoplasm	targetBased	54509	528	0.699511170028026	49
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	nasopharyngeal neoplasm	targetBased	54513	338	0.699511170028026	49
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	nasopharyngeal neoplasm	targetBased	125394	1890	0.699511170028026	49
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	nasopharyngeal neoplasm	targetBased	124022	1156	0.699511170028026	49
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	nasopharyngeal neoplasm	targetBased	194628	267	0.501942833355626	6
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	myeloproliferative disorder	targetBased	359207	1432	0.6008959180227	3170
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	lymph node metastatic carcinoma	pathwayBased	376029	3978	0.54643680192594	81
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	lymph node metastatic carcinoma	targetBased	322361	619	0.537572300872626	29
qHTS assay for re-activators of p53 using a Luc reporter	TP53	glioma	pathwayBased	321427	201	0.518623288479843	2036
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	glioma	targetBased	54509	528	0.518623288479843	2036
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	glioma	targetBased	54513	338	0.518623288479843	2036
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	glioma	targetBased	125394	1890	0.518623288479843	2036
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	glioma	targetBased	124022	1156	0.518623288479843	2036
qHTS assay for re-activators of p53 using a Luc reporter	TP53	cholangiocarcinoma	pathwayBased	321427	201	0.598602455799827	436
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	cholangiocarcinoma	targetBased	54509	528	0.598602455799827	436
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	cholangiocarcinoma	targetBased	54513	338	0.598602455799827	436
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	cholangiocarcinoma	targetBased	125394	1890	0.598602455799827	436
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	cholangiocarcinoma	targetBased	124022	1156	0.598602455799827	436
HTS for BAP1 Enzyme inhibitors	BAP1_inhibitors	cholangiocarcinoma	targetBased	71016	346	0.512777658836874	32
qHTS assay for re-activators of p53 using a Luc reporter	TP53	esophageal squamous cell carcinoma	pathwayBased	321427	201	0.64655628137229	1225
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	esophageal squamous cell carcinoma	targetBased	54509	528	0.64655628137229	1225
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	esophageal squamous cell carcinoma	targetBased	54513	338	0.64655628137229	1225
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	esophageal squamous cell carcinoma	targetBased	125394	1890	0.64655628137229	1225
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	esophageal squamous cell carcinoma	targetBased	124022	1156	0.64655628137229	1225
HCS assay for microtubule stabilizers	TUBB	esophageal squamous cell carcinoma	targetBased	195821	1625	0.581722333143848	150
qHTS assay for re-activators of p53 using a Luc reporter	TP53	head and neck neoplasia	pathwayBased	321427	201	0.50151206457427	2001
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	head and neck neoplasia	targetBased	54509	528	0.50151206457427	2001
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	head and neck neoplasia	targetBased	54513	338	0.50151206457427	2001
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	head and neck neoplasia	targetBased	125394	1890	0.50151206457427	2001
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	head and neck neoplasia	targetBased	124022	1156	0.50151206457427	2001
HCS assay for microtubule stabilizers	TUBB	head and neck neoplasia	targetBased	195821	1625	0.554202837992371	247
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2_inhibitors	non-Hodgkins lymphoma	targetBased	57013	201	0.638504676439922	510
qHTS assay for re-activators of p53 using a Luc reporter	TP53	non-Hodgkins lymphoma	pathwayBased	321427	201	0.695708969907574	1850
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	non-Hodgkins lymphoma	targetBased	54509	528	0.695708969907574	1850
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	non-Hodgkins lymphoma	targetBased	54513	338	0.695708969907574	1850
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	non-Hodgkins lymphoma	targetBased	125394	1890	0.695708969907574	1850
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	non-Hodgkins lymphoma	targetBased	124022	1156	0.695708969907574	1850
Primary cell-based high throughput screening assay to measure STAT3 activation	STAT3	non-Hodgkins lymphoma	pathwayBased	194666	1772	0.558721101467953	569
Primary cell-based high throughput screening assay to measure STAT3 inhibition	STAT3	non-Hodgkins lymphoma	pathwayBased	194666	1722	0.558721101467953	569
HCS assay for microtubule stabilizers	TUBB	non-Hodgkins lymphoma	targetBased	195821	1625	0.643640984649825	451
qHTS assay for re-activators of p53 using a Luc reporter	TP53	head and neck malignant neoplasia	pathwayBased	321427	201	0.541944538639202	1771
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	head and neck malignant neoplasia	targetBased	54509	528	0.541944538639202	1771
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	head and neck malignant neoplasia	targetBased	54513	338	0.541944538639202	1771
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	head and neck malignant neoplasia	targetBased	125394	1890	0.541944538639202	1771
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	head and neck malignant neoplasia	targetBased	124022	1156	0.541944538639202	1771
HCS assay for microtubule stabilizers	TUBB	head and neck malignant neoplasia	targetBased	195821	1625	0.61852796016747	404
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	male breast carcinoma	targetBased	86095	1442	0.657373889939552	47
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	male breast carcinoma	targetBased	86095	1151	0.657373889939552	47
Nrf2 qHTS screen for inhibitors	nrf2Inhibitors	bladder transitional cell carcinoma	targetBased	360873	7438	0.510720357404753	27
qHTS of Nrf2 Activators	Nrf2 activators	bladder transitional cell carcinoma	pathwayBased	403871	1243	0.510720357404753	27
qHTS assay for re-activators of p53 using a Luc reporter	TP53	bladder transitional cell carcinoma	pathwayBased	321427	201	0.588845903637662	602
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	bladder transitional cell carcinoma	targetBased	54509	528	0.588845903637662	602
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	bladder transitional cell carcinoma	targetBased	54513	338	0.588845903637662	602
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	bladder transitional cell carcinoma	targetBased	125394	1890	0.588845903637662	602
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	bladder transitional cell carcinoma	targetBased	124022	1156	0.588845903637662	602
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	bladder transitional cell carcinoma	targetBased	193542	587	0.530771379279681	47
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	bladder transitional cell carcinoma	targetBased	194628	267	0.545118569063374	43
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	male reproductive organ cancer	targetBased	322361	619	0.518186328667181	44
Dicer-mediated maturation of pre-microRNA	Dicer_inhibitors	pulmonary blastoma	targetBased	46715	2829	0.540460032301018	138
qHTS assay for re-activators of p53 using a Luc reporter	TP53	urothelial carcinoma	pathwayBased	321427	201	0.51408234512013	433
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	urothelial carcinoma	targetBased	54509	528	0.51408234512013	433
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	urothelial carcinoma	targetBased	54513	338	0.51408234512013	433
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	urothelial carcinoma	targetBased	125394	1890	0.51408234512013	433
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	urothelial carcinoma	targetBased	124022	1156	0.51408234512013	433
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	digestive system neoplasm	targetBased	322361	619	0.599548825894144	391
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	Hepatobiliary Neoplasm	targetBased	86095	1442	0.510429822432812	274
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	Hepatobiliary Neoplasm	targetBased	86095	1151	0.510429822432812	274
Nrf2 qHTS screen for inhibitors	nrf2Inhibitors	Hepatobiliary Neoplasm	targetBased	360873	7438	0.535619794263082	174
qHTS of Nrf2 Activators	Nrf2 activators	Hepatobiliary Neoplasm	pathwayBased	403871	1243	0.535619794263082	174
qHTS assay for re-activators of p53 using a Luc reporter	TP53	Hepatobiliary Neoplasm	pathwayBased	321427	201	0.510567791113922	2837
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	Hepatobiliary Neoplasm	targetBased	54509	528	0.510567791113922	2837
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	Hepatobiliary Neoplasm	targetBased	54513	338	0.510567791113922	2837
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	Hepatobiliary Neoplasm	targetBased	125394	1890	0.510567791113922	2837
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	Hepatobiliary Neoplasm	targetBased	124022	1156	0.510567791113922	2837
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	Hepatobiliary Neoplasm	targetBased	193542	587	0.575005198667495	744
Dicer-mediated maturation of pre-microRNA	Dicer_inhibitors	Pleuropulmonary blastoma	targetBased	46715	2829	0.780118945779228	395
qHTS assay for re-activators of p53 using a Luc reporter	TP53	skin carcinoma	pathwayBased	321427	201	0.51020778667764	424
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	skin carcinoma	targetBased	54509	528	0.51020778667764	424
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	skin carcinoma	targetBased	54513	338	0.51020778667764	424
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	skin carcinoma	targetBased	125394	1890	0.51020778667764	424
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	skin carcinoma	targetBased	124022	1156	0.51020778667764	424
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	Pilomatrixoma	targetBased	193542	587	0.8876009025445	134
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	susceptibility to breast cancer	targetBased	322361	619	0.718849250077404	32
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	secondary malignant neoplasm	pathwayBased	376029	3978	0.604165201566678	34
qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide	Menin-MLL_inhibitors	pancreatic neuroendocrine tumor	targetBased	263421	615	0.633611610827445	356
HTS for BAP1 Enzyme inhibitors	BAP1_inhibitors	Malignant Mesothelioma	targetBased	71016	346	0.54276713631072	132
qHTS assay for re-activators of p53 using a Luc reporter	TP53	Malignant Pancreatic Neoplasm	pathwayBased	321427	201	0.662742907080579	519
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	Malignant Pancreatic Neoplasm	targetBased	54509	528	0.662742907080579	519
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	Malignant Pancreatic Neoplasm	targetBased	54513	338	0.662742907080579	519
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	Malignant Pancreatic Neoplasm	targetBased	125394	1890	0.662742907080579	519
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	Malignant Pancreatic Neoplasm	targetBased	124022	1156	0.662742907080579	519
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	Malignant Pancreatic Neoplasm	targetBased	322361	619	0.510758820729503	70
HCS assay for microtubule stabilizers	TUBB	Malignant Pancreatic Neoplasm	targetBased	195821	1625	0.572204935185042	204
qHTS assay for re-activators of p53 using a Luc reporter	TP53	Malignant Urinary System Neoplasm	pathwayBased	321427	201	0.52220433972734	1683
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	Malignant Urinary System Neoplasm	targetBased	54509	528	0.52220433972734	1683
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	Malignant Urinary System Neoplasm	targetBased	54513	338	0.52220433972734	1683
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	Malignant Urinary System Neoplasm	targetBased	125394	1890	0.52220433972734	1683
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	Malignant Urinary System Neoplasm	targetBased	124022	1156	0.52220433972734	1683
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	Myelodysplastic/Myeloproliferative Neoplasm	targetBased	217959	2390	0.515763988754042	39
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	Benign Skin Appendage Neoplasm	targetBased	193542	587	0.746464058544635	29
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	Hepatoblastoma	targetBased	193542	587	0.643412414649967	21
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	HER2 Positive Breast Carcinoma	targetBased	86095	1442	0.501942833355626	6
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	HER2 Positive Breast Carcinoma	targetBased	86095	1151	0.501942833355626	6
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive	targetBased	359207	1432	0.667521194648004	21
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay	MAPK1	cervical squamous cell carcinoma	pathwayBased	70898	707	0.569304558236886	12
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF	MAPK1	cervical squamous cell carcinoma	pathwayBased	131324	544	0.569304558236886	12
Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity	SMARCA4	Ovarian Small Cell Carcinoma	targetBased	344733	7043	0.514054706433331	164
uHTS identification of HIF-2a Inhibitors in a luminesence assay	HIF-2a_inhibitors	Paraganglioma	targetBased	363840	2624	0.543000850613236	125
qHTS assay for re-activators of p53 using a Luc reporter	TP53	cervical squamous cell carcinoma	pathwayBased	321427	201	0.5768924431085	118
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	cervical squamous cell carcinoma	targetBased	54509	528	0.5768924431085	118
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	cervical squamous cell carcinoma	targetBased	54513	338	0.5768924431085	118
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	cervical squamous cell carcinoma	targetBased	125394	1890	0.5768924431085	118
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	cervical squamous cell carcinoma	targetBased	124022	1156	0.5768924431085	118
qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide	Menin-MLL_inhibitors	lung carcinoid tumor	targetBased	263421	615	0.67824858781795	26
Dicer-mediated maturation of pre-microRNA	Dicer_inhibitors	Pineoblastoma	targetBased	46715	2829	0.633859219992769	56
qHTS assay for re-activators of p53 using a Luc reporter	TP53	Choroid Plexus Papilloma	pathwayBased	321427	201	0.756303928580139	80
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	Choroid Plexus Papilloma	targetBased	54509	528	0.756303928580139	80
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	Choroid Plexus Papilloma	targetBased	54513	338	0.756303928580139	80
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	Choroid Plexus Papilloma	targetBased	125394	1890	0.756303928580139	80
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	Choroid Plexus Papilloma	targetBased	124022	1156	0.756303928580139	80
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	Pituitary Gland Adenoma	targetBased	334825	423	0.726268004475537	170
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	Pituitary Gland Adenoma	targetBased	337446	1356	0.726268004475537	170
qHTS assay for re-activators of p53 using a Luc reporter	TP53	Lung Sarcomatoid Carcinoma	pathwayBased	321427	201	0.543809040454276	22
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	Lung Sarcomatoid Carcinoma	targetBased	54509	528	0.543809040454276	22
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	Lung Sarcomatoid Carcinoma	targetBased	54513	338	0.543809040454276	22
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	Lung Sarcomatoid Carcinoma	targetBased	125394	1890	0.543809040454276	22
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	Lung Sarcomatoid Carcinoma	targetBased	124022	1156	0.543809040454276	22
qHTS assay for re-activators of p53 using a Luc reporter	TP53	Pleural Mesothelioma	pathwayBased	321427	201	0.642612657221498	75
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	Pleural Mesothelioma	targetBased	54509	528	0.642612657221498	75
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	Pleural Mesothelioma	targetBased	54513	338	0.642612657221498	75
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	Pleural Mesothelioma	targetBased	125394	1890	0.642612657221498	75
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	Pleural Mesothelioma	targetBased	124022	1156	0.642612657221498	75
HTS for BAP1 Enzyme inhibitors	BAP1_inhibitors	Pleural Mesothelioma	targetBased	71016	346	0.735350430677337	70
qHTS assay for re-activators of p53 using a Luc reporter	TP53	Digestive System Carcinoma	pathwayBased	321427	201	0.525636156396741	5759
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	Digestive System Carcinoma	targetBased	54509	528	0.525636156396741	5759
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	Digestive System Carcinoma	targetBased	54513	338	0.525636156396741	5759
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	Digestive System Carcinoma	targetBased	125394	1890	0.525636156396741	5759
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	Digestive System Carcinoma	targetBased	124022	1156	0.525636156396741	5759
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	Digestive System Carcinoma	targetBased	322361	619	0.503659990048741	223
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	Digestive System Carcinoma	targetBased	193542	587	0.512405747440022	957
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	pancreatic adenocarcinoma	targetBased	334825	423	0.678833343678363	36
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	pancreatic adenocarcinoma	targetBased	337446	1356	0.678833343678363	36
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	T-Cell Prolymphocytic Leukemia	targetBased	322361	619	0.623514123973518	57
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pancreatic adenocarcinoma	pathwayBased	321427	201	0.787429982948732	847
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	pancreatic adenocarcinoma	targetBased	54509	528	0.787429982948732	847
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	pancreatic adenocarcinoma	targetBased	54513	338	0.787429982948732	847
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	pancreatic adenocarcinoma	targetBased	125394	1890	0.787429982948732	847
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	pancreatic adenocarcinoma	targetBased	124022	1156	0.787429982948732	847
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	Endometrial Polyp	targetBased	86095	1442	0.516802768100669	42
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	Endometrial Polyp	targetBased	86095	1151	0.516802768100669	42
HCS assay for microtubule stabilizers	TUBB	pancreatic adenocarcinoma	targetBased	195821	1625	0.606244963636864	149
qHTS assay for re-activators of p53 using a Luc reporter	TP53	Uterine Carcinosarcoma	pathwayBased	321427	201	0.671124202650939	228
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	Uterine Carcinosarcoma	targetBased	54509	528	0.671124202650939	228
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	Uterine Carcinosarcoma	targetBased	54513	338	0.671124202650939	228
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	Uterine Carcinosarcoma	targetBased	125394	1890	0.671124202650939	228
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	Uterine Carcinosarcoma	targetBased	124022	1156	0.671124202650939	228
HTS for BAP1 Enzyme inhibitors	BAP1_inhibitors	Uveal Melanoma	targetBased	71016	346	0.842672768448216	66
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	marginal zone B-cell lymphoma	targetBased	359207	1432	0.510788412662706	8
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	hemangioma	targetBased	339297	1446	0.641219378530656	62
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	Genital neoplasm, female	pathwayBased	376029	3978	0.756154198723462	7331
qHTS assay for re-activators of p53 using a Luc reporter	TP53	adrenal cortex carcinoma	pathwayBased	321427	201	0.772501421851151	549
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	adrenal cortex carcinoma	targetBased	54509	528	0.772501421851151	549
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	adrenal cortex carcinoma	targetBased	54513	338	0.772501421851151	549
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	adrenal cortex carcinoma	targetBased	125394	1890	0.772501421851151	549
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	adrenal cortex carcinoma	targetBased	124022	1156	0.772501421851151	549
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	adrenal cortex carcinoma	targetBased	193542	587	0.653106561534341	90
qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide	Menin-MLL_inhibitors	parathyroid adenoma	targetBased	263421	615	0.740465619640904	206
HCS assay for microtubule stabilizers	TUBB	peritoneal neoplasm	targetBased	195821	1625	0.557952605286964	96
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	metastatic colorectal cancer	targetBased	359207	1432	0.589434707125137	59
qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide	Menin-MLL_inhibitors	Angiofibroma	targetBased	263421	615	0.702187728399871	38
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	chronic myelomonocytic leukemia	targetBased	359244	2975	0.641149353645763	58
Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity	SMARCA4	soft tissue sarcoma	targetBased	344733	7043	0.500101901111415	2368
uHTS identification of small molecule inhibitors of Artemis endonuclease activity via a fluorescence intensity assay	artemis_inhibitors	histiocytic medullary reticulosis	targetBased	30104	235	0.616539346649504	312
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	endometrial carcinoma	pathwayBased	376029	3978	0.617724297967159	47
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	endometrial carcinoma	targetBased	322361	619	0.62230136368295	16
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	Mantle cell lymphoma	targetBased	143816	859	0.598331794844814	50
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	Mantle cell lymphoma	targetBased	322361	619	0.616608879193016	210
HCS assay for microtubule stabilizers	TUBB	Mantle cell lymphoma	targetBased	195821	1625	0.569305702678426	72
qHTS assay for re-activators of p53 using a Luc reporter	TP53	differentiated thyroid carcinoma	pathwayBased	321427	201	0.544852674219891	180
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	differentiated thyroid carcinoma	targetBased	54509	528	0.544852674219891	180
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	differentiated thyroid carcinoma	targetBased	54513	338	0.544852674219891	180
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	differentiated thyroid carcinoma	targetBased	125394	1890	0.544852674219891	180
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	differentiated thyroid carcinoma	targetBased	124022	1156	0.544852674219891	180
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	differentiated thyroid carcinoma	targetBased	276265	806	0.615477369838719	35
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	differentiated thyroid carcinoma	targetBased	194628	267	0.606300003374867	58
qHTS assay for re-activators of p53 using a Luc reporter	TP53	cutaneous squamous cell carcinoma	pathwayBased	321427	201	0.535642478113645	93
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	cutaneous squamous cell carcinoma	targetBased	54509	528	0.535642478113645	93
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	cutaneous squamous cell carcinoma	targetBased	54513	338	0.535642478113645	93
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	cutaneous squamous cell carcinoma	targetBased	125394	1890	0.535642478113645	93
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	cutaneous squamous cell carcinoma	targetBased	124022	1156	0.535642478113645	93
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	B-cell non-Hodgkins lymphoma	targetBased	322361	619	0.5234572186721	233
qHTS assay for re-activators of p53 using a Luc reporter	TP53	colon adenocarcinoma	pathwayBased	321427	201	0.563271617866096	225
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	colon adenocarcinoma	targetBased	54509	528	0.563271617866096	225
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	colon adenocarcinoma	targetBased	54513	338	0.563271617866096	225
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	colon adenocarcinoma	targetBased	125394	1890	0.563271617866096	225
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	colon adenocarcinoma	targetBased	124022	1156	0.563271617866096	225
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	colon carcinoma	targetBased	99314	335	0.592081065759334	57
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	colon carcinoma	targetBased	196176	782	0.592081065759334	57
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	colon carcinoma	targetBased	99314	390	0.592081065759334	57
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	colon carcinoma	targetBased	196177	811	0.592081065759334	57
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	colon carcinoma	targetBased	196176	670	0.592081065759334	57
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	colon carcinoma	targetBased	196177	519	0.592081065759334	57
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	colon carcinoma	targetBased	322361	619	0.563185208148079	25
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	colon carcinoma	targetBased	193542	587	0.588130234119545	137
qHTS assay for re-activators of p53 using a Luc reporter	TP53	gallbladder carcinoma	pathwayBased	321427	201	0.573784445368201	151
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	gallbladder carcinoma	targetBased	54509	528	0.573784445368201	151
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	gallbladder carcinoma	targetBased	54513	338	0.573784445368201	151
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	gallbladder carcinoma	targetBased	125394	1890	0.573784445368201	151
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	gallbladder carcinoma	targetBased	124022	1156	0.573784445368201	151
qHTS assay for re-activators of p53 using a Luc reporter	TP53	colon carcinoma	pathwayBased	321427	201	0.661335987264173	950
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	colon carcinoma	targetBased	54509	528	0.661335987264173	950
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	colon carcinoma	targetBased	54513	338	0.661335987264173	950
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	colon carcinoma	targetBased	125394	1890	0.661335987264173	950
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	colon carcinoma	targetBased	124022	1156	0.661335987264173	950
HTS for BAP1 Enzyme inhibitors	BAP1_inhibitors	Uveal melanoma	targetBased	71016	346	0.542772169908436	179
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	gastric cancer	pathwayBased	376029	3978	0.644706663355619	76
qHTS assay for re-activators of p53 using a Luc reporter	TP53	gastric cancer	pathwayBased	321427	201	0.72652111587925	459
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	gastric cancer	targetBased	54509	528	0.72652111587925	459
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	gastric cancer	targetBased	54513	338	0.72652111587925	459
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	gastric cancer	targetBased	125394	1890	0.72652111587925	459
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	gastric cancer	targetBased	124022	1156	0.72652111587925	459
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	gastric cancer	targetBased	322361	619	0.696672156439903	159
HCS assay for microtubule stabilizers	TUBB	gastric cancer	targetBased	195821	1625	0.583218527587673	405
qHTS assay for re-activators of p53 using a Luc reporter	TP53	brain cancer	pathwayBased	321427	201	0.537444841116938	459
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	brain cancer	targetBased	54509	528	0.537444841116938	459
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	brain cancer	targetBased	54513	338	0.537444841116938	459
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	brain cancer	targetBased	125394	1890	0.537444841116938	459
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	brain cancer	targetBased	124022	1156	0.537444841116938	459
Nrf2 qHTS screen for inhibitors	nrf2Inhibitors	urinary bladder cancer	targetBased	360873	7438	0.532337192362235	30
qHTS of Nrf2 Activators	Nrf2 activators	urinary bladder cancer	pathwayBased	403871	1243	0.532337192362235	30
qHTS assay for re-activators of p53 using a Luc reporter	TP53	urinary bladder cancer	pathwayBased	321427	201	0.761976143434719	875
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	urinary bladder cancer	targetBased	54509	528	0.761976143434719	875
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	urinary bladder cancer	targetBased	54513	338	0.761976143434719	875
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	urinary bladder cancer	targetBased	125394	1890	0.761976143434719	875
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	urinary bladder cancer	targetBased	124022	1156	0.761976143434719	875
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	urinary bladder cancer	targetBased	322361	619	0.634051822221657	72
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	urinary bladder cancer	targetBased	194628	267	0.756664701286372	130
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	ovarian epithelial tumor	pathwayBased	376029	3978	0.665791319751206	7078
qHTS assay for re-activators of p53 using a Luc reporter	TP53	ovarian epithelial tumor	pathwayBased	321427	201	0.69364717737818	786
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	ovarian epithelial tumor	targetBased	54509	528	0.69364717737818	786
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	ovarian epithelial tumor	targetBased	54513	338	0.69364717737818	786
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	ovarian epithelial tumor	targetBased	125394	1890	0.69364717737818	786
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	ovarian epithelial tumor	targetBased	124022	1156	0.69364717737818	786
qHTS assay for re-activators of p53 using a Luc reporter	TP53	vaginal cancer	pathwayBased	321427	201	0.525105070833845	10
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	vaginal cancer	targetBased	54509	528	0.525105070833845	10
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	vaginal cancer	targetBased	54513	338	0.525105070833845	10
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	vaginal cancer	targetBased	125394	1890	0.525105070833845	10
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	vaginal cancer	targetBased	124022	1156	0.525105070833845	10
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	epidermal appendage tumor	targetBased	193542	587	0.503317945774591	53
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	digestive system cancer	targetBased	322361	619	0.715610156304212	337
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	hematopoietic and lymphoid system neoplasm	targetBased	322361	619	0.511943760414391	550
qHTS assay for re-activators of p53 using a Luc reporter	TP53	head and neck carcinoma	pathwayBased	321427	201	0.511917474474916	1579
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	head and neck carcinoma	targetBased	54509	528	0.511917474474916	1579
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	head and neck carcinoma	targetBased	54513	338	0.511917474474916	1579
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	head and neck carcinoma	targetBased	125394	1890	0.511917474474916	1579
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	head and neck carcinoma	targetBased	124022	1156	0.511917474474916	1579
qHTS assay for re-activators of p53 using a Luc reporter	TP53	skin squamous cell carcinoma	pathwayBased	321427	201	0.608411208348797	413
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	skin squamous cell carcinoma	targetBased	54509	528	0.608411208348797	413
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	skin squamous cell carcinoma	targetBased	54513	338	0.608411208348797	413
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	skin squamous cell carcinoma	targetBased	125394	1890	0.608411208348797	413
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	skin squamous cell carcinoma	targetBased	124022	1156	0.608411208348797	413
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	skin squamous cell carcinoma	targetBased	194628	267	0.556633806525779	44
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	peritoneum cancer	pathwayBased	376029	3978	0.513391963949566	148
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	thyroid cancer	targetBased	276265	806	0.588445160784701	43
Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	thyroid cancer	targetBased	329153	670	0.603822893407619	156
Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	thyroid cancer	targetBased	329153	670	0.603822893407619	156
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor	TSHR	thyroid cancer	targetBased	72026	352	0.603822893407619	156
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293	TSHR	thyroid cancer	targetBased	72026	1794	0.603822893407619	156
HCS assay for microtubule stabilizers	TUBB	cervical cancer	targetBased	195821	1625	0.58247055398953	168
qHTS assay for re-activators of p53 using a Luc reporter	TP53	bone osteosarcoma	pathwayBased	321427	201	0.677273520190282	56
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	bone osteosarcoma	targetBased	54509	528	0.677273520190282	56
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	bone osteosarcoma	targetBased	54513	338	0.677273520190282	56
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	bone osteosarcoma	targetBased	125394	1890	0.677273520190282	56
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	bone osteosarcoma	targetBased	124022	1156	0.677273520190282	56
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	breast carcinoma in situ	targetBased	86095	1442	0.600945355982923	284
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	breast carcinoma in situ	targetBased	86095	1151	0.600945355982923	284
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	breast carcinoma in situ	targetBased	86095	1114	0.51521839195996	16
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	bile duct adenocarcinoma	pathwayBased	376029	3978	0.583775539396127	20
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	bile duct adenocarcinoma	targetBased	322361	619	0.50193157436328	15
HCS assay for microtubule stabilizers	TUBB	adult acute lymphoblastic leukemia	targetBased	195821	1625	0.6264758721618	42
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	hereditary breast ovarian cancer syndrome	pathwayBased	376029	3978	0.738790451491213	11288
qHTS assay for re-activators of p53 using a Luc reporter	TP53	hereditary breast ovarian cancer syndrome	pathwayBased	321427	201	0.577008661057121	104
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	hereditary breast ovarian cancer syndrome	targetBased	54509	528	0.577008661057121	104
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	hereditary breast ovarian cancer syndrome	targetBased	54513	338	0.577008661057121	104
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	hereditary breast ovarian cancer syndrome	targetBased	125394	1890	0.577008661057121	104
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	hereditary breast ovarian cancer syndrome	targetBased	124022	1156	0.577008661057121	104
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	hereditary breast ovarian cancer syndrome	targetBased	322361	619	0.592435458669846	338
HCS assay for microtubule stabilizers	TUBB	pancreatic ductal adenocarcinoma	targetBased	195821	1625	0.543444771738886	68
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	myeloid leukemia	targetBased	359207	1432	0.715357066963333	2551
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	myeloid leukemia	targetBased	359244	2975	0.537254273842718	378
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	urinary bladder carcinoma	pathwayBased	376029	3978	0.663159024758506	62
qHTS assay for re-activators of p53 using a Luc reporter	TP53	urinary bladder carcinoma	pathwayBased	321427	201	0.715943490770942	1968
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	urinary bladder carcinoma	targetBased	54509	528	0.715943490770942	1968
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	urinary bladder carcinoma	targetBased	54513	338	0.715943490770942	1968
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	urinary bladder carcinoma	targetBased	125394	1890	0.715943490770942	1968
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	urinary bladder carcinoma	targetBased	124022	1156	0.715943490770942	1968
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	urinary bladder carcinoma	targetBased	322361	619	0.732157805652173	127
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	urinary bladder carcinoma	targetBased	193542	587	0.579693725876986	67
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	urinary bladder carcinoma	targetBased	194628	267	0.733331528757895	307
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	cancer	pathwayBased	376029	3978	0.889745401546417	20752
qHTS assay for re-activators of p53 using a Luc reporter	TP53	gallbladder cancer	pathwayBased	321427	201	0.5934612972816	77
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	gallbladder cancer	targetBased	54509	528	0.5934612972816	77
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	gallbladder cancer	targetBased	54513	338	0.5934612972816	77
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	gallbladder cancer	targetBased	125394	1890	0.5934612972816	77
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	gallbladder cancer	targetBased	124022	1156	0.5934612972816	77
Small Molecule Inhibitors of FGF22-Mediated Excitatory Synaptogenesis & Epilepsy Measured in Biochemical System Using RT-PCR - 7012-01_Inhibitor_SinglePoint_HTS_Activity	FGF22_inhibitors	cancer	targetBased	339650	5128	0.668938724864321	38
HTS for Tumor Hsp90 Inhibitors	HSP90 known inhibitor displacement	cancer	targetBased	63696	220	0.742522421363885	1330
Luminescence-based primary biochemical high throughput screening assay to identify inhibitors of the Heat Shock Protein 90 (HSP90)	HSP90AA1	cancer	targetBased	290726	2649	0.742522421363885	1330
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	cancer	targetBased	290355	265	0.612317425813566	73
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	colorectal cancer	pathwayBased	376029	3978	0.557138707214907	161
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	colorectal cancer	targetBased	359207	1432	0.616184208009642	82
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	cancer	targetBased	86095	1442	0.669757231333485	16724
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	cancer	targetBased	86095	1151	0.669757231333485	16724
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	cancer	targetBased	217959	2390	0.753722443923473	6564
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	cancer	targetBased	359207	1432	0.54326808569933	4699
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay	MAPK1	cancer	pathwayBased	70898	707	0.762437302926748	1581
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF	MAPK1	cancer	pathwayBased	131324	544	0.762437302926748	1581
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	cancer	targetBased	143816	859	0.728959503512403	614
qHTS Assay for Inhibitors of the CtBP/E1A Interaction	RBBP8	cancer	targetBased	335214	1652	0.653448141858887	163
qHTS for Inhibitors of TGF-b	TGFB1	cancer	pathwayBased	403345	4970	0.624251650790347	22455
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	colorectal cancer	targetBased	335239	991	0.517736107458662	9
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	colorectal cancer	targetBased	335239	695	0.517736107458662	9
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2_inhibitors	cancer	targetBased	57013	201	0.596441371396059	6110
qHTS Assay for Inhibitors of GCN5L2	KAT2A	cancer	targetBased	381571	792	0.679538557997074	140
Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex	PRKAR1A	cancer	targetBased	343468	285	0.677194877664189	166
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	cancer	targetBased	335239	991	0.705430116689074	449
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	cancer	targetBased	335239	695	0.705430116689074	449
qHTS assay for re-activators of p53 using a Luc reporter	TP53	colorectal cancer	pathwayBased	321427	201	0.824947173642699	1104
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	colorectal cancer	targetBased	54509	528	0.824947173642699	1104
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	colorectal cancer	targetBased	54513	338	0.824947173642699	1104
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	colorectal cancer	targetBased	125394	1890	0.824947173642699	1104
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	colorectal cancer	targetBased	124022	1156	0.824947173642699	1104
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	colorectal cancer	targetBased	322361	619	0.692377036344037	58
qHTS for Inhibitors of WRN Helicase	WRN	colorectal cancer	targetBased	364011	1678	0.507044449991793	11
HTS of Smad transcription factor inhibitors	SMAD3	colorectal cancer	targetBased	88033	251	0.591112604809797	25
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	colorectal cancer	targetBased	193542	587	0.682157692026859	193
Primary cell-based high throughput screening assay to measure STAT1 activation	STAT1 activation	cancer	pathwayBased	195980	5134	0.63814917384931	1823
Primary cell-based high throughput screening assay to measure STAT1 inhibition	STAT1	cancer	targetBased	195980	695	0.63814917384931	1823
qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM)	BLM_inhibitors	colorectal cancer	targetBased	347933	673	0.546180532377725	11
Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-gamma1).	PLCG1	cancer	targetBased	369953	3123	0.730312854683163	391
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	cancer	targetBased	359244	2975	0.728900443873601	3505
E3 Ligase HTS_1536	MDM2	cancer	targetBased	207811	220	0.572600603058696	5421
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac activated mutant	RAC1	cancer	targetBased	194629	219	0.577800245386886	206
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac wildtype	RAC1	cancer	targetBased	194628	521	0.577800245386886	206
Assay for Inhibitors of the beta-Arrestin-Adaptor Protein 2 Interaction That Mediate GPCR Degradation and Recycling	ARRB1_inhibitors	cancer	targetBased	338373	1061	0.69134586295159	158
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	Beckwith-Wiedemann syndrome	targetBased	305610	3878	0.610955952556363	174
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	Beckwith-Wiedemann syndrome	targetBased	305610	1082	0.610955952556363	174
qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide	Menin-MLL_inhibitors	multiple endocrine neoplasia type 1	targetBased	263421	615	0.955651497731723	4107
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	cancer	targetBased	86095	1114	0.607180358680722	1859
qHTS assay for re-activators of p53 using a Luc reporter	TP53	cancer	pathwayBased	321427	201	0.798462583624305	70480
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	cancer	targetBased	54509	528	0.798462583624305	70480
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	cancer	targetBased	54513	338	0.798462583624305	70480
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	cancer	targetBased	125394	1890	0.798462583624305	70480
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	cancer	targetBased	124022	1156	0.798462583624305	70480
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	cancer	targetBased	356517	1139	0.835992187469882	39501
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	cancer	targetBased	108286	1415	0.504017619130342	164
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	cancer	targetBased	359518	300	0.573653134243772	251
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	cancer	targetBased	335652	1779	0.573653134243772	251
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	cancer	targetBased	362274	1056	0.573653134243772	251
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	cancer	targetBased	336308	6862	0.573653134243772	251
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	cancer	targetBased	357537	806	0.573653134243772	251
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	cancer	targetBased	339887	1178	0.573653134243772	251
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	cancer	targetBased	322361	619	0.887742187650375	6406
Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.	BCL2L11_inhibitors	cancer	targetBased	325630	216	0.663322592053893	1001
HTS for BAP1 Enzyme inhibitors	BAP1_inhibitors	cancer	targetBased	71016	346	0.503838946288405	618
Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity	SMARCA4	esophageal cancer	targetBased	344733	7043	0.572918676553839	22
qHTS assay for re-activators of p53 using a Luc reporter	TP53	esophageal cancer	pathwayBased	321427	201	0.755733859976898	808
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	esophageal cancer	targetBased	54509	528	0.755733859976898	808
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	esophageal cancer	targetBased	54513	338	0.755733859976898	808
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	esophageal cancer	targetBased	125394	1890	0.755733859976898	808
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	esophageal cancer	targetBased	124022	1156	0.755733859976898	808
HCS assay for microtubule stabilizers	TUBB	esophageal cancer	targetBased	195821	1625	0.500369861549014	257
HTS of Smad transcription factor inhibitors	SMAD3	cancer	targetBased	88033	251	0.660773367238811	1157
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	cancer	targetBased	193542	587	0.729137686870591	4215
Primary cell-based high throughput screening assay to measure STAT3 activation	STAT3	cancer	pathwayBased	194666	1772	0.74895001267032	16259
Primary cell-based high throughput screening assay to measure STAT3 inhibition	STAT3	cancer	pathwayBased	194666	1722	0.74895001267032	16259
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	cancer	targetBased	339297	1446	0.521979003500729	323
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	cancer	targetBased	305610	3794	0.565605347025387	92
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	cancer	targetBased	339674	2841	0.56085201851383	53
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	cancer	targetBased	369953	760	0.695643178729002	130
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	cancer	targetBased	369953	498	0.695643178729002	130
Primary cell-based high-throughput screening assay to measure PERK inhibition	PERK_inhibitors	cancer	targetBased	217959	370	0.590706185930871	934
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	cancer	targetBased	194628	267	0.80515992647272	2411
HCS assay for microtubule stabilizers	TUBB	cancer	targetBased	195821	1625	0.66498110324478	4383
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	cancer	targetBased	316642	617	0.532685560698662	562
qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM)	BLM_inhibitors	cancer	targetBased	347933	673	0.70224437864131	665
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	cancer	pathwayBased	43989	342	0.501389938673998	20821
Dicer-mediated maturation of pre-microRNA	Dicer_inhibitors	goiter, multinodular 1, with or without Sertoli-Leydig cell tumors	targetBased	46715	2829	0.786101469175161	83
qHTS for Inhibitors of WRN Helicase	WRN	cancer	targetBased	364011	1678	0.713286180158294	565
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	breast cancer	pathwayBased	376029	3978	0.864119807394064	12264
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	breast cancer	targetBased	86095	1442	0.837897580570166	12265
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	breast cancer	targetBased	86095	1151	0.837897580570166	12265
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	breast cancer	targetBased	359207	1432	0.528340798710332	266
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	breast cancer	targetBased	335239	991	0.570632065715757	30
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	breast cancer	targetBased	335239	695	0.570632065715757	30
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	nevus, epidermal	targetBased	194628	267	0.765990926960034	47
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	linear nevus sebaceous syndrome	targetBased	194628	267	0.803862671575397	54
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	breast cancer	targetBased	86095	1114	0.690361420729005	871
qHTS assay for re-activators of p53 using a Luc reporter	TP53	breast cancer	pathwayBased	321427	201	0.793469661384171	4260
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	breast cancer	targetBased	54509	528	0.793469661384171	4260
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	breast cancer	targetBased	54513	338	0.793469661384171	4260
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	breast cancer	targetBased	125394	1890	0.793469661384171	4260
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	breast cancer	targetBased	124022	1156	0.793469661384171	4260
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	breast cancer	targetBased	356517	1139	0.612252208871859	2961
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	breast cancer	targetBased	322361	619	0.771774175297562	2611
qHTS assay for re-activators of p53 using a Luc reporter	TP53	adrenocortical carcinoma, hereditary	pathwayBased	321427	201	0.732277820907482	320
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	adrenocortical carcinoma, hereditary	targetBased	54509	528	0.732277820907482	320
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	adrenocortical carcinoma, hereditary	targetBased	54513	338	0.732277820907482	320
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	adrenocortical carcinoma, hereditary	targetBased	125394	1890	0.732277820907482	320
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	adrenocortical carcinoma, hereditary	targetBased	124022	1156	0.732277820907482	320
HCS assay for microtubule stabilizers	TUBB	breast cancer	targetBased	195821	1625	0.686684940581599	2847
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	ovarian cancer	pathwayBased	376029	3978	0.902464031304924	7268
Dicer-mediated maturation of pre-microRNA	Dicer_inhibitors	ovarian cancer	targetBased	46715	2829	0.501322871917439	40
uHTS identification of small molecule modulators of NR3A	GRIN3A	breast cancer	targetBased	339772	8480	0.520819643474188	6
qHTS assay for re-activators of p53 using a Luc reporter	TP53	ovarian cancer	pathwayBased	321427	201	0.783276111831291	1196
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	ovarian cancer	targetBased	54509	528	0.783276111831291	1196
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	ovarian cancer	targetBased	54513	338	0.783276111831291	1196
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	ovarian cancer	targetBased	125394	1890	0.783276111831291	1196
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	ovarian cancer	targetBased	124022	1156	0.783276111831291	1196
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	ovarian cancer	targetBased	356517	1139	0.509499952146859	147
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	ovarian cancer	targetBased	322361	619	0.533934187309719	334
qHTS for Inhibitors of WRN Helicase	WRN	ovarian cancer	targetBased	364011	1678	0.549119798919808	36
Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	ovarian cancer	targetBased	329153	670	0.510139151355727	22
Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	ovarian cancer	targetBased	329153	670	0.510139151355727	22
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor	TSHR	ovarian cancer	targetBased	72026	352	0.510139151355727	22
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293	TSHR	ovarian cancer	targetBased	72026	1794	0.510139151355727	22
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	ovarian cancer	targetBased	193542	587	0.732513052579539	72
HCS assay for microtubule stabilizers	TUBB	ovarian cancer	targetBased	195821	1625	0.596469532383122	482
qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM)	BLM_inhibitors	ovarian cancer	targetBased	347933	673	0.520714652864584	43
qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM)	BLM_inhibitors	Bloom syndrome	targetBased	347933	673	0.937191544742725	5934
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	lung cancer	targetBased	335239	991	0.528383497749928	27
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	lung cancer	targetBased	335239	695	0.528383497749928	27
HCS assay for microtubule stabilizers	TUBB	lung cancer	targetBased	195821	1625	0.536966635791938	1331
qHTS for Inhibitors of Polymerase Kappa	POLK	prostate cancer	targetBased	395295	2034	0.600041049899183	53
qHTS assay for re-activators of p53 using a Luc reporter	TP53	prostate cancer	pathwayBased	321427	201	0.56074255087829	294
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	prostate cancer	targetBased	54509	528	0.56074255087829	294
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	prostate cancer	targetBased	54513	338	0.56074255087829	294
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	prostate cancer	targetBased	125394	1890	0.56074255087829	294
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	prostate cancer	targetBased	124022	1156	0.56074255087829	294
HCS assay for microtubule stabilizers	TUBB	prostate cancer	targetBased	195821	1625	0.650787355768156	872
Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex	PRKAR1A	familial atrial myxoma	targetBased	343468	285	0.669881265397799	39
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	hereditary thrombocytopenia and hematologic cancer predisposition syndrome	targetBased	215667	993	0.796724875126738	3169
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	hereditary thrombocytopenia and hematologic cancer predisposition syndrome	targetBased	218234	1620	0.796724875126738	3169
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	endometrial cancer	targetBased	86095	1442	0.551806592823691	253
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	endometrial cancer	targetBased	86095	1151	0.551806592823691	253
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	gastrointestinal stromal tumor	targetBased	359207	1432	0.666559986194665	320
qHTS assay for re-activators of p53 using a Luc reporter	TP53	endometrial cancer	pathwayBased	321427	201	0.719716014087321	348
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	endometrial cancer	targetBased	54509	528	0.719716014087321	348
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	endometrial cancer	targetBased	54513	338	0.719716014087321	348
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	endometrial cancer	targetBased	125394	1890	0.719716014087321	348
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	endometrial cancer	targetBased	124022	1156	0.719716014087321	348
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	endometrial cancer	targetBased	356517	1139	0.582805616721057	119
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	endometrial cancer	targetBased	322361	619	0.539805519610671	45
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	endometrial cancer	targetBased	193542	587	0.674111345989311	123
HTS for BAP1 Enzyme inhibitors	BAP1_inhibitors	BAP1-related tumor predisposition syndrome	targetBased	71016	346	0.895619429083368	3174
qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide	Menin-MLL_inhibitors	familial isolated hyperparathyroidism	targetBased	263421	615	0.55473784931811	85
High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen	NFKB1	common variable immunodeficiency	pathwayBased	193265	3100	0.834779616196932	290
uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay	NFKB1	common variable immunodeficiency	pathwayBased	359244	3094	0.834779616196932	290
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	familial pancreatic carcinoma	pathwayBased	376029	3978	0.502665805472282	18
qHTS assay for re-activators of p53 using a Luc reporter	TP53	familial pancreatic carcinoma	pathwayBased	321427	201	0.690429985228812	80
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	familial pancreatic carcinoma	targetBased	54509	528	0.690429985228812	80
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	familial pancreatic carcinoma	targetBased	54513	338	0.690429985228812	80
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	familial pancreatic carcinoma	targetBased	125394	1890	0.690429985228812	80
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	familial pancreatic carcinoma	targetBased	124022	1156	0.690429985228812	80
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	familial pancreatic carcinoma	targetBased	322361	619	0.557390044105614	26
qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1)	RECQL	hereditary neoplastic syndrome	targetBased	234915	1245	0.555826756510399	103
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	hereditary neoplastic syndrome	pathwayBased	376029	3978	0.738658920587182	17319
Dicer-mediated maturation of pre-microRNA	Dicer_inhibitors	hereditary neoplastic syndrome	targetBased	46715	2829	0.694777963492794	4859
Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex	PRKAR1A	hereditary neoplastic syndrome	targetBased	343468	285	0.59216265599301	644
Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity	SMARCA4	hereditary neoplastic syndrome	targetBased	344733	7043	0.706743784625669	6520
qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide	Menin-MLL_inhibitors	hereditary neoplastic syndrome	targetBased	263421	615	0.733240953654702	3378
qHTS assay for re-activators of p53 using a Luc reporter	TP53	hereditary neoplastic syndrome	pathwayBased	321427	201	0.745817539826029	5525
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	hereditary neoplastic syndrome	targetBased	54509	528	0.745817539826029	5525
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	hereditary neoplastic syndrome	targetBased	54513	338	0.745817539826029	5525
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	hereditary neoplastic syndrome	targetBased	125394	1890	0.745817539826029	5525
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	hereditary neoplastic syndrome	targetBased	124022	1156	0.745817539826029	5525
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	hereditary neoplastic syndrome	targetBased	322361	619	0.657217545791875	14264
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	hereditary neoplastic syndrome	targetBased	215667	993	0.545499608537802	1596
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	hereditary neoplastic syndrome	targetBased	218234	1620	0.545499608537802	1596
HTS for BAP1 Enzyme inhibitors	BAP1_inhibitors	hereditary neoplastic syndrome	targetBased	71016	346	0.720820341742928	3689
MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity	MITF	hereditary neoplastic syndrome	targetBased	331360	2760	0.570307346678232	260
AlphaScreen-based biochemical high throughput primary assay to identify inhibitors of microphthalmia-associated transcription factor (MITF)	MITF inhibitors	hereditary neoplastic syndrome	targetBased	642362	5830	0.570307346678232	260
qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM)	BLM_inhibitors	hereditary neoplastic syndrome	targetBased	347933	673	0.635838473701773	3305
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	Cowden disease	targetBased	356517	1139	0.535270059891584	275
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	hereditary breast carcinoma	pathwayBased	376029	3978	0.89275999234869	1170
Identification of Molecular Probes that Activate MRP-1	ABCC1_activators	hereditary breast carcinoma	targetBased	138717	842	0.521402826406466	18
qHTS assay for re-activators of p53 using a Luc reporter	TP53	hereditary breast carcinoma	pathwayBased	321427	201	0.746971472284402	108
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	hereditary breast carcinoma	targetBased	54509	528	0.746971472284402	108
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	hereditary breast carcinoma	targetBased	54513	338	0.746971472284402	108
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	hereditary breast carcinoma	targetBased	125394	1890	0.746971472284402	108
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	hereditary breast carcinoma	targetBased	124022	1156	0.746971472284402	108
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	hereditary breast carcinoma	targetBased	322361	619	0.79096845653944	4641
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	systemic mastocytosis	targetBased	359207	1432	0.516815843873698	12
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	meningioma	targetBased	356517	1139	0.516735037687015	12
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	phakomatosis pigmentokeratotica	targetBased	194628	267	0.508862452109535	6
Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3	HDAC3	T-cell non-Hodgkin lymphoma	targetBased	318291	483	0.563737443355213	18
qHTS assay for re-activators of p53 using a Luc reporter	TP53	choroid plexus carcinoma	pathwayBased	321427	201	0.592216076816502	68
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	choroid plexus carcinoma	targetBased	54509	528	0.592216076816502	68
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	choroid plexus carcinoma	targetBased	54513	338	0.592216076816502	68
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	choroid plexus carcinoma	targetBased	125394	1890	0.592216076816502	68
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	choroid plexus carcinoma	targetBased	124022	1156	0.592216076816502	68
Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity	SMARCA4	familial rhabdoid tumor	targetBased	344733	7043	0.874158218818574	6884
qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide	Menin-MLL_inhibitors	multiple endocrine neoplasia	targetBased	263421	615	0.767584741814198	1559
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	epidermal nevus syndrome	targetBased	194628	267	0.519410926301161	6
Dicer-mediated maturation of pre-microRNA	Dicer_inhibitors	global developmental delay - lung cysts - overgrowth - Wilms tumor syndrome	targetBased	46715	2829	0.773844445367218	506
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	carcinoma of liver and intrahepatic biliary tract	pathwayBased	376029	3978	0.502012600305333	78
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	carcinoma of liver and intrahepatic biliary tract	targetBased	334825	423	0.51063753622872	34
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	carcinoma of liver and intrahepatic biliary tract	targetBased	337446	1356	0.51063753622872	34
qHTS assay for re-activators of p53 using a Luc reporter	TP53	Li-Fraumeni syndrome	pathwayBased	321427	201	0.961183981598178	6950
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	Li-Fraumeni syndrome	targetBased	54509	528	0.961183981598178	6950
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	Li-Fraumeni syndrome	targetBased	54513	338	0.961183981598178	6950
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	Li-Fraumeni syndrome	targetBased	125394	1890	0.961183981598178	6950
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	Li-Fraumeni syndrome	targetBased	124022	1156	0.961183981598178	6950
Nrf2 qHTS screen for inhibitors	nrf2Inhibitors	carcinoma of liver and intrahepatic biliary tract	targetBased	360873	7438	0.529180688127008	146
qHTS of Nrf2 Activators	Nrf2 activators	carcinoma of liver and intrahepatic biliary tract	pathwayBased	403871	1243	0.529180688127008	146
qHTS assay for re-activators of p53 using a Luc reporter	TP53	carcinoma of liver and intrahepatic biliary tract	pathwayBased	321427	201	0.508700009478479	2659
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	carcinoma of liver and intrahepatic biliary tract	targetBased	54509	528	0.508700009478479	2659
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	carcinoma of liver and intrahepatic biliary tract	targetBased	54513	338	0.508700009478479	2659
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	carcinoma of liver and intrahepatic biliary tract	targetBased	125394	1890	0.508700009478479	2659
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	carcinoma of liver and intrahepatic biliary tract	targetBased	124022	1156	0.508700009478479	2659
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	carcinoma of liver and intrahepatic biliary tract	targetBased	322361	619	0.510579263830081	59
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	carcinoma of liver and intrahepatic biliary tract	targetBased	193542	587	0.56918270779896	653
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	follicular lymphoma	targetBased	359207	1432	0.589403135644704	24
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2_inhibitors	follicular lymphoma	targetBased	57013	201	0.560395370472155	227
HCS assay for microtubule stabilizers	TUBB	follicular lymphoma	targetBased	195821	1625	0.625483391400951	95
HCS assay for microtubule stabilizers	TUBB	adult T-cell leukemia/lymphoma	targetBased	195821	1625	0.55928325716652	8
qHTS assay for re-activators of p53 using a Luc reporter	TP53	low grade glioma	pathwayBased	321427	201	0.647024924444588	163
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	low grade glioma	targetBased	54509	528	0.647024924444588	163
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	low grade glioma	targetBased	54513	338	0.647024924444588	163
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	low grade glioma	targetBased	125394	1890	0.647024924444588	163
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	low grade glioma	targetBased	124022	1156	0.647024924444588	163
Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex	PRKAR1A	malignant endocrine neoplasm	targetBased	343468	285	0.63675759302262	43
qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide	Menin-MLL_inhibitors	malignant endocrine neoplasm	targetBased	263421	615	0.607624213372651	402
qHTS assay for re-activators of p53 using a Luc reporter	TP53	malignant endocrine neoplasm	pathwayBased	321427	201	0.63110038811149	4107
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	malignant endocrine neoplasm	targetBased	54509	528	0.63110038811149	4107
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	malignant endocrine neoplasm	targetBased	54513	338	0.63110038811149	4107
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	malignant endocrine neoplasm	targetBased	125394	1890	0.63110038811149	4107
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	malignant endocrine neoplasm	targetBased	124022	1156	0.63110038811149	4107
HCS assay for microtubule stabilizers	TUBB	lung neoplasm	targetBased	195821	1625	0.517562541508203	954
qHTS assay for re-activators of p53 using a Luc reporter	TP53	lip and oral cavity carcinoma	pathwayBased	321427	201	0.661600167112357	634
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	lip and oral cavity carcinoma	targetBased	54509	528	0.661600167112357	634
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	lip and oral cavity carcinoma	targetBased	54513	338	0.661600167112357	634
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	lip and oral cavity carcinoma	targetBased	125394	1890	0.661600167112357	634
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	lip and oral cavity carcinoma	targetBased	124022	1156	0.661600167112357	634
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	lip and oral cavity carcinoma	targetBased	194628	267	0.626887753244379	60
HTS for BAP1 Enzyme inhibitors	BAP1_inhibitors	melanocytic neoplasm	targetBased	71016	346	0.504583292790778	93
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	melanocytic neoplasm	targetBased	194628	267	0.57720847430598	187
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	familial prostate carcinoma	targetBased	322361	619	0.516875235389713	6
qHTS assay for re-activators of p53 using a Luc reporter	TP53	uterine cervix neoplasm	pathwayBased	321427	201	0.544959939222638	510
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	uterine cervix neoplasm	targetBased	54509	528	0.544959939222638	510
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	uterine cervix neoplasm	targetBased	54513	338	0.544959939222638	510
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	uterine cervix neoplasm	targetBased	125394	1890	0.544959939222638	510
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	uterine cervix neoplasm	targetBased	124022	1156	0.544959939222638	510
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	endometrium neoplasm	targetBased	193542	587	0.516566251982747	98
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	hereditary thrombocytopenia and hematological cancer predisposition syndrome associated with RUNX1	targetBased	215667	993	0.882670337369514	2060
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	hereditary thrombocytopenia and hematological cancer predisposition syndrome associated with RUNX1	targetBased	218234	1620	0.882670337369514	2060
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	large congenital melanocytic nevus	targetBased	194628	267	0.654965888031878	32
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	oral cavity carcinoma	targetBased	194628	267	0.51917183544761	40
qHTS for Inhibitors of Polymerase Kappa	POLK	Familial prostate cancer	targetBased	395295	2034	0.596214509781827	32
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	Hereditary breast cancer	pathwayBased	376029	3978	0.836992105233513	7631
qHTS assay for re-activators of p53 using a Luc reporter	TP53	malignant glioma	pathwayBased	321427	201	0.667419094877046	1888
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	malignant glioma	targetBased	54509	528	0.667419094877046	1888
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	malignant glioma	targetBased	54513	338	0.667419094877046	1888
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	malignant glioma	targetBased	125394	1890	0.667419094877046	1888
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	malignant glioma	targetBased	124022	1156	0.667419094877046	1888
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	Hereditary breast and ovarian cancer syndrome	pathwayBased	376029	3978	0.905263436460505	20171
qHTS assay for re-activators of p53 using a Luc reporter	TP53	Hereditary breast and ovarian cancer syndrome	pathwayBased	321427	201	0.617356887059384	249
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	Hereditary breast and ovarian cancer syndrome	targetBased	54509	528	0.617356887059384	249
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	Hereditary breast and ovarian cancer syndrome	targetBased	54513	338	0.617356887059384	249
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	Hereditary breast and ovarian cancer syndrome	targetBased	125394	1890	0.617356887059384	249
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	Hereditary breast and ovarian cancer syndrome	targetBased	124022	1156	0.617356887059384	249
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	Hereditary breast and ovarian cancer syndrome	targetBased	322361	619	0.628101650010634	752
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	Linear nevus sebaceus syndrome	targetBased	194628	267	0.782821035564354	47
Primary Cell-based High Throughput Screening assay for activators of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	Genetic 46,XY disorder of sex development	targetBased	64908	1225	0.540259668835204	12
Primary Cell-based High Throughput Screening assay for inhibitors of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	Genetic 46,XY disorder of sex development	targetBased	64908	359	0.540259668835204	12
Dicer-mediated maturation of pre-microRNA	Dicer_inhibitors	Global developmental delay-lung cysts-overgrowth-Wilms tumor syndrome	targetBased	46715	2829	0.509035254749426	9

Some of these associations have also gone through clinical trials, as those in the graph below.

Find clinical trials details in table. Use scroll bar or search funtion to select specific drugs, molecular targets or diseases.

BioAssay Name	program	gene	protName	diseaseName	molname	assayMode	clinicalPhase	clinicalStatus	studyStartDate	url	score	variantEffect	directionOnTrait	studyStopReason
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	prostate cancer	DIETHYLSTILBESTROL	targetBased	3	Completed	01/12/2002	https://clinicaltrials.gov/study/NCT00316927	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	prostate cancer	DIETHYLSTILBESTROL	targetBased	3	Completed	01/12/2002	https://clinicaltrials.gov/study/NCT00316927	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	neoplasm	DIETHYLSTILBESTROL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=L02AA01	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	neoplasm	DIETHYLSTILBESTROL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=L02AA01	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	cirrhosis of liver	PROPRANOLOL	targetBased	3	Unknown status		https://clinicaltrials.gov/study/NCT01134692	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	alcoholic liver cirrhosis	PROPRANOLOL	targetBased	4	Terminated	01/04/1995	https://clinicaltrials.gov/study/NCT00188045	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hemangioma	PROPRANOLOL	targetBased	3	Terminated	01/11/2012	https://clinicaltrials.gov/study/NCT01743885	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hemangioma	PROPRANOLOL	targetBased	4	Recruiting	23/06/2022	https://clinicaltrials.gov/study/NCT05479123	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hemangioma	PROPRANOLOL	targetBased	3	Unknown status	24/03/2017	https://clinicaltrials.gov/study/NCT03237637	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hemangioma	PROPRANOLOL	targetBased	3	Completed	01/10/2013	https://clinicaltrials.gov/study/NCT02342275	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hemangioma	PROPRANOLOL	targetBased	4	Recruiting	01/10/2019	https://clinicaltrials.gov/study/NCT04288700	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hemangioma	PROPRANOLOL	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/hemangiol	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hemangioma	PROPRANOLOL	targetBased	3	Completed	01/09/2015	https://clinicaltrials.gov/study/NCT02505971	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hemangioma	PROPRANOLOL	targetBased	4	Completed	01/06/2013	https://clinicaltrials.gov/study/NCT01908972	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	colorectal neoplasm	PROPRANOLOL	targetBased	3	Unknown status	01/01/2010	https://clinicaltrials.gov/study/NCT00888797	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	cancer	THALIDOMIDE	targetBased	4	Not yet recruiting	10/12/2018	https://clinicaltrials.gov/study/NCT03777930	1	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	kidney cancer	THALIDOMIDE	targetBased	3	Completed	01/10/2000	https://clinicaltrials.gov/study/NCT00005966	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	THALIDOMIDE	targetBased	3	Completed	01/02/2003	https://clinicaltrials.gov/study/NCT00057564	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	THALIDOMIDE	targetBased	3	Completed	01/01/2005	https://clinicaltrials.gov/study/NCT00097981	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	THALIDOMIDE	targetBased	3	Active, not recruiting	03/11/2004	https://clinicaltrials.gov/study/NCT00098475	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	THALIDOMIDE	targetBased	3	Active, not recruiting	29/02/2008	https://clinicaltrials.gov/study/NCT00602641	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	THALIDOMIDE	targetBased	3	Completed	01/10/2013	https://clinicaltrials.gov/study/NCT01971658	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	THALIDOMIDE	targetBased	3	Completed	01/05/2000	https://clinicaltrials.gov/study/NCT00367185	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	THALIDOMIDE	targetBased	3	Completed	01/04/2002	https://clinicaltrials.gov/study/NCT00033332	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	THALIDOMIDE	targetBased	3	Terminated	01/06/2003	https://clinicaltrials.gov/study/NCT00215943	0.7	LoF	protect	Poor accrual, changes in management of newly diagnosed myeloma patients, new drugs/more effective regimens.
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	THALIDOMIDE	targetBased	4	Unknown status	01/06/2010	https://clinicaltrials.gov/study/NCT01249690	1	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	THALIDOMIDE	targetBased	3	Completed	01/02/2006	https://clinicaltrials.gov/study/NCT00452569	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	THALIDOMIDE	targetBased	3	Completed	01/05/2003	https://clinicaltrials.gov/study/NCT01070862	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	THALIDOMIDE	targetBased	3	Terminated	01/07/2006	https://clinicaltrials.gov/study/NCT00574080	0.7	LoF	protect	low accrual
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	THALIDOMIDE	targetBased	3	Recruiting	20/03/2017	https://clinicaltrials.gov/study/NCT03562169	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	THALIDOMIDE	targetBased	4	Completed	01/01/2007	https://clinicaltrials.gov/study/NCT00652041	1	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	THALIDOMIDE	targetBased	3	Unknown status	01/05/2006	https://clinicaltrials.gov/study/NCT01134484	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	THALIDOMIDE	targetBased	3	Completed	13/01/2012	https://clinicaltrials.gov/study/NCT01539083	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	THALIDOMIDE	targetBased	3	Completed	01/03/2005	https://clinicaltrials.gov/study/NCT00443235	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	THALIDOMIDE	targetBased	3	Completed	01/01/2002	https://clinicaltrials.gov/study/NCT00232934	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	THALIDOMIDE	targetBased	3	Completed	15/10/2002	https://clinicaltrials.gov/study/NCT00049673	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	THALIDOMIDE	targetBased	3	Unknown status	01/03/2008	https://clinicaltrials.gov/study/NCT00910897	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	THALIDOMIDE	targetBased	3	Completed	15/06/2009	https://clinicaltrials.gov/study/NCT03402295	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	THALIDOMIDE	targetBased	3	Completed	01/06/2007	https://clinicaltrials.gov/study/NCT00507416	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	THALIDOMIDE	targetBased	3	Completed	01/10/2003	https://clinicaltrials.gov/study/NCT01296503	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	THALIDOMIDE	targetBased	3	Terminated	01/08/2006	https://clinicaltrials.gov/study/NCT00573391	0.7	LoF	protect	low accrual
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	THALIDOMIDE	targetBased	3	Completed	01/10/2007	https://clinicaltrials.gov/study/NCT00602511	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	THALIDOMIDE	targetBased	3	Terminated	01/04/2000	https://clinicaltrials.gov/study/NCT00005834	0.7	LoF	protect	poor accrual
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	THALIDOMIDE	targetBased	3	Completed	01/07/2003	https://clinicaltrials.gov/study/NCT00432458	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	THALIDOMIDE	targetBased	3	Completed	01/09/1998	https://clinicaltrials.gov/study/NCT00083876	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	THALIDOMIDE	targetBased	3	Completed	01/05/2006	https://clinicaltrials.gov/study/NCT01063179	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	THALIDOMIDE	targetBased	3	Completed	01/02/2005	https://clinicaltrials.gov/study/NCT00111748	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	THALIDOMIDE	targetBased	3	Active, not recruiting	01/09/2015	https://clinicaltrials.gov/study/NCT02541383	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	THALIDOMIDE	targetBased	3	Terminated	01/07/2005	https://clinicaltrials.gov/study/NCT00256776	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	THALIDOMIDE	targetBased	3	Unknown status	01/04/2012	https://clinicaltrials.gov/study/NCT02248428	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	THALIDOMIDE	targetBased	3	Active, not recruiting	01/07/2008	https://clinicaltrials.gov/study/NCT00734877	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	THALIDOMIDE	targetBased	3	Completed	01/05/1999	https://clinicaltrials.gov/study/NCT00038233	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	THALIDOMIDE	targetBased	3	Terminated	01/04/2002	https://clinicaltrials.gov/study/NCT00644306	0.35	LoF	protect	survival advantage demonstrated
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	THALIDOMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2eda833b-1357-4ed4-a093-194524fcb061	1	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	THALIDOMIDE	targetBased	3	Completed	01/06/2001	https://clinicaltrials.gov/study/NCT00083915	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	THALIDOMIDE	targetBased	3	Completed	01/03/2006	https://clinicaltrials.gov/study/NCT00934154	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	THALIDOMIDE	targetBased	3	Completed	01/04/2000	https://clinicaltrials.gov/study/NCT00222053	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	THALIDOMIDE	targetBased	3	Unknown status	01/05/2010	https://clinicaltrials.gov/study/NCT01554852	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	THALIDOMIDE	targetBased	3	Completed	21/08/2008	https://clinicaltrials.gov/study/NCT00689936	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	THALIDOMIDE	targetBased	3	Active, not recruiting	01/11/2006	https://clinicaltrials.gov/study/NCT00572169	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	THALIDOMIDE	targetBased	3	Completed	01/08/1998	https://clinicaltrials.gov/study/NCT00083551	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	THALIDOMIDE	targetBased	4	Unknown status	01/07/2010	https://clinicaltrials.gov/study/NCT02559154	1	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	THALIDOMIDE	targetBased	3	Completed	01/03/2006	https://clinicaltrials.gov/study/NCT00461747	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	THALIDOMIDE	targetBased	3	Unknown status	01/01/2007	https://clinicaltrials.gov/study/NCT01532856	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	THALIDOMIDE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/thalidomide-lipomed	1	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	THALIDOMIDE	targetBased	3	Unknown status	01/03/2001	https://clinicaltrials.gov/study/NCT00028886	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	THALIDOMIDE	targetBased	3	Completed	01/12/2003	https://clinicaltrials.gov/study/NCT00075829	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	THALIDOMIDE	targetBased	3	Completed	01/01/2002	https://clinicaltrials.gov/study/NCT00218855	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	THALIDOMIDE	targetBased	3	Completed	01/06/2003	https://clinicaltrials.gov/study/NCT00633542	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	gastric cancer	THALIDOMIDE	targetBased	4	Unknown status	01/08/2014	https://clinicaltrials.gov/study/NCT02401971	1	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	neoplasm	THALIDOMIDE	targetBased	3	Completed	01/03/2002	https://clinicaltrials.gov/study/NCT00033254	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	neoplasm	THALIDOMIDE	targetBased	3	Completed	01/07/2014	https://clinicaltrials.gov/study/NCT02203253	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	fallopian tube cancer	THALIDOMIDE	targetBased	3	Completed	01/02/2003	https://clinicaltrials.gov/study/NCT00041080	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	prostate cancer	THALIDOMIDE	targetBased	3	Completed	01/03/2000	https://clinicaltrials.gov/study/NCT00004635	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	extranodal nasal NK/T cell lymphoma	THALIDOMIDE	targetBased	3	Unknown status	25/04/2013	https://clinicaltrials.gov/study/NCT02085655	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	colorectal neoplasm	THALIDOMIDE	targetBased	3	Unknown status	01/01/2016	https://clinicaltrials.gov/study/NCT02748772	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	hepatocellular carcinoma	THALIDOMIDE	targetBased	3	Terminated	01/02/2003	https://clinicaltrials.gov/study/NCT00225290	0.7	LoF	protect	slowly recruitment rate
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	hepatocellular carcinoma	THALIDOMIDE	targetBased	3	Unknown status	01/06/2009	https://clinicaltrials.gov/study/NCT00921531	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	peritoneum cancer	THALIDOMIDE	targetBased	3	Completed	01/02/2003	https://clinicaltrials.gov/study/NCT00041080	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	plasma cell neoplasm	THALIDOMIDE	targetBased	3	Completed	01/04/2002	https://clinicaltrials.gov/study/NCT00033332	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	malignant epithelial tumor of ovary	THALIDOMIDE	targetBased	3	Completed	01/02/2003	https://clinicaltrials.gov/study/NCT00041080	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	myelodysplastic syndrome	THALIDOMIDE	targetBased	3	Completed	01/08/2001	https://clinicaltrials.gov/study/NCT00050843	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	Mantle cell lymphoma	THALIDOMIDE	targetBased	4	Unknown status	01/01/2016	https://clinicaltrials.gov/study/NCT02858804	1	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	diffuse large B-cell lymphoma	THALIDOMIDE	targetBased	3	Unknown status	26/07/2017	https://clinicaltrials.gov/study/NCT03016000	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	lung cancer	THALIDOMIDE	targetBased	3	Terminated	01/01/2000	https://clinicaltrials.gov/study/NCT00004859	0.7	LoF	protect	Trial was stopped early for futility
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	lung cancer	THALIDOMIDE	targetBased	3	Completed	01/04/2003	https://clinicaltrials.gov/study/NCT00061919	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	Waldenstrom macroglobulinemia	THALIDOMIDE	targetBased	4	Unknown status	01/05/2016	https://clinicaltrials.gov/study/NCT02844309	1	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	idiopathic pulmonary fibrosis	THALIDOMIDE	targetBased	3	Completed	01/12/2007	https://clinicaltrials.gov/study/NCT00600028	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	non-small cell lung carcinoma	THALIDOMIDE	targetBased	4	Unknown status	01/03/2016	https://clinicaltrials.gov/study/NCT02778893	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	neoplasm	MORPHINE	targetBased	4	Unknown status	01/11/2016	https://clinicaltrials.gov/study/NCT02929147	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	neoplasm	MORPHINE	targetBased	4	Unknown status	01/11/2016	https://clinicaltrials.gov/study/NCT02929147	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	neoplasm	MORPHINE	targetBased	3	Completed	01/08/2010	https://clinicaltrials.gov/study/NCT01309386	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	neoplasm	MORPHINE	targetBased	3	Completed	01/08/2010	https://clinicaltrials.gov/study/NCT01309386	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	neoplasm	MORPHINE	targetBased	3	Unknown status	01/04/2013	https://clinicaltrials.gov/study/NCT01825993	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	neoplasm	MORPHINE	targetBased	3	Unknown status	01/04/2013	https://clinicaltrials.gov/study/NCT01825993	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	acute myeloid leukemia	MORPHINE	targetBased	3	Completed	01/02/2018	https://clinicaltrials.gov/study/NCT03825887	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	acute myeloid leukemia	MORPHINE	targetBased	3	Completed	01/02/2018	https://clinicaltrials.gov/study/NCT03825887	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	prostate cancer	MORPHINE	targetBased	3	Completed	01/09/2010	https://clinicaltrials.gov/study/NCT01367418	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	prostate cancer	MORPHINE	targetBased	3	Completed	01/09/2010	https://clinicaltrials.gov/study/NCT01367418	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	breast cancer	MORPHINE	targetBased	4	Unknown status	02/02/2017	https://clinicaltrials.gov/study/NCT03051503	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	breast cancer	MORPHINE	targetBased	4	Unknown status	02/02/2017	https://clinicaltrials.gov/study/NCT03051503	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	idiopathic pulmonary fibrosis	MORPHINE	targetBased	3	Not yet recruiting	21/09/2020	https://clinicaltrials.gov/study/NCT04497831	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	idiopathic pulmonary fibrosis	MORPHINE	targetBased	3	Not yet recruiting	21/09/2020	https://clinicaltrials.gov/study/NCT04497831	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	idiopathic pulmonary fibrosis	MORPHINE	targetBased	3	Completed	17/12/2020	https://clinicaltrials.gov/study/NCT04429516	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	idiopathic pulmonary fibrosis	MORPHINE	targetBased	3	Completed	17/12/2020	https://clinicaltrials.gov/study/NCT04429516	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer	MORPHINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e360d6b6-d9ef-487d-bf14-fcbbee8beb29	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer	MORPHINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e360d6b6-d9ef-487d-bf14-fcbbee8beb29	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer	MORPHINE	targetBased	3	Terminated	01/02/2008	https://clinicaltrials.gov/study/NCT00634010	0.7	GoF	protect	Slow Accrual
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer	MORPHINE	targetBased	3	Terminated	01/02/2008	https://clinicaltrials.gov/study/NCT00634010	0.7	GoF	protect	Slow Accrual
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer	MORPHINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cadc3fdb-8edc-44cd-aaea-89e68aaf9a04	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer	MORPHINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cadc3fdb-8edc-44cd-aaea-89e68aaf9a04	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer	MORPHINE	targetBased	3	Unknown status	01/06/2014	https://clinicaltrials.gov/study/NCT02173756	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer	MORPHINE	targetBased	3	Unknown status	01/06/2014	https://clinicaltrials.gov/study/NCT02173756	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer	MORPHINE	targetBased	3	Completed	01/04/2002	https://clinicaltrials.gov/study/NCT00201539	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer	MORPHINE	targetBased	3	Completed	01/04/2002	https://clinicaltrials.gov/study/NCT00201539	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer	MORPHINE	targetBased	3	Completed	01/01/2011	https://clinicaltrials.gov/study/NCT01675622	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer	MORPHINE	targetBased	3	Completed	01/01/2011	https://clinicaltrials.gov/study/NCT01675622	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer	MORPHINE	targetBased	4	Completed	01/04/2011	https://clinicaltrials.gov/study/NCT01809106	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer	MORPHINE	targetBased	4	Completed	01/04/2011	https://clinicaltrials.gov/study/NCT01809106	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer	MORPHINE	targetBased	4	Completed	20/03/2020	https://clinicaltrials.gov/study/NCT04316871	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer	MORPHINE	targetBased	4	Completed	20/03/2020	https://clinicaltrials.gov/study/NCT04316871	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer	MORPHINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c6e2b3fd-691b-4f1f-94a4-ede191e0de78	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer	MORPHINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c6e2b3fd-691b-4f1f-94a4-ede191e0de78	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	colorectal cancer	MORPHINE	targetBased	4	Completed	07/01/2019	https://clinicaltrials.gov/study/NCT03700411	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	colorectal cancer	MORPHINE	targetBased	4	Completed	07/01/2019	https://clinicaltrials.gov/study/NCT03700411	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	colorectal cancer	MORPHINE	targetBased	4	Completed	07/01/2019	https://clinicaltrials.gov/study/NCT03700541	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	colorectal cancer	MORPHINE	targetBased	4	Completed	07/01/2019	https://clinicaltrials.gov/study/NCT03700541	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	leukemia	MORPHINE	targetBased	3	Completed	01/02/2018	https://clinicaltrials.gov/study/NCT03825887	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	leukemia	MORPHINE	targetBased	3	Completed	01/02/2018	https://clinicaltrials.gov/study/NCT03825887	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	brain neoplasm	MORPHINE	targetBased	4	Completed	01/08/2016	https://clinicaltrials.gov/study/NCT04313374	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	brain neoplasm	MORPHINE	targetBased	4	Completed	01/08/2016	https://clinicaltrials.gov/study/NCT04313374	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	gastric cancer	MORPHINE	targetBased	4	Completed	01/08/2010	https://clinicaltrials.gov/study/NCT01234272	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	gastric cancer	MORPHINE	targetBased	4	Completed	01/08/2010	https://clinicaltrials.gov/study/NCT01234272	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	cancer	NALOXONE	targetBased	4	Completed	01/07/2012	https://clinicaltrials.gov/study/NCT01719757	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	cancer	NALOXONE	targetBased	4	Completed	01/05/2011	https://clinicaltrials.gov/study/NCT01313780	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Sezary's disease	NALOXONE	targetBased	3	Terminated	01/01/2017	https://clinicaltrials.gov/study/NCT02811783	0.7	LoF	protect	Sponsor decision
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	mycosis fungoides	NALOXONE	targetBased	3	Terminated	01/01/2017	https://clinicaltrials.gov/study/NCT02811783	0.7	LoF	protect	Sponsor decision
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer	NALOXONE	targetBased	4	Completed	01/05/2011	https://clinicaltrials.gov/study/NCT01313780	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer	NALOXONE	targetBased	4	Completed	01/05/2011	https://clinicaltrials.gov/study/NCT01313780	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer	NALOXONE	targetBased	4	Completed	01/07/2012	https://clinicaltrials.gov/study/NCT01719757	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer	NALOXONE	targetBased	4	Completed	01/07/2012	https://clinicaltrials.gov/study/NCT01719757	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Sezary's disease	NALOXONE	targetBased	3	Terminated	01/01/2017	https://clinicaltrials.gov/study/NCT02811783	0.7	LoF	protect	Sponsor decision
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Sezary's disease	NALOXONE	targetBased	3	Terminated	01/01/2017	https://clinicaltrials.gov/study/NCT02811783	0.7	LoF	protect	Sponsor decision
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	mycosis fungoides	NALOXONE	targetBased	3	Terminated	01/01/2017	https://clinicaltrials.gov/study/NCT02811783	0.7	LoF	protect	Sponsor decision
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	mycosis fungoides	NALOXONE	targetBased	3	Terminated	01/01/2017	https://clinicaltrials.gov/study/NCT02811783	0.7	LoF	protect	Sponsor decision
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	breast cancer	RALOXIFENE	targetBased	3	Completed	01/05/1999	https://clinicaltrials.gov/study/NCT00003906	0.7		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	breast cancer	RALOXIFENE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fcaaa6dc-74e8-4fb8-800c-5574bf0f8de9	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	endometrial cancer	TAMOXIFEN	targetBased	3	Terminated	01/05/2001	https://clinicaltrials.gov/study/NCT00016341	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	endometrial cancer	TAMOXIFEN	targetBased	3	Terminated	01/05/2001	https://clinicaltrials.gov/study/NCT00016341	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	endometrial cancer	TAMOXIFEN	targetBased	3	Completed	01/03/1997	https://clinicaltrials.gov/study/NCT00002920	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	endometrial cancer	TAMOXIFEN	targetBased	3	Completed	01/03/1997	https://clinicaltrials.gov/study/NCT00002920	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast adenocarcinoma	TAMOXIFEN	targetBased	3	Completed	19/05/2000	https://clinicaltrials.gov/study/NCT00005970	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast adenocarcinoma	TAMOXIFEN	targetBased	3	Completed	19/05/2000	https://clinicaltrials.gov/study/NCT00005970	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast adenocarcinoma	TAMOXIFEN	targetBased	3	Active, not recruiting	07/04/2006	https://clinicaltrials.gov/study/NCT00310180	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast adenocarcinoma	TAMOXIFEN	targetBased	3	Active, not recruiting	07/04/2006	https://clinicaltrials.gov/study/NCT00310180	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	liver cancer	TAMOXIFEN	targetBased	3	Completed	01/04/1997	https://clinicaltrials.gov/study/NCT00003424	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	liver cancer	TAMOXIFEN	targetBased	3	Completed	01/04/1997	https://clinicaltrials.gov/study/NCT00003424	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast neoplasm	TAMOXIFEN	targetBased	3	Completed	01/02/1998	https://clinicaltrials.gov/study/NCT00038467	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast neoplasm	TAMOXIFEN	targetBased	3	Completed	01/02/1998	https://clinicaltrials.gov/study/NCT00038467	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast neoplasm	TAMOXIFEN	targetBased	3	Completed	01/01/2002	https://clinicaltrials.gov/study/NCT00279448	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast neoplasm	TAMOXIFEN	targetBased	3	Completed	01/01/2002	https://clinicaltrials.gov/study/NCT00279448	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast neoplasm	TAMOXIFEN	targetBased	3	Recruiting	04/10/2022	https://clinicaltrials.gov/study/NCT05514054	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast neoplasm	TAMOXIFEN	targetBased	3	Recruiting	04/10/2022	https://clinicaltrials.gov/study/NCT05514054	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast neoplasm	TAMOXIFEN	targetBased	3	Completed	01/08/2001	https://clinicaltrials.gov/study/NCT00036270	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast neoplasm	TAMOXIFEN	targetBased	3	Completed	01/08/2001	https://clinicaltrials.gov/study/NCT00036270	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast neoplasm	TAMOXIFEN	targetBased	3	Active, not recruiting	12/11/2008	https://clinicaltrials.gov/study/NCT01357772	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast neoplasm	TAMOXIFEN	targetBased	3	Active, not recruiting	12/11/2008	https://clinicaltrials.gov/study/NCT01357772	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast neoplasm	TAMOXIFEN	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00034125	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast neoplasm	TAMOXIFEN	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00034125	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast neoplasm	TAMOXIFEN	targetBased	3	Active, not recruiting	09/02/2018	https://clinicaltrials.gov/study/NCT03423199	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast neoplasm	TAMOXIFEN	targetBased	3	Active, not recruiting	09/02/2018	https://clinicaltrials.gov/study/NCT03423199	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	malignant epithelial tumor of ovary	TAMOXIFEN	targetBased	3	Completed	01/02/2003	https://clinicaltrials.gov/study/NCT00041080	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	malignant epithelial tumor of ovary	TAMOXIFEN	targetBased	3	Completed	01/02/2003	https://clinicaltrials.gov/study/NCT00041080	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	ovarian cancer	TAMOXIFEN	targetBased	3	Completed	01/03/2002	https://clinicaltrials.gov/study/NCT02728622	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	ovarian cancer	TAMOXIFEN	targetBased	3	Completed	01/03/2002	https://clinicaltrials.gov/study/NCT02728622	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	HER2 Positive Breast Carcinoma	TAMOXIFEN	targetBased	3	Completed	19/05/2000	https://clinicaltrials.gov/study/NCT00005970	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	HER2 Positive Breast Carcinoma	TAMOXIFEN	targetBased	3	Completed	19/05/2000	https://clinicaltrials.gov/study/NCT00005970	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	prostate cancer	TAMOXIFEN	targetBased	3	Completed	01/12/2003	https://clinicaltrials.gov/study/NCT00233610	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	prostate cancer	TAMOXIFEN	targetBased	3	Completed	01/12/2003	https://clinicaltrials.gov/study/NCT00233610	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	hyperplasia	TAMOXIFEN	targetBased	3	Active, not recruiting	12/11/2008	https://clinicaltrials.gov/study/NCT01357772	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	hyperplasia	TAMOXIFEN	targetBased	3	Active, not recruiting	12/11/2008	https://clinicaltrials.gov/study/NCT01357772	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	neoplasm	TAMOXIFEN	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=L02BA01	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	neoplasm	TAMOXIFEN	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=L02BA01	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	inflammatory breast carcinoma	TAMOXIFEN	targetBased	3	Terminated	01/05/2001	https://clinicaltrials.gov/study/NCT00016276	0.7		protect	Administratively complete.
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	inflammatory breast carcinoma	TAMOXIFEN	targetBased	3	Terminated	01/05/2001	https://clinicaltrials.gov/study/NCT00016276	0.7		protect	Administratively complete.
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Fallopian Tube Carcinoma	TAMOXIFEN	targetBased	3	Completed	01/03/2002	https://clinicaltrials.gov/study/NCT02728622	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Fallopian Tube Carcinoma	TAMOXIFEN	targetBased	3	Completed	01/03/2002	https://clinicaltrials.gov/study/NCT02728622	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	male breast carcinoma	TAMOXIFEN	targetBased	3	Completed	01/08/2012	https://clinicaltrials.gov/study/NCT01638247	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	male breast carcinoma	TAMOXIFEN	targetBased	3	Completed	01/08/2012	https://clinicaltrials.gov/study/NCT01638247	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast ductal carcinoma in situ	TAMOXIFEN	targetBased	3	Active, not recruiting	15/01/2011	https://clinicaltrials.gov/study/NCT01272037	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast ductal carcinoma in situ	TAMOXIFEN	targetBased	3	Active, not recruiting	15/01/2011	https://clinicaltrials.gov/study/NCT01272037	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast ductal carcinoma in situ	TAMOXIFEN	targetBased	3	Active, not recruiting	12/11/2008	https://clinicaltrials.gov/study/NCT01357772	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast ductal carcinoma in situ	TAMOXIFEN	targetBased	3	Active, not recruiting	12/11/2008	https://clinicaltrials.gov/study/NCT01357772	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	peritoneum cancer	TAMOXIFEN	targetBased	3	Completed	01/03/2002	https://clinicaltrials.gov/study/NCT02728622	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	peritoneum cancer	TAMOXIFEN	targetBased	3	Completed	01/03/2002	https://clinicaltrials.gov/study/NCT02728622	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	peritoneum cancer	TAMOXIFEN	targetBased	3	Completed	01/02/2003	https://clinicaltrials.gov/study/NCT00041080	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	peritoneum cancer	TAMOXIFEN	targetBased	3	Completed	01/02/2003	https://clinicaltrials.gov/study/NCT00041080	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast carcinoma in situ	TAMOXIFEN	targetBased	4	Withdrawn	01/09/2018	https://clinicaltrials.gov/study/NCT03238703	1		protect	Administrative closure based on sponsor recommendation, prior to subject enrollment
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast carcinoma in situ	TAMOXIFEN	targetBased	4	Withdrawn	01/09/2018	https://clinicaltrials.gov/study/NCT03238703	1		protect	Administrative closure based on sponsor recommendation, prior to subject enrollment
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	fallopian tube cancer	TAMOXIFEN	targetBased	3	Completed	01/02/2003	https://clinicaltrials.gov/study/NCT00041080	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	fallopian tube cancer	TAMOXIFEN	targetBased	3	Completed	01/02/2003	https://clinicaltrials.gov/study/NCT00041080	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Completed	01/11/1998	https://clinicaltrials.gov/study/NCT00241449	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Completed	01/11/1998	https://clinicaltrials.gov/study/NCT00241449	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	4	Completed	01/09/2007	https://clinicaltrials.gov/study/NCT00537771	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	4	Completed	01/09/2007	https://clinicaltrials.gov/study/NCT00537771	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Terminated	01/07/1996	https://clinicaltrials.gov/study/NCT00002772	0.7		protect	poor accrual
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Terminated	01/07/1996	https://clinicaltrials.gov/study/NCT00002772	0.7		protect	poor accrual
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Recruiting	30/03/2016	https://clinicaltrials.gov/study/NCT02914158	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Recruiting	30/03/2016	https://clinicaltrials.gov/study/NCT02914158	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Terminated	17/02/2022	https://clinicaltrials.gov/study/NCT05128773	0.7		protect	Sponsor decision to prematurely stop the study, not linked to any safety concern
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Terminated	17/02/2022	https://clinicaltrials.gov/study/NCT05128773	0.7		protect	Sponsor decision to prematurely stop the study, not linked to any safety concern
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Completed	01/12/1995	https://clinicaltrials.gov/study/NCT00002720	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Completed	01/12/1995	https://clinicaltrials.gov/study/NCT00002720	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Terminated	01/11/2002	https://clinicaltrials.gov/study/NCT00053911	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Terminated	01/11/2002	https://clinicaltrials.gov/study/NCT00053911	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Completed	01/06/1993	https://clinicaltrials.gov/study/NCT00002581	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Completed	01/06/1993	https://clinicaltrials.gov/study/NCT00002581	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bd72fd53-ae0c-4080-9b7f-2d294b14cc86	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bd72fd53-ae0c-4080-9b7f-2d294b14cc86	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Completed	01/02/2007	https://clinicaltrials.gov/study/NCT00433589	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Completed	01/02/2007	https://clinicaltrials.gov/study/NCT00433589	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Completed	01/06/1999	https://clinicaltrials.gov/study/NCT00295646	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Completed	01/06/1999	https://clinicaltrials.gov/study/NCT00295646	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Completed	01/06/1998	https://clinicaltrials.gov/study/NCT00784862	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Completed	01/06/1998	https://clinicaltrials.gov/study/NCT00784862	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Terminated	01/08/2003	https://clinicaltrials.gov/study/NCT00066807	0.7		protect	Poor accrual, patients were followed until completion of 5 yrs treatment
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Terminated	01/08/2003	https://clinicaltrials.gov/study/NCT00066807	0.7		protect	Poor accrual, patients were followed until completion of 5 yrs treatment
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	4	Completed	01/12/2014	https://clinicaltrials.gov/study/NCT02344940	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	4	Completed	01/12/2014	https://clinicaltrials.gov/study/NCT02344940	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Completed	01/12/1990	https://clinicaltrials.gov/study/NCT00309478	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Completed	01/12/1990	https://clinicaltrials.gov/study/NCT00309478	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Unknown status	01/01/1992	https://clinicaltrials.gov/study/NCT00006030	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Unknown status	01/01/1992	https://clinicaltrials.gov/study/NCT00006030	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Completed	01/07/1998	https://clinicaltrials.gov/study/NCT00003972	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Completed	01/07/1998	https://clinicaltrials.gov/study/NCT00003972	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Recruiting	01/11/2017	https://clinicaltrials.gov/study/NCT03351062	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Recruiting	01/11/2017	https://clinicaltrials.gov/study/NCT03351062	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Completed	01/07/1996	https://clinicaltrials.gov/study/NCT00849030	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Completed	01/07/1996	https://clinicaltrials.gov/study/NCT00849030	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Completed	01/06/1993	https://clinicaltrials.gov/study/NCT00002582	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Completed	01/06/1993	https://clinicaltrials.gov/study/NCT00002582	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	4	Completed	27/06/2012	https://clinicaltrials.gov/study/NCT01612871	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	4	Completed	27/06/2012	https://clinicaltrials.gov/study/NCT01612871	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Completed	01/03/1998	https://clinicaltrials.gov/study/NCT00004205	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Completed	01/03/1998	https://clinicaltrials.gov/study/NCT00004205	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	4	Recruiting	01/01/2009	https://clinicaltrials.gov/study/NCT00900744	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	4	Recruiting	01/01/2009	https://clinicaltrials.gov/study/NCT00900744	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Unknown status	01/03/2007	https://clinicaltrials.gov/study/NCT00541086	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Unknown status	01/03/2007	https://clinicaltrials.gov/study/NCT00541086	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Completed	01/08/2001	https://clinicaltrials.gov/study/NCT00047099	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Completed	01/08/2001	https://clinicaltrials.gov/study/NCT00047099	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Recruiting	03/08/2022	https://clinicaltrials.gov/study/NCT05306340	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Recruiting	03/08/2022	https://clinicaltrials.gov/study/NCT05306340	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Recruiting	30/03/2023	https://clinicaltrials.gov/study/NCT05780567	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Recruiting	30/03/2023	https://clinicaltrials.gov/study/NCT05780567	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Unknown status	01/05/1991	https://clinicaltrials.gov/study/NCT00003678	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Unknown status	01/05/1991	https://clinicaltrials.gov/study/NCT00003678	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Completed	01/11/1995	https://clinicaltrials.gov/study/NCT00002755	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Completed	01/11/1995	https://clinicaltrials.gov/study/NCT00002755	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Completed	01/10/1995	https://clinicaltrials.gov/study/NCT00002646	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Completed	01/10/1995	https://clinicaltrials.gov/study/NCT00002646	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Active, not recruiting	01/03/2002	https://clinicaltrials.gov/study/NCT01579734	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Active, not recruiting	01/03/2002	https://clinicaltrials.gov/study/NCT01579734	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Completed	01/10/1996	https://clinicaltrials.gov/study/NCT00003013	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Completed	01/10/1996	https://clinicaltrials.gov/study/NCT00003013	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Not yet recruiting	02/05/2024	https://clinicaltrials.gov/study/NCT06223698	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Not yet recruiting	02/05/2024	https://clinicaltrials.gov/study/NCT06223698	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Completed	25/04/1997	https://clinicaltrials.gov/study/NCT00003032	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Completed	25/04/1997	https://clinicaltrials.gov/study/NCT00003032	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Completed	24/09/1996	https://clinicaltrials.gov/study/NCT00002864	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Completed	24/09/1996	https://clinicaltrials.gov/study/NCT00002864	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00793377	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00793377	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Recruiting	01/03/2014	https://clinicaltrials.gov/study/NCT02097459	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Recruiting	01/03/2014	https://clinicaltrials.gov/study/NCT02097459	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Active, not recruiting	12/09/2013	https://clinicaltrials.gov/study/NCT01674140	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Active, not recruiting	12/09/2013	https://clinicaltrials.gov/study/NCT01674140	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Recruiting	01/06/2023	https://clinicaltrials.gov/study/NCT05891093	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Recruiting	01/06/2023	https://clinicaltrials.gov/study/NCT05891093	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Completed	01/01/1996	https://clinicaltrials.gov/study/NCT00291759	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Completed	01/01/1996	https://clinicaltrials.gov/study/NCT00291759	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Recruiting	15/12/2023	https://clinicaltrials.gov/study/NCT05512364	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Recruiting	15/12/2023	https://clinicaltrials.gov/study/NCT05512364	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Completed	01/04/2005	https://clinicaltrials.gov/study/NCT00171704	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Completed	01/04/2005	https://clinicaltrials.gov/study/NCT00171704	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Completed	01/12/2001	https://clinicaltrials.gov/study/NCT00032136	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Completed	01/12/2001	https://clinicaltrials.gov/study/NCT00032136	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Recruiting	01/05/2014	https://clinicaltrials.gov/study/NCT02062489	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Recruiting	01/05/2014	https://clinicaltrials.gov/study/NCT02062489	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Recruiting	31/03/2023	https://clinicaltrials.gov/study/NCT05774951	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Recruiting	31/03/2023	https://clinicaltrials.gov/study/NCT05774951	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Withdrawn		https://clinicaltrials.gov/study/NCT00053339	0.7		protect	The study was not activated.
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Withdrawn		https://clinicaltrials.gov/study/NCT00053339	0.7		protect	The study was not activated.
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Unknown status	01/01/2012	https://clinicaltrials.gov/study/NCT01758146	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Unknown status	01/01/2012	https://clinicaltrials.gov/study/NCT01758146	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	4	Completed	17/06/2010	https://clinicaltrials.gov/study/NCT01127295	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	4	Completed	17/06/2010	https://clinicaltrials.gov/study/NCT01127295	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Completed	01/12/1990	https://clinicaltrials.gov/study/NCT00309491	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Completed	01/12/1990	https://clinicaltrials.gov/study/NCT00309491	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Completed	01/01/2004	https://clinicaltrials.gov/study/NCT00201851	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Completed	01/01/2004	https://clinicaltrials.gov/study/NCT00201851	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Completed	01/12/2008	https://clinicaltrials.gov/study/NCT00949598	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Completed	01/12/2008	https://clinicaltrials.gov/study/NCT00949598	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Completed	01/05/1996	https://clinicaltrials.gov/study/NCT00002777	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Completed	01/05/1996	https://clinicaltrials.gov/study/NCT00002777	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Unknown status	01/11/1998	https://clinicaltrials.gov/study/NCT00003679	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Unknown status	01/11/1998	https://clinicaltrials.gov/study/NCT00003679	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Completed	20/11/2014	https://clinicaltrials.gov/study/NCT02278120	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Completed	20/11/2014	https://clinicaltrials.gov/study/NCT02278120	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Unknown status	01/09/1987	https://clinicaltrials.gov/study/NCT00002460	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Unknown status	01/09/1987	https://clinicaltrials.gov/study/NCT00002460	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Completed	01/06/1993	https://clinicaltrials.gov/study/NCT00002580	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Completed	01/06/1993	https://clinicaltrials.gov/study/NCT00002580	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Completed	01/12/1999	https://clinicaltrials.gov/study/NCT00003857	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Completed	01/12/1999	https://clinicaltrials.gov/study/NCT00003857	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Active, not recruiting	01/03/2004	https://clinicaltrials.gov/study/NCT00412022	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Active, not recruiting	01/03/2004	https://clinicaltrials.gov/study/NCT00412022	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Completed	01/08/2000	https://clinicaltrials.gov/study/NCT00232661	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Completed	01/08/2000	https://clinicaltrials.gov/study/NCT00232661	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Completed	01/07/1996	https://clinicaltrials.gov/study/NCT00152178	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Completed	01/07/1996	https://clinicaltrials.gov/study/NCT00152178	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Completed	01/12/1995	https://clinicaltrials.gov/study/NCT00002707	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Completed	01/12/1995	https://clinicaltrials.gov/study/NCT00002707	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Recruiting	05/10/2023	https://clinicaltrials.gov/study/NCT05952557	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Recruiting	05/10/2023	https://clinicaltrials.gov/study/NCT05952557	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Completed	01/02/2006	https://clinicaltrials.gov/study/NCT00293540	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Completed	01/02/2006	https://clinicaltrials.gov/study/NCT00293540	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Completed	13/08/1996	https://clinicaltrials.gov/study/NCT00590785	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Completed	13/08/1996	https://clinicaltrials.gov/study/NCT00590785	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	4	Completed	01/12/2011	https://clinicaltrials.gov/study/NCT01553903	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	4	Completed	01/12/2011	https://clinicaltrials.gov/study/NCT01553903	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Unknown status	01/11/1998	https://clinicaltrials.gov/study/NCT00003680	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Unknown status	01/11/1998	https://clinicaltrials.gov/study/NCT00003680	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=151ce76c-2d44-4c82-850d-ab213bea4d6b	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=151ce76c-2d44-4c82-850d-ab213bea4d6b	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	4	Recruiting	01/11/2022	https://clinicaltrials.gov/study/NCT05525481	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	4	Recruiting	01/11/2022	https://clinicaltrials.gov/study/NCT05525481	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Completed	01/11/2011	https://clinicaltrials.gov/study/NCT02995772	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Completed	01/11/2011	https://clinicaltrials.gov/study/NCT02995772	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	4	Recruiting	01/03/2018	https://clinicaltrials.gov/study/NCT03355157	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	4	Recruiting	01/03/2018	https://clinicaltrials.gov/study/NCT03355157	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Unknown status	01/12/2007	https://clinicaltrials.gov/study/NCT00629278	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Unknown status	01/12/2007	https://clinicaltrials.gov/study/NCT00629278	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Unknown status	01/08/1997	https://clinicaltrials.gov/study/NCT00010140	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Unknown status	01/08/1997	https://clinicaltrials.gov/study/NCT00010140	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Unknown status	01/06/2009	https://clinicaltrials.gov/study/NCT00963209	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Unknown status	01/06/2009	https://clinicaltrials.gov/study/NCT00963209	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Not yet recruiting	01/08/2021	https://clinicaltrials.gov/study/NCT05016349	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Not yet recruiting	01/08/2021	https://clinicaltrials.gov/study/NCT05016349	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Recruiting	01/07/2021	https://clinicaltrials.gov/study/NCT04906395	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Recruiting	01/07/2021	https://clinicaltrials.gov/study/NCT04906395	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Active, not recruiting	24/09/2008	https://clinicaltrials.gov/study/NCT00601900	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Active, not recruiting	24/09/2008	https://clinicaltrials.gov/study/NCT00601900	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Completed	01/06/1997	https://clinicaltrials.gov/study/NCT00814125	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Completed	01/06/1997	https://clinicaltrials.gov/study/NCT00814125	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Completed	01/05/1989	https://clinicaltrials.gov/study/NCT00929591	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Completed	01/05/1989	https://clinicaltrials.gov/study/NCT00929591	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Unknown status	01/02/1998	https://clinicaltrials.gov/study/NCT00003418	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Unknown status	01/02/1998	https://clinicaltrials.gov/study/NCT00003418	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Enrolling by invitation	28/12/2022	https://clinicaltrials.gov/study/NCT05645536	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Enrolling by invitation	28/12/2022	https://clinicaltrials.gov/study/NCT05645536	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Completed	20/07/1993	https://clinicaltrials.gov/study/NCT00002542	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Completed	20/07/1993	https://clinicaltrials.gov/study/NCT00002542	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Completed	01/05/1997	https://clinicaltrials.gov/study/NCT00002967	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Completed	01/05/1997	https://clinicaltrials.gov/study/NCT00002967	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Completed	01/01/2003	https://clinicaltrials.gov/study/NCT00053898	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Completed	01/01/2003	https://clinicaltrials.gov/study/NCT00053898	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Completed	16/11/1999	https://clinicaltrials.gov/study/NCT00004125	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Completed	16/11/1999	https://clinicaltrials.gov/study/NCT00004125	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Completed	01/05/1999	https://clinicaltrials.gov/study/NCT00003906	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Completed	01/05/1999	https://clinicaltrials.gov/study/NCT00003906	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Completed	01/05/1993	https://clinicaltrials.gov/study/NCT00002528	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Completed	01/05/1993	https://clinicaltrials.gov/study/NCT00002528	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Recruiting	08/02/2021	https://clinicaltrials.gov/study/NCT04134598	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Recruiting	08/02/2021	https://clinicaltrials.gov/study/NCT04134598	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Unknown status	01/05/2009	https://clinicaltrials.gov/study/NCT00912548	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Unknown status	01/05/2009	https://clinicaltrials.gov/study/NCT00912548	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Unknown status	01/10/1995	https://clinicaltrials.gov/study/NCT00003016	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Unknown status	01/10/1995	https://clinicaltrials.gov/study/NCT00003016	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Active, not recruiting	03/11/2003	https://clinicaltrials.gov/study/NCT00066703	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Active, not recruiting	03/11/2003	https://clinicaltrials.gov/study/NCT00066703	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Completed	01/06/1996	https://clinicaltrials.gov/study/NCT00002784	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Completed	01/06/1996	https://clinicaltrials.gov/study/NCT00002784	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Completed	01/03/1998	https://clinicaltrials.gov/study/NCT00286117	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Completed	01/03/1998	https://clinicaltrials.gov/study/NCT00286117	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Completed	01/09/2003	https://clinicaltrials.gov/study/NCT00072462	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Completed	01/09/2003	https://clinicaltrials.gov/study/NCT00072462	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Completed	16/03/2009	https://clinicaltrials.gov/study/NCT00893061	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Completed	16/03/2009	https://clinicaltrials.gov/study/NCT00893061	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Unknown status	01/06/2012	https://clinicaltrials.gov/study/NCT01622361	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Unknown status	01/06/2012	https://clinicaltrials.gov/study/NCT01622361	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Completed	01/05/1993	https://clinicaltrials.gov/study/NCT00002529	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Completed	01/05/1993	https://clinicaltrials.gov/study/NCT00002529	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Completed	01/10/2007	https://clinicaltrials.gov/study/NCT00605267	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Completed	01/10/2007	https://clinicaltrials.gov/study/NCT00605267	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Active, not recruiting	01/01/1994	https://clinicaltrials.gov/study/NCT00002644	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Active, not recruiting	01/01/1994	https://clinicaltrials.gov/study/NCT00002644	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Recruiting	23/12/2020	https://clinicaltrials.gov/study/NCT04584853	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Recruiting	23/12/2020	https://clinicaltrials.gov/study/NCT04584853	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Completed	01/03/1993	https://clinicaltrials.gov/study/NCT00002579	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN	targetBased	3	Completed	01/03/1993	https://clinicaltrials.gov/study/NCT00002579	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast carcinoma	TAMOXIFEN	targetBased	3	Active, not recruiting	17/12/2003	https://clinicaltrials.gov/study/NCT00066690	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast carcinoma	TAMOXIFEN	targetBased	3	Active, not recruiting	17/12/2003	https://clinicaltrials.gov/study/NCT00066690	0.7		protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	adenoma	BROMOCRIPTINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fc2a08dd-4fb6-4ac4-9082-f99552fae25c	1	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	adenoma	BROMOCRIPTINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fc2a08dd-4fb6-4ac4-9082-f99552fae25c	1	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	adenoma	BROMOCRIPTINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fc2a08dd-4fb6-4ac4-9082-f99552fae25c	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	adenoma	BROMOCRIPTINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fc2a08dd-4fb6-4ac4-9082-f99552fae25c	1	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	adenoma	BROMOCRIPTINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fc2a08dd-4fb6-4ac4-9082-f99552fae25c	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	adenoma	BROMOCRIPTINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fc2a08dd-4fb6-4ac4-9082-f99552fae25c	1	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	adenoma	BROMOCRIPTINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fc2a08dd-4fb6-4ac4-9082-f99552fae25c	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	adenoma	BROMOCRIPTINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fc2a08dd-4fb6-4ac4-9082-f99552fae25c	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	adenoma	BROMOCRIPTINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fc2a08dd-4fb6-4ac4-9082-f99552fae25c	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	neoplasm	METOCLOPRAMIDE	targetBased	3	Completed	01/06/2013	https://clinicaltrials.gov/study/NCT02135510	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	neoplasm	METOCLOPRAMIDE	targetBased	3	Completed	01/06/2013	https://clinicaltrials.gov/study/NCT02135510	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	neoplasm	METOCLOPRAMIDE	targetBased	3	Completed	01/06/2013	https://clinicaltrials.gov/study/NCT02135510	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	neoplasm	METOCLOPRAMIDE	targetBased	3	Completed	01/06/2013	https://clinicaltrials.gov/study/NCT02135510	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	neoplasm	METOCLOPRAMIDE	targetBased	3	Completed	01/06/2013	https://clinicaltrials.gov/study/NCT02135510	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	neoplasm	METOCLOPRAMIDE	targetBased	3	Completed	01/06/2013	https://clinicaltrials.gov/study/NCT02135510	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	prostate cancer	METOCLOPRAMIDE	targetBased	4	Completed	01/04/2015	https://clinicaltrials.gov/study/NCT02441894	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	prostate cancer	METOCLOPRAMIDE	targetBased	4	Completed	01/04/2015	https://clinicaltrials.gov/study/NCT02441894	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	prostate cancer	METOCLOPRAMIDE	targetBased	4	Completed	01/04/2015	https://clinicaltrials.gov/study/NCT02441894	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	prostate cancer	METOCLOPRAMIDE	targetBased	4	Completed	01/04/2015	https://clinicaltrials.gov/study/NCT02441894	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	prostate cancer	METOCLOPRAMIDE	targetBased	4	Completed	01/04/2015	https://clinicaltrials.gov/study/NCT02441894	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	prostate cancer	METOCLOPRAMIDE	targetBased	4	Completed	01/04/2015	https://clinicaltrials.gov/study/NCT02441894	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	cancer	METOCLOPRAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=94e5acdf-f19c-749a-e053-2995a90ae451	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	cancer	METOCLOPRAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=94e5acdf-f19c-749a-e053-2995a90ae451	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	cancer	METOCLOPRAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=94e5acdf-f19c-749a-e053-2995a90ae451	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	cancer	METOCLOPRAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=94e5acdf-f19c-749a-e053-2995a90ae451	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	cancer	METOCLOPRAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=94e5acdf-f19c-749a-e053-2995a90ae451	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	cancer	METOCLOPRAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=94e5acdf-f19c-749a-e053-2995a90ae451	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	squamous cell carcinoma	PACLITAXEL	targetBased	3	Terminated	01/04/2008	https://clinicaltrials.gov/study/NCT00596830	0.7	LoF	protect	See termination reason in detailed description.
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	squamous cell carcinoma	PACLITAXEL	targetBased	3	Completed	11/02/2014	https://clinicaltrials.gov/study/NCT02027428	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	squamous cell carcinoma	PACLITAXEL	targetBased	3	Unknown status	01/11/2012	https://clinicaltrials.gov/study/NCT01752205	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	squamous cell carcinoma	PACLITAXEL	targetBased	3	Active, not recruiting	23/06/2021	https://clinicaltrials.gov/study/NCT04848753	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	squamous cell carcinoma	PACLITAXEL	targetBased	3	Completed	01/07/2015	https://clinicaltrials.gov/study/NCT02459457	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	squamous cell carcinoma	PACLITAXEL	targetBased	3	Completed	01/05/2003	https://clinicaltrials.gov/study/NCT00064077	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	squamous cell carcinoma	PACLITAXEL	targetBased	3	Completed	01/06/2010	https://clinicaltrials.gov/study/NCT01166542	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	4	Not yet recruiting	12/03/2022	https://clinicaltrials.gov/study/NCT05291910	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Completed	01/09/2005	https://clinicaltrials.gov/study/NCT00236899	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Completed	02/08/2018	https://clinicaltrials.gov/study/NCT03498716	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Completed	05/12/2013	https://clinicaltrials.gov/study/NCT02019277	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Not yet recruiting	01/02/2024	https://clinicaltrials.gov/study/NCT06255392	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Completed	17/07/2014	https://clinicaltrials.gov/study/NCT02163694	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Completed	16/11/1999	https://clinicaltrials.gov/study/NCT00004125	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Terminated	01/07/1996	https://clinicaltrials.gov/study/NCT00002772	0.7	LoF	protect	poor accrual
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	4	Recruiting	28/03/2022	https://clinicaltrials.gov/study/NCT05183126	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Completed	31/01/2014	https://clinicaltrials.gov/study/NCT01966471	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Active, not recruiting	24/07/2020	https://clinicaltrials.gov/study/NCT04494425	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Recruiting	22/02/2019	https://clinicaltrials.gov/study/NCT03876886	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Completed	01/12/2008	https://clinicaltrials.gov/study/NCT00789581	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Not yet recruiting	01/05/2023	https://clinicaltrials.gov/study/NCT05753865	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	4	Completed	18/08/2015	https://clinicaltrials.gov/study/NCT02419742	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	4	Recruiting	01/03/2018	https://clinicaltrials.gov/study/NCT03355157	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Completed	01/07/2012	https://clinicaltrials.gov/study/NCT01644890	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Completed	01/08/2004	https://clinicaltrials.gov/study/NCT00431080	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Unknown status	01/05/2010	https://clinicaltrials.gov/study/NCT01134523	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Completed	01/06/2010	https://clinicaltrials.gov/study/NCT01314833	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Unknown status	01/07/2007	https://clinicaltrials.gov/study/NCT00486668	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Completed	02/12/2015	https://clinicaltrials.gov/study/NCT02594371	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Active, not recruiting	01/07/2014	https://clinicaltrials.gov/study/NCT02214381	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Recruiting	28/07/2023	https://clinicaltrials.gov/study/NCT05894239	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Completed	01/09/2003	https://clinicaltrials.gov/study/NCT00311636	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Recruiting	01/01/2021	https://clinicaltrials.gov/study/NCT05429684	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	4	Recruiting	11/03/2021	https://clinicaltrials.gov/study/NCT05033769	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Completed	18/07/2014	https://clinicaltrials.gov/study/NCT02194166	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Recruiting	04/07/2022	https://clinicaltrials.gov/study/NCT05296798	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Recruiting	20/12/2019	https://clinicaltrials.gov/study/NCT04335669	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Completed	01/10/2012	https://clinicaltrials.gov/study/NCT01764022	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Completed	01/12/2008	https://clinicaltrials.gov/study/NCT00876486	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Completed	04/12/2000	https://clinicaltrials.gov/study/NCT00014222	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Completed	07/10/2008	https://clinicaltrials.gov/study/NCT00667251	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Recruiting	08/05/2023	https://clinicaltrials.gov/study/NCT05840211	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Active, not recruiting	07/09/2018	https://clinicaltrials.gov/study/NCT03595592	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Completed	01/04/2001	https://clinicaltrials.gov/study/NCT00038402	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	4	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT01301729	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	4	Unknown status	01/05/2009	https://clinicaltrials.gov/study/NCT00912639	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Completed	23/06/2015	https://clinicaltrials.gov/study/NCT02425891	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Completed	01/09/2006	https://clinicaltrials.gov/study/NCT00448591	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Completed	01/09/2012	https://clinicaltrials.gov/study/NCT01690702	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Completed	13/02/2012	https://clinicaltrials.gov/study/NCT01526369	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Recruiting	01/09/2017	https://clinicaltrials.gov/study/NCT03949634	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Unknown status	01/01/2005	https://clinicaltrials.gov/study/NCT00070278	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Completed	01/10/2004	https://clinicaltrials.gov/study/NCT00093795	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Completed	01/05/2001	https://clinicaltrials.gov/study/NCT00016406	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Completed	28/06/2018	https://clinicaltrials.gov/study/NCT03556358	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Active, not recruiting	08/11/2011	https://clinicaltrials.gov/study/NCT01358877	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Completed	01/07/2000	https://clinicaltrials.gov/study/NCT00006459	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Recruiting	01/08/2018	https://clinicaltrials.gov/study/NCT04193059	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=24d10449-2936-4cd3-b7db-a7683db721e4	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Completed	01/05/2002	https://clinicaltrials.gov/study/NCT00041119	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Recruiting	19/07/2021	https://clinicaltrials.gov/study/NCT04137653	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Completed	29/04/2013	https://clinicaltrials.gov/study/NCT01901146	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Unknown status	01/08/2001	https://clinicaltrials.gov/study/NCT00039546	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Completed	01/05/2007	https://clinicaltrials.gov/study/NCT00561119	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Active, not recruiting	01/11/2003	https://clinicaltrials.gov/study/NCT00070564	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Completed	01/07/2007	https://clinicaltrials.gov/study/NCT00513292	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Completed	27/07/2016	https://clinicaltrials.gov/study/NCT02819518	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	4	Recruiting	19/07/2021	https://clinicaltrials.gov/study/NCT04136782	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Recruiting	23/11/2023	https://clinicaltrials.gov/study/NCT06103864	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Completed	01/08/1994	https://clinicaltrials.gov/study/NCT00002662	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Withdrawn	01/09/2016	https://clinicaltrials.gov/study/NCT02929576	0.7	LoF	protect	Further understanding about the role of androgen signaling in TNBC was required
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Completed	01/01/2011	https://clinicaltrials.gov/study/NCT01216111	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Completed	01/08/2002	https://clinicaltrials.gov/study/NCT00544232	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Active, not recruiting	01/04/2010	https://clinicaltrials.gov/study/NCT03168880	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	4	Unknown status	01/05/2014	https://clinicaltrials.gov/study/NCT02142790	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Completed	21/02/2014	https://clinicaltrials.gov/study/NCT01964391	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	4	Withdrawn	01/10/2010	https://clinicaltrials.gov/study/NCT01156961	1	LoF	protect	Absence of patient's recruitment in the study due to administrative reasons
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Recruiting	18/01/2024	https://clinicaltrials.gov/study/NCT06018337	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Completed	01/12/1996	https://clinicaltrials.gov/study/NCT00002953	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Completed	01/11/1996	https://clinicaltrials.gov/study/NCT02450058	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Completed	01/10/1996	https://clinicaltrials.gov/study/NCT00003013	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	4	Recruiting	02/01/2024	https://clinicaltrials.gov/study/NCT06217185	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Unknown status	01/04/1998	https://clinicaltrials.gov/study/NCT00289263	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Completed	01/07/2012	https://clinicaltrials.gov/study/NCT02472964	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Recruiting	29/09/2020	https://clinicaltrials.gov/study/NCT04400695	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Completed	01/04/2008	https://clinicaltrials.gov/study/NCT00600340	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Unknown status	01/08/2015	https://clinicaltrials.gov/study/NCT02514681	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Recruiting	18/09/2020	https://clinicaltrials.gov/study/NCT04547907	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Completed	01/12/2002	https://clinicaltrials.gov/study/NCT01433614	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Recruiting	12/01/2021	https://clinicaltrials.gov/study/NCT04540692	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Unknown status	01/05/2011	https://clinicaltrials.gov/study/NCT01378533	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Recruiting	28/03/2022	https://clinicaltrials.gov/study/NCT05207709	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Terminated	01/07/2009	https://clinicaltrials.gov/study/NCT01200212	0.35	LoF	protect	A planed interim analysis shows no benefits, but higher adverse event rates for the experimental arm.
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Completed	20/11/2019	https://clinicaltrials.gov/study/NCT04109066	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	4	Recruiting	21/08/2019	https://clinicaltrials.gov/study/NCT04182568	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Completed	01/09/2003	https://clinicaltrials.gov/study/NCT00336791	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Recruiting	28/08/2017	https://clinicaltrials.gov/study/NCT03264547	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Terminated	01/06/2006	https://clinicaltrials.gov/study/NCT02054338	0.7	LoF	protect	Study was stopped before progressive disease or death of alive subjects.
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Active, not recruiting	01/12/2013	https://clinicaltrials.gov/study/NCT01996267	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Active, not recruiting	27/12/2018	https://clinicaltrials.gov/study/NCT03734029	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Completed	19/07/2010	https://clinicaltrials.gov/study/NCT01131195	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Completed	01/09/1997	https://clinicaltrials.gov/study/NCT00003088	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Not yet recruiting	06/05/2023	https://clinicaltrials.gov/study/NCT05841381	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Completed	14/06/2018	https://clinicaltrials.gov/study/NCT03493854	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Not yet recruiting	15/12/2022	https://clinicaltrials.gov/study/NCT05388500	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Unknown status	01/06/2002	https://clinicaltrials.gov/study/NCT02393833	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Completed	11/01/2019	https://clinicaltrials.gov/study/NCT03726879	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Completed	01/01/2011	https://clinicaltrials.gov/study/NCT01287624	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Completed	01/07/1998	https://clinicaltrials.gov/study/NCT00003440	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Completed	29/01/2002	https://clinicaltrials.gov/study/NCT00028990	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Completed	01/11/1999	https://clinicaltrials.gov/study/NCT00129922	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Unknown status	01/01/2001	https://clinicaltrials.gov/study/NCT00025688	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Completed	01/06/2010	https://clinicaltrials.gov/study/NCT04127019	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Completed	01/10/2007	https://clinicaltrials.gov/study/NCT00567554	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Completed	31/07/2010	https://clinicaltrials.gov/study/NCT01120184	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Unknown status	01/12/2007	https://clinicaltrials.gov/study/NCT00629278	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Not yet recruiting	17/04/2020	https://clinicaltrials.gov/study/NCT04301739	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Terminated	01/06/2010	https://clinicaltrials.gov/study/NCT01303679	0.35	LoF	protect	Not reveal any significant difference between the 2 treatment arms
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Unknown status	04/03/2011	https://clinicaltrials.gov/study/NCT01019616	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Active, not recruiting	01/04/2003	https://clinicaltrials.gov/study/NCT00433420	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Recruiting	30/06/2023	https://clinicaltrials.gov/study/NCT05814354	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Completed	01/04/2013	https://clinicaltrials.gov/study/NCT01822314	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Completed	01/07/2004	https://clinicaltrials.gov/study/NCT00196872	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	4	Recruiting	10/07/2022	https://clinicaltrials.gov/study/NCT05420467	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Completed	19/09/2003	https://clinicaltrials.gov/study/NCT00129389	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Active, not recruiting	27/12/2018	https://clinicaltrials.gov/study/NCT03725059	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Recruiting	30/10/2023	https://clinicaltrials.gov/study/NCT06143553	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Terminated	01/11/2007	https://clinicaltrials.gov/study/NCT00520975	0.7	LoF	protect	Closed early due to slow accrual
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Completed	27/08/2012	https://clinicaltrials.gov/study/NCT01663727	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	4	Unknown status	01/12/2013	https://clinicaltrials.gov/study/NCT02207361	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Unknown status	01/04/2012	https://clinicaltrials.gov/study/NCT01547741	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Not yet recruiting	01/12/2023	https://clinicaltrials.gov/study/NCT06079983	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	4	Recruiting	10/07/2022	https://clinicaltrials.gov/study/NCT05420454	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Completed	10/09/2009	https://clinicaltrials.gov/study/NCT00876395	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Unknown status	01/06/2010	https://clinicaltrials.gov/study/NCT01084876	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Completed	24/02/2014	https://clinicaltrials.gov/study/NCT01989676	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Active, not recruiting	25/10/2021	https://clinicaltrials.gov/study/NCT05113251	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Completed	15/11/2013	https://clinicaltrials.gov/study/NCT01940497	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Completed	01/07/1998	https://clinicaltrials.gov/study/NCT00003972	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Completed	06/01/2018	https://clinicaltrials.gov/study/NCT03337724	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Completed	01/05/2002	https://clinicaltrials.gov/study/NCT01998906	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Completed	01/01/2011	https://clinicaltrials.gov/study/NCT04031703	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Completed	01/08/2001	https://clinicaltrials.gov/study/NCT00146549	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Terminated	14/07/2020	https://clinicaltrials.gov/study/NCT04335006	0.7	LoF	protect	Sponsor R & D Strategy Adjustment
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Completed	24/05/2018	https://clinicaltrials.gov/study/NCT03462251	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Active, not recruiting	01/09/2014	https://clinicaltrials.gov/study/NCT01646034	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Unknown status	01/06/2000	https://clinicaltrials.gov/study/NCT00005581	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Completed	01/03/2000	https://clinicaltrials.gov/study/NCT00668616	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Active, not recruiting	21/01/2021	https://clinicaltrials.gov/study/NCT04732598	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Completed	01/02/2000	https://clinicaltrials.gov/study/NCT00004067	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Recruiting	14/11/2023	https://clinicaltrials.gov/study/NCT06112379	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Recruiting	16/05/2022	https://clinicaltrials.gov/study/NCT05374512	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Suspended	21/12/2018	https://clinicaltrials.gov/study/NCT03777579	0.7	LoF	protect	trial handovered to another sponser.
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2ca3c0d4-e629-4d89-a969-3515a62886c6	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	4	Completed	01/03/2010	https://clinicaltrials.gov/study/NCT01094184	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Completed	02/04/2014	https://clinicaltrials.gov/study/NCT02032277	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	PACLITAXEL	targetBased	3	Not yet recruiting	01/03/2022	https://clinicaltrials.gov/study/NCT05172518	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	ovarian mucinous adenocarcinoma	PACLITAXEL	targetBased	3	Active, not recruiting	27/09/2010	https://clinicaltrials.gov/study/NCT01167712	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	ovarian mucinous adenocarcinoma	PACLITAXEL	targetBased	3	Completed	01/09/2005	https://clinicaltrials.gov/study/NCT00262847	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	ovarian mucinous adenocarcinoma	PACLITAXEL	targetBased	3	Unknown status	21/03/2005	https://clinicaltrials.gov/study/NCT00108745	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	mucosal melanoma	PACLITAXEL	targetBased	3	Completed	01/06/2005	https://clinicaltrials.gov/study/NCT00110019	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Uterine Carcinosarcoma	PACLITAXEL	targetBased	3	Unknown status	17/08/2009	https://clinicaltrials.gov/study/NCT00954174	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	gestational trophoblastic neoplasm	PACLITAXEL	targetBased	3	Recruiting	01/03/2016	https://clinicaltrials.gov/study/NCT02639650	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Malignant Ovarian Mixed Epithelial Tumor	PACLITAXEL	targetBased	3	Completed	01/09/2005	https://clinicaltrials.gov/study/NCT00262847	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	peritoneal neoplasm	PACLITAXEL	targetBased	3	Completed	01/10/2002	https://clinicaltrials.gov/study/NCT00191646	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	peritoneal neoplasm	PACLITAXEL	targetBased	3	Terminated	01/02/2004	https://clinicaltrials.gov/study/NCT00189371	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	peritoneal neoplasm	PACLITAXEL	targetBased	3	Completed	08/03/2017	https://clinicaltrials.gov/study/NCT03038100	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	melanoma	PACLITAXEL	targetBased	3	Unknown status	01/10/2008	https://clinicaltrials.gov/study/NCT00779714	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	melanoma	PACLITAXEL	targetBased	3	Completed	01/05/2005	https://clinicaltrials.gov/study/NCT00111007	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	melanoma	PACLITAXEL	targetBased	3	Terminated	01/08/2007	https://clinicaltrials.gov/study/NCT00522834	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	melanoma	PACLITAXEL	targetBased	3	Terminated	01/12/2009	https://clinicaltrials.gov/study/NCT01006252	0.35	LoF	protect	More possibly treatment-related deaths on tasisulam-sodium arm.
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	melanoma	PACLITAXEL	targetBased	3	Recruiting	02/11/2023	https://clinicaltrials.gov/study/NCT06008106	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	melanoma	PACLITAXEL	targetBased	3	Completed	23/04/2009	https://clinicaltrials.gov/study/NCT00864253	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	ovarian serous adenocarcinoma	PACLITAXEL	targetBased	3	Completed	01/09/2005	https://clinicaltrials.gov/study/NCT00262847	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	ovarian serous adenocarcinoma	PACLITAXEL	targetBased	3	Unknown status	21/03/2005	https://clinicaltrials.gov/study/NCT00108745	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	ovarian serous adenocarcinoma	PACLITAXEL	targetBased	3	Recruiting	22/09/2022	https://clinicaltrials.gov/study/NCT05601700	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	ovarian serous adenocarcinoma	PACLITAXEL	targetBased	3	Active, not recruiting	27/09/2010	https://clinicaltrials.gov/study/NCT01167712	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Malignant Pancreatic Neoplasm	PACLITAXEL	targetBased	3	Recruiting	12/03/2018	https://clinicaltrials.gov/study/NCT03257033	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Malignant Pancreatic Neoplasm	PACLITAXEL	targetBased	3	Not yet recruiting	20/12/2022	https://clinicaltrials.gov/study/NCT05653453	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Malignant Pancreatic Neoplasm	PACLITAXEL	targetBased	3	Recruiting	13/06/2023	https://clinicaltrials.gov/study/NCT05751850	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Malignant Pancreatic Neoplasm	PACLITAXEL	targetBased	4	Not yet recruiting	01/01/2020	https://clinicaltrials.gov/study/NCT04217096	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	ovarian cancer	PACLITAXEL	targetBased	3	Terminated	22/04/2021	https://clinicaltrials.gov/study/NCT04729608	0.35	LoF	protect	There were no significant differences in median PFS between batiraxcept + paclitaxel or paclitaxel alone arms. There was no detriment to overall survival. No new safety signals were identified.
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	ovarian cancer	PACLITAXEL	targetBased	4	Active, not recruiting	01/10/2012	https://clinicaltrials.gov/study/NCT01706120	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	ovarian cancer	PACLITAXEL	targetBased	3	Completed	01/04/2003	https://clinicaltrials.gov/study/NCT00226915	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	ovarian cancer	PACLITAXEL	targetBased	3	Recruiting	16/08/2019	https://clinicaltrials.gov/study/NCT04000295	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	ovarian cancer	PACLITAXEL	targetBased	3	Completed	01/10/1998	https://clinicaltrials.gov/study/NCT00003998	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	ovarian cancer	PACLITAXEL	targetBased	3	Recruiting	18/03/2024	https://clinicaltrials.gov/study/NCT06072781	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	ovarian cancer	PACLITAXEL	targetBased	3	Active, not recruiting	11/06/2021	https://clinicaltrials.gov/study/NCT04908787	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	ovarian cancer	PACLITAXEL	targetBased	3	Completed	01/09/1998	https://clinicaltrials.gov/study/NCT00004921	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	ovarian cancer	PACLITAXEL	targetBased	3	Active, not recruiting	01/11/2013	https://clinicaltrials.gov/study/NCT01802749	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	ovarian cancer	PACLITAXEL	targetBased	3	Completed	22/10/2012	https://clinicaltrials.gov/study/NCT01684878	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	ovarian cancer	PACLITAXEL	targetBased	3	Recruiting	01/08/2017	https://clinicaltrials.gov/study/NCT04337632	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	ovarian cancer	PACLITAXEL	targetBased	3	Completed	01/01/2001	https://clinicaltrials.gov/study/NCT00011986	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	ovarian cancer	PACLITAXEL	targetBased	3	Withdrawn	01/12/2019	https://clinicaltrials.gov/study/NCT03806049	0.7	LoF	protect	Lack of financial support
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	ovarian cancer	PACLITAXEL	targetBased	3	Completed	01/08/1999	https://clinicaltrials.gov/study/NCT00004934	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	ovarian cancer	PACLITAXEL	targetBased	3	Completed	01/12/1999	https://clinicaltrials.gov/study/NCT00006454	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	ovarian cancer	PACLITAXEL	targetBased	3	Unknown status	01/06/2011	https://clinicaltrials.gov/study/NCT01654146	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	ovarian cancer	PACLITAXEL	targetBased	3	Completed	01/06/1994	https://clinicaltrials.gov/study/NCT00002568	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	ovarian cancer	PACLITAXEL	targetBased	3	Recruiting	21/01/2022	https://clinicaltrials.gov/study/NCT05255471	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	ovarian cancer	PACLITAXEL	targetBased	3	Recruiting	16/07/2021	https://clinicaltrials.gov/study/NCT05371301	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	ovarian cancer	PACLITAXEL	targetBased	3	Recruiting	01/12/2020	https://clinicaltrials.gov/study/NCT04679064	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	ovarian cancer	PACLITAXEL	targetBased	3	Completed	19/12/2017	https://clinicaltrials.gov/study/NCT03398655	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	ovarian cancer	PACLITAXEL	targetBased	3	Completed	01/02/2009	https://clinicaltrials.gov/study/NCT00989131	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	ovarian cancer	PACLITAXEL	targetBased	3	Completed	01/03/1998	https://clinicaltrials.gov/study/NCT00003322	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	ovarian cancer	PACLITAXEL	targetBased	3	Completed	08/03/2017	https://clinicaltrials.gov/study/NCT03038100	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	ovarian cancer	PACLITAXEL	targetBased	3	Completed	01/11/2010	https://clinicaltrials.gov/study/NCT01204749	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	ovarian cancer	PACLITAXEL	targetBased	3	Terminated	29/06/2015	https://clinicaltrials.gov/study/NCT02470585	0.7	LoF	protect	Business decision not related to patient safety
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	ovarian cancer	PACLITAXEL	targetBased	3	Completed	01/07/1996	https://clinicaltrials.gov/study/NCT00003214	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	ovarian cancer	PACLITAXEL	targetBased	3	Completed	01/10/1998	https://clinicaltrials.gov/study/NCT00003644	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	ovarian cancer	PACLITAXEL	targetBased	3	Terminated	19/05/2016	https://clinicaltrials.gov/study/NCT02718417	0.35	LoF	protect	The study was terminated based on the results of a planned interim analysis that showed futility of efficacy.
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	ovarian cancer	PACLITAXEL	targetBased	3	Terminated	01/02/2004	https://clinicaltrials.gov/study/NCT00189371	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	ovarian cancer	PACLITAXEL	targetBased	3	Active, not recruiting	01/11/2008	https://clinicaltrials.gov/study/NCT00660842	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	ovarian cancer	PACLITAXEL	targetBased	3	Completed	15/08/2018	https://clinicaltrials.gov/study/NCT03635489	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	ovarian cancer	PACLITAXEL	targetBased	3	Completed	01/03/1996	https://clinicaltrials.gov/study/NCT00002894	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	ovarian cancer	PACLITAXEL	targetBased	3	Completed	01/08/2002	https://clinicaltrials.gov/study/NCT00052468	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	ovarian cancer	PACLITAXEL	targetBased	3	Completed	31/08/2001	https://clinicaltrials.gov/study/NCT00028743	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	ovarian cancer	PACLITAXEL	targetBased	3	Recruiting	01/04/2015	https://clinicaltrials.gov/study/NCT02429687	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	ovarian cancer	PACLITAXEL	targetBased	3	Completed	29/10/2009	https://clinicaltrials.gov/study/NCT00976911	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	ovarian cancer	PACLITAXEL	targetBased	3	Completed	01/03/1996	https://clinicaltrials.gov/study/NCT00002717	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	ovarian cancer	PACLITAXEL	targetBased	3	Completed	01/04/2006	https://clinicaltrials.gov/study/NCT00483782	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	ovarian cancer	PACLITAXEL	targetBased	3	Terminated	01/11/1996	https://clinicaltrials.gov/study/NCT00002819	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	ovarian cancer	PACLITAXEL	targetBased	3	Completed	11/08/2009	https://clinicaltrials.gov/study/NCT00951496	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	ovarian cancer	PACLITAXEL	targetBased	3	Terminated	01/01/2012	https://clinicaltrials.gov/study/NCT01493505	0.7	LoF	protect	Amgen Administrative Decision - termination of LTFU
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	ovarian cancer	PACLITAXEL	targetBased	3	Active, not recruiting	01/01/2003	https://clinicaltrials.gov/study/NCT00326456	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	ovarian cancer	PACLITAXEL	targetBased	3	Completed	22/03/2019	https://clinicaltrials.gov/study/NCT03940196	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	ovarian cancer	PACLITAXEL	targetBased	3	Completed	01/12/2010	https://clinicaltrials.gov/study/NCT01239732	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	ovarian cancer	PACLITAXEL	targetBased	3	Active, not recruiting	04/01/2019	https://clinicaltrials.gov/study/NCT03737643	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	ovarian cancer	PACLITAXEL	targetBased	3	Completed	01/11/1997	https://clinicaltrials.gov/study/NCT00003120	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	ovarian cancer	PACLITAXEL	targetBased	3	Active, not recruiting	01/11/2008	https://clinicaltrials.gov/study/NCT00657878	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	ovarian cancer	PACLITAXEL	targetBased	3	Recruiting	28/09/2021	https://clinicaltrials.gov/study/NCT05145218	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	ovarian cancer	PACLITAXEL	targetBased	3	Completed	01/04/2005	https://clinicaltrials.gov/study/NCT00189553	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	adenosquamous lung carcinoma	PACLITAXEL	targetBased	3	Completed	01/10/1996	https://clinicaltrials.gov/study/NCT00002852	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	adenosquamous lung carcinoma	PACLITAXEL	targetBased	3	Completed	01/03/2000	https://clinicaltrials.gov/study/NCT00005838	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	head and neck malignant neoplasia	PACLITAXEL	targetBased	3	Completed	22/04/1999	https://clinicaltrials.gov/study/NCT00003592	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	head and neck malignant neoplasia	PACLITAXEL	targetBased	3	Terminated	01/04/2005	https://clinicaltrials.gov/study/NCT00113399	0.7	LoF	protect	Terminated early due to low accrual.
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	head and neck malignant neoplasia	PACLITAXEL	targetBased	3	Active, not recruiting	12/12/2020	https://clinicaltrials.gov/study/NCT04338399	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	head and neck malignant neoplasia	PACLITAXEL	targetBased	3	Terminated	01/06/2010	https://clinicaltrials.gov/study/NCT01126216	0.35	LoF	protect	After an Interims analysis the Data Safety Monitoring board recommended this because no significant difference between the two arms was seen and was not expected with an reasonable recruitment of patients. No interruptions of the trial were made.
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	head and neck malignant neoplasia	PACLITAXEL	targetBased	3	Completed	01/03/1997	https://clinicaltrials.gov/study/NCT00002888	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Fallopian Tube Serous Adenocarcinoma	PACLITAXEL	targetBased	3	Unknown status	21/03/2005	https://clinicaltrials.gov/study/NCT00108745	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Fallopian Tube Serous Adenocarcinoma	PACLITAXEL	targetBased	3	Completed	01/09/2005	https://clinicaltrials.gov/study/NCT00262847	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Malignant Ovarian Brenner Tumor	PACLITAXEL	targetBased	3	Active, not recruiting	27/09/2010	https://clinicaltrials.gov/study/NCT01167712	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Malignant Ovarian Brenner Tumor	PACLITAXEL	targetBased	3	Completed	01/09/2005	https://clinicaltrials.gov/study/NCT00262847	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Malignant Ovarian Brenner Tumor	PACLITAXEL	targetBased	3	Unknown status	21/03/2005	https://clinicaltrials.gov/study/NCT00108745	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Malignant Ovarian Brenner Tumor	PACLITAXEL	targetBased	3	Completed	11/08/2009	https://clinicaltrials.gov/study/NCT00951496	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	esophageal adenocarcinoma	PACLITAXEL	targetBased	3	Recruiting	09/03/2022	https://clinicaltrials.gov/study/NCT05188313	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	inflammatory breast carcinoma	PACLITAXEL	targetBased	3	Completed	01/07/2012	https://clinicaltrials.gov/study/NCT01583426	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	inflammatory breast carcinoma	PACLITAXEL	targetBased	3	Completed	01/12/2014	https://clinicaltrials.gov/study/NCT02125344	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	inflammatory breast carcinoma	PACLITAXEL	targetBased	3	Unknown status	01/01/2014	https://clinicaltrials.gov/study/NCT02879513	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	inflammatory breast carcinoma	PACLITAXEL	targetBased	3	Terminated	01/05/2001	https://clinicaltrials.gov/study/NCT00016276	0.7	LoF	protect	Administratively complete.
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Endometrial Serous Adenocarcinoma	PACLITAXEL	targetBased	3	Completed	01/07/2000	https://clinicaltrials.gov/study/NCT00006011	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	extragonadal germ cell tumor	PACLITAXEL	targetBased	3	Terminated	01/04/2004	https://clinicaltrials.gov/study/NCT00072215	0.7	LoF	protect	poor accrual
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	extragonadal germ cell tumor	PACLITAXEL	targetBased	3	Active, not recruiting	26/11/2003	https://clinicaltrials.gov/study/NCT00104676	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung neoplasm	PACLITAXEL	targetBased	3	Active, not recruiting	06/07/2020	https://clinicaltrials.gov/study/NCT04380636	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	ovarian clear cell adenocarcinoma	PACLITAXEL	targetBased	3	Unknown status	21/03/2005	https://clinicaltrials.gov/study/NCT00108745	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	ovarian clear cell adenocarcinoma	PACLITAXEL	targetBased	3	Completed	01/09/2005	https://clinicaltrials.gov/study/NCT00262847	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	urothelial carcinoma	PACLITAXEL	targetBased	3	Recruiting	06/04/2023	https://clinicaltrials.gov/study/NCT05754853	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	head and neck squamous cell carcinoma	PACLITAXEL	targetBased	4	Active, not recruiting	27/10/2020	https://clinicaltrials.gov/study/NCT04489888	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	head and neck squamous cell carcinoma	PACLITAXEL	targetBased	3	Recruiting	01/05/2023	https://clinicaltrials.gov/study/NCT06102395	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	head and neck squamous cell carcinoma	PACLITAXEL	targetBased	3	Recruiting	28/10/2022	https://clinicaltrials.gov/study/NCT05582265	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	head and neck squamous cell carcinoma	PACLITAXEL	targetBased	4	Recruiting	12/12/2020	https://clinicaltrials.gov/study/NCT04766827	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	uterine corpus cancer	PACLITAXEL	targetBased	3	Completed	01/07/2000	https://clinicaltrials.gov/study/NCT00006011	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	uterine corpus cancer	PACLITAXEL	targetBased	3	Completed	25/08/2003	https://clinicaltrials.gov/study/NCT00063999	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	urogenital neoplasm	PACLITAXEL	targetBased	3	Active, not recruiting	13/01/2021	https://clinicaltrials.gov/study/NCT04527991	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	urogenital neoplasm	PACLITAXEL	targetBased	3	Completed	22/10/2014	https://clinicaltrials.gov/study/NCT02256436	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	sarcoma	PACLITAXEL	targetBased	3	Completed	01/11/1997	https://clinicaltrials.gov/study/NCT00003128	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	pancreatic carcinoma	PACLITAXEL	targetBased	4	Recruiting	25/03/2021	https://clinicaltrials.gov/study/NCT05035147	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	pancreatic carcinoma	PACLITAXEL	targetBased	3	Active, not recruiting	31/01/2020	https://clinicaltrials.gov/study/NCT04229004	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	pancreatic carcinoma	PACLITAXEL	targetBased	3	Terminated	01/05/2013	https://clinicaltrials.gov/study/NCT01836432	0.7	LoF	protect	Company decision
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	pancreatic carcinoma	PACLITAXEL	targetBased	3	Completed	01/03/2009	https://clinicaltrials.gov/study/NCT00844649	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	pancreatic carcinoma	PACLITAXEL	targetBased	3	Active, not recruiting	11/02/2020	https://clinicaltrials.gov/study/NCT04083235	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	pancreatic carcinoma	PACLITAXEL	targetBased	3	Active, not recruiting	10/05/2019	https://clinicaltrials.gov/study/NCT03941093	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	pancreatic carcinoma	PACLITAXEL	targetBased	3	Recruiting	04/03/2021	https://clinicaltrials.gov/study/NCT04674956	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	pancreatic carcinoma	PACLITAXEL	targetBased	3	Unknown status	01/06/2015	https://clinicaltrials.gov/study/NCT02506842	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	pancreatic adenocarcinoma	PACLITAXEL	targetBased	3	Not yet recruiting	01/04/2021	https://clinicaltrials.gov/study/NCT04835064	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	pancreatic adenocarcinoma	PACLITAXEL	targetBased	3	Active, not recruiting	10/02/2018	https://clinicaltrials.gov/study/NCT03377491	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	pancreatic adenocarcinoma	PACLITAXEL	targetBased	3	Active, not recruiting	31/01/2020	https://clinicaltrials.gov/study/NCT04229004	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	pancreatic adenocarcinoma	PACLITAXEL	targetBased	3	Recruiting	15/05/2024	https://clinicaltrials.gov/study/NCT06250972	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	pancreatic adenocarcinoma	PACLITAXEL	targetBased	3	Active, not recruiting	11/02/2020	https://clinicaltrials.gov/study/NCT04083235	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	pancreatic adenocarcinoma	PACLITAXEL	targetBased	3	Completed	23/05/2019	https://clinicaltrials.gov/study/NCT03943667	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	pancreatic adenocarcinoma	PACLITAXEL	targetBased	3	Recruiting	20/08/2023	https://clinicaltrials.gov/study/NCT06018883	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	pancreatic adenocarcinoma	PACLITAXEL	targetBased	4	Completed	01/06/2016	https://clinicaltrials.gov/study/NCT02812992	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	pancreatic adenocarcinoma	PACLITAXEL	targetBased	4	Unknown status	01/03/2018	https://clinicaltrials.gov/study/NCT03401827	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	pancreatic adenocarcinoma	PACLITAXEL	targetBased	3	Completed	01/05/2015	https://clinicaltrials.gov/study/NCT02436668	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	pancreatic adenocarcinoma	PACLITAXEL	targetBased	3	Recruiting	01/09/2021	https://clinicaltrials.gov/study/NCT04617821	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	gastric carcinoma	PACLITAXEL	targetBased	3	Recruiting	24/03/2021	https://clinicaltrials.gov/study/NCT04714190	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	cutaneous melanoma	PACLITAXEL	targetBased	3	Completed	01/06/2005	https://clinicaltrials.gov/study/NCT00110019	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Primary Peritoneal Serous Adenocarcinoma	PACLITAXEL	targetBased	3	Active, not recruiting	27/09/2010	https://clinicaltrials.gov/study/NCT01167712	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Primary Peritoneal Serous Adenocarcinoma	PACLITAXEL	targetBased	3	Completed	01/09/2005	https://clinicaltrials.gov/study/NCT00262847	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Primary Peritoneal Serous Adenocarcinoma	PACLITAXEL	targetBased	3	Unknown status	21/03/2005	https://clinicaltrials.gov/study/NCT00108745	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	esophageal carcinoma	PACLITAXEL	targetBased	3	Recruiting	01/11/2022	https://clinicaltrials.gov/study/NCT05357846	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	esophageal carcinoma	PACLITAXEL	targetBased	3	Unknown status	01/01/2016	https://clinicaltrials.gov/study/NCT02891083	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	esophageal carcinoma	PACLITAXEL	targetBased	3	Recruiting	01/12/2017	https://clinicaltrials.gov/study/NCT03308552	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	upper aerodigestive tract neoplasm	PACLITAXEL	targetBased	3	Unknown status	01/06/2013	https://clinicaltrials.gov/study/NCT02630264	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	esophageal cancer	PACLITAXEL	targetBased	3	Recruiting	09/03/2022	https://clinicaltrials.gov/study/NCT05188313	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	esophageal cancer	PACLITAXEL	targetBased	3	Active, not recruiting	30/06/2020	https://clinicaltrials.gov/study/NCT04426955	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	esophageal cancer	PACLITAXEL	targetBased	3	Not yet recruiting	01/02/2018	https://clinicaltrials.gov/study/NCT03366883	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	esophageal cancer	PACLITAXEL	targetBased	3	Withdrawn	01/11/2013	https://clinicaltrials.gov/study/NCT01998347	0.7	LoF	protect	slow enrollment
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	esophageal cancer	PACLITAXEL	targetBased	3	Unknown status	01/05/2015	https://clinicaltrials.gov/study/NCT02570893	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	esophageal cancer	PACLITAXEL	targetBased	3	Completed	01/06/2008	https://clinicaltrials.gov/study/NCT00655876	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	esophageal cancer	PACLITAXEL	targetBased	3	Unknown status	01/04/2015	https://clinicaltrials.gov/study/NCT02461043	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	esophageal cancer	PACLITAXEL	targetBased	3	Unknown status	01/05/2008	https://clinicaltrials.gov/study/NCT00686114	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	esophageal cancer	PACLITAXEL	targetBased	3	Completed	03/12/2018	https://clinicaltrials.gov/study/NCT03691090	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	esophageal cancer	PACLITAXEL	targetBased	3	Recruiting	01/11/2018	https://clinicaltrials.gov/study/NCT03731442	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	esophageal cancer	PACLITAXEL	targetBased	3	Completed	14/12/2015	https://clinicaltrials.gov/study/NCT02569242	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	esophageal cancer	PACLITAXEL	targetBased	3	Active, not recruiting	01/06/2021	https://clinicaltrials.gov/study/NCT04879368	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	esophageal cancer	PACLITAXEL	targetBased	3	Active, not recruiting	30/10/2020	https://clinicaltrials.gov/study/NCT04540211	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	esophageal cancer	PACLITAXEL	targetBased	3	Recruiting	01/11/2022	https://clinicaltrials.gov/study/NCT05357846	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	esophageal cancer	PACLITAXEL	targetBased	3	Recruiting	01/09/2017	https://clinicaltrials.gov/study/NCT03328234	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung adenocarcinoma	PACLITAXEL	targetBased	3	Completed	01/10/1996	https://clinicaltrials.gov/study/NCT00002852	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung adenocarcinoma	PACLITAXEL	targetBased	3	Completed	01/03/2000	https://clinicaltrials.gov/study/NCT00005838	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast neoplasm	PACLITAXEL	targetBased	3	Completed	02/01/2006	https://clinicaltrials.gov/study/NCT00281658	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast neoplasm	PACLITAXEL	targetBased	3	Active, not recruiting	25/06/2019	https://clinicaltrials.gov/study/NCT03997123	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast neoplasm	PACLITAXEL	targetBased	3	Terminated	13/12/2005	https://clinicaltrials.gov/study/NCT00272987	0.7	LoF	protect	Enrollment was closed after the open label stage due to poor recruitment rate (randomized stage never opened).
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast neoplasm	PACLITAXEL	targetBased	3	Completed	01/06/2001	https://clinicaltrials.gov/study/NCT00046527	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast neoplasm	PACLITAXEL	targetBased	3	Terminated	01/09/2005	https://clinicaltrials.gov/study/NCT00251095	0.35	LoF	protect	Failed primary endpoint
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast neoplasm	PACLITAXEL	targetBased	3	Completed	01/11/2006	https://clinicaltrials.gov/study/NCT00373256	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast neoplasm	PACLITAXEL	targetBased	3	Active, not recruiting	25/10/2021	https://clinicaltrials.gov/study/NCT05113251	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast neoplasm	PACLITAXEL	targetBased	3	Recruiting	14/04/2024	https://clinicaltrials.gov/study/NCT06312176	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast neoplasm	PACLITAXEL	targetBased	3	Completed	05/01/2008	https://clinicaltrials.gov/study/NCT00553358	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast neoplasm	PACLITAXEL	targetBased	3	Active, not recruiting	18/06/2021	https://clinicaltrials.gov/study/NCT04895358	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast neoplasm	PACLITAXEL	targetBased	3	Active, not recruiting	08/06/2020	https://clinicaltrials.gov/study/NCT04251533	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast neoplasm	PACLITAXEL	targetBased	3	Completed	01/12/2009	https://clinicaltrials.gov/study/NCT01026116	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast neoplasm	PACLITAXEL	targetBased	3	Completed	01/06/2012	https://clinicaltrials.gov/study/NCT01572038	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast neoplasm	PACLITAXEL	targetBased	3	Completed	01/05/2019	https://clinicaltrials.gov/study/NCT03705429	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast neoplasm	PACLITAXEL	targetBased	3	Completed	01/01/2004	https://clinicaltrials.gov/study/NCT00075270	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast neoplasm	PACLITAXEL	targetBased	3	Active, not recruiting	07/03/2017	https://clinicaltrials.gov/study/NCT03036488	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast neoplasm	PACLITAXEL	targetBased	4	Completed	13/03/2017	https://clinicaltrials.gov/study/NCT03096418	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast neoplasm	PACLITAXEL	targetBased	3	Unknown status	01/07/2015	https://clinicaltrials.gov/study/NCT02455141	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast neoplasm	PACLITAXEL	targetBased	4	Recruiting	11/03/2021	https://clinicaltrials.gov/study/NCT05033769	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast neoplasm	PACLITAXEL	targetBased	3	Recruiting	20/12/2019	https://clinicaltrials.gov/study/NCT04335669	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Genital neoplasm, female	PACLITAXEL	targetBased	3	Completed	01/10/2002	https://clinicaltrials.gov/study/NCT00191646	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	endometrial adenosquamous carcinoma	PACLITAXEL	targetBased	3	Completed	01/07/2000	https://clinicaltrials.gov/study/NCT00006011	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	testicular neoplasm	PACLITAXEL	targetBased	3	Terminated	01/04/2004	https://clinicaltrials.gov/study/NCT00072215	0.7	LoF	protect	poor accrual
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	testicular neoplasm	PACLITAXEL	targetBased	3	Active, not recruiting	26/11/2003	https://clinicaltrials.gov/study/NCT00104676	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	invasive breast ductal carcinoma	PACLITAXEL	targetBased	3	Completed	01/04/2016	https://clinicaltrials.gov/study/NCT02620280	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast carcinoma	PACLITAXEL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4dbbb7c8-a4b5-484d-a2a4-4d925010fc44	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast carcinoma	PACLITAXEL	targetBased	3	Recruiting	27/11/2023	https://clinicaltrials.gov/study/NCT06058377	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast carcinoma	PACLITAXEL	targetBased	3	Recruiting	27/07/2017	https://clinicaltrials.gov/study/NCT03201861	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast carcinoma	PACLITAXEL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1e1a3a8d-6a6b-46fd-90ae-c7ad9e9b364b	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast carcinoma	PACLITAXEL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9ffd3e34-537f-4f65-b00e-57c25bab3b01	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast carcinoma	PACLITAXEL	targetBased	3	Active, not recruiting	06/01/2011	https://clinicaltrials.gov/study/NCT01275677	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast carcinoma	PACLITAXEL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ea28753a-8631-460a-bfdc-b101eb8ac84a	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast carcinoma	PACLITAXEL	targetBased	3	Active, not recruiting	05/04/2019	https://clinicaltrials.gov/study/NCT03199885	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast carcinoma	PACLITAXEL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=24d10449-2936-4cd3-b7db-a7683db721e4	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast carcinoma	PACLITAXEL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d499be2-fdb5-4b9d-a7ce-3662ec9b2e34	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast carcinoma	PACLITAXEL	targetBased	3	Completed	01/11/2010	https://clinicaltrials.gov/study/NCT01935492	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast carcinoma	PACLITAXEL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f10f730f-6479-4f6a-8edc-fa4bd2140c1b	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast carcinoma	PACLITAXEL	targetBased	3	Suspended	17/01/2014	https://clinicaltrials.gov/study/NCT02037529	0.7	LoF	protect	Total enrollment number is being lowered
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast carcinoma	PACLITAXEL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=88d7cdd2-e650-4a16-adec-873927e03e93	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast carcinoma	PACLITAXEL	targetBased	3	Terminated	01/11/2007	https://clinicaltrials.gov/study/NCT00520975	0.7	LoF	protect	Closed early due to slow accrual
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast carcinoma	PACLITAXEL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6cefbdb9-1141-4a53-9d05-f6fcc2746834	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast carcinoma	PACLITAXEL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=973efa93-7f9d-440a-a09f-521cf331b5e7	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast carcinoma	PACLITAXEL	targetBased	3	Completed	13/10/2008	https://clinicaltrials.gov/study/NCT00785291	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast carcinoma	PACLITAXEL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=566a00ae-47c0-4cd2-b602-79909bdfd9b1	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast carcinoma	PACLITAXEL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a6c24189-293f-42ca-b969-75870bb55af0	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	ovarian carcinoma	PACLITAXEL	targetBased	3	Terminated	09/08/2019	https://clinicaltrials.gov/study/NCT03690739	0.7	LoF	protect	Insufficient Recruitment
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	ovarian carcinoma	PACLITAXEL	targetBased	3	Not yet recruiting	31/05/2024	https://clinicaltrials.gov/study/NCT06394492	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	ovarian carcinoma	PACLITAXEL	targetBased	3	Completed	11/08/2009	https://clinicaltrials.gov/study/NCT00951496	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	ovarian carcinoma	PACLITAXEL	targetBased	3	Active, not recruiting	21/11/2018	https://clinicaltrials.gov/study/NCT03598270	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	peritoneum cancer	PACLITAXEL	targetBased	3	Completed	31/08/2001	https://clinicaltrials.gov/study/NCT00028743	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	peritoneum cancer	PACLITAXEL	targetBased	3	Terminated	01/01/2012	https://clinicaltrials.gov/study/NCT01493505	0.7	LoF	protect	Amgen Administrative Decision - termination of LTFU
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	peritoneum cancer	PACLITAXEL	targetBased	3	Completed	01/10/1998	https://clinicaltrials.gov/study/NCT00003998	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	peritoneum cancer	PACLITAXEL	targetBased	3	Completed	01/11/1997	https://clinicaltrials.gov/study/NCT00003120	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	peritoneum cancer	PACLITAXEL	targetBased	3	Completed	01/03/1998	https://clinicaltrials.gov/study/NCT00003322	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	peritoneum cancer	PACLITAXEL	targetBased	3	Completed	01/03/1996	https://clinicaltrials.gov/study/NCT00002894	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	peritoneum cancer	PACLITAXEL	targetBased	3	Completed	01/04/2006	https://clinicaltrials.gov/study/NCT00483782	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	peritoneum cancer	PACLITAXEL	targetBased	3	Completed	01/08/1999	https://clinicaltrials.gov/study/NCT00004934	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	peritoneum cancer	PACLITAXEL	targetBased	3	Completed	01/03/1996	https://clinicaltrials.gov/study/NCT00002717	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	thyroid cancer	PACLITAXEL	targetBased	3	Withdrawn	01/03/2015	https://clinicaltrials.gov/study/NCT01701349	0.7	LoF	protect	Expected inability to recruit study participants in a reasonable amount of time.
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	nasopharyngeal neoplasm	PACLITAXEL	targetBased	3	Unknown status	21/07/2018	https://clinicaltrials.gov/study/NCT03604965	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	nasopharyngeal neoplasm	PACLITAXEL	targetBased	3	Recruiting	24/05/2018	https://clinicaltrials.gov/study/NCT03574324	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	oral squamous cell carcinoma	PACLITAXEL	targetBased	3	Recruiting	20/02/2024	https://clinicaltrials.gov/study/NCT06258811	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	ovarian sex cord-stromal tumor	PACLITAXEL	targetBased	3	Recruiting	01/04/2015	https://clinicaltrials.gov/study/NCT02429700	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	cervical squamous cell carcinoma	PACLITAXEL	targetBased	3	Completed	01/05/2003	https://clinicaltrials.gov/study/NCT00064077	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	cervical adenocarcinoma	PACLITAXEL	targetBased	3	Completed	01/05/2003	https://clinicaltrials.gov/study/NCT00064077	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	cervical adenocarcinoma	PACLITAXEL	targetBased	3	Recruiting	01/07/2022	https://clinicaltrials.gov/study/NCT05735145	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	cervical adenocarcinoma	PACLITAXEL	targetBased	3	Active, not recruiting	01/11/2012	https://clinicaltrials.gov/study/NCT01755897	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	cervical adenocarcinoma	PACLITAXEL	targetBased	3	Recruiting	01/02/2021	https://clinicaltrials.gov/study/NCT04723875	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	cervical adenocarcinoma	PACLITAXEL	targetBased	3	Completed	01/02/2006	https://clinicaltrials.gov/study/NCT00295789	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	stomach neoplasm	PACLITAXEL	targetBased	3	Unknown status	16/03/2018	https://clinicaltrials.gov/study/NCT03475615	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	stomach neoplasm	PACLITAXEL	targetBased	3	Unknown status	01/12/2016	https://clinicaltrials.gov/study/NCT02934464	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	endometrial cancer	PACLITAXEL	targetBased	3	Not yet recruiting	01/08/2024	https://clinicaltrials.gov/study/NCT06340568	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	endometrial cancer	PACLITAXEL	targetBased	3	Completed	01/08/2000	https://clinicaltrials.gov/study/NCT00006027	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	endometrial cancer	PACLITAXEL	targetBased	3	Recruiting	06/12/2023	https://clinicaltrials.gov/study/NCT06132958	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	endometrial cancer	PACLITAXEL	targetBased	3	Not yet recruiting	01/07/2024	https://clinicaltrials.gov/study/NCT06475599	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	endometrial cancer	PACLITAXEL	targetBased	3	Terminated	01/05/2001	https://clinicaltrials.gov/study/NCT00016341	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	endometrial cancer	PACLITAXEL	targetBased	3	Not yet recruiting	01/09/2024	https://clinicaltrials.gov/study/NCT06486441	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	endometrial cancer	PACLITAXEL	targetBased	3	Active, not recruiting	23/11/2006	https://clinicaltrials.gov/study/NCT00411138	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	endometrial cancer	PACLITAXEL	targetBased	3	Completed	01/12/1998	https://clinicaltrials.gov/study/NCT00003691	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	endometrial cancer	PACLITAXEL	targetBased	3	Active, not recruiting	02/10/2018	https://clinicaltrials.gov/study/NCT03603184	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	endometrial cancer	PACLITAXEL	targetBased	3	Recruiting	15/04/2022	https://clinicaltrials.gov/study/NCT05201547	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	endometrial cancer	PACLITAXEL	targetBased	3	Terminated	01/08/2009	https://clinicaltrials.gov/study/NCT00883116	0.7	LoF	protect	Interim analysis results showed that ixabepilone did not improve survival compared with control chemotherapies.
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	cancer	PACLITAXEL	targetBased	3	Recruiting	11/06/2020	https://clinicaltrials.gov/study/NCT04158362	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	cancer	PACLITAXEL	targetBased	3	Recruiting	28/02/2019	https://clinicaltrials.gov/study/NCT03768063	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	cancer	PACLITAXEL	targetBased	4	Completed	01/02/2008	https://clinicaltrials.gov/study/NCT00606515	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	fallopian tube cancer	PACLITAXEL	targetBased	3	Completed	01/12/1999	https://clinicaltrials.gov/study/NCT00006454	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	fallopian tube cancer	PACLITAXEL	targetBased	3	Completed	01/08/2002	https://clinicaltrials.gov/study/NCT00052468	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	fallopian tube cancer	PACLITAXEL	targetBased	3	Completed	01/11/1997	https://clinicaltrials.gov/study/NCT00003120	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	fallopian tube cancer	PACLITAXEL	targetBased	3	Completed	01/08/1999	https://clinicaltrials.gov/study/NCT00004934	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	fallopian tube cancer	PACLITAXEL	targetBased	3	Completed	01/09/2005	https://clinicaltrials.gov/study/NCT00262847	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	fallopian tube cancer	PACLITAXEL	targetBased	3	Terminated	01/01/2012	https://clinicaltrials.gov/study/NCT01493505	0.7	LoF	protect	Amgen Administrative Decision - termination of LTFU
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	fallopian tube cancer	PACLITAXEL	targetBased	3	Completed	31/08/2001	https://clinicaltrials.gov/study/NCT00028743	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	fallopian tube cancer	PACLITAXEL	targetBased	3	Completed	01/02/2009	https://clinicaltrials.gov/study/NCT00989131	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	fallopian tube cancer	PACLITAXEL	targetBased	3	Completed	01/04/2005	https://clinicaltrials.gov/study/NCT00189553	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	fallopian tube cancer	PACLITAXEL	targetBased	3	Completed	01/04/2006	https://clinicaltrials.gov/study/NCT00483782	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	fallopian tube cancer	PACLITAXEL	targetBased	3	Completed	08/03/2017	https://clinicaltrials.gov/study/NCT03038100	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	fallopian tube cancer	PACLITAXEL	targetBased	3	Completed	15/08/2018	https://clinicaltrials.gov/study/NCT03635489	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	fallopian tube cancer	PACLITAXEL	targetBased	3	Completed	01/04/2003	https://clinicaltrials.gov/study/NCT00226915	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	fallopian tube cancer	PACLITAXEL	targetBased	3	Completed	01/11/2010	https://clinicaltrials.gov/study/NCT01204749	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Endometrial Clear Cell Adenocarcinoma	PACLITAXEL	targetBased	3	Completed	01/07/2000	https://clinicaltrials.gov/study/NCT00006011	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	carcinoma	PACLITAXEL	targetBased	3	Unknown status	01/07/2011	https://clinicaltrials.gov/study/NCT01593306	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	carcinoma	PACLITAXEL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2ca3c0d4-e629-4d89-a969-3515a62886c6	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	carcinoma	PACLITAXEL	targetBased	3	Unknown status	01/08/1998	https://clinicaltrials.gov/study/NCT00003558	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	uterine sarcoma	PACLITAXEL	targetBased	3	Unknown status	17/08/2009	https://clinicaltrials.gov/study/NCT00954174	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	endometrial endometrioid adenocarcinoma, variant with squamous differentiation	PACLITAXEL	targetBased	3	Completed	01/07/2000	https://clinicaltrials.gov/study/NCT00006011	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	bladder transitional cell carcinoma	PACLITAXEL	targetBased	3	Recruiting	28/06/2021	https://clinicaltrials.gov/study/NCT04579224	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	male breast carcinoma	PACLITAXEL	targetBased	3	Active, not recruiting	01/12/2008	https://clinicaltrials.gov/study/NCT00770809	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	ureter urothelial carcinoma	PACLITAXEL	targetBased	3	Recruiting	28/06/2021	https://clinicaltrials.gov/study/NCT04579224	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	primary peritoneal carcinoma	PACLITAXEL	targetBased	3	Completed	15/08/2018	https://clinicaltrials.gov/study/NCT03635489	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	primary peritoneal carcinoma	PACLITAXEL	targetBased	3	Unknown status	21/03/2005	https://clinicaltrials.gov/study/NCT00108745	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	primary peritoneal carcinoma	PACLITAXEL	targetBased	3	Completed	01/09/2005	https://clinicaltrials.gov/study/NCT00262847	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	primary peritoneal carcinoma	PACLITAXEL	targetBased	3	Completed	01/04/2003	https://clinicaltrials.gov/study/NCT00226915	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	primary peritoneal carcinoma	PACLITAXEL	targetBased	3	Completed	01/01/2001	https://clinicaltrials.gov/study/NCT00011986	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	primary peritoneal carcinoma	PACLITAXEL	targetBased	3	Unknown status	17/08/2009	https://clinicaltrials.gov/study/NCT00954174	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	primary peritoneal carcinoma	PACLITAXEL	targetBased	3	Completed	01/02/2009	https://clinicaltrials.gov/study/NCT00989131	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	primary peritoneal carcinoma	PACLITAXEL	targetBased	3	Active, not recruiting	27/09/2010	https://clinicaltrials.gov/study/NCT01167712	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	primary peritoneal carcinoma	PACLITAXEL	targetBased	3	Completed	01/11/2010	https://clinicaltrials.gov/study/NCT01204749	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	endometrial neoplasm	PACLITAXEL	targetBased	3	Active, not recruiting	10/01/2021	https://clinicaltrials.gov/study/NCT04634877	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	endometrial neoplasm	PACLITAXEL	targetBased	3	Active, not recruiting	11/06/2018	https://clinicaltrials.gov/study/NCT03517449	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	endometrial neoplasm	PACLITAXEL	targetBased	3	Active, not recruiting	11/04/2019	https://clinicaltrials.gov/study/NCT03884101	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	endometrial neoplasm	PACLITAXEL	targetBased	3	Active, not recruiting	22/10/2019	https://clinicaltrials.gov/study/NCT04865289	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	endometrial neoplasm	PACLITAXEL	targetBased	3	Active, not recruiting	05/05/2020	https://clinicaltrials.gov/study/NCT04269200	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	endometrial neoplasm	PACLITAXEL	targetBased	3	Active, not recruiting	03/02/2022	https://clinicaltrials.gov/study/NCT05173987	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	endometrial neoplasm	PACLITAXEL	targetBased	3	Active, not recruiting	01/11/2012	https://clinicaltrials.gov/study/NCT01820858	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	pancreatic ductal adenocarcinoma	PACLITAXEL	targetBased	3	Terminated	30/06/2020	https://clinicaltrials.gov/study/NCT04329949	0.35	LoF	protect	The independent data monitoring committee found no safety issues, however the observed response rate did not meet the predefined threshold for continuing the study. The study was terminated by the Sponsor.
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	pancreatic ductal adenocarcinoma	PACLITAXEL	targetBased	4	Recruiting	08/07/2020	https://clinicaltrials.gov/study/NCT04480268	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	pancreatic ductal adenocarcinoma	PACLITAXEL	targetBased	3	Completed	01/12/2016	https://clinicaltrials.gov/study/NCT02993731	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	pancreatic ductal adenocarcinoma	PACLITAXEL	targetBased	3	Terminated	02/06/2014	https://clinicaltrials.gov/study/NCT02101021	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	pancreatic ductal adenocarcinoma	PACLITAXEL	targetBased	3	Terminated	14/03/2016	https://clinicaltrials.gov/study/NCT02715804	0.7	LoF	protect	Sponsor decision
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	uterine neoplasm	PACLITAXEL	targetBased	3	Completed	25/08/2003	https://clinicaltrials.gov/study/NCT00063999	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	large cell lung carcinoma	PACLITAXEL	targetBased	3	Terminated	01/04/2008	https://clinicaltrials.gov/study/NCT00596830	0.7	LoF	protect	See termination reason in detailed description.
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	ovarian neoplasm	PACLITAXEL	targetBased	3	Completed	01/10/2002	https://clinicaltrials.gov/study/NCT00191646	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	ovarian neoplasm	PACLITAXEL	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/apealea	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	ovarian neoplasm	PACLITAXEL	targetBased	3	Terminated	29/06/2015	https://clinicaltrials.gov/study/NCT02470585	0.7	LoF	protect	Business decision not related to patient safety
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	ovarian neoplasm	PACLITAXEL	targetBased	3	Terminated	01/05/1997	https://clinicaltrials.gov/study/NCT00653952	0.7	LoF	protect	Poor accrual
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	ovarian neoplasm	PACLITAXEL	targetBased	3	Completed	11/04/2016	https://clinicaltrials.gov/study/NCT02903004	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Paraganglioma	PACLITAXEL	targetBased	3	Recruiting	01/04/2024	https://clinicaltrials.gov/study/NCT06330337	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	metastatic melanoma	PACLITAXEL	targetBased	3	Completed	21/12/2012	https://clinicaltrials.gov/study/NCT01721746	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Fallopian Tube Carcinoma	PACLITAXEL	targetBased	3	Completed	01/10/2002	https://clinicaltrials.gov/study/NCT00191646	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Fallopian Tube Carcinoma	PACLITAXEL	targetBased	3	Unknown status	17/08/2009	https://clinicaltrials.gov/study/NCT00954174	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-Hodgkins lymphoma	PACLITAXEL	targetBased	3	Completed	01/07/2004	https://clinicaltrials.gov/study/NCT00088530	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	renal pelvis/ureter urothelial carcinoma	PACLITAXEL	targetBased	3	Completed	03/12/1998	https://clinicaltrials.gov/study/NCT00003376	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	renal pelvis/ureter urothelial carcinoma	PACLITAXEL	targetBased	3	Completed	01/05/2001	https://clinicaltrials.gov/study/NCT00022191	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	cervical cancer	PACLITAXEL	targetBased	3	Completed	01/05/2003	https://clinicaltrials.gov/study/NCT00064077	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	cervical cancer	PACLITAXEL	targetBased	3	Unknown status	01/01/2011	https://clinicaltrials.gov/study/NCT01756170	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	cervical cancer	PACLITAXEL	targetBased	3	Recruiting	01/10/2019	https://clinicaltrials.gov/study/NCT03912415	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	cervical cancer	PACLITAXEL	targetBased	3	Unknown status	01/01/2014	https://clinicaltrials.gov/study/NCT02036164	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	cervical cancer	PACLITAXEL	targetBased	3	Active, not recruiting	08/11/2012	https://clinicaltrials.gov/study/NCT01566240	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	cervical cancer	PACLITAXEL	targetBased	3	Completed	25/10/2018	https://clinicaltrials.gov/study/NCT03635567	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	cervical cancer	PACLITAXEL	targetBased	3	Recruiting	17/07/2020	https://clinicaltrials.gov/study/NCT03534713	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	cervical cancer	PACLITAXEL	targetBased	3	Withdrawn	30/09/2022	https://clinicaltrials.gov/study/NCT04806945	0.7	LoF	protect	The sponsor terminated the trial.
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	cervical cancer	PACLITAXEL	targetBased	3	Not yet recruiting	31/01/2023	https://clinicaltrials.gov/study/NCT05715840	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	cervical cancer	PACLITAXEL	targetBased	3	Recruiting	23/09/2022	https://clinicaltrials.gov/study/NCT05446883	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	cervical cancer	PACLITAXEL	targetBased	3	Recruiting	27/08/2021	https://clinicaltrials.gov/study/NCT04982237	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	cervical cancer	PACLITAXEL	targetBased	3	Not yet recruiting	01/05/2023	https://clinicaltrials.gov/study/NCT05798819	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	cervical cancer	PACLITAXEL	targetBased	3	Unknown status	01/01/2011	https://clinicaltrials.gov/study/NCT01755845	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	cervical cancer	PACLITAXEL	targetBased	3	Recruiting	26/02/2022	https://clinicaltrials.gov/study/NCT05179239	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	cervical cancer	PACLITAXEL	targetBased	3	Unknown status	01/09/2006	https://clinicaltrials.gov/study/NCT01405235	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	cervical cancer	PACLITAXEL	targetBased	3	Active, not recruiting	01/09/2009	https://clinicaltrials.gov/study/NCT00980954	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	cervical cancer	PACLITAXEL	targetBased	3	Not yet recruiting	01/10/2015	https://clinicaltrials.gov/study/NCT02422563	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	cervical cancer	PACLITAXEL	targetBased	3	Unknown status	01/07/2015	https://clinicaltrials.gov/study/NCT02446652	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	cervical cancer	PACLITAXEL	targetBased	3	Withdrawn	01/04/2003	https://clinicaltrials.gov/study/NCT00057928	0.7	LoF	protect	lack of accrual
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	cervical cancer	PACLITAXEL	targetBased	3	Active, not recruiting	01/11/2012	https://clinicaltrials.gov/study/NCT01755897	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	cervical cancer	PACLITAXEL	targetBased	3	Recruiting	14/03/2022	https://clinicaltrials.gov/study/NCT05367206	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	biliary tract cancer	PACLITAXEL	targetBased	3	Recruiting	16/08/2023	https://clinicaltrials.gov/study/NCT05771480	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	urinary bladder carcinoma	PACLITAXEL	targetBased	3	Recruiting	29/12/2022	https://clinicaltrials.gov/study/NCT05024773	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	HER2 Positive Breast Carcinoma	PACLITAXEL	targetBased	3	Completed	19/05/2000	https://clinicaltrials.gov/study/NCT00005970	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	gastric adenocarcinoma	PACLITAXEL	targetBased	3	Completed	28/12/2015	https://clinicaltrials.gov/study/NCT02625623	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	cervical carcinoma	PACLITAXEL	targetBased	3	Unknown status	01/11/2015	https://clinicaltrials.gov/study/NCT02595554	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	cervical carcinoma	PACLITAXEL	targetBased	3	Active, not recruiting	25/09/2018	https://clinicaltrials.gov/study/NCT03556839	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	neoplasm	PACLITAXEL	targetBased	3	Completed	01/09/1997	https://clinicaltrials.gov/study/NCT00003092	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	neoplasm	PACLITAXEL	targetBased	3	Active, not recruiting	18/07/2019	https://clinicaltrials.gov/study/NCT03981796	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	neoplasm	PACLITAXEL	targetBased	3	Completed	01/09/2003	https://clinicaltrials.gov/study/NCT00193596	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	neoplasm	PACLITAXEL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=L01CD01	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	neoplasm	PACLITAXEL	targetBased	3	Completed	01/05/2012	https://clinicaltrials.gov/study/NCT01593228	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	neoplasm	PACLITAXEL	targetBased	3	Completed	01/07/2007	https://clinicaltrials.gov/study/NCT00486954	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	neoplasm	PACLITAXEL	targetBased	4	Unknown status	01/08/2014	https://clinicaltrials.gov/study/NCT01994031	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	neoplasm	PACLITAXEL	targetBased	3	Recruiting	01/12/2021	https://clinicaltrials.gov/study/NCT05112965	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	squamous cell lung carcinoma	PACLITAXEL	targetBased	3	Completed	20/12/2018	https://clinicaltrials.gov/study/NCT03866993	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	triple-negative breast cancer	PACLITAXEL	targetBased	3	Recruiting	25/04/2023	https://clinicaltrials.gov/study/NCT05806060	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	triple-negative breast cancer	PACLITAXEL	targetBased	3	Recruiting	05/03/2020	https://clinicaltrials.gov/study/NCT04296175	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	triple-negative breast cancer	PACLITAXEL	targetBased	3	Recruiting	01/06/2023	https://clinicaltrials.gov/study/NCT05862064	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	triple-negative breast cancer	PACLITAXEL	targetBased	3	Completed	24/07/2017	https://clinicaltrials.gov/study/NCT03197935	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	triple-negative breast cancer	PACLITAXEL	targetBased	3	Completed	25/11/2019	https://clinicaltrials.gov/study/NCT04177108	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	triple-negative breast cancer	PACLITAXEL	targetBased	3	Active, not recruiting	17/12/2019	https://clinicaltrials.gov/study/NCT04148911	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	triple-negative breast cancer	PACLITAXEL	targetBased	3	Active, not recruiting	21/12/2018	https://clinicaltrials.gov/study/NCT04085276	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	triple-negative breast cancer	PACLITAXEL	targetBased	3	Suspended	23/11/2016	https://clinicaltrials.gov/study/NCT03002103	0.7	LoF	protect	study design reconsideration
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	triple-negative breast cancer	PACLITAXEL	targetBased	3	Not yet recruiting	01/06/2024	https://clinicaltrials.gov/study/NCT06419621	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	triple-negative breast cancer	PACLITAXEL	targetBased	3	Completed	25/08/2017	https://clinicaltrials.gov/study/NCT03125902	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	prostate cancer	PACLITAXEL	targetBased	3	Completed	01/01/2000	https://clinicaltrials.gov/study/NCT00004054	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Ovarian Transitional Cell Carcinoma	PACLITAXEL	targetBased	3	Unknown status	21/03/2005	https://clinicaltrials.gov/study/NCT00108745	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Ovarian Transitional Cell Carcinoma	PACLITAXEL	targetBased	3	Active, not recruiting	27/09/2010	https://clinicaltrials.gov/study/NCT01167712	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Ovarian Transitional Cell Carcinoma	PACLITAXEL	targetBased	3	Completed	01/09/2005	https://clinicaltrials.gov/study/NCT00262847	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Ovarian Carcinosarcoma	PACLITAXEL	targetBased	3	Unknown status	17/08/2009	https://clinicaltrials.gov/study/NCT00954174	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	prostate cancer	PACLITAXEL	targetBased	3	Completed	01/10/2002	https://clinicaltrials.gov/study/NCT00030654	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Kaposi's sarcoma	PACLITAXEL	targetBased	3	Completed	01/03/1999	https://clinicaltrials.gov/study/NCT00003350	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	anal canal squamous cell carcinoma	PACLITAXEL	targetBased	3	Active, not recruiting	12/01/2021	https://clinicaltrials.gov/study/NCT04472429	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung cancer	PACLITAXEL	targetBased	3	Unknown status	01/09/1997	https://clinicaltrials.gov/study/NCT00011921	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung cancer	PACLITAXEL	targetBased	3	Completed	01/11/2000	https://clinicaltrials.gov/study/NCT00006484	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung cancer	PACLITAXEL	targetBased	3	Completed	13/10/2014	https://clinicaltrials.gov/study/NCT02279732	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung cancer	PACLITAXEL	targetBased	3	Completed	01/06/2004	https://clinicaltrials.gov/study/NCT00193362	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung cancer	PACLITAXEL	targetBased	3	Completed	25/10/2010	https://clinicaltrials.gov/study/NCT01107626	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung cancer	PACLITAXEL	targetBased	3	Withdrawn	01/09/2001	https://clinicaltrials.gov/study/NCT00054392	0.7	LoF	protect	Not opened at Fox Chase Cancer Center
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung cancer	PACLITAXEL	targetBased	3	Withdrawn	01/11/2002	https://clinicaltrials.gov/study/NCT00055887	0.7	LoF	protect	Study never started. No patients were enrolled.
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung cancer	PACLITAXEL	targetBased	3	Completed	01/03/2000	https://clinicaltrials.gov/study/NCT00005838	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung cancer	PACLITAXEL	targetBased	3	Completed	05/07/2016	https://clinicaltrials.gov/study/NCT02754882	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung cancer	PACLITAXEL	targetBased	3	Terminated	01/08/2007	https://clinicaltrials.gov/study/NCT00551733	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung cancer	PACLITAXEL	targetBased	3	Unknown status	01/10/1998	https://clinicaltrials.gov/study/NCT00003696	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung cancer	PACLITAXEL	targetBased	3	Completed	04/02/2009	https://clinicaltrials.gov/study/NCT00795340	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung cancer	PACLITAXEL	targetBased	3	Terminated	01/10/2009	https://clinicaltrials.gov/study/NCT00801736	0.35	LoF	protect	The antibody used did not appear prognostic/predictive based on interim results.
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung cancer	PACLITAXEL	targetBased	3	Unknown status	01/02/2000	https://clinicaltrials.gov/study/NCT00039039	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung cancer	PACLITAXEL	targetBased	3	Completed	01/04/1998	https://clinicaltrials.gov/study/NCT00003299	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung cancer	PACLITAXEL	targetBased	3	Unknown status	01/05/2000	https://clinicaltrials.gov/study/NCT00006049	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung cancer	PACLITAXEL	targetBased	3	Completed	16/01/2011	https://clinicaltrials.gov/study/NCT01285609	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung cancer	PACLITAXEL	targetBased	3	Completed	01/06/1998	https://clinicaltrials.gov/study/NCT00003235	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung cancer	PACLITAXEL	targetBased	3	Completed	01/05/1998	https://clinicaltrials.gov/study/NCT00003317	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung cancer	PACLITAXEL	targetBased	3	Completed	01/10/1999	https://clinicaltrials.gov/study/NCT00004011	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung cancer	PACLITAXEL	targetBased	3	Completed	01/08/1997	https://clinicaltrials.gov/study/NCT00003159	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung cancer	PACLITAXEL	targetBased	3	Completed	01/09/1998	https://clinicaltrials.gov/study/NCT00003313	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung cancer	PACLITAXEL	targetBased	3	Terminated	27/12/2017	https://clinicaltrials.gov/study/NCT03348904	0.7	LoF	protect	Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention.
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung cancer	PACLITAXEL	targetBased	3	Completed	01/03/2001	https://clinicaltrials.gov/study/NCT00079287	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung cancer	PACLITAXEL	targetBased	3	Recruiting	10/05/2023	https://clinicaltrials.gov/study/NCT05624996	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung cancer	PACLITAXEL	targetBased	3	Completed	01/07/1998	https://clinicaltrials.gov/study/NCT00003387	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung cancer	PACLITAXEL	targetBased	3	Completed	01/10/1997	https://clinicaltrials.gov/study/NCT00003117	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung cancer	PACLITAXEL	targetBased	3	Unknown status	01/06/2002	https://clinicaltrials.gov/study/NCT00077220	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung cancer	PACLITAXEL	targetBased	3	Completed	01/04/2001	https://clinicaltrials.gov/study/NCT00144053	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung cancer	PACLITAXEL	targetBased	3	Completed	01/11/2007	https://clinicaltrials.gov/study/NCT00533949	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung cancer	PACLITAXEL	targetBased	3	Completed	01/01/2002	https://clinicaltrials.gov/study/NCT00028938	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung cancer	PACLITAXEL	targetBased	3	Terminated	01/01/2003	https://clinicaltrials.gov/study/NCT00054210	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung cancer	PACLITAXEL	targetBased	3	Completed	01/08/1998	https://clinicaltrials.gov/study/NCT00003589	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung cancer	PACLITAXEL	targetBased	3	Completed	13/10/2000	https://clinicaltrials.gov/study/NCT00017407	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung cancer	PACLITAXEL	targetBased	3	Terminated	01/01/2000	https://clinicaltrials.gov/study/NCT00004859	0.7	LoF	protect	Trial was stopped early for futility
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung cancer	PACLITAXEL	targetBased	3	Unknown status	01/01/1999	https://clinicaltrials.gov/study/NCT00004887	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	intrahepatic cholangiocarcinoma	PACLITAXEL	targetBased	3	Active, not recruiting	07/02/2019	https://clinicaltrials.gov/study/NCT03768414	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	neoplasm of esophagus	PACLITAXEL	targetBased	3	Completed	01/06/2015	https://clinicaltrials.gov/study/NCT02395705	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	esophageal squamous cell carcinoma	PACLITAXEL	targetBased	3	Unknown status	01/01/2016	https://clinicaltrials.gov/study/NCT02677597	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	esophageal squamous cell carcinoma	PACLITAXEL	targetBased	3	Unknown status	01/11/2015	https://clinicaltrials.gov/study/NCT02611700	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	esophageal squamous cell carcinoma	PACLITAXEL	targetBased	3	Completed	01/04/2012	https://clinicaltrials.gov/study/NCT01591135	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	esophageal squamous cell carcinoma	PACLITAXEL	targetBased	3	Active, not recruiting	12/06/2019	https://clinicaltrials.gov/study/NCT03957590	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	esophageal squamous cell carcinoma	PACLITAXEL	targetBased	3	Completed	26/01/2018	https://clinicaltrials.gov/study/NCT03430843	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	esophageal squamous cell carcinoma	PACLITAXEL	targetBased	3	Active, not recruiting	11/12/2018	https://clinicaltrials.gov/study/NCT03783442	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	esophageal squamous cell carcinoma	PACLITAXEL	targetBased	3	Recruiting	01/07/2023	https://clinicaltrials.gov/study/NCT05919030	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	esophageal squamous cell carcinoma	PACLITAXEL	targetBased	3	Recruiting	01/12/2021	https://clinicaltrials.gov/study/NCT04807673	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	esophageal squamous cell carcinoma	PACLITAXEL	targetBased	3	Completed	24/12/2018	https://clinicaltrials.gov/study/NCT03748134	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	esophageal squamous cell carcinoma	PACLITAXEL	targetBased	3	Recruiting	22/10/2019	https://clinicaltrials.gov/study/NCT04138212	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	esophageal squamous cell carcinoma	PACLITAXEL	targetBased	3	Recruiting	27/11/2020	https://clinicaltrials.gov/study/NCT04460352	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	esophageal squamous cell carcinoma	PACLITAXEL	targetBased	4	Active, not recruiting	10/10/2022	https://clinicaltrials.gov/study/NCT05603065	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	esophageal squamous cell carcinoma	PACLITAXEL	targetBased	3	Recruiting	28/07/2021	https://clinicaltrials.gov/study/NCT04949256	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	esophageal squamous cell carcinoma	PACLITAXEL	targetBased	3	Recruiting	19/03/2024	https://clinicaltrials.gov/study/NCT06304974	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	squamous cell carcinoma of penis	PACLITAXEL	targetBased	3	Recruiting	12/05/2017	https://clinicaltrials.gov/study/NCT02305654	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	teratoma	PACLITAXEL	targetBased	3	Active, not recruiting	26/11/2003	https://clinicaltrials.gov/study/NCT00104676	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	urethra cancer	PACLITAXEL	targetBased	3	Completed	03/12/1998	https://clinicaltrials.gov/study/NCT00003376	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	urethra cancer	PACLITAXEL	targetBased	3	Completed	01/05/2001	https://clinicaltrials.gov/study/NCT00022191	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	transitional cell carcinoma of kidney	PACLITAXEL	targetBased	3	Recruiting	28/06/2021	https://clinicaltrials.gov/study/NCT04579224	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	undifferentiated carcinoma	PACLITAXEL	targetBased	3	Unknown status	21/03/2005	https://clinicaltrials.gov/study/NCT00108745	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast adenocarcinoma	PACLITAXEL	targetBased	3	Suspended	17/01/2014	https://clinicaltrials.gov/study/NCT02037529	0.7	LoF	protect	Total enrollment number is being lowered
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast adenocarcinoma	PACLITAXEL	targetBased	3	Completed	19/05/2000	https://clinicaltrials.gov/study/NCT00005970	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast adenocarcinoma	PACLITAXEL	targetBased	3	Active, not recruiting	05/04/2019	https://clinicaltrials.gov/study/NCT03199885	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast adenocarcinoma	PACLITAXEL	targetBased	3	Active, not recruiting	26/07/2015	https://clinicaltrials.gov/study/NCT02488967	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast adenocarcinoma	PACLITAXEL	targetBased	3	Active, not recruiting	02/11/2007	https://clinicaltrials.gov/study/NCT00433511	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	gastric cancer	PACLITAXEL	targetBased	3	Completed	28/12/2015	https://clinicaltrials.gov/study/NCT02625623	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	gastric cancer	PACLITAXEL	targetBased	3	Completed	01/03/2013	https://clinicaltrials.gov/study/NCT01839773	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	gastric cancer	PACLITAXEL	targetBased	3	Unknown status	16/03/2018	https://clinicaltrials.gov/study/NCT03475615	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	gastric cancer	PACLITAXEL	targetBased	3	Recruiting	21/09/2020	https://clinicaltrials.gov/study/NCT04342910	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	gastric cancer	PACLITAXEL	targetBased	3	Unknown status	01/11/2009	https://clinicaltrials.gov/study/NCT01015339	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	gastric cancer	PACLITAXEL	targetBased	3	Completed	01/12/2010	https://clinicaltrials.gov/study/NCT01170663	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	gastric cancer	PACLITAXEL	targetBased	3	Active, not recruiting	18/10/2017	https://clinicaltrials.gov/study/NCT03223376	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	gastric cancer	PACLITAXEL	targetBased	3	Recruiting	01/03/2020	https://clinicaltrials.gov/study/NCT04135781	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	gastric cancer	PACLITAXEL	targetBased	3	Not yet recruiting	01/11/2022	https://clinicaltrials.gov/study/NCT05610332	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	gastric cancer	PACLITAXEL	targetBased	3	Recruiting	08/03/2019	https://clinicaltrials.gov/study/NCT03801668	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	gastric cancer	PACLITAXEL	targetBased	4	Recruiting	30/12/2023	https://clinicaltrials.gov/study/NCT06169410	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	gastric cancer	PACLITAXEL	targetBased	3	Completed	03/09/2013	https://clinicaltrials.gov/study/NCT01924533	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	gastric cancer	PACLITAXEL	targetBased	3	Completed	01/10/2011	https://clinicaltrials.gov/study/NCT01248403	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	gastric cancer	PACLITAXEL	targetBased	3	Unknown status		https://clinicaltrials.gov/study/NCT01224652	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	gastric cancer	PACLITAXEL	targetBased	3	Recruiting	24/03/2021	https://clinicaltrials.gov/study/NCT04714190	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	gastroesophageal junction adenocarcinoma	PACLITAXEL	targetBased	3	Not yet recruiting	01/09/2023	https://clinicaltrials.gov/study/NCT05978050	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	gastroesophageal junction adenocarcinoma	PACLITAXEL	targetBased	3	Recruiting	19/06/2024	https://clinicaltrials.gov/study/NCT06341335	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	malignant germ cell tumor of ovary	PACLITAXEL	targetBased	3	Recruiting	01/04/2015	https://clinicaltrials.gov/study/NCT02429687	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Active, not recruiting	02/01/2017	https://clinicaltrials.gov/study/NCT03003962	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT01326767	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Recruiting	31/05/2023	https://clinicaltrials.gov/study/NCT05654454	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Completed	01/05/2013	https://clinicaltrials.gov/study/NCT01763671	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Completed	01/05/2002	https://clinicaltrials.gov/study/NCT00050960	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Active, not recruiting	29/03/2018	https://clinicaltrials.gov/study/NCT03519971	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Terminated	01/02/2015	https://clinicaltrials.gov/study/NCT02322281	0.7	LoF	protect	Sponsor discontinued development of CO-1686 for NSCLC
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f10f730f-6479-4f6a-8edc-fa4bd2140c1b	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Completed	01/03/2006	https://clinicaltrials.gov/study/NCT00298415	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Completed	11/06/2015	https://clinicaltrials.gov/study/NCT02367794	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1e1a3a8d-6a6b-46fd-90ae-c7ad9e9b364b	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9ffd3e34-537f-4f65-b00e-57c25bab3b01	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Completed	09/06/2016	https://clinicaltrials.gov/study/NCT02775435	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Active, not recruiting	24/04/2018	https://clinicaltrials.gov/study/NCT03456063	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Not yet recruiting	31/10/2019	https://clinicaltrials.gov/study/NCT04073537	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Completed	06/02/2018	https://clinicaltrials.gov/study/NCT03296163	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	4	Completed	01/01/2017	https://clinicaltrials.gov/study/NCT03092986	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Active, not recruiting	21/07/2015	https://clinicaltrials.gov/study/NCT02453282	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Active, not recruiting	03/11/2015	https://clinicaltrials.gov/study/NCT02542293	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Active, not recruiting	08/02/2021	https://clinicaltrials.gov/study/NCT04736173	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Completed	29/10/2015	https://clinicaltrials.gov/study/NCT02576574	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Active, not recruiting	29/05/2017	https://clinicaltrials.gov/study/NCT03088540	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Terminated	01/04/2008	https://clinicaltrials.gov/study/NCT00596830	0.7	LoF	protect	See termination reason in detailed description.
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Active, not recruiting	05/11/2019	https://clinicaltrials.gov/study/NCT04025879	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Recruiting	29/12/2022	https://clinicaltrials.gov/study/NCT05687266	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=566a00ae-47c0-4cd2-b602-79909bdfd9b1	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Terminated	14/12/2022	https://clinicaltrials.gov/study/NCT05493501	0.7	LoF	protect	The study is being closed based on corporate changes at EQRx and is not related to any efficacy or safety issues with aumolertinib.
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6cefbdb9-1141-4a53-9d05-f6fcc2746834	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Unknown status	01/10/2016	https://clinicaltrials.gov/study/NCT02579564	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Active, not recruiting	09/04/2020	https://clinicaltrials.gov/study/NCT04194203	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Unknown status	01/12/2016	https://clinicaltrials.gov/study/NCT02879097	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Completed	01/03/2006	https://clinicaltrials.gov/study/NCT00322452	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Completed	01/12/2004	https://clinicaltrials.gov/study/NCT00112294	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Active, not recruiting	24/03/2022	https://clinicaltrials.gov/study/NCT05226598	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Recruiting	11/11/2024	https://clinicaltrials.gov/study/NCT06096844	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Terminated	01/04/2008	https://clinicaltrials.gov/study/NCT00662597	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Active, not recruiting	18/05/2018	https://clinicaltrials.gov/study/NCT03520686	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Active, not recruiting	04/03/2017	https://clinicaltrials.gov/study/NCT02998528	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Active, not recruiting	29/04/2020	https://clinicaltrials.gov/study/NCT04092283	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4dbbb7c8-a4b5-484d-a2a4-4d925010fc44	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=88d7cdd2-e650-4a16-adec-873927e03e93	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Active, not recruiting	14/02/2023	https://clinicaltrials.gov/study/NCT05722015	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Active, not recruiting	13/01/2021	https://clinicaltrials.gov/study/NCT04564157	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Not yet recruiting	14/11/2023	https://clinicaltrials.gov/study/NCT05990127	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Withdrawn	31/07/2020	https://clinicaltrials.gov/study/NCT04203511	0.7	LoF	protect	Sponsor Strategic/Business Decision
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Terminated	01/09/2007	https://clinicaltrials.gov/study/NCT00558636	0.35	LoF	protect	Terminated early when the results from Study NCT00300885 showed an overall lack of efficacy in NSCLC and increased mortality in subjects with squamous subtype.
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Recruiting	03/05/2022	https://clinicaltrials.gov/study/NCT05298423	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	4	Recruiting	18/01/2024	https://clinicaltrials.gov/study/NCT06357598	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Completed	31/03/2015	https://clinicaltrials.gov/study/NCT02366143	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Recruiting	25/08/2021	https://clinicaltrials.gov/study/NCT04585490	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Recruiting	16/06/2020	https://clinicaltrials.gov/study/NCT04267848	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Recruiting	01/06/2019	https://clinicaltrials.gov/study/NCT04840290	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Active, not recruiting	03/02/2014	https://clinicaltrials.gov/study/NCT01993810	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	4	Unknown status	01/02/2015	https://clinicaltrials.gov/study/NCT02513355	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Completed	13/06/2017	https://clinicaltrials.gov/study/NCT03117049	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Completed	25/01/2018	https://clinicaltrials.gov/study/NCT05169801	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Completed	30/09/2014	https://clinicaltrials.gov/study/NCT02264990	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Recruiting	17/08/2020	https://clinicaltrials.gov/study/NCT04416035	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Unknown status	01/10/2017	https://clinicaltrials.gov/study/NCT03262948	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Active, not recruiting	05/08/2015	https://clinicaltrials.gov/study/NCT02477826	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Active, not recruiting	23/07/2019	https://clinicaltrials.gov/study/NCT03977194	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Terminated	01/08/2001	https://clinicaltrials.gov/study/NCT00437749	0.7	LoF	protect	slow accrual rate; interim accrual objective met
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Withdrawn	01/09/2007	https://clinicaltrials.gov/study/NCT00576225	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Not yet recruiting	15/06/2020	https://clinicaltrials.gov/study/NCT04203485	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Completed	28/11/2016	https://clinicaltrials.gov/study/NCT02954172	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a6c24189-293f-42ca-b969-75870bb55af0	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Recruiting	14/07/2020	https://clinicaltrials.gov/study/NCT04316364	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Completed	28/03/2017	https://clinicaltrials.gov/study/NCT03169335	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Not yet recruiting	01/02/2019	https://clinicaltrials.gov/study/NCT03792074	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Withdrawn	28/07/2023	https://clinicaltrials.gov/study/NCT05791097	0.7	LoF	protect	Business decision, not driven by safety concerns; no new safety signals have been observed in the ociperlimab program.
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Active, not recruiting	06/12/2018	https://clinicaltrials.gov/study/NCT03800134	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Completed	20/10/2017	https://clinicaltrials.gov/study/NCT03329911	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Completed	05/07/2016	https://clinicaltrials.gov/study/NCT02754882	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Completed	01/05/2001	https://clinicaltrials.gov/study/NCT00198354	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Active, not recruiting	15/11/2019	https://clinicaltrials.gov/study/NCT03390686	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Terminated	01/06/2002	https://clinicaltrials.gov/study/NCT00042302	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Active, not recruiting	01/06/2017	https://clinicaltrials.gov/study/NCT03164616	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d499be2-fdb5-4b9d-a7ce-3662ec9b2e34	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Active, not recruiting	24/08/2017	https://clinicaltrials.gov/study/NCT03215706	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Withdrawn	15/05/2021	https://clinicaltrials.gov/study/NCT04466917	0.7	LoF	protect	Sponsor decision to early terminate the study
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Completed	01/09/2008	https://clinicaltrials.gov/study/NCT00686959	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Terminated	01/12/2005	https://clinicaltrials.gov/study/NCT00269828	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Completed	11/11/2013	https://clinicaltrials.gov/study/NCT01966003	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Active, not recruiting	21/12/2018	https://clinicaltrials.gov/study/NCT03631199	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Terminated	01/07/2007	https://clinicaltrials.gov/study/NCT00460317	0.7	LoF	protect	Amgen discontinued the development of AMG706 because 20050201 did not meet its primary objective.
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Active, not recruiting	29/05/2020	https://clinicaltrials.gov/study/NCT04379635	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Completed	27/03/2014	https://clinicaltrials.gov/study/NCT02041533	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Completed	30/10/2014	https://clinicaltrials.gov/study/NCT02220894	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Terminated	01/01/1998	https://clinicaltrials.gov/study/NCT00273507	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Completed	01/04/2010	https://clinicaltrials.gov/study/NCT00966914	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Active, not recruiting	27/08/2019	https://clinicaltrials.gov/study/NCT03991403	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Recruiting	12/10/2022	https://clinicaltrials.gov/study/NCT05502237	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Terminated	01/02/2006	https://clinicaltrials.gov/study/NCT00300885	0.35	LoF	protect	Based on the results of the interim analysis, it was determined that the study would not meet its primary efficacy endpoint and the study was terminated early.
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Recruiting	10/05/2023	https://clinicaltrials.gov/study/NCT05624996	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Completed	10/04/2014	https://clinicaltrials.gov/study/NCT02106546	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	4	Active, not recruiting	01/02/2023	https://clinicaltrials.gov/study/NCT05583188	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Active, not recruiting	05/08/2021	https://clinicaltrials.gov/study/NCT04956692	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=973efa93-7f9d-440a-a09f-521cf331b5e7	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Not yet recruiting	01/10/2022	https://clinicaltrials.gov/study/NCT05487391	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Completed	17/04/2020	https://clinicaltrials.gov/study/NCT05318443	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Completed	01/03/2004	https://clinicaltrials.gov/study/NCT00087802	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Completed	21/04/2017	https://clinicaltrials.gov/study/NCT03875092	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Unknown status	01/04/2016	https://clinicaltrials.gov/study/NCT02743923	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Completed	01/09/2009	https://clinicaltrials.gov/study/NCT00948675	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Completed	01/10/2012	https://clinicaltrials.gov/study/NCT01763645	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Unknown status	01/01/2014	https://clinicaltrials.gov/study/NCT02058433	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Completed	25/08/2014	https://clinicaltrials.gov/study/NCT02142738	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Terminated	01/11/2005	https://clinicaltrials.gov/study/NCT00254891	0.7	LoF	protect	See Termination Reason in Detailed Description
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Completed	30/07/2018	https://clinicaltrials.gov/study/NCT03594747	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Active, not recruiting	14/08/2019	https://clinicaltrials.gov/study/NCT04033354	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Terminated	01/11/2016	https://clinicaltrials.gov/study/NCT02826161	0.7	LoF	protect	Change of treatment landscape and evolving standard of care
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Completed	01/08/2016	https://clinicaltrials.gov/study/NCT03850444	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Completed	01/12/2008	https://clinicaltrials.gov/study/NCT00762034	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=24d10449-2936-4cd3-b7db-a7683db721e4	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Terminated	11/06/2020	https://clinicaltrials.gov/study/NCT04325698	0.7	LoF	protect	The study was terminated as part of the decision by Pfizer to halt its biosimilars programs in China.
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Completed	01/04/2015	https://clinicaltrials.gov/study/NCT02364999	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Not yet recruiting	05/03/2021	https://clinicaltrials.gov/study/NCT04768075	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Active, not recruiting	06/07/2020	https://clinicaltrials.gov/study/NCT04380636	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Unknown status	01/01/2010	https://clinicaltrials.gov/study/NCT01303926	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	4	Completed	01/04/2008	https://clinicaltrials.gov/study/NCT00686322	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Completed	01/11/2006	https://clinicaltrials.gov/study/NCT00347412	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Completed	01/11/2007	https://clinicaltrials.gov/study/NCT00540514	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Recruiting	11/11/2022	https://clinicaltrials.gov/study/NCT05429463	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Active, not recruiting	28/06/2019	https://clinicaltrials.gov/study/NCT03976362	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	4	Recruiting	06/12/2023	https://clinicaltrials.gov/study/NCT05689671	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Recruiting	15/03/2024	https://clinicaltrials.gov/study/NCT05116462	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	4	Unknown status	01/11/2016	https://clinicaltrials.gov/study/NCT02996214	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Terminated	01/07/2012	https://clinicaltrials.gov/study/NCT02629848	0.35	LoF	protect	Sponsor decision to terminate the study because the study did not meet the primary endpoint.
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Completed	23/05/2011	https://clinicaltrials.gov/study/NCT01364012	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Active, not recruiting	11/09/2020	https://clinicaltrials.gov/study/NCT04205812	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Completed	01/06/2000	https://clinicaltrials.gov/study/NCT00035152	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Unknown status	01/05/2015	https://clinicaltrials.gov/study/NCT02667743	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL	targetBased	3	Completed	07/09/2016	https://clinicaltrials.gov/study/NCT02810457	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	urinary bladder cancer	PACLITAXEL	targetBased	3	Completed	02/04/1999	https://clinicaltrials.gov/study/NCT00003701	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	urinary bladder cancer	PACLITAXEL	targetBased	3	Completed	03/12/1998	https://clinicaltrials.gov/study/NCT00003376	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	urinary bladder cancer	PACLITAXEL	targetBased	3	Completed	13/01/2015	https://clinicaltrials.gov/study/NCT02302807	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	urinary bladder cancer	PACLITAXEL	targetBased	3	Completed	01/05/2001	https://clinicaltrials.gov/study/NCT00022191	0.7	LoF	protect
Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen	PTGER2	PTGER2	Prostaglandin E2 receptor EP2 subtype	prostate cancer	ALPROSTADIL	targetBased	3	Terminated	01/01/2006	https://clinicaltrials.gov/study/NCT00544076	0.7	GoF	protect	Accrual too slow
Modulators of the EP2 prostaglandin E2 receptor - Primary Screening	PTGER2	PTGER2	Prostaglandin E2 receptor EP2 subtype	prostate cancer	ALPROSTADIL	targetBased	3	Terminated	01/01/2006	https://clinicaltrials.gov/study/NCT00544076	0.7	GoF	protect	Accrual too slow
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	melanoma	TIMOLOL	targetBased	3	Unknown status	01/01/2011	https://clinicaltrials.gov/study/NCT01272609	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hemangioma	TIMOLOL	targetBased	3	Completed	01/09/2012	https://clinicaltrials.gov/study/NCT01685398	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hemangioma	TIMOLOL	targetBased	4	Recruiting	01/10/2019	https://clinicaltrials.gov/study/NCT04288700	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hemangioma	TIMOLOL	targetBased	4	Recruiting	23/06/2022	https://clinicaltrials.gov/study/NCT05479123	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	oral cavity cancer	DOCETAXEL	targetBased	3	Completed	01/11/2004	https://clinicaltrials.gov/study/NCT00117572	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	squamous cell carcinoma	DOCETAXEL	targetBased	3	Completed	17/11/2014	https://clinicaltrials.gov/study/NCT02252042	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	squamous cell carcinoma	DOCETAXEL	targetBased	4	Completed	01/12/2013	https://clinicaltrials.gov/study/NCT02088515	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	squamous cell carcinoma	DOCETAXEL	targetBased	3	Completed	01/11/2002	https://clinicaltrials.gov/study/NCT00539630	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	prostate adenocarcinoma	DOCETAXEL	targetBased	3	Active, not recruiting	01/02/2009	https://clinicaltrials.gov/study/NCT03119857	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	prostate adenocarcinoma	DOCETAXEL	targetBased	3	Terminated	01/08/2006	https://clinicaltrials.gov/study/NCT00705822	0.7	LoF	protect	low recruitment rate
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	prostate adenocarcinoma	DOCETAXEL	targetBased	3	Unknown status	01/06/2003	https://clinicaltrials.gov/study/NCT00764166	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	prostate adenocarcinoma	DOCETAXEL	targetBased	3	Terminated	23/09/2020	https://clinicaltrials.gov/study/NCT04907227	0.35	LoF	protect	The data did not support study endpoints
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	prostate adenocarcinoma	DOCETAXEL	targetBased	3	Completed	01/04/2005	https://clinicaltrials.gov/study/NCT00110214	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	prostate adenocarcinoma	DOCETAXEL	targetBased	3	Completed	02/05/2019	https://clinicaltrials.gov/study/NCT03834506	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	prostate adenocarcinoma	DOCETAXEL	targetBased	3	Terminated	01/07/2007	https://clinicaltrials.gov/study/NCT00514917	0.7	LoF	protect	Company decision to discontinue the study, not due to any safety or efficacy concerns
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	prostate adenocarcinoma	DOCETAXEL	targetBased	4	Completed	01/01/2006	https://clinicaltrials.gov/study/NCT00280098	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	prostate adenocarcinoma	DOCETAXEL	targetBased	3	Completed	01/10/2008	https://clinicaltrials.gov/study/NCT00744497	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	prostate adenocarcinoma	DOCETAXEL	targetBased	3	Completed	01/01/2007	https://clinicaltrials.gov/study/NCT00436839	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	prostate adenocarcinoma	DOCETAXEL	targetBased	3	Completed	01/12/2005	https://clinicaltrials.gov/study/NCT00283062	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	metastatic prostate cancer	DOCETAXEL	targetBased	3	Active, not recruiting	01/09/2019	https://clinicaltrials.gov/study/NCT04139772	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	metastatic prostate cancer	DOCETAXEL	targetBased	3	Active, not recruiting	13/11/2013	https://clinicaltrials.gov/study/NCT01957436	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Completed	16/11/1999	https://clinicaltrials.gov/study/NCT00004125	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Completed	01/06/1997	https://clinicaltrials.gov/study/NCT00688740	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Completed	01/05/2002	https://clinicaltrials.gov/study/NCT00429871	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Withdrawn	01/01/2019	https://clinicaltrials.gov/study/NCT03811418	0.7	LoF	protect	Study approved with treatment regimen based on current guidelines. However, reimbursement of IMP was not feasible.
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Completed	16/10/2009	https://clinicaltrials.gov/study/NCT00950300	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Completed	01/01/1999	https://clinicaltrials.gov/study/NCT00190489	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	4	Unknown status	01/12/2016	https://clinicaltrials.gov/study/NCT03123770	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Completed	01/09/2006	https://clinicaltrials.gov/study/NCT00448591	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Completed	01/02/2005	https://clinicaltrials.gov/study/NCT00309556	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Unknown status	01/11/2006	https://clinicaltrials.gov/study/NCT00408408	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Completed	01/10/2004	https://clinicaltrials.gov/study/NCT00093795	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Completed	09/07/2016	https://clinicaltrials.gov/study/NCT03425656	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Completed	01/04/2010	https://clinicaltrials.gov/study/NCT01099436	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Completed	01/09/2003	https://clinicaltrials.gov/study/NCT00311636	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Completed	29/04/2020	https://clinicaltrials.gov/study/NCT05629949	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Not yet recruiting	01/03/2022	https://clinicaltrials.gov/study/NCT05172518	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Unknown status	01/06/2012	https://clinicaltrials.gov/study/NCT01642771	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Completed	01/02/2004	https://clinicaltrials.gov/study/NCT00540800	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Completed	12/02/2008	https://clinicaltrials.gov/study/NCT00567190	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Completed	01/01/2005	https://clinicaltrials.gov/study/NCT00288002	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Completed	01/06/2002	https://clinicaltrials.gov/study/NCT00352378	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Completed	19/02/2018	https://clinicaltrials.gov/study/NCT03013504	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	4	Completed	18/08/2015	https://clinicaltrials.gov/study/NCT02419742	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	4	Completed	17/08/2015	https://clinicaltrials.gov/study/NCT02445586	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Completed	01/06/2001	https://clinicaltrials.gov/study/NCT00424606	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Terminated	01/07/2009	https://clinicaltrials.gov/study/NCT01200212	0.35	LoF	protect	A planed interim analysis shows no benefits, but higher adverse event rates for the experimental arm.
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	paranasal sinus neoplasm	DOCETAXEL	targetBased	3	Completed	01/11/2004	https://clinicaltrials.gov/study/NCT00117572	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Completed	13/09/2016	https://clinicaltrials.gov/study/NCT02896855	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Completed	15/11/2013	https://clinicaltrials.gov/study/NCT01940497	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Completed	01/05/2009	https://clinicaltrials.gov/study/NCT00887536	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	4	Completed	01/08/2005	https://clinicaltrials.gov/study/NCT00127933	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Completed	01/10/2004	https://clinicaltrials.gov/study/NCT00615602	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00793377	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Recruiting	29/09/2020	https://clinicaltrials.gov/study/NCT04400695	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Completed	01/06/2001	https://clinicaltrials.gov/study/NCT00054587	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Recruiting	10/07/2018	https://clinicaltrials.gov/study/NCT03671044	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Completed	01/05/2013	https://clinicaltrials.gov/study/NCT02980965	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Recruiting	04/07/2022	https://clinicaltrials.gov/study/NCT05296798	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Recruiting	07/06/2023	https://clinicaltrials.gov/study/NCT05883852	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Completed	01/11/2001	https://clinicaltrials.gov/study/NCT00312208	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	4	Recruiting	19/07/2021	https://clinicaltrials.gov/study/NCT04136782	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Completed	01/10/2007	https://clinicaltrials.gov/study/NCT00567554	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	4	Completed	09/02/2016	https://clinicaltrials.gov/study/NCT02502864	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Completed	01/09/2005	https://clinicaltrials.gov/study/NCT00236899	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Active, not recruiting	08/11/2011	https://clinicaltrials.gov/study/NCT01358877	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Withdrawn	11/05/2022	https://clinicaltrials.gov/study/NCT05474690	0.7	LoF	protect	The new treatment plan for HER2 positive breast cancer has entered the diagnosis and treatment guide. The treatment plan ECHP-THP in this study is not the optimal treatment plan, therefore this study was terminated.
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Completed	01/02/2002	https://clinicaltrials.gov/study/NCT00191152	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Recruiting	20/12/2021	https://clinicaltrials.gov/study/NCT05159193	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Completed	01/02/2007	https://clinicaltrials.gov/study/NCT00433589	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	4	Not yet recruiting	19/07/2021	https://clinicaltrials.gov/study/NCT04137640	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Completed	01/11/2016	https://clinicaltrials.gov/study/NCT03084237	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Completed	01/06/2002	https://clinicaltrials.gov/study/NCT00294385	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Completed	01/05/2002	https://clinicaltrials.gov/study/NCT00047255	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Completed	01/09/2007	https://clinicaltrials.gov/study/NCT00630032	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Completed	31/07/2010	https://clinicaltrials.gov/study/NCT01120184	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Unknown status	01/05/2005	https://clinicaltrials.gov/study/NCT00430001	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Unknown status	01/12/2007	https://clinicaltrials.gov/study/NCT00629278	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	4	Recruiting	01/10/2015	https://clinicaltrials.gov/study/NCT02627248	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Recruiting	28/07/2023	https://clinicaltrials.gov/study/NCT05894239	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Terminated	01/11/2002	https://clinicaltrials.gov/study/NCT00053911	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Unknown status	01/04/2012	https://clinicaltrials.gov/study/NCT01547741	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Recruiting	28/08/2017	https://clinicaltrials.gov/study/NCT03264547	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Recruiting	12/01/2021	https://clinicaltrials.gov/study/NCT04540692	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Unknown status	01/01/2008	https://clinicaltrials.gov/study/NCT00532727	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Recruiting	01/04/2019	https://clinicaltrials.gov/study/NCT03926091	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Completed	21/02/2014	https://clinicaltrials.gov/study/NCT01964391	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Completed	01/01/2004	https://clinicaltrials.gov/study/NCT00114816	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Not yet recruiting	01/12/2023	https://clinicaltrials.gov/study/NCT06079983	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Completed	01/12/1999	https://clinicaltrials.gov/study/NCT00008411	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Withdrawn		https://clinicaltrials.gov/study/NCT00041171	0.7	LoF	protect	The study was not activated.
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Completed	01/08/2001	https://clinicaltrials.gov/study/NCT00047099	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Completed	01/01/2011	https://clinicaltrials.gov/study/NCT01216111	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Completed	01/08/1994	https://clinicaltrials.gov/study/NCT00002662	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Terminated	31/03/2022	https://clinicaltrials.gov/study/NCT05207514	0.7	LoF	protect	The Decision to Terminate Early Due to Difficulties in Recruiting Participants and Conducting the Study.
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Unknown status	01/07/2009	https://clinicaltrials.gov/study/NCT00944424	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Completed	01/08/2001	https://clinicaltrials.gov/study/NCT00146549	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Completed	06/08/2008	https://clinicaltrials.gov/study/NCT00703326	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Completed	01/02/2004	https://clinicaltrials.gov/study/NCT00129935	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Not yet recruiting	01/10/2023	https://clinicaltrials.gov/study/NCT06057610	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	4	Completed	01/03/2010	https://clinicaltrials.gov/study/NCT01094184	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Completed	02/02/2018	https://clinicaltrials.gov/study/NCT05301010	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Completed	23/09/2014	https://clinicaltrials.gov/study/NCT02187744	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	4	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT01301729	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	4	Recruiting	10/07/2022	https://clinicaltrials.gov/study/NCT05420467	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Completed	01/09/2006	https://clinicaltrials.gov/study/NCT00391092	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Terminated	01/07/2009	https://clinicaltrials.gov/study/NCT00912444	0.35	LoF	protect	TAC treatment was associated with better survial outcome compared with TC treatment, we terminated recruiting and waiting for longer follow up period.
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Completed	01/10/2007	https://clinicaltrials.gov/study/NCT01985724	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Active, not recruiting	01/09/2014	https://clinicaltrials.gov/study/NCT01646034	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Unknown status	01/01/2002	https://clinicaltrials.gov/study/NCT01222052	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Completed	11/08/2018	https://clinicaltrials.gov/study/NCT04957212	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Completed	18/07/2014	https://clinicaltrials.gov/study/NCT02194166	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Completed	01/03/1999	https://clinicaltrials.gov/study/NCT00003782	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	4	Completed	01/04/2011	https://clinicaltrials.gov/study/NCT01660542	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Completed	01/02/2006	https://clinicaltrials.gov/study/NCT00314977	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Active, not recruiting	24/07/2018	https://clinicaltrials.gov/study/NCT03588091	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Not yet recruiting	15/09/2024	https://clinicaltrials.gov/study/NCT06038539	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Unknown status	01/10/2011	https://clinicaltrials.gov/study/NCT01479036	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Terminated	01/06/2014	https://clinicaltrials.gov/study/NCT02144012	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Completed	01/07/2012	https://clinicaltrials.gov/study/NCT02472964	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Completed	01/12/1995	https://clinicaltrials.gov/study/NCT00002707	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Recruiting	01/06/2023	https://clinicaltrials.gov/study/NCT05901428	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Completed	01/01/2011	https://clinicaltrials.gov/study/NCT04031703	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Completed	23/11/2020	https://clinicaltrials.gov/study/NCT04629846	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Unknown status	01/08/2015	https://clinicaltrials.gov/study/NCT02514681	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Completed	29/05/2008	https://clinicaltrials.gov/study/NCT00776724	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=45e6dce4-92e2-4ad1-bf11-bbcefb753636	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Completed	14/03/2016	https://clinicaltrials.gov/study/NCT02586025	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Completed	01/01/2002	https://clinicaltrials.gov/study/NCT02681003	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Not yet recruiting	01/03/2021	https://clinicaltrials.gov/study/NCT04665986	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Not yet recruiting	01/07/2023	https://clinicaltrials.gov/study/NCT05838066	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Completed	20/08/1998	https://clinicaltrials.gov/study/NCT00003519	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Unknown status	01/11/1998	https://clinicaltrials.gov/study/NCT00003679	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Active, not recruiting	22/04/2019	https://clinicaltrials.gov/study/NCT03863223	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Completed	01/07/2003	https://clinicaltrials.gov/study/NCT00331097	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Completed	14/06/2018	https://clinicaltrials.gov/study/NCT03493854	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Completed	05/02/2009	https://clinicaltrials.gov/study/NCT01049425	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Completed	01/09/2004	https://clinicaltrials.gov/study/NCT00091442	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Completed	01/09/2012	https://clinicaltrials.gov/study/NCT01690702	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	4	Withdrawn	01/01/2010	https://clinicaltrials.gov/study/NCT00774241	1	LoF	protect	Study was put on hold then out of Medical Plan therefore cancelled
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Completed	01/06/2010	https://clinicaltrials.gov/study/NCT01314833	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Active, not recruiting	20/10/2020	https://clinicaltrials.gov/study/NCT05985187	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Unknown status	01/06/2002	https://clinicaltrials.gov/study/NCT02393833	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Completed	01/09/2008	https://clinicaltrials.gov/study/NCT00963729	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Recruiting	30/05/2023	https://clinicaltrials.gov/study/NCT05673629	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Completed	01/06/2010	https://clinicaltrials.gov/study/NCT04127019	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Completed	01/08/2004	https://clinicaltrials.gov/study/NCT00431080	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Recruiting	01/09/2017	https://clinicaltrials.gov/study/NCT03949634	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Completed	06/05/2015	https://clinicaltrials.gov/study/NCT02402712	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Completed	01/03/2006	https://clinicaltrials.gov/study/NCT00333775	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Recruiting	18/09/2020	https://clinicaltrials.gov/study/NCT04547907	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Completed	05/12/2013	https://clinicaltrials.gov/study/NCT02019277	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Unknown status	01/08/1997	https://clinicaltrials.gov/study/NCT00010140	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Unknown status	01/06/2012	https://clinicaltrials.gov/study/NCT01622361	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Completed	01/05/1993	https://clinicaltrials.gov/study/NCT00002544	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Completed	27/06/2019	https://clinicaltrials.gov/study/NCT03989037	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	4	Recruiting	21/08/2019	https://clinicaltrials.gov/study/NCT04182568	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Completed	01/03/2001	https://clinicaltrials.gov/study/NCT00017095	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Completed	01/03/2002	https://clinicaltrials.gov/study/NCT00193011	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Completed	01/06/2000	https://clinicaltrials.gov/study/NCT02115204	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Terminated	01/04/2008	https://clinicaltrials.gov/study/NCT00625898	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Recruiting	01/08/2018	https://clinicaltrials.gov/study/NCT04193059	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Active, not recruiting	05/02/2020	https://clinicaltrials.gov/study/NCT04024462	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Unknown status	01/05/2011	https://clinicaltrials.gov/study/NCT01354522	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	4	Recruiting	10/07/2022	https://clinicaltrials.gov/study/NCT05420454	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Completed	07/10/2008	https://clinicaltrials.gov/study/NCT00667251	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Completed	29/05/2007	https://clinicaltrials.gov/study/NCT00493870	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Recruiting	21/06/2022	https://clinicaltrials.gov/study/NCT05430399	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Completed	31/01/2014	https://clinicaltrials.gov/study/NCT01966471	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	4	Recruiting	02/01/2024	https://clinicaltrials.gov/study/NCT06217185	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Completed	01/08/2002	https://clinicaltrials.gov/study/NCT00089479	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	DOCETAXEL	targetBased	3	Recruiting	09/01/2023	https://clinicaltrials.gov/study/NCT05720026	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	adenocarcinoma	DOCETAXEL	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/docetaxel-zentiva-previously-docetaxel-winthrop	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	laryngeal neoplasm	DOCETAXEL	targetBased	3	Completed	01/11/2004	https://clinicaltrials.gov/study/NCT00117572	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	laryngeal neoplasm	DOCETAXEL	targetBased	3	Completed	15/12/2001	https://clinicaltrials.gov/study/NCT00169182	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	ovarian cancer	DOCETAXEL	targetBased	3	Completed	01/10/1998	https://clinicaltrials.gov/study/NCT00003998	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	head and neck malignant neoplasia	DOCETAXEL	targetBased	3	Terminated	01/12/2005	https://clinicaltrials.gov/study/NCT00268372	0.7	LoF	protect	SWOG eliminated its head and neck committee
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	head and neck malignant neoplasia	DOCETAXEL	targetBased	3	Withdrawn		https://clinicaltrials.gov/study/NCT00041171	0.7	LoF	protect	The study was not activated.
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	head and neck malignant neoplasia	DOCETAXEL	targetBased	3	Completed	01/08/2004	https://clinicaltrials.gov/study/NCT00095875	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	head and neck malignant neoplasia	DOCETAXEL	targetBased	3	Completed	01/04/1999	https://clinicaltrials.gov/study/NCT00003888	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	head and neck malignant neoplasia	DOCETAXEL	targetBased	3	Terminated	01/04/2005	https://clinicaltrials.gov/study/NCT00113399	0.7	LoF	protect	Terminated early due to low accrual.
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	head and neck malignant neoplasia	DOCETAXEL	targetBased	4	Completed	15/07/2015	https://clinicaltrials.gov/study/NCT02484677	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	head and neck malignant neoplasia	DOCETAXEL	targetBased	3	Terminated	01/08/2004	https://clinicaltrials.gov/study/NCT00088907	0.35	LoF	protect	It was unlikely that the primary endpoint would be reached based on the fifth interim analysis results.
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	soft tissue sarcoma	DOCETAXEL	targetBased	3	Completed	01/01/2014	https://clinicaltrials.gov/study/NCT02049905	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	soft tissue sarcoma	DOCETAXEL	targetBased	3	Active, not recruiting	01/06/2011	https://clinicaltrials.gov/study/NCT01710176	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	inflammatory breast carcinoma	DOCETAXEL	targetBased	3	Completed	01/10/2000	https://clinicaltrials.gov/study/NCT02324088	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung neoplasm	DOCETAXEL	targetBased	3	Unknown status	01/04/2008	https://clinicaltrials.gov/study/NCT00657423	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung neoplasm	DOCETAXEL	targetBased	3	Completed	01/06/2001	https://clinicaltrials.gov/study/NCT00174629	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung neoplasm	DOCETAXEL	targetBased	3	Completed	01/11/2009	https://clinicaltrials.gov/study/NCT01038661	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	urothelial carcinoma	DOCETAXEL	targetBased	3	Completed	13/07/2015	https://clinicaltrials.gov/study/NCT02426125	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	urothelial carcinoma	DOCETAXEL	targetBased	3	Recruiting	06/04/2023	https://clinicaltrials.gov/study/NCT05754853	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	head and neck squamous cell carcinoma	DOCETAXEL	targetBased	3	Unknown status	01/09/2009	https://clinicaltrials.gov/study/NCT00999700	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	head and neck squamous cell carcinoma	DOCETAXEL	targetBased	3	Completed	29/05/2014	https://clinicaltrials.gov/study/NCT02105636	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	head and neck squamous cell carcinoma	DOCETAXEL	targetBased	3	Not yet recruiting	01/04/2021	https://clinicaltrials.gov/study/NCT04780750	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	head and neck squamous cell carcinoma	DOCETAXEL	targetBased	3	Active, not recruiting	25/06/2015	https://clinicaltrials.gov/study/NCT03340896	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	head and neck squamous cell carcinoma	DOCETAXEL	targetBased	3	Recruiting	01/05/2023	https://clinicaltrials.gov/study/NCT06102395	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	head and neck squamous cell carcinoma	DOCETAXEL	targetBased	3	Completed	01/03/2008	https://clinicaltrials.gov/study/NCT01086826	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	urogenital neoplasm	DOCETAXEL	targetBased	3	Active, not recruiting	13/01/2021	https://clinicaltrials.gov/study/NCT04527991	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	urogenital neoplasm	DOCETAXEL	targetBased	3	Completed	22/10/2014	https://clinicaltrials.gov/study/NCT02256436	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	sarcoma	DOCETAXEL	targetBased	3	Completed	01/01/2003	https://clinicaltrials.gov/study/NCT00142571	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	gastric carcinoma	DOCETAXEL	targetBased	3	Active, not recruiting	19/12/2016	https://clinicaltrials.gov/study/NCT03006432	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	esophageal carcinoma	DOCETAXEL	targetBased	3	Completed	05/05/2017	https://clinicaltrials.gov/study/NCT03099382	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	upper aerodigestive tract neoplasm	DOCETAXEL	targetBased	4	Completed	01/10/2004	https://clinicaltrials.gov/study/NCT00772681	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	upper aerodigestive tract neoplasm	DOCETAXEL	targetBased	3	Completed	27/08/2009	https://clinicaltrials.gov/study/NCT00995293	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	esophageal cancer	DOCETAXEL	targetBased	3	Completed	14/12/2015	https://clinicaltrials.gov/study/NCT02569242	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	esophageal cancer	DOCETAXEL	targetBased	3	Unknown status	01/12/2016	https://clinicaltrials.gov/study/NCT03002064	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	esophageal cancer	DOCETAXEL	targetBased	3	Completed	01/06/2007	https://clinicaltrials.gov/study/NCT00525200	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	esophageal cancer	DOCETAXEL	targetBased	3	Active, not recruiting	01/06/2021	https://clinicaltrials.gov/study/NCT04879368	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung adenocarcinoma	DOCETAXEL	targetBased	3	Completed	01/06/2001	https://clinicaltrials.gov/study/NCT00020709	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung adenocarcinoma	DOCETAXEL	targetBased	3	Terminated	01/04/2013	https://clinicaltrials.gov/study/NCT01798485	0.35	LoF	protect	The study was stopped after the first Interim Analysis due to futility.
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast neoplasm	DOCETAXEL	targetBased	3	Completed	01/07/1999	https://clinicaltrials.gov/study/NCT00121992	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast neoplasm	DOCETAXEL	targetBased	3	Completed	01/04/2001	https://clinicaltrials.gov/study/NCT00021255	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast neoplasm	DOCETAXEL	targetBased	3	Completed	25/06/2014	https://clinicaltrials.gov/study/NCT02131064	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast neoplasm	DOCETAXEL	targetBased	3	Completed	01/06/1998	https://clinicaltrials.gov/study/NCT00174655	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast neoplasm	DOCETAXEL	targetBased	3	Completed	01/01/2008	https://clinicaltrials.gov/study/NCT00593697	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast neoplasm	DOCETAXEL	targetBased	3	Completed	01/10/2002	https://clinicaltrials.gov/study/NCT00191438	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast neoplasm	DOCETAXEL	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/docetaxel-zentiva-previously-docetaxel-winthrop	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast neoplasm	DOCETAXEL	targetBased	3	Completed	01/12/1997	https://clinicaltrials.gov/study/NCT00174707	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast neoplasm	DOCETAXEL	targetBased	4	Completed	01/10/2015	https://clinicaltrials.gov/study/NCT02549677	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast neoplasm	DOCETAXEL	targetBased	3	Completed	01/02/2007	https://clinicaltrials.gov/study/NCT00393939	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast neoplasm	DOCETAXEL	targetBased	3	Completed	01/06/2008	https://clinicaltrials.gov/study/NCT00689156	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast neoplasm	DOCETAXEL	targetBased	3	Unknown status	01/07/2015	https://clinicaltrials.gov/study/NCT02455141	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast neoplasm	DOCETAXEL	targetBased	3	Completed	01/06/2012	https://clinicaltrials.gov/study/NCT01572038	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast neoplasm	DOCETAXEL	targetBased	3	Completed	01/02/2002	https://clinicaltrials.gov/study/NCT00191152	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast neoplasm	DOCETAXEL	targetBased	3	Completed	01/07/2009	https://clinicaltrials.gov/study/NCT02613026	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast neoplasm	DOCETAXEL	targetBased	3	Recruiting	21/06/2022	https://clinicaltrials.gov/study/NCT05430399	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast carcinoma	DOCETAXEL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a630937b-8369-74ad-b68a-f940eb16ff0f	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast carcinoma	DOCETAXEL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c482c813-1eb7-40dd-907a-845a7df112bf	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast carcinoma	DOCETAXEL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a0ec4bcc-93ea-4c41-a4b6-95ec19491807	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast carcinoma	DOCETAXEL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=70aeb960-426c-4805-b956-476bebccd926	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast carcinoma	DOCETAXEL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dd0ca36d-1f54-4568-8d19-a7152addcd52	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast carcinoma	DOCETAXEL	targetBased	3	Completed	01/02/2002	https://clinicaltrials.gov/study/NCT00191152	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast carcinoma	DOCETAXEL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2dc690b-4c69-428a-a67e-8ad007c39548	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast carcinoma	DOCETAXEL	targetBased	3	Active, not recruiting	06/01/2011	https://clinicaltrials.gov/study/NCT01275677	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast carcinoma	DOCETAXEL	targetBased	3	Active, not recruiting	05/04/2019	https://clinicaltrials.gov/study/NCT03199885	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast carcinoma	DOCETAXEL	targetBased	3	Recruiting	27/07/2017	https://clinicaltrials.gov/study/NCT03201861	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast carcinoma	DOCETAXEL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e03d1378-6889-43d5-a34c-f96132cffa88	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast carcinoma	DOCETAXEL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f59f7811-70b7-4c44-99f7-4f4fdce3ed22	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast carcinoma	DOCETAXEL	targetBased	3	Active, not recruiting	15/01/2014	https://clinicaltrials.gov/study/NCT02003209	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast carcinoma	DOCETAXEL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b35e3633-8893-4b0b-af1e-92e342557199	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast carcinoma	DOCETAXEL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2c806400-5fdc-4398-8475-37f700b3191f	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast carcinoma	DOCETAXEL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=45e6dce4-92e2-4ad1-bf11-bbcefb753636	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	peritoneum cancer	DOCETAXEL	targetBased	3	Completed	01/10/1998	https://clinicaltrials.gov/study/NCT00003998	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	nasopharyngeal neoplasm	DOCETAXEL	targetBased	3	Recruiting	01/12/2016	https://clinicaltrials.gov/study/NCT03015727	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	nasopharyngeal neoplasm	DOCETAXEL	targetBased	3	Completed	18/04/2016	https://clinicaltrials.gov/study/NCT02611960	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	oral squamous cell carcinoma	DOCETAXEL	targetBased	3	Recruiting	21/11/2023	https://clinicaltrials.gov/study/NCT05798793	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	oropharynx cancer	DOCETAXEL	targetBased	3	Active, not recruiting	03/10/2016	https://clinicaltrials.gov/study/NCT02908477	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	metastatic malignant neoplasm	DOCETAXEL	targetBased	3	Completed	01/05/2008	https://clinicaltrials.gov/study/NCT00685646	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	metastatic malignant neoplasm	DOCETAXEL	targetBased	3	Completed	01/08/2006	https://clinicaltrials.gov/study/NCT00134056	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	cervical adenocarcinoma	DOCETAXEL	targetBased	3	Recruiting	01/02/2021	https://clinicaltrials.gov/study/NCT04723875	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	stomach neoplasm	DOCETAXEL	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/docetaxel-zentiva-previously-docetaxel-winthrop	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	stomach neoplasm	DOCETAXEL	targetBased	3	Unknown status	01/04/2013	https://clinicaltrials.gov/study/NCT03061058	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	stomach neoplasm	DOCETAXEL	targetBased	3	Not yet recruiting	01/06/2020	https://clinicaltrials.gov/study/NCT04351867	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	stomach neoplasm	DOCETAXEL	targetBased	3	Completed	01/11/2008	https://clinicaltrials.gov/study/NCT00811447	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	cancer	DOCETAXEL	targetBased	3	Completed	01/03/2013	https://clinicaltrials.gov/study/NCT02900742	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	cancer	DOCETAXEL	targetBased	3	Completed	01/05/1999	https://clinicaltrials.gov/study/NCT00273546	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	cancer	DOCETAXEL	targetBased	3	Active, not recruiting	23/03/2018	https://clinicaltrials.gov/study/NCT03390504	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	carcinoma	DOCETAXEL	targetBased	3	Unknown status	01/07/2010	https://clinicaltrials.gov/study/NCT01126138	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	uterine sarcoma	DOCETAXEL	targetBased	3	Terminated	01/11/2009	https://clinicaltrials.gov/study/NCT01012297	0.35	LoF	protect	The study was targeted to accrue 130 patients, but closed early for futility.
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	bladder transitional cell carcinoma	DOCETAXEL	targetBased	3	Recruiting	28/06/2021	https://clinicaltrials.gov/study/NCT04579224	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	male reproductive organ cancer	DOCETAXEL	targetBased	3	Withdrawn		https://clinicaltrials.gov/study/NCT00041171	0.7	LoF	protect	The study was not activated.
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	ureter urothelial carcinoma	DOCETAXEL	targetBased	3	Recruiting	28/06/2021	https://clinicaltrials.gov/study/NCT04579224	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	endometrial neoplasm	DOCETAXEL	targetBased	3	Active, not recruiting	03/02/2022	https://clinicaltrials.gov/study/NCT05173987	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	endometrial neoplasm	DOCETAXEL	targetBased	3	Active, not recruiting	10/01/2021	https://clinicaltrials.gov/study/NCT04634877	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	pharynx cancer	DOCETAXEL	targetBased	3	Completed	15/12/2001	https://clinicaltrials.gov/study/NCT00169182	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	pharynx cancer	DOCETAXEL	targetBased	3	Completed	01/11/2004	https://clinicaltrials.gov/study/NCT00117572	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	cervical cancer	DOCETAXEL	targetBased	3	Unknown status	01/02/2016	https://clinicaltrials.gov/study/NCT02703961	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	head and neck neoplasia	DOCETAXEL	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/docetaxel-zentiva-previously-docetaxel-winthrop	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	kidney neoplasm	DOCETAXEL	targetBased	3	Withdrawn		https://clinicaltrials.gov/study/NCT00041171	0.7	LoF	protect	The study was not activated.
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	gastric adenocarcinoma	DOCETAXEL	targetBased	3	Recruiting	28/01/2023	https://clinicaltrials.gov/study/NCT05813015	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	gastric adenocarcinoma	DOCETAXEL	targetBased	3	Unknown status	01/07/2015	https://clinicaltrials.gov/study/NCT02512380	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	neoplasm	DOCETAXEL	targetBased	4	Unknown status	01/10/2014	https://clinicaltrials.gov/study/NCT02283424	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	neoplasm	DOCETAXEL	targetBased	3	Completed	29/04/2021	https://clinicaltrials.gov/study/NCT04889599	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	neoplasm	DOCETAXEL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=L01CD02	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	squamous cell lung carcinoma	DOCETAXEL	targetBased	4	Unknown status	01/03/2015	https://clinicaltrials.gov/study/NCT02513342	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	squamous cell lung carcinoma	DOCETAXEL	targetBased	3	Completed	01/06/2001	https://clinicaltrials.gov/study/NCT00020709	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	prostate cancer	DOCETAXEL	targetBased	3	Active, not recruiting	08/05/2007	https://clinicaltrials.gov/study/NCT00430183	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	prostate cancer	DOCETAXEL	targetBased	3	Recruiting	01/02/2019	https://clinicaltrials.gov/study/NCT03903835	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	prostate cancer	DOCETAXEL	targetBased	3	Completed	01/08/2006	https://clinicaltrials.gov/study/NCT00134056	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	prostate cancer	DOCETAXEL	targetBased	3	Terminated	02/06/2008	https://clinicaltrials.gov/study/NCT00651326	0.7	LoF	protect	Poor accrual
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	prostate cancer	DOCETAXEL	targetBased	3	Active, not recruiting	06/02/2020	https://clinicaltrials.gov/study/NCT04100018	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	prostate cancer	DOCETAXEL	targetBased	3	Completed	01/01/2008	https://clinicaltrials.gov/study/NCT00617669	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	prostate cancer	DOCETAXEL	targetBased	3	Active, not recruiting	26/09/2006	https://clinicaltrials.gov/study/NCT00309985	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	prostate cancer	DOCETAXEL	targetBased	3	Unknown status	01/05/2007	https://clinicaltrials.gov/study/NCT00653848	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	prostate cancer	DOCETAXEL	targetBased	3	Unknown status	01/10/2005	https://clinicaltrials.gov/study/NCT00376792	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	prostate cancer	DOCETAXEL	targetBased	3	Recruiting	19/06/2018	https://clinicaltrials.gov/study/NCT03574571	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	prostate cancer	DOCETAXEL	targetBased	3	Terminated	01/04/2002	https://clinicaltrials.gov/study/NCT00024167	0.7	LoF	protect	Terminated due to slow accrual
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	prostate cancer	DOCETAXEL	targetBased	3	Completed	01/09/2014	https://clinicaltrials.gov/study/NCT03761225	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	prostate cancer	DOCETAXEL	targetBased	3	Completed	01/10/1999	https://clinicaltrials.gov/study/NCT00004001	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	prostate cancer	DOCETAXEL	targetBased	3	Unknown status	01/04/2010	https://clinicaltrials.gov/study/NCT01224405	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	prostate cancer	DOCETAXEL	targetBased	3	Completed	01/08/2005	https://clinicaltrials.gov/study/NCT00255606	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	prostate cancer	DOCETAXEL	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/docetaxel-zentiva-previously-docetaxel-winthrop	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	prostate cancer	DOCETAXEL	targetBased	3	Completed	18/10/2004	https://clinicaltrials.gov/study/NCT00104715	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	prostate cancer	DOCETAXEL	targetBased	3	Recruiting	25/03/2022	https://clinicaltrials.gov/study/NCT05348577	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	prostate cancer	DOCETAXEL	targetBased	3	Completed	01/06/2005	https://clinicaltrials.gov/study/NCT00116142	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	prostate cancer	DOCETAXEL	targetBased	3	Completed	01/04/2005	https://clinicaltrials.gov/study/NCT00110214	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	prostate cancer	DOCETAXEL	targetBased	3	Completed	01/10/2002	https://clinicaltrials.gov/study/NCT00030654	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	prostate cancer	DOCETAXEL	targetBased	3	Completed	08/10/2003	https://clinicaltrials.gov/study/NCT00027859	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	prostate cancer	DOCETAXEL	targetBased	3	Completed	01/11/2010	https://clinicaltrials.gov/study/NCT01188187	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	prostate cancer	DOCETAXEL	targetBased	3	Terminated	01/01/2006	https://clinicaltrials.gov/study/NCT00273338	0.7	LoF	protect	DSMB
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	prostate cancer	DOCETAXEL	targetBased	3	Unknown status	22/05/2014	https://clinicaltrials.gov/study/NCT02044354	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	prostate cancer	DOCETAXEL	targetBased	3	Completed	05/05/2011	https://clinicaltrials.gov/study/NCT01308567	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	prostate cancer	DOCETAXEL	targetBased	3	Not yet recruiting	01/04/2024	https://clinicaltrials.gov/study/NCT06320067	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	prostate cancer	DOCETAXEL	targetBased	3	Completed	01/05/2008	https://clinicaltrials.gov/study/NCT00685646	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	prostate cancer	DOCETAXEL	targetBased	3	Completed	14/11/2002	https://clinicaltrials.gov/study/NCT00055731	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	prostate cancer	DOCETAXEL	targetBased	3	Terminated	01/07/2005	https://clinicaltrials.gov/study/NCT00133224	0.35	LoF	protect	Accrual and treatment with CG1940/CG8711 stopped due to IDMC recommendation.
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	prostate cancer	DOCETAXEL	targetBased	3	Completed	11/11/2009	https://clinicaltrials.gov/study/NCT00988208	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	prostate cancer	DOCETAXEL	targetBased	3	Active, not recruiting	13/06/2017	https://clinicaltrials.gov/study/NCT02975934	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	prostate cancer	DOCETAXEL	targetBased	3	Completed	30/11/2016	https://clinicaltrials.gov/study/NCT02799602	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	prostate cancer	DOCETAXEL	targetBased	3	Terminated	01/03/2010	https://clinicaltrials.gov/study/NCT01083615	0.7	LoF	protect	Unable to enroll due to criteria for stable baseline pain
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	prostate cancer	DOCETAXEL	targetBased	3	Terminated	01/07/2004	https://clinicaltrials.gov/study/NCT00089856	0.35	LoF	protect	Based on futility analysis showing <30% chance of meeting primary endpoint.
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	prostate cancer	DOCETAXEL	targetBased	3	Completed	01/12/2005	https://clinicaltrials.gov/study/NCT00288080	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	prostate cancer	DOCETAXEL	targetBased	3	Recruiting	16/05/2023	https://clinicaltrials.gov/study/NCT05676203	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	prostate cancer	DOCETAXEL	targetBased	3	Completed	01/06/2006	https://clinicaltrials.gov/study/NCT00132301	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	prostate cancer	DOCETAXEL	targetBased	3	Completed	01/12/2014	https://clinicaltrials.gov/study/NCT02288247	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung cancer	DOCETAXEL	targetBased	3	Completed	01/06/1999	https://clinicaltrials.gov/study/NCT00148291	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung cancer	DOCETAXEL	targetBased	3	Recruiting	01/06/2019	https://clinicaltrials.gov/study/NCT03944980	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung cancer	DOCETAXEL	targetBased	3	Terminated	01/01/2003	https://clinicaltrials.gov/study/NCT00054184	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung cancer	DOCETAXEL	targetBased	3	Completed	01/10/2003	https://clinicaltrials.gov/study/NCT00074204	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung cancer	DOCETAXEL	targetBased	3	Completed	01/03/2001	https://clinicaltrials.gov/study/NCT00079287	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung cancer	DOCETAXEL	targetBased	3	Completed	01/10/2010	https://clinicaltrials.gov/study/NCT01207011	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung cancer	DOCETAXEL	targetBased	3	Completed	01/05/2006	https://clinicaltrials.gov/study/NCT00312377	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung cancer	DOCETAXEL	targetBased	3	Unknown status	01/02/2008	https://clinicaltrials.gov/study/NCT00989690	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung cancer	DOCETAXEL	targetBased	3	Terminated	01/03/2009	https://clinicaltrials.gov/study/NCT00863512	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung cancer	DOCETAXEL	targetBased	3	Unknown status	01/12/2000	https://clinicaltrials.gov/study/NCT00022022	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung cancer	DOCETAXEL	targetBased	3	Completed	04/04/2001	https://clinicaltrials.gov/study/NCT00030771	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung cancer	DOCETAXEL	targetBased	3	Completed	01/08/1997	https://clinicaltrials.gov/study/NCT00003159	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung cancer	DOCETAXEL	targetBased	3	Completed	01/10/2002	https://clinicaltrials.gov/study/NCT00040885	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung cancer	DOCETAXEL	targetBased	3	Terminated	01/04/2005	https://clinicaltrials.gov/study/NCT00113386	0.7	LoF	protect	This study terminated early due to low accrual.
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	esophageal squamous cell carcinoma	DOCETAXEL	targetBased	3	Recruiting	05/02/2024	https://clinicaltrials.gov/study/NCT06194734	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	esophageal squamous cell carcinoma	DOCETAXEL	targetBased	3	Completed	26/01/2018	https://clinicaltrials.gov/study/NCT03430843	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	esophageal squamous cell carcinoma	DOCETAXEL	targetBased	3	Active, not recruiting	01/03/2012	https://clinicaltrials.gov/study/NCT01551589	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	esophageal squamous cell carcinoma	DOCETAXEL	targetBased	3	Recruiting	19/03/2024	https://clinicaltrials.gov/study/NCT06304974	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	esophageal squamous cell carcinoma	DOCETAXEL	targetBased	3	Active, not recruiting	01/07/2015	https://clinicaltrials.gov/study/NCT02465736	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	nasal cavity carcinoma	DOCETAXEL	targetBased	3	Completed	01/11/2004	https://clinicaltrials.gov/study/NCT00117572	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	transitional cell carcinoma of kidney	DOCETAXEL	targetBased	3	Recruiting	28/06/2021	https://clinicaltrials.gov/study/NCT04579224	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	uterine leiomyosarcoma	DOCETAXEL	targetBased	3	Terminated	04/06/2012	https://clinicaltrials.gov/study/NCT01533207	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	uterine leiomyosarcoma	DOCETAXEL	targetBased	3	Terminated	01/11/2009	https://clinicaltrials.gov/study/NCT01012297	0.35	LoF	protect	The study was targeted to accrue 130 patients, but closed early for futility.
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast adenocarcinoma	DOCETAXEL	targetBased	3	Active, not recruiting	05/04/2019	https://clinicaltrials.gov/study/NCT03199885	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	gastric cancer	DOCETAXEL	targetBased	3	Completed	01/03/2006	https://clinicaltrials.gov/study/NCT00287768	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	gastric cancer	DOCETAXEL	targetBased	3	Unknown status	01/01/2017	https://clinicaltrials.gov/study/NCT03001726	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	gastric cancer	DOCETAXEL	targetBased	3	Not yet recruiting	01/03/2024	https://clinicaltrials.gov/study/NCT06296706	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	gastric cancer	DOCETAXEL	targetBased	3	Completed	01/11/1999	https://clinicaltrials.gov/study/NCT00005060	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	gastric cancer	DOCETAXEL	targetBased	3	Terminated	01/01/2013	https://clinicaltrials.gov/study/NCT02076594	0.35	LoF	protect	The interim analysis performed on 09 November 2018, showed the failure to achieve the primary objective of effectiveness of the experimental treatment.
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	gastric cancer	DOCETAXEL	targetBased	3	Completed	01/12/2014	https://clinicaltrials.gov/study/NCT03067792	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	gastric cancer	DOCETAXEL	targetBased	3	Recruiting	15/09/2020	https://clinicaltrials.gov/study/NCT03961867	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	gastric cancer	DOCETAXEL	targetBased	3	Completed	30/12/2011	https://clinicaltrials.gov/study/NCT01515748	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	gastric cancer	DOCETAXEL	targetBased	3	Active, not recruiting	01/02/2016	https://clinicaltrials.gov/study/NCT02578368	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	gastric cancer	DOCETAXEL	targetBased	3	Recruiting	02/10/2013	https://clinicaltrials.gov/study/NCT01935778	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	gastroesophageal junction adenocarcinoma	DOCETAXEL	targetBased	3	Active, not recruiting	03/06/2020	https://clinicaltrials.gov/study/NCT04375605	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	3	Completed	01/01/2005	https://clinicaltrials.gov/study/NCT00095199	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	3	Terminated	22/10/2019	https://clinicaltrials.gov/study/NCT04171284	0.7	LoF	protect	Strategy adjustments, independent of the safety and efficacy of the trial medication
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	4	Unknown status	01/03/2019	https://clinicaltrials.gov/study/NCT03799601	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	4	Completed	01/05/2009	https://clinicaltrials.gov/study/NCT00883675	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	3	Terminated	01/12/2008	https://clinicaltrials.gov/study/NCT00738387	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	3	Recruiting	21/02/2024	https://clinicaltrials.gov/study/NCT06012435	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	3	Active, not recruiting	01/06/2007	https://clinicaltrials.gov/study/NCT00324805	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2c806400-5fdc-4398-8475-37f700b3191f	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	3	Completed	01/07/2004	https://clinicaltrials.gov/study/NCT00430651	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	3	Completed	09/12/2011	https://clinicaltrials.gov/study/NCT01454934	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	3	Terminated	27/07/2021	https://clinicaltrials.gov/study/NCT04921358	0.35	LoF	protect	Due to safety risks and unfavorable risk-benefit assessment results, the sponsor has decided to voluntarily terminate the study.
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	3	Recruiting	08/06/2023	https://clinicaltrials.gov/study/NCT05922345	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	3	Completed	30/11/2017	https://clinicaltrials.gov/study/NCT03358875	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	3	Unknown status	01/10/2015	https://clinicaltrials.gov/study/NCT02643407	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	3	Completed	25/06/2011	https://clinicaltrials.gov/study/NCT01351415	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	3	Active, not recruiting	31/10/2015	https://clinicaltrials.gov/study/NCT02486718	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	3	Recruiting	17/05/2024	https://clinicaltrials.gov/study/NCT06382129	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	3	Terminated	01/02/2015	https://clinicaltrials.gov/study/NCT02322281	0.7	LoF	protect	Sponsor discontinued development of CO-1686 for NSCLC
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	3	Completed	28/06/2013	https://clinicaltrials.gov/study/NCT01828112	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	3	Active, not recruiting	26/06/2019	https://clinicaltrials.gov/study/NCT03976375	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	3	Terminated	06/01/2022	https://clinicaltrials.gov/study/NCT05106335	0.7	LoF	protect	Sponsor R \& D Strategy Adjustment
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	3	Completed	02/11/2012	https://clinicaltrials.gov/study/NCT01673867	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	3	Terminated	01/01/2006	https://clinicaltrials.gov/study/NCT00243204	0.7	LoF	protect	FDA Hold May 2007
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	3	Completed	11/03/2014	https://clinicaltrials.gov/study/NCT02008227	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a630937b-8369-74ad-b68a-f940eb16ff0f	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	3	Completed	03/11/2015	https://clinicaltrials.gov/study/NCT02604342	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	3	Active, not recruiting	01/10/2020	https://clinicaltrials.gov/study/NCT04471428	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	3	Terminated	01/10/2014	https://clinicaltrials.gov/study/NCT02231164	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	3	Completed	01/02/2004	https://clinicaltrials.gov/study/NCT00622349	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	3	Terminated	01/05/2005	https://clinicaltrials.gov/study/NCT00345059	0.7	LoF	protect	slow accrual
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	3	Active, not recruiting	25/09/2013	https://clinicaltrials.gov/study/NCT01933932	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/docetaxel-zentiva-previously-docetaxel-winthrop	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	3	Unknown status	30/09/2016	https://clinicaltrials.gov/study/NCT03269162	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	3	Unknown status	01/10/2013	https://clinicaltrials.gov/study/NCT02001168	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	3	Suspended	12/05/2022	https://clinicaltrials.gov/study/NCT05378763	0.7	LoF	protect	The study has not enrolled any patients. The study design is under discussion and will likely be redesigned in consultation with the FDA.
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	3	Active, not recruiting	15/06/2022	https://clinicaltrials.gov/study/NCT05132075	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	3	Completed	01/12/2013	https://clinicaltrials.gov/study/NCT01999673	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	3	Completed	01/02/2002	https://clinicaltrials.gov/study/NCT00216125	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	4	Unknown status	01/10/2008	https://clinicaltrials.gov/study/NCT00813332	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	3	Not yet recruiting	30/06/2024	https://clinicaltrials.gov/study/NCT06472245	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	3	Completed	01/01/2003	https://clinicaltrials.gov/study/NCT00441922	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	3	Completed	01/05/2013	https://clinicaltrials.gov/study/NCT01763671	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=45e6dce4-92e2-4ad1-bf11-bbcefb753636	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	3	Completed	01/01/2010	https://clinicaltrials.gov/study/NCT01257139	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	3	Completed	01/12/2010	https://clinicaltrials.gov/study/NCT01168973	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	4	Completed	01/03/2008	https://clinicaltrials.gov/study/NCT01442909	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	3	Recruiting	12/05/2023	https://clinicaltrials.gov/study/NCT05673590	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=70aeb960-426c-4805-b956-476bebccd926	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	3	Unknown status	01/01/2014	https://clinicaltrials.gov/study/NCT02076477	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b35e3633-8893-4b0b-af1e-92e342557199	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	3	Completed	01/10/2006	https://clinicaltrials.gov/study/NCT00391274	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	3	Completed	01/04/2010	https://clinicaltrials.gov/study/NCT00966914	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	3	Completed	01/04/2004	https://clinicaltrials.gov/study/NCT00441740	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	3	Terminated	23/01/2019	https://clinicaltrials.gov/study/NCT03626545	0.35	LoF	protect	The study was early terminated due to the lack of efficacy of study treatment observed in the analysis of the primary endpoint of the randomized part
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a0ec4bcc-93ea-4c41-a4b6-95ec19491807	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	3	Completed	01/10/2007	https://clinicaltrials.gov/study/NCT00520676	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	3	Terminated	01/01/2007	https://clinicaltrials.gov/study/NCT00633568	0.7	LoF	protect	Slow recruitment
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	3	Terminated	14/10/2016	https://clinicaltrials.gov/study/NCT02775006	0.7	LoF	protect	accrual to slow, target not achievable
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	3	Completed	01/10/2009	https://clinicaltrials.gov/study/NCT00931008	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	3	Terminated	01/04/2003	https://clinicaltrials.gov/study/NCT00190476	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	3	Completed	01/02/2004	https://clinicaltrials.gov/study/NCT00076388	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2dc690b-4c69-428a-a67e-8ad007c39548	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	3	Active, not recruiting	06/02/2020	https://clinicaltrials.gov/study/NCT04154956	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	3	Completed	01/06/2008	https://clinicaltrials.gov/study/NCT00771563	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	3	Completed	24/03/2015	https://clinicaltrials.gov/study/NCT02395172	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	3	Completed	01/09/2009	https://clinicaltrials.gov/study/NCT00932893	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	3	Completed	07/09/2016	https://clinicaltrials.gov/study/NCT02864394	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	3	Completed	01/12/2015	https://clinicaltrials.gov/study/NCT02504489	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	3	Terminated	01/06/2016	https://clinicaltrials.gov/study/NCT02766140	0.7	LoF	protect	difficulty in recruitment
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	3	Completed	01/12/2004	https://clinicaltrials.gov/study/NCT00112294	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	3	Active, not recruiting	21/12/2020	https://clinicaltrials.gov/study/NCT04656652	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	3	Active, not recruiting	15/07/2019	https://clinicaltrials.gov/study/NCT03906071	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	3	Completed	01/06/2007	https://clinicaltrials.gov/study/NCT00478699	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	3	Terminated	01/07/2011	https://clinicaltrials.gov/study/NCT01282151	0.7	LoF	protect	Difficulty in recruitment due to approval of maintenance pemetrexed treatment
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c482c813-1eb7-40dd-907a-845a7df112bf	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e03d1378-6889-43d5-a34c-f96132cffa88	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	3	Active, not recruiting	05/11/2019	https://clinicaltrials.gov/study/NCT04025879	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	3	Completed	11/12/2015	https://clinicaltrials.gov/study/NCT02613507	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	3	Recruiting	28/03/2024	https://clinicaltrials.gov/study/NCT06300177	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f59f7811-70b7-4c44-99f7-4f4fdce3ed22	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	3	Completed	01/02/2006	https://clinicaltrials.gov/study/NCT00284778	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	3	Active, not recruiting	01/04/2021	https://clinicaltrials.gov/study/NCT04685135	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	3	Completed	01/08/2012	https://clinicaltrials.gov/study/NCT01652469	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	3	Completed	16/10/2012	https://clinicaltrials.gov/study/NCT01642004	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	3	Completed	01/09/2005	https://clinicaltrials.gov/study/NCT00478049	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	3	Completed	01/05/2006	https://clinicaltrials.gov/study/NCT00312377	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	3	Active, not recruiting	15/09/2022	https://clinicaltrials.gov/study/NCT05450692	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	3	Completed	01/09/2003	https://clinicaltrials.gov/study/NCT00252707	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	3	Unknown status	01/11/2007	https://clinicaltrials.gov/study/NCT00637910	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	3	Completed	01/02/2007	https://clinicaltrials.gov/study/NCT00446225	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	3	Recruiting	25/03/2022	https://clinicaltrials.gov/study/NCT04928846	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dd0ca36d-1f54-4568-8d19-a7152addcd52	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	3	Active, not recruiting	01/12/2016	https://clinicaltrials.gov/study/NCT02973789	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	3	Terminated	12/02/2016	https://clinicaltrials.gov/study/NCT02654587	0.7	LoF	protect	due to COVID-19
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	3	Terminated	01/12/2006	https://clinicaltrials.gov/study/NCT00442026	0.7	LoF	protect	Due to poor accrual
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	3	Active, not recruiting	04/06/2020	https://clinicaltrials.gov/study/NCT04303780	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	3	Completed	01/09/2017	https://clinicaltrials.gov/study/NCT03150875	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	3	Unknown status	01/09/2012	https://clinicaltrials.gov/study/NCT01630733	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	3	Completed	01/07/2016	https://clinicaltrials.gov/study/NCT02813785	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	3	Active, not recruiting	17/11/2021	https://clinicaltrials.gov/study/NCT05089734	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	4	Unknown status	01/01/2014	https://clinicaltrials.gov/study/NCT02031601	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	3	Active, not recruiting	11/09/2020	https://clinicaltrials.gov/study/NCT04447118	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	3	Completed	01/05/2007	https://clinicaltrials.gov/study/NCT00499109	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	4	Terminated	01/10/2007	https://clinicaltrials.gov/study/NCT00536107	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	3	Completed	01/03/2006	https://clinicaltrials.gov/study/NCT00556322	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	3	Completed	01/04/2004	https://clinicaltrials.gov/study/NCT00086268	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	3	Completed	01/09/2007	https://clinicaltrials.gov/study/NCT00532155	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	3	Completed	25/09/2020	https://clinicaltrials.gov/study/NCT04427072	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	3	Completed	03/12/2008	https://clinicaltrials.gov/study/NCT00805194	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	3	Active, not recruiting	04/03/2017	https://clinicaltrials.gov/study/NCT02998528	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	3	Terminated	01/04/2013	https://clinicaltrials.gov/study/NCT01798485	0.35	LoF	protect	The study was stopped after the first Interim Analysis due to futility.
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	DOCETAXEL	targetBased	3	Completed	01/10/2005	https://clinicaltrials.gov/study/NCT00326378	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	urinary bladder cancer	DOCETAXEL	targetBased	3	Completed	13/01/2015	https://clinicaltrials.gov/study/NCT02302807	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	urinary bladder cancer	DOCETAXEL	targetBased	3	Recruiting	07/02/2023	https://clinicaltrials.gov/study/NCT05538663	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	hypopharyngeal carcinoma	DOCETAXEL	targetBased	3	Recruiting	01/08/2020	https://clinicaltrials.gov/study/NCT04502641	0.7	LoF	protect
Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3	HDAC3	HDAC3	Histone deacetylase 3	lymphoma	VORINOSTAT	targetBased	3	Withdrawn	01/01/2012	https://clinicaltrials.gov/study/NCT01386398	0.7	LoF	protect	Company withdrew interest
Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3	HDAC3	HDAC3	Histone deacetylase 3	T-cell non-Hodgkin lymphoma	VORINOSTAT	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cd86ee78-2781-468b-930c-3c4677bcc092	1	LoF	protect
Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3	HDAC3	HDAC3	Histone deacetylase 3	multiple myeloma	VORINOSTAT	targetBased	3	Unknown status	01/05/2010	https://clinicaltrials.gov/study/NCT01554852	0.7	LoF	protect
Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3	HDAC3	HDAC3	Histone deacetylase 3	multiple myeloma	VORINOSTAT	targetBased	3	Completed	01/12/2008	https://clinicaltrials.gov/study/NCT00773747	0.7	LoF	protect
Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3	HDAC3	HDAC3	Histone deacetylase 3	mesothelioma	VORINOSTAT	targetBased	3	Completed	30/06/2005	https://clinicaltrials.gov/study/NCT00128102	0.7	LoF	protect
Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3	HDAC3	HDAC3	Histone deacetylase 3	Cutaneous T-cell lymphoma	VORINOSTAT	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cd86ee78-2781-468b-930c-3c4677bcc092	1	LoF	protect
Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3	HDAC3	HDAC3	Histone deacetylase 3	Cutaneous T-cell lymphoma	VORINOSTAT	targetBased	3	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01728805	0.7	LoF	protect
Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3	HDAC3	HDAC3	Histone deacetylase 3	lung cancer	VORINOSTAT	targetBased	3	Completed	30/06/2005	https://clinicaltrials.gov/study/NCT00128102	0.7	LoF	protect
Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3	HDAC3	HDAC3	Histone deacetylase 3	acute myeloid leukemia	VORINOSTAT	targetBased	3	Completed	12/02/2013	https://clinicaltrials.gov/study/NCT01802333	0.7	LoF	protect
Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3	HDAC3	HDAC3	Histone deacetylase 3	neoplasm	VORINOSTAT	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=L01XH01	1	LoF	protect
Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen	PTGER2	PTGER2	Prostaglandin E2 receptor EP2 subtype	benign muscle neoplasm	DINOPROSTONE	targetBased	3	Completed	01/03/2018	https://clinicaltrials.gov/study/NCT05761418	0.7	GoF	protect
Modulators of the EP2 prostaglandin E2 receptor - Primary Screening	PTGER2	PTGER2	Prostaglandin E2 receptor EP2 subtype	benign muscle neoplasm	DINOPROSTONE	targetBased	3	Completed	01/03/2018	https://clinicaltrials.gov/study/NCT05761418	0.7	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	head and neck malignant neoplasia	PILOCARPINE	targetBased	3	Completed	01/04/2002	https://clinicaltrials.gov/study/NCT00168181	0.7	GoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	head and neck malignant neoplasia	PILOCARPINE	targetBased	3	Completed	01/04/2002	https://clinicaltrials.gov/study/NCT00168181	0.7	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	head and neck malignant neoplasia	PILOCARPINE	targetBased	3	Completed	01/04/2002	https://clinicaltrials.gov/study/NCT00168181	0.7	GoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	head and neck malignant neoplasia	PILOCARPINE	targetBased	3	Completed	01/04/2002	https://clinicaltrials.gov/study/NCT00168181	0.7	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	head and neck malignant neoplasia	PILOCARPINE	targetBased	3	Completed	01/04/2002	https://clinicaltrials.gov/study/NCT00168181	0.7	GoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	primary biliary cirrhosis	COLCHICINE	targetBased	3	Completed	01/11/1989	https://clinicaltrials.gov/study/NCT00004748	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	multiple myeloma	COLCHICINE	targetBased	3	Recruiting	30/03/2022	https://clinicaltrials.gov/study/NCT05802992	0.7	LoF	protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	multiple myeloma	ACETAMINOPHEN	targetBased	3	Active, not recruiting	16/06/2020	https://clinicaltrials.gov/study/NCT04270409	0.7		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	cancer	ACETAMINOPHEN	targetBased	4	Completed	01/07/2004	https://clinicaltrials.gov/study/NCT01968018	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	cancer	ACETAMINOPHEN	targetBased	3	Recruiting	20/10/2021	https://clinicaltrials.gov/study/NCT05051735	0.7		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	uterine fibroid	ACETAMINOPHEN	targetBased	4	Completed	01/08/2014	https://clinicaltrials.gov/study/NCT02227316	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	non-melanoma skin carcinoma	ACETAMINOPHEN	targetBased	3	Completed	01/07/2016	https://clinicaltrials.gov/study/NCT03131713	0.7		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Extramammary Paget Disease	ACETAMINOPHEN	targetBased	3	Completed	01/05/2015	https://clinicaltrials.gov/study/NCT02385188	0.7		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Adenomyosis	ACETAMINOPHEN	targetBased	4	Completed	01/08/2014	https://clinicaltrials.gov/study/NCT02227316	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	lung neoplasm	ACETAMINOPHEN	targetBased	4	Completed	01/06/2013	https://clinicaltrials.gov/study/NCT01783236	1		protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	prostate cancer	FENTANYL	targetBased	4	Completed	01/11/2011	https://clinicaltrials.gov/study/NCT01547416	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	prostate cancer	FENTANYL	targetBased	4	Completed	01/11/2011	https://clinicaltrials.gov/study/NCT01547416	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	breast cancer	FENTANYL	targetBased	4	Unknown status	02/02/2017	https://clinicaltrials.gov/study/NCT03051503	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	breast cancer	FENTANYL	targetBased	4	Unknown status	02/02/2017	https://clinicaltrials.gov/study/NCT03051503	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	thyroid neoplasm	FENTANYL	targetBased	4	Completed	01/02/2010	https://clinicaltrials.gov/study/NCT01308320	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	thyroid neoplasm	FENTANYL	targetBased	4	Completed	01/02/2010	https://clinicaltrials.gov/study/NCT01308320	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer	FENTANYL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=73f38bde-2132-2b5a-e053-2a91aa0a6efb	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer	FENTANYL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=73f38bde-2132-2b5a-e053-2a91aa0a6efb	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer	FENTANYL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=39531d0c-db12-4627-81c9-6563076b637b	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer	FENTANYL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=39531d0c-db12-4627-81c9-6563076b637b	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer	FENTANYL	targetBased	3	Completed	01/10/2007	https://clinicaltrials.gov/study/NCT00538850	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer	FENTANYL	targetBased	3	Completed	01/10/2007	https://clinicaltrials.gov/study/NCT00538850	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer	FENTANYL	targetBased	4	Completed	01/04/2011	https://clinicaltrials.gov/study/NCT01809106	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer	FENTANYL	targetBased	4	Completed	01/04/2011	https://clinicaltrials.gov/study/NCT01809106	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer	FENTANYL	targetBased	3	Completed	01/03/2008	https://clinicaltrials.gov/study/NCT00683995	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer	FENTANYL	targetBased	3	Completed	01/03/2008	https://clinicaltrials.gov/study/NCT00683995	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer	FENTANYL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ad7ac196-4c6e-4aab-8742-bdb9f38f4be6	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer	FENTANYL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ad7ac196-4c6e-4aab-8742-bdb9f38f4be6	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer	FENTANYL	targetBased	4	Completed	23/01/2017	https://clinicaltrials.gov/study/NCT02009306	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer	FENTANYL	targetBased	4	Completed	23/01/2017	https://clinicaltrials.gov/study/NCT02009306	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer	FENTANYL	targetBased	3	Completed	01/03/2008	https://clinicaltrials.gov/study/NCT00684632	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer	FENTANYL	targetBased	3	Completed	01/03/2008	https://clinicaltrials.gov/study/NCT00684632	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer	FENTANYL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=18a413e9-11e0-4a8f-86c0-d33b37b7b771	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer	FENTANYL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=18a413e9-11e0-4a8f-86c0-d33b37b7b771	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer	FENTANYL	targetBased	3	Completed	01/06/2006	https://clinicaltrials.gov/study/NCT00362583	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer	FENTANYL	targetBased	3	Completed	01/06/2006	https://clinicaltrials.gov/study/NCT00362583	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer	FENTANYL	targetBased	4	Completed	01/10/2008	https://clinicaltrials.gov/study/NCT00771199	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer	FENTANYL	targetBased	4	Completed	01/10/2008	https://clinicaltrials.gov/study/NCT00771199	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer	FENTANYL	targetBased	4	Terminated	27/04/2016	https://clinicaltrials.gov/study/NCT02623959	1	GoF	protect	Slow Accrual
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer	FENTANYL	targetBased	4	Terminated	27/04/2016	https://clinicaltrials.gov/study/NCT02623959	1	GoF	protect	Slow Accrual
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer	FENTANYL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=90b94524-f913-48b3-3771-7b2fcffd888a	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer	FENTANYL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=90b94524-f913-48b3-3771-7b2fcffd888a	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pancreatic carcinoma	FENTANYL	targetBased	3	Active, not recruiting	30/01/2018	https://clinicaltrials.gov/study/NCT03434678	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pancreatic carcinoma	FENTANYL	targetBased	3	Active, not recruiting	30/01/2018	https://clinicaltrials.gov/study/NCT03434678	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	adenoma	FENTANYL	targetBased	3	Completed	01/02/2005	https://clinicaltrials.gov/study/NCT00286143	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	adenoma	FENTANYL	targetBased	3	Completed	01/02/2005	https://clinicaltrials.gov/study/NCT00286143	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	gastric cancer	FENTANYL	targetBased	3	Completed	01/09/2013	https://clinicaltrials.gov/study/NCT02444897	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	gastric cancer	FENTANYL	targetBased	3	Completed	01/09/2013	https://clinicaltrials.gov/study/NCT02444897	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cirrhosis of liver	FENTANYL	targetBased	4	Unknown status	01/03/2008	https://clinicaltrials.gov/study/NCT00906139	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cirrhosis of liver	FENTANYL	targetBased	4	Unknown status	01/03/2008	https://clinicaltrials.gov/study/NCT00906139	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	prostate adenocarcinoma	ROSIGLITAZONE	targetBased	3	Completed	01/09/2000	https://clinicaltrials.gov/study/NCT00182052	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	prostate adenocarcinoma	ROSIGLITAZONE	targetBased	3	Completed	01/09/2000	https://clinicaltrials.gov/study/NCT00182052	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	prostate adenocarcinoma	ROSIGLITAZONE	targetBased	3	Completed	01/09/2000	https://clinicaltrials.gov/study/NCT00182052	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	prostate adenocarcinoma	ROSIGLITAZONE	targetBased	3	Completed	01/09/2000	https://clinicaltrials.gov/study/NCT00182052	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	prostate adenocarcinoma	ROSIGLITAZONE	targetBased	3	Completed	01/09/2000	https://clinicaltrials.gov/study/NCT00182052	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	prostate adenocarcinoma	ROSIGLITAZONE	targetBased	3	Completed	01/09/2000	https://clinicaltrials.gov/study/NCT00182052	0.7	GoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	Paraganglioma	DEXTROAMPHETAMINE	targetBased	3	Unknown status	01/04/2013	https://clinicaltrials.gov/study/NCT02363075	0.7		protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	lung cancer	ALFENTANIL	targetBased	4	Completed		https://clinicaltrials.gov/study/NCT00440960	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	lung cancer	ALFENTANIL	targetBased	4	Completed		https://clinicaltrials.gov/study/NCT00440960	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer	METHADONE	targetBased	3	Completed	01/08/2004	https://clinicaltrials.gov/study/NCT00184496	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer	METHADONE	targetBased	3	Completed	01/08/2004	https://clinicaltrials.gov/study/NCT00184496	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer	METHADONE	targetBased	3	Terminated	01/02/2008	https://clinicaltrials.gov/study/NCT00634010	0.7	GoF	protect	Slow Accrual
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer	METHADONE	targetBased	3	Terminated	01/02/2008	https://clinicaltrials.gov/study/NCT00634010	0.7	GoF	protect	Slow Accrual
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer	OXYCODONE	targetBased	3	Completed	01/01/2011	https://clinicaltrials.gov/study/NCT01675622	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer	OXYCODONE	targetBased	3	Completed	01/01/2011	https://clinicaltrials.gov/study/NCT01675622	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer	OXYCODONE	targetBased	4	Completed	01/07/2012	https://clinicaltrials.gov/study/NCT01719757	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer	OXYCODONE	targetBased	4	Completed	01/07/2012	https://clinicaltrials.gov/study/NCT01719757	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer	OXYCODONE	targetBased	4	Completed	01/05/2011	https://clinicaltrials.gov/study/NCT01313780	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer	OXYCODONE	targetBased	4	Completed	01/05/2011	https://clinicaltrials.gov/study/NCT01313780	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer	OXYCODONE	targetBased	4	Completed	01/04/2011	https://clinicaltrials.gov/study/NCT01809106	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer	OXYCODONE	targetBased	4	Completed	01/04/2011	https://clinicaltrials.gov/study/NCT01809106	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Genital neoplasm, female	OXYCODONE	targetBased	3	Terminated	31/08/2016	https://clinicaltrials.gov/study/NCT02740114	0.7	GoF	protect	Per PIs request
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Genital neoplasm, female	OXYCODONE	targetBased	3	Terminated	31/08/2016	https://clinicaltrials.gov/study/NCT02740114	0.7	GoF	protect	Per PIs request
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Adenomyosis	ESTRADIOL	targetBased	3	Withdrawn	29/04/2022	https://clinicaltrials.gov/study/NCT03940807	0.7	GoF	protect	Principal investigator departure
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Adenomyosis	ESTRADIOL	targetBased	3	Withdrawn	29/04/2022	https://clinicaltrials.gov/study/NCT03940807	0.7	GoF	protect	Principal investigator departure
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	uterine fibroid	ESTRADIOL	targetBased	3	Completed	16/10/2018	https://clinicaltrials.gov/study/NCT03751124	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	uterine fibroid	ESTRADIOL	targetBased	3	Completed	16/10/2018	https://clinicaltrials.gov/study/NCT03751124	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Endometrial Polyp	ESTRADIOL	targetBased	4	Completed	01/01/2023	https://clinicaltrials.gov/study/NCT06316206	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Endometrial Polyp	ESTRADIOL	targetBased	4	Completed	01/01/2023	https://clinicaltrials.gov/study/NCT06316206	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	prostate cancer	ESTRADIOL	targetBased	3	Unknown status	01/03/2006	https://clinicaltrials.gov/study/NCT00303784	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	prostate cancer	ESTRADIOL	targetBased	3	Unknown status	01/03/2006	https://clinicaltrials.gov/study/NCT00303784	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	ESTRADIOL	targetBased	4	Recruiting	08/02/2022	https://clinicaltrials.gov/study/NCT05486182	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	ESTRADIOL	targetBased	4	Recruiting	08/02/2022	https://clinicaltrials.gov/study/NCT05486182	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=12fea717-3ee5-47af-ba43-2c6fd4d85d5b	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=12fea717-3ee5-47af-ba43-2c6fd4d85d5b	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=596a20bd-d93d-4c48-e053-2991aa0ad4ca	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=596a20bd-d93d-4c48-e053-2991aa0ad4ca	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	ESTRADIOL	targetBased	3	Completed	01/09/1997	https://clinicaltrials.gov/study/NCT00003771	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	ESTRADIOL	targetBased	3	Completed	01/09/1997	https://clinicaltrials.gov/study/NCT00003771	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Endometrial Hyperplasia without Atypia	ESTRADIOL	targetBased	4	Completed	01/10/2014	https://clinicaltrials.gov/study/NCT02872818	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Endometrial Hyperplasia without Atypia	ESTRADIOL	targetBased	4	Completed	01/10/2014	https://clinicaltrials.gov/study/NCT02872818	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	breast ductal carcinoma in situ	SUFENTANIL	targetBased	4	Completed	29/11/2019	https://clinicaltrials.gov/study/NCT04248179	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	breast ductal carcinoma in situ	SUFENTANIL	targetBased	4	Completed	29/11/2019	https://clinicaltrials.gov/study/NCT04248179	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	cirrhosis of liver	CYCLOBENZAPRINE	targetBased	3	Unknown status	01/10/2018	https://clinicaltrials.gov/study/NCT02642861	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	polyp of colon	EPINEPHRINE	targetBased	4	Completed	06/01/2020	https://clinicaltrials.gov/study/NCT04065451	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	gastric cancer	EPINEPHRINE	targetBased	3	Completed	10/01/2020	https://clinicaltrials.gov/study/NCT04032119	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	lung cancer	EPINEPHRINE	targetBased	3	Completed	05/07/2018	https://clinicaltrials.gov/study/NCT03682224	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	male reproductive organ cancer	EPINEPHRINE	targetBased	3	Completed	01/06/2016	https://clinicaltrials.gov/study/NCT02740127	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Nasal Cavity Polyp	EPINEPHRINE	targetBased	4	Completed	14/06/2018	https://clinicaltrials.gov/study/NCT03228914	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	non-small cell lung carcinoma	EPINEPHRINE	targetBased	3	Completed	05/07/2018	https://clinicaltrials.gov/study/NCT03682224	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	benign muscle neoplasm	EPINEPHRINE	targetBased	3	Completed	01/05/2013	https://clinicaltrials.gov/study/NCT01861015	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	pterygium	EPINEPHRINE	targetBased	4	Recruiting	01/09/2023	https://clinicaltrials.gov/study/NCT05978687	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	thyroid neoplasm	FENTANYL CITRATE	targetBased	4	Completed	01/02/2010	https://clinicaltrials.gov/study/NCT01308320	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	thyroid neoplasm	FENTANYL CITRATE	targetBased	4	Completed	01/02/2010	https://clinicaltrials.gov/study/NCT01308320	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer	FENTANYL CITRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ad7ac196-4c6e-4aab-8742-bdb9f38f4be6	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer	FENTANYL CITRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ad7ac196-4c6e-4aab-8742-bdb9f38f4be6	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer	FENTANYL CITRATE	targetBased	4	Terminated	27/04/2016	https://clinicaltrials.gov/study/NCT02623959	1	GoF	protect	Slow Accrual
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer	FENTANYL CITRATE	targetBased	4	Terminated	27/04/2016	https://clinicaltrials.gov/study/NCT02623959	1	GoF	protect	Slow Accrual
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer	FENTANYL CITRATE	targetBased	3	Completed	01/03/2008	https://clinicaltrials.gov/study/NCT00683995	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer	FENTANYL CITRATE	targetBased	3	Completed	01/03/2008	https://clinicaltrials.gov/study/NCT00683995	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer	FENTANYL CITRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=39531d0c-db12-4627-81c9-6563076b637b	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer	FENTANYL CITRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=39531d0c-db12-4627-81c9-6563076b637b	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer	FENTANYL CITRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=90b94524-f913-48b3-3771-7b2fcffd888a	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer	FENTANYL CITRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=90b94524-f913-48b3-3771-7b2fcffd888a	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer	FENTANYL CITRATE	targetBased	3	Completed	01/03/2008	https://clinicaltrials.gov/study/NCT00684632	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer	FENTANYL CITRATE	targetBased	3	Completed	01/03/2008	https://clinicaltrials.gov/study/NCT00684632	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Endometrial Polyp	ETHINYL ESTRADIOL	targetBased	4	Completed	01/01/2023	https://clinicaltrials.gov/study/NCT06316206	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Endometrial Polyp	ETHINYL ESTRADIOL	targetBased	4	Completed	01/01/2023	https://clinicaltrials.gov/study/NCT06316206	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	neoplasm	ETHINYL ESTRADIOL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=L02AA03	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	neoplasm	ETHINYL ESTRADIOL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=L02AA03	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	ETHINYL ESTRADIOL	targetBased	3	Terminated	01/07/2005	https://clinicaltrials.gov/study/NCT00193726	0.7	GoF	protect	The accrual was very slow and there were many competing studies ongoing/initiated .
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	ETHINYL ESTRADIOL	targetBased	3	Terminated	01/07/2005	https://clinicaltrials.gov/study/NCT00193726	0.7	GoF	protect	The accrual was very slow and there were many competing studies ongoing/initiated .
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	neoplasm	OLANZAPINE	targetBased	3	Not yet recruiting	01/10/2020	https://clinicaltrials.gov/study/NCT04536558	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	neoplasm	OLANZAPINE	targetBased	3	Not yet recruiting	01/10/2020	https://clinicaltrials.gov/study/NCT04536558	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	neoplasm	OLANZAPINE	targetBased	3	Not yet recruiting	01/10/2020	https://clinicaltrials.gov/study/NCT04536558	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	neoplasm	OLANZAPINE	targetBased	3	Not yet recruiting	01/10/2020	https://clinicaltrials.gov/study/NCT04536558	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	neoplasm	OLANZAPINE	targetBased	3	Not yet recruiting	01/10/2020	https://clinicaltrials.gov/study/NCT04536558	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	neoplasm	OLANZAPINE	targetBased	3	Not yet recruiting	01/10/2020	https://clinicaltrials.gov/study/NCT04536558	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Genital neoplasm, female	OLANZAPINE	targetBased	3	Terminated	28/12/2020	https://clinicaltrials.gov/study/NCT04503668	0.7	LoF	protect	Lack of Patient Population
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Genital neoplasm, female	OLANZAPINE	targetBased	3	Terminated	28/12/2020	https://clinicaltrials.gov/study/NCT04503668	0.7	LoF	protect	Lack of Patient Population
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Genital neoplasm, female	OLANZAPINE	targetBased	3	Terminated	28/12/2020	https://clinicaltrials.gov/study/NCT04503668	0.7	LoF	protect	Lack of Patient Population
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	neoplasm	OLANZAPINE	targetBased	3	Not yet recruiting	01/10/2020	https://clinicaltrials.gov/study/NCT04536558	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	neoplasm	OLANZAPINE	targetBased	3	Not yet recruiting	01/10/2020	https://clinicaltrials.gov/study/NCT04536558	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	neoplasm	OLANZAPINE	targetBased	3	Not yet recruiting	01/10/2020	https://clinicaltrials.gov/study/NCT04536558	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	neoplasm	OLANZAPINE	targetBased	3	Not yet recruiting	01/10/2020	https://clinicaltrials.gov/study/NCT04536558	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Genital neoplasm, female	OLANZAPINE	targetBased	3	Terminated	28/12/2020	https://clinicaltrials.gov/study/NCT04503668	0.7	LoF	protect	Lack of Patient Population
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Genital neoplasm, female	OLANZAPINE	targetBased	3	Terminated	28/12/2020	https://clinicaltrials.gov/study/NCT04503668	0.7	LoF	protect	Lack of Patient Population
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Genital neoplasm, female	OLANZAPINE	targetBased	3	Terminated	28/12/2020	https://clinicaltrials.gov/study/NCT04503668	0.7	LoF	protect	Lack of Patient Population
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Genital neoplasm, female	OLANZAPINE	targetBased	3	Terminated	28/12/2020	https://clinicaltrials.gov/study/NCT04503668	0.7	LoF	protect	Lack of Patient Population
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Genital neoplasm, female	OLANZAPINE	targetBased	3	Terminated	28/12/2020	https://clinicaltrials.gov/study/NCT04503668	0.7	LoF	protect	Lack of Patient Population
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Genital neoplasm, female	OLANZAPINE	targetBased	3	Terminated	28/12/2020	https://clinicaltrials.gov/study/NCT04503668	0.7	LoF	protect	Lack of Patient Population
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Genital neoplasm, female	OLANZAPINE	targetBased	3	Terminated	28/12/2020	https://clinicaltrials.gov/study/NCT04503668	0.7	LoF	protect	Lack of Patient Population
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	testicular carcinoma	OLANZAPINE	targetBased	3	Recruiting	18/01/2022	https://clinicaltrials.gov/study/NCT05244577	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	testicular carcinoma	OLANZAPINE	targetBased	3	Recruiting	18/01/2022	https://clinicaltrials.gov/study/NCT05244577	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	testicular carcinoma	OLANZAPINE	targetBased	3	Recruiting	18/01/2022	https://clinicaltrials.gov/study/NCT05244577	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	testicular carcinoma	OLANZAPINE	targetBased	3	Recruiting	18/01/2022	https://clinicaltrials.gov/study/NCT05244577	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	testicular carcinoma	OLANZAPINE	targetBased	3	Recruiting	18/01/2022	https://clinicaltrials.gov/study/NCT05244577	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	testicular carcinoma	OLANZAPINE	targetBased	3	Recruiting	18/01/2022	https://clinicaltrials.gov/study/NCT05244577	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	testicular carcinoma	OLANZAPINE	targetBased	3	Recruiting	18/01/2022	https://clinicaltrials.gov/study/NCT05244577	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	testicular carcinoma	OLANZAPINE	targetBased	3	Recruiting	18/01/2022	https://clinicaltrials.gov/study/NCT05244577	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	testicular carcinoma	OLANZAPINE	targetBased	3	Recruiting	18/01/2022	https://clinicaltrials.gov/study/NCT05244577	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	testicular carcinoma	OLANZAPINE	targetBased	3	Recruiting	18/01/2022	https://clinicaltrials.gov/study/NCT05244577	0.7	LoF	protect
Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3	HDAC3	HDAC3	Histone deacetylase 3	breast adenocarcinoma	ENTINOSTAT	targetBased	3	Active, not recruiting	29/03/2014	https://clinicaltrials.gov/study/NCT02115282	0.7	LoF	protect
Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3	HDAC3	HDAC3	Histone deacetylase 3	breast cancer	ENTINOSTAT	targetBased	3	Active, not recruiting	15/05/2018	https://clinicaltrials.gov/study/NCT03538171	0.7	LoF	protect
Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3	HDAC3	HDAC3	Histone deacetylase 3	neoplasm	ENTINOSTAT	targetBased	3			https://www.whocc.no/atc_ddd_index/?code=L01XH05	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	lymphoid neoplasm	CARVEDILOL	targetBased	3	Completed	01/04/2008	https://clinicaltrials.gov/study/NCT01110824	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	cirrhosis of liver	CARVEDILOL	targetBased	4	Unknown status	01/12/2015	https://clinicaltrials.gov/study/NCT02638415	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	acute myeloid leukemia	CARVEDILOL	targetBased	3	Completed	01/04/2008	https://clinicaltrials.gov/study/NCT01110824	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	lymphoid leukemia	CARVEDILOL	targetBased	3	Completed	01/04/2008	https://clinicaltrials.gov/study/NCT01110824	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	lymphoma	CARVEDILOL	targetBased	3	Completed	01/04/2008	https://clinicaltrials.gov/study/NCT01110824	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	multiple myeloma	CARVEDILOL	targetBased	3	Completed	01/04/2008	https://clinicaltrials.gov/study/NCT01110824	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	cancer	CARVEDILOL	targetBased	4	Recruiting	01/08/2021	https://clinicaltrials.gov/study/NCT04939883	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Genital neoplasm, female	PROCHLORPERAZINE	targetBased	3	Terminated	28/12/2020	https://clinicaltrials.gov/study/NCT04503668	0.7	LoF	protect	Lack of Patient Population
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Genital neoplasm, female	PROCHLORPERAZINE	targetBased	3	Terminated	28/12/2020	https://clinicaltrials.gov/study/NCT04503668	0.7	LoF	protect	Lack of Patient Population
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Genital neoplasm, female	PROCHLORPERAZINE	targetBased	3	Terminated	28/12/2020	https://clinicaltrials.gov/study/NCT04503668	0.7	LoF	protect	Lack of Patient Population
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Genital neoplasm, female	PROCHLORPERAZINE	targetBased	3	Terminated	28/12/2020	https://clinicaltrials.gov/study/NCT04503668	0.7	LoF	protect	Lack of Patient Population
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Genital neoplasm, female	PROCHLORPERAZINE	targetBased	3	Terminated	28/12/2020	https://clinicaltrials.gov/study/NCT04503668	0.7	LoF	protect	Lack of Patient Population
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Genital neoplasm, female	PROCHLORPERAZINE	targetBased	3	Terminated	28/12/2020	https://clinicaltrials.gov/study/NCT04503668	0.7	LoF	protect	Lack of Patient Population
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		laryngeal carcinoma	KETAMINE	targetBased	4	Terminated	17/03/2017	https://clinicaltrials.gov/study/NCT03040024	1	LoF	protect	Halted due to COVID 19; we believe we have adequate data for analysis
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		breast cancer	KETAMINE	targetBased	4	Unknown status	20/09/2018	https://clinicaltrials.gov/study/NCT03676114	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		prostate cancer	KETAMINE	targetBased	4	Completed	01/04/2016	https://clinicaltrials.gov/study/NCT02909049	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		childhood acute lymphoblastic leukemia	KETAMINE	targetBased	4	Completed	25/03/2021	https://clinicaltrials.gov/study/NCT05176119	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		endometrium adenocarcinoma	KETAMINE	targetBased	4	Completed	01/06/2017	https://clinicaltrials.gov/study/NCT03164590	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		cancer	KETAMINE	targetBased	3	Unknown status	01/04/2009	https://clinicaltrials.gov/study/NCT01316744	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		cancer	KETAMINE	targetBased	3	Completed	01/06/2016	https://clinicaltrials.gov/study/NCT02927379	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		cirrhosis of liver	KETAMINE	targetBased	3	Completed	01/12/2022	https://clinicaltrials.gov/study/NCT05674877	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		breast neoplasm	KETAMINE	targetBased	4	Completed	01/08/2017	https://clinicaltrials.gov/study/NCT03586154	1	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	endometrial cancer	TAMOXIFEN CITRATE	targetBased	3	Terminated	01/05/2001	https://clinicaltrials.gov/study/NCT00016341	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	endometrial cancer	TAMOXIFEN CITRATE	targetBased	3	Terminated	01/05/2001	https://clinicaltrials.gov/study/NCT00016341	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	endometrial cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	01/03/1997	https://clinicaltrials.gov/study/NCT00002920	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	endometrial cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	01/03/1997	https://clinicaltrials.gov/study/NCT00002920	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast adenocarcinoma	TAMOXIFEN CITRATE	targetBased	3	Completed	19/05/2000	https://clinicaltrials.gov/study/NCT00005970	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast adenocarcinoma	TAMOXIFEN CITRATE	targetBased	3	Completed	19/05/2000	https://clinicaltrials.gov/study/NCT00005970	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast adenocarcinoma	TAMOXIFEN CITRATE	targetBased	3	Active, not recruiting	07/04/2006	https://clinicaltrials.gov/study/NCT00310180	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast adenocarcinoma	TAMOXIFEN CITRATE	targetBased	3	Active, not recruiting	07/04/2006	https://clinicaltrials.gov/study/NCT00310180	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	liver cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	01/04/1997	https://clinicaltrials.gov/study/NCT00003424	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	liver cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	01/04/1997	https://clinicaltrials.gov/study/NCT00003424	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast neoplasm	TAMOXIFEN CITRATE	targetBased	3	Active, not recruiting	12/11/2008	https://clinicaltrials.gov/study/NCT01357772	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast neoplasm	TAMOXIFEN CITRATE	targetBased	3	Active, not recruiting	12/11/2008	https://clinicaltrials.gov/study/NCT01357772	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast neoplasm	TAMOXIFEN CITRATE	targetBased	3	Completed	01/02/1998	https://clinicaltrials.gov/study/NCT00038467	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast neoplasm	TAMOXIFEN CITRATE	targetBased	3	Completed	01/02/1998	https://clinicaltrials.gov/study/NCT00038467	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast neoplasm	TAMOXIFEN CITRATE	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00034125	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast neoplasm	TAMOXIFEN CITRATE	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00034125	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast neoplasm	TAMOXIFEN CITRATE	targetBased	3	Completed	01/01/2002	https://clinicaltrials.gov/study/NCT00279448	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast neoplasm	TAMOXIFEN CITRATE	targetBased	3	Completed	01/01/2002	https://clinicaltrials.gov/study/NCT00279448	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast neoplasm	TAMOXIFEN CITRATE	targetBased	3	Completed	01/08/2001	https://clinicaltrials.gov/study/NCT00036270	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast neoplasm	TAMOXIFEN CITRATE	targetBased	3	Completed	01/08/2001	https://clinicaltrials.gov/study/NCT00036270	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast neoplasm	TAMOXIFEN CITRATE	targetBased	3	Active, not recruiting	09/02/2018	https://clinicaltrials.gov/study/NCT03423199	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast neoplasm	TAMOXIFEN CITRATE	targetBased	3	Active, not recruiting	09/02/2018	https://clinicaltrials.gov/study/NCT03423199	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast neoplasm	TAMOXIFEN CITRATE	targetBased	3	Recruiting	04/10/2022	https://clinicaltrials.gov/study/NCT05514054	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast neoplasm	TAMOXIFEN CITRATE	targetBased	3	Recruiting	04/10/2022	https://clinicaltrials.gov/study/NCT05514054	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	malignant epithelial tumor of ovary	TAMOXIFEN CITRATE	targetBased	3	Completed	01/02/2003	https://clinicaltrials.gov/study/NCT00041080	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	malignant epithelial tumor of ovary	TAMOXIFEN CITRATE	targetBased	3	Completed	01/02/2003	https://clinicaltrials.gov/study/NCT00041080	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	ovarian cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	01/03/2002	https://clinicaltrials.gov/study/NCT02728622	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	ovarian cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	01/03/2002	https://clinicaltrials.gov/study/NCT02728622	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	HER2 Positive Breast Carcinoma	TAMOXIFEN CITRATE	targetBased	3	Completed	19/05/2000	https://clinicaltrials.gov/study/NCT00005970	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	HER2 Positive Breast Carcinoma	TAMOXIFEN CITRATE	targetBased	3	Completed	19/05/2000	https://clinicaltrials.gov/study/NCT00005970	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	prostate cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	01/12/2003	https://clinicaltrials.gov/study/NCT00233610	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	prostate cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	01/12/2003	https://clinicaltrials.gov/study/NCT00233610	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	hyperplasia	TAMOXIFEN CITRATE	targetBased	3	Active, not recruiting	12/11/2008	https://clinicaltrials.gov/study/NCT01357772	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	hyperplasia	TAMOXIFEN CITRATE	targetBased	3	Active, not recruiting	12/11/2008	https://clinicaltrials.gov/study/NCT01357772	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	inflammatory breast carcinoma	TAMOXIFEN CITRATE	targetBased	3	Terminated	01/05/2001	https://clinicaltrials.gov/study/NCT00016276	0.7		protect	Administratively complete.
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	inflammatory breast carcinoma	TAMOXIFEN CITRATE	targetBased	3	Terminated	01/05/2001	https://clinicaltrials.gov/study/NCT00016276	0.7		protect	Administratively complete.
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Fallopian Tube Carcinoma	TAMOXIFEN CITRATE	targetBased	3	Completed	01/03/2002	https://clinicaltrials.gov/study/NCT02728622	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Fallopian Tube Carcinoma	TAMOXIFEN CITRATE	targetBased	3	Completed	01/03/2002	https://clinicaltrials.gov/study/NCT02728622	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	male breast carcinoma	TAMOXIFEN CITRATE	targetBased	3	Completed	01/08/2012	https://clinicaltrials.gov/study/NCT01638247	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	male breast carcinoma	TAMOXIFEN CITRATE	targetBased	3	Completed	01/08/2012	https://clinicaltrials.gov/study/NCT01638247	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast ductal carcinoma in situ	TAMOXIFEN CITRATE	targetBased	3	Active, not recruiting	12/11/2008	https://clinicaltrials.gov/study/NCT01357772	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast ductal carcinoma in situ	TAMOXIFEN CITRATE	targetBased	3	Active, not recruiting	12/11/2008	https://clinicaltrials.gov/study/NCT01357772	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast ductal carcinoma in situ	TAMOXIFEN CITRATE	targetBased	3	Active, not recruiting	15/01/2011	https://clinicaltrials.gov/study/NCT01272037	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast ductal carcinoma in situ	TAMOXIFEN CITRATE	targetBased	3	Active, not recruiting	15/01/2011	https://clinicaltrials.gov/study/NCT01272037	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	peritoneum cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	01/03/2002	https://clinicaltrials.gov/study/NCT02728622	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	peritoneum cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	01/03/2002	https://clinicaltrials.gov/study/NCT02728622	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	peritoneum cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	01/02/2003	https://clinicaltrials.gov/study/NCT00041080	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	peritoneum cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	01/02/2003	https://clinicaltrials.gov/study/NCT00041080	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast carcinoma in situ	TAMOXIFEN CITRATE	targetBased	4	Withdrawn	01/09/2018	https://clinicaltrials.gov/study/NCT03238703	1		protect	Administrative closure based on sponsor recommendation, prior to subject enrollment
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast carcinoma in situ	TAMOXIFEN CITRATE	targetBased	4	Withdrawn	01/09/2018	https://clinicaltrials.gov/study/NCT03238703	1		protect	Administrative closure based on sponsor recommendation, prior to subject enrollment
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	fallopian tube cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	01/02/2003	https://clinicaltrials.gov/study/NCT00041080	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	fallopian tube cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	01/02/2003	https://clinicaltrials.gov/study/NCT00041080	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Unknown status	01/06/2009	https://clinicaltrials.gov/study/NCT00963209	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Unknown status	01/06/2009	https://clinicaltrials.gov/study/NCT00963209	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Not yet recruiting	01/08/2021	https://clinicaltrials.gov/study/NCT05016349	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Not yet recruiting	01/08/2021	https://clinicaltrials.gov/study/NCT05016349	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Unknown status	01/05/1991	https://clinicaltrials.gov/study/NCT00003678	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Unknown status	01/05/1991	https://clinicaltrials.gov/study/NCT00003678	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	01/10/1995	https://clinicaltrials.gov/study/NCT00002646	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	01/10/1995	https://clinicaltrials.gov/study/NCT00002646	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	20/07/1993	https://clinicaltrials.gov/study/NCT00002542	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	20/07/1993	https://clinicaltrials.gov/study/NCT00002542	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bd72fd53-ae0c-4080-9b7f-2d294b14cc86	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bd72fd53-ae0c-4080-9b7f-2d294b14cc86	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	01/07/1998	https://clinicaltrials.gov/study/NCT00003972	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	01/07/1998	https://clinicaltrials.gov/study/NCT00003972	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Recruiting	30/03/2023	https://clinicaltrials.gov/study/NCT05780567	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Recruiting	30/03/2023	https://clinicaltrials.gov/study/NCT05780567	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	01/10/1996	https://clinicaltrials.gov/study/NCT00003013	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	01/10/1996	https://clinicaltrials.gov/study/NCT00003013	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	13/08/1996	https://clinicaltrials.gov/study/NCT00590785	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	13/08/1996	https://clinicaltrials.gov/study/NCT00590785	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=151ce76c-2d44-4c82-850d-ab213bea4d6b	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=151ce76c-2d44-4c82-850d-ab213bea4d6b	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	16/11/1999	https://clinicaltrials.gov/study/NCT00004125	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	16/11/1999	https://clinicaltrials.gov/study/NCT00004125	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Active, not recruiting	24/09/2008	https://clinicaltrials.gov/study/NCT00601900	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Active, not recruiting	24/09/2008	https://clinicaltrials.gov/study/NCT00601900	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Not yet recruiting	02/05/2024	https://clinicaltrials.gov/study/NCT06223698	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Not yet recruiting	02/05/2024	https://clinicaltrials.gov/study/NCT06223698	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Recruiting	30/03/2016	https://clinicaltrials.gov/study/NCT02914158	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Recruiting	30/03/2016	https://clinicaltrials.gov/study/NCT02914158	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	01/12/1990	https://clinicaltrials.gov/study/NCT00309478	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	01/12/1990	https://clinicaltrials.gov/study/NCT00309478	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	4	Completed	27/06/2012	https://clinicaltrials.gov/study/NCT01612871	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	4	Completed	27/06/2012	https://clinicaltrials.gov/study/NCT01612871	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Active, not recruiting	12/09/2013	https://clinicaltrials.gov/study/NCT01674140	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Active, not recruiting	12/09/2013	https://clinicaltrials.gov/study/NCT01674140	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	01/12/2008	https://clinicaltrials.gov/study/NCT00949598	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	01/12/2008	https://clinicaltrials.gov/study/NCT00949598	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Unknown status	01/09/1987	https://clinicaltrials.gov/study/NCT00002460	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Unknown status	01/09/1987	https://clinicaltrials.gov/study/NCT00002460	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	01/05/1993	https://clinicaltrials.gov/study/NCT00002528	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	01/05/1993	https://clinicaltrials.gov/study/NCT00002528	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Unknown status	01/03/2007	https://clinicaltrials.gov/study/NCT00541086	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Unknown status	01/03/2007	https://clinicaltrials.gov/study/NCT00541086	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Active, not recruiting	01/03/2004	https://clinicaltrials.gov/study/NCT00412022	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Active, not recruiting	01/03/2004	https://clinicaltrials.gov/study/NCT00412022	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Active, not recruiting	01/03/2002	https://clinicaltrials.gov/study/NCT01579734	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Active, not recruiting	01/03/2002	https://clinicaltrials.gov/study/NCT01579734	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	25/04/1997	https://clinicaltrials.gov/study/NCT00003032	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	25/04/1997	https://clinicaltrials.gov/study/NCT00003032	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Unknown status	01/08/1997	https://clinicaltrials.gov/study/NCT00010140	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Unknown status	01/08/1997	https://clinicaltrials.gov/study/NCT00010140	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	01/06/1996	https://clinicaltrials.gov/study/NCT00002784	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	01/06/1996	https://clinicaltrials.gov/study/NCT00002784	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	01/03/1998	https://clinicaltrials.gov/study/NCT00004205	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	01/03/1998	https://clinicaltrials.gov/study/NCT00004205	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	01/11/2011	https://clinicaltrials.gov/study/NCT02995772	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	01/11/2011	https://clinicaltrials.gov/study/NCT02995772	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	16/03/2009	https://clinicaltrials.gov/study/NCT00893061	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	16/03/2009	https://clinicaltrials.gov/study/NCT00893061	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	01/11/1998	https://clinicaltrials.gov/study/NCT00241449	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	01/11/1998	https://clinicaltrials.gov/study/NCT00241449	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Unknown status	01/01/1992	https://clinicaltrials.gov/study/NCT00006030	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Unknown status	01/01/1992	https://clinicaltrials.gov/study/NCT00006030	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Recruiting	01/07/2021	https://clinicaltrials.gov/study/NCT04906395	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Recruiting	01/07/2021	https://clinicaltrials.gov/study/NCT04906395	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	01/12/1990	https://clinicaltrials.gov/study/NCT00309491	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	01/12/1990	https://clinicaltrials.gov/study/NCT00309491	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	01/06/1993	https://clinicaltrials.gov/study/NCT00002582	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	01/06/1993	https://clinicaltrials.gov/study/NCT00002582	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Terminated	01/07/1996	https://clinicaltrials.gov/study/NCT00002772	0.7		protect	poor accrual
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Terminated	01/07/1996	https://clinicaltrials.gov/study/NCT00002772	0.7		protect	poor accrual
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Recruiting	15/12/2023	https://clinicaltrials.gov/study/NCT05512364	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Recruiting	15/12/2023	https://clinicaltrials.gov/study/NCT05512364	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Unknown status	01/10/1995	https://clinicaltrials.gov/study/NCT00003016	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Unknown status	01/10/1995	https://clinicaltrials.gov/study/NCT00003016	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Unknown status	01/01/2012	https://clinicaltrials.gov/study/NCT01758146	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Unknown status	01/01/2012	https://clinicaltrials.gov/study/NCT01758146	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Recruiting	01/06/2023	https://clinicaltrials.gov/study/NCT05891093	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Recruiting	01/06/2023	https://clinicaltrials.gov/study/NCT05891093	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	01/08/2001	https://clinicaltrials.gov/study/NCT00047099	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	01/08/2001	https://clinicaltrials.gov/study/NCT00047099	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	24/09/1996	https://clinicaltrials.gov/study/NCT00002864	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	24/09/1996	https://clinicaltrials.gov/study/NCT00002864	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	01/12/1999	https://clinicaltrials.gov/study/NCT00003857	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	01/12/1999	https://clinicaltrials.gov/study/NCT00003857	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Terminated	17/02/2022	https://clinicaltrials.gov/study/NCT05128773	0.7		protect	Sponsor decision to prematurely stop the study, not linked to any safety concern
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Terminated	17/02/2022	https://clinicaltrials.gov/study/NCT05128773	0.7		protect	Sponsor decision to prematurely stop the study, not linked to any safety concern
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	01/03/1993	https://clinicaltrials.gov/study/NCT00002579	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	01/03/1993	https://clinicaltrials.gov/study/NCT00002579	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Recruiting	01/11/2017	https://clinicaltrials.gov/study/NCT03351062	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Recruiting	01/11/2017	https://clinicaltrials.gov/study/NCT03351062	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	01/01/1996	https://clinicaltrials.gov/study/NCT00291759	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	01/01/1996	https://clinicaltrials.gov/study/NCT00291759	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	01/12/2001	https://clinicaltrials.gov/study/NCT00032136	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	01/12/2001	https://clinicaltrials.gov/study/NCT00032136	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Withdrawn		https://clinicaltrials.gov/study/NCT00053339	0.7		protect	The study was not activated.
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Withdrawn		https://clinicaltrials.gov/study/NCT00053339	0.7		protect	The study was not activated.
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	01/06/1999	https://clinicaltrials.gov/study/NCT00295646	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	01/06/1999	https://clinicaltrials.gov/study/NCT00295646	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	01/01/2004	https://clinicaltrials.gov/study/NCT00201851	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	01/01/2004	https://clinicaltrials.gov/study/NCT00201851	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Unknown status	01/02/1998	https://clinicaltrials.gov/study/NCT00003418	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Unknown status	01/02/1998	https://clinicaltrials.gov/study/NCT00003418	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	01/03/1998	https://clinicaltrials.gov/study/NCT00286117	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	01/03/1998	https://clinicaltrials.gov/study/NCT00286117	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	01/12/1995	https://clinicaltrials.gov/study/NCT00002720	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	01/12/1995	https://clinicaltrials.gov/study/NCT00002720	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	01/10/2007	https://clinicaltrials.gov/study/NCT00605267	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	01/10/2007	https://clinicaltrials.gov/study/NCT00605267	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Recruiting	01/03/2014	https://clinicaltrials.gov/study/NCT02097459	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Recruiting	01/03/2014	https://clinicaltrials.gov/study/NCT02097459	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Recruiting	05/10/2023	https://clinicaltrials.gov/study/NCT05952557	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Recruiting	05/10/2023	https://clinicaltrials.gov/study/NCT05952557	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	4	Completed	01/09/2007	https://clinicaltrials.gov/study/NCT00537771	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	4	Completed	01/09/2007	https://clinicaltrials.gov/study/NCT00537771	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Unknown status	01/11/1998	https://clinicaltrials.gov/study/NCT00003680	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Unknown status	01/11/1998	https://clinicaltrials.gov/study/NCT00003680	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Active, not recruiting	01/01/1994	https://clinicaltrials.gov/study/NCT00002644	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Active, not recruiting	01/01/1994	https://clinicaltrials.gov/study/NCT00002644	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Unknown status	01/05/2009	https://clinicaltrials.gov/study/NCT00912548	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Unknown status	01/05/2009	https://clinicaltrials.gov/study/NCT00912548	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	01/11/1995	https://clinicaltrials.gov/study/NCT00002755	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	01/11/1995	https://clinicaltrials.gov/study/NCT00002755	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	4	Completed	01/12/2014	https://clinicaltrials.gov/study/NCT02344940	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	4	Completed	01/12/2014	https://clinicaltrials.gov/study/NCT02344940	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	01/05/1997	https://clinicaltrials.gov/study/NCT00002967	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	01/05/1997	https://clinicaltrials.gov/study/NCT00002967	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Recruiting	31/03/2023	https://clinicaltrials.gov/study/NCT05774951	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Recruiting	31/03/2023	https://clinicaltrials.gov/study/NCT05774951	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	01/04/2005	https://clinicaltrials.gov/study/NCT00171704	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	01/04/2005	https://clinicaltrials.gov/study/NCT00171704	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	01/01/2003	https://clinicaltrials.gov/study/NCT00053898	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	01/01/2003	https://clinicaltrials.gov/study/NCT00053898	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	4	Recruiting	01/03/2018	https://clinicaltrials.gov/study/NCT03355157	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	4	Recruiting	01/03/2018	https://clinicaltrials.gov/study/NCT03355157	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Recruiting	08/02/2021	https://clinicaltrials.gov/study/NCT04134598	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Recruiting	08/02/2021	https://clinicaltrials.gov/study/NCT04134598	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Enrolling by invitation	28/12/2022	https://clinicaltrials.gov/study/NCT05645536	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Enrolling by invitation	28/12/2022	https://clinicaltrials.gov/study/NCT05645536	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	4	Recruiting	01/01/2009	https://clinicaltrials.gov/study/NCT00900744	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	4	Recruiting	01/01/2009	https://clinicaltrials.gov/study/NCT00900744	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	01/05/1996	https://clinicaltrials.gov/study/NCT00002777	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	01/05/1996	https://clinicaltrials.gov/study/NCT00002777	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	01/05/1989	https://clinicaltrials.gov/study/NCT00929591	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	01/05/1989	https://clinicaltrials.gov/study/NCT00929591	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Recruiting	03/08/2022	https://clinicaltrials.gov/study/NCT05306340	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Recruiting	03/08/2022	https://clinicaltrials.gov/study/NCT05306340	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	4	Completed	01/12/2011	https://clinicaltrials.gov/study/NCT01553903	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	4	Completed	01/12/2011	https://clinicaltrials.gov/study/NCT01553903	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	01/09/2003	https://clinicaltrials.gov/study/NCT00072462	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	01/09/2003	https://clinicaltrials.gov/study/NCT00072462	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	01/07/1996	https://clinicaltrials.gov/study/NCT00849030	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	01/07/1996	https://clinicaltrials.gov/study/NCT00849030	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	4	Recruiting	01/11/2022	https://clinicaltrials.gov/study/NCT05525481	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	4	Recruiting	01/11/2022	https://clinicaltrials.gov/study/NCT05525481	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	20/11/2014	https://clinicaltrials.gov/study/NCT02278120	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	20/11/2014	https://clinicaltrials.gov/study/NCT02278120	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00793377	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00793377	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	01/06/1997	https://clinicaltrials.gov/study/NCT00814125	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	01/06/1997	https://clinicaltrials.gov/study/NCT00814125	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	01/07/1996	https://clinicaltrials.gov/study/NCT00152178	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	01/07/1996	https://clinicaltrials.gov/study/NCT00152178	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Recruiting	01/05/2014	https://clinicaltrials.gov/study/NCT02062489	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Recruiting	01/05/2014	https://clinicaltrials.gov/study/NCT02062489	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	01/02/2006	https://clinicaltrials.gov/study/NCT00293540	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	01/02/2006	https://clinicaltrials.gov/study/NCT00293540	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Unknown status	01/12/2007	https://clinicaltrials.gov/study/NCT00629278	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Unknown status	01/12/2007	https://clinicaltrials.gov/study/NCT00629278	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Unknown status	01/11/1998	https://clinicaltrials.gov/study/NCT00003679	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Unknown status	01/11/1998	https://clinicaltrials.gov/study/NCT00003679	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Active, not recruiting	03/11/2003	https://clinicaltrials.gov/study/NCT00066703	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Active, not recruiting	03/11/2003	https://clinicaltrials.gov/study/NCT00066703	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	01/06/1993	https://clinicaltrials.gov/study/NCT00002581	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	01/06/1993	https://clinicaltrials.gov/study/NCT00002581	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Unknown status	01/06/2012	https://clinicaltrials.gov/study/NCT01622361	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Unknown status	01/06/2012	https://clinicaltrials.gov/study/NCT01622361	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	01/06/1993	https://clinicaltrials.gov/study/NCT00002580	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	01/06/1993	https://clinicaltrials.gov/study/NCT00002580	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	01/05/1993	https://clinicaltrials.gov/study/NCT00002529	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	01/05/1993	https://clinicaltrials.gov/study/NCT00002529	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	01/12/1995	https://clinicaltrials.gov/study/NCT00002707	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	01/12/1995	https://clinicaltrials.gov/study/NCT00002707	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	01/05/1999	https://clinicaltrials.gov/study/NCT00003906	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	01/05/1999	https://clinicaltrials.gov/study/NCT00003906	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Terminated	01/08/2003	https://clinicaltrials.gov/study/NCT00066807	0.7		protect	Poor accrual, patients were followed until completion of 5 yrs treatment
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Terminated	01/08/2003	https://clinicaltrials.gov/study/NCT00066807	0.7		protect	Poor accrual, patients were followed until completion of 5 yrs treatment
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	01/06/1998	https://clinicaltrials.gov/study/NCT00784862	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	01/06/1998	https://clinicaltrials.gov/study/NCT00784862	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Terminated	01/11/2002	https://clinicaltrials.gov/study/NCT00053911	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Terminated	01/11/2002	https://clinicaltrials.gov/study/NCT00053911	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	01/02/2007	https://clinicaltrials.gov/study/NCT00433589	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TAMOXIFEN CITRATE	targetBased	3	Completed	01/02/2007	https://clinicaltrials.gov/study/NCT00433589	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast carcinoma	TAMOXIFEN CITRATE	targetBased	3	Active, not recruiting	17/12/2003	https://clinicaltrials.gov/study/NCT00066690	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast carcinoma	TAMOXIFEN CITRATE	targetBased	3	Active, not recruiting	17/12/2003	https://clinicaltrials.gov/study/NCT00066690	0.7		protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	neurofibromatosis type 1	METHYLPHENIDATE	targetBased	4	Completed	01/01/2004	https://clinicaltrials.gov/study/NCT00169611	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	cancer	METHYLPHENIDATE	targetBased	3	Active, not recruiting	02/08/2018	https://clinicaltrials.gov/study/NCT03525873	0.7	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	lymphoid neoplasm	METHYLPHENIDATE	targetBased	3	Recruiting	08/06/2018	https://clinicaltrials.gov/study/NCT03218254	0.7	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	brain neoplasm	METHYLPHENIDATE	targetBased	3	Terminated	01/02/2004	https://clinicaltrials.gov/study/NCT00418691	0.7	LoF	protect	Closed early due to slow accrual.
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	metastatic malignant neoplasm	METHYLPHENIDATE	targetBased	3	Active, not recruiting	02/08/2018	https://clinicaltrials.gov/study/NCT03525873	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	small cell carcinoma	GUANIDINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=903fbd33-e5d9-41fb-9414-7bd6f42a8593	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	small cell carcinoma	GUANIDINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=903fbd33-e5d9-41fb-9414-7bd6f42a8593	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	small cell carcinoma	GUANIDINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=903fbd33-e5d9-41fb-9414-7bd6f42a8593	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	small cell carcinoma	GUANIDINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=903fbd33-e5d9-41fb-9414-7bd6f42a8593	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	neuroendocrine neoplasm	GUANIDINE	targetBased	3	Completed	01/11/2001	https://clinicaltrials.gov/study/NCT00037869	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	neuroendocrine neoplasm	GUANIDINE	targetBased	3	Completed	01/11/2001	https://clinicaltrials.gov/study/NCT00037869	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	neuroendocrine neoplasm	GUANIDINE	targetBased	3	Completed	01/11/2001	https://clinicaltrials.gov/study/NCT00037869	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	neuroendocrine neoplasm	GUANIDINE	targetBased	3	Completed	01/11/2001	https://clinicaltrials.gov/study/NCT00037869	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	neuroendocrine neoplasm	GUANIDINE	targetBased	3	Completed	01/11/2001	https://clinicaltrials.gov/study/NCT00037869	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	neuroendocrine neoplasm	GUANIDINE	targetBased	3	Completed	01/11/2001	https://clinicaltrials.gov/study/NCT00037869	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	neuroendocrine neoplasm	GUANIDINE	targetBased	3	Completed	01/11/2001	https://clinicaltrials.gov/study/NCT00037869	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	small cell carcinoma	GUANIDINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=903fbd33-e5d9-41fb-9414-7bd6f42a8593	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	small cell carcinoma	GUANIDINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=903fbd33-e5d9-41fb-9414-7bd6f42a8593	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	small cell carcinoma	GUANIDINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=903fbd33-e5d9-41fb-9414-7bd6f42a8593	1	LoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	primary biliary cirrhosis	BEZAFIBRATE	targetBased	3	Active, not recruiting	02/10/2020	https://clinicaltrials.gov/study/NCT04751188	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	primary biliary cirrhosis	BEZAFIBRATE	targetBased	3	Active, not recruiting	02/10/2020	https://clinicaltrials.gov/study/NCT04751188	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	primary biliary cirrhosis	BEZAFIBRATE	targetBased	3	Active, not recruiting	02/10/2020	https://clinicaltrials.gov/study/NCT04751188	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	primary biliary cirrhosis	BEZAFIBRATE	targetBased	3	Active, not recruiting	02/10/2020	https://clinicaltrials.gov/study/NCT04751188	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	primary biliary cirrhosis	BEZAFIBRATE	targetBased	3	Active, not recruiting	02/10/2020	https://clinicaltrials.gov/study/NCT04751188	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	primary biliary cirrhosis	BEZAFIBRATE	targetBased	3	Active, not recruiting	02/10/2020	https://clinicaltrials.gov/study/NCT04751188	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	primary biliary cirrhosis	BEZAFIBRATE	targetBased	3	Unknown status	01/10/2016	https://clinicaltrials.gov/study/NCT02937012	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	primary biliary cirrhosis	BEZAFIBRATE	targetBased	3	Unknown status	01/10/2016	https://clinicaltrials.gov/study/NCT02937012	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	primary biliary cirrhosis	BEZAFIBRATE	targetBased	3	Unknown status	01/10/2016	https://clinicaltrials.gov/study/NCT02937012	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	primary biliary cirrhosis	BEZAFIBRATE	targetBased	3	Unknown status	01/10/2016	https://clinicaltrials.gov/study/NCT02937012	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	primary biliary cirrhosis	BEZAFIBRATE	targetBased	3	Unknown status	01/10/2016	https://clinicaltrials.gov/study/NCT02937012	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	primary biliary cirrhosis	BEZAFIBRATE	targetBased	3	Unknown status	01/10/2016	https://clinicaltrials.gov/study/NCT02937012	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	primary biliary cirrhosis	BEZAFIBRATE	targetBased	3	Unknown status	01/02/2016	https://clinicaltrials.gov/study/NCT02701166	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	primary biliary cirrhosis	BEZAFIBRATE	targetBased	3	Unknown status	01/02/2016	https://clinicaltrials.gov/study/NCT02701166	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	primary biliary cirrhosis	BEZAFIBRATE	targetBased	3	Unknown status	01/02/2016	https://clinicaltrials.gov/study/NCT02701166	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	primary biliary cirrhosis	BEZAFIBRATE	targetBased	3	Unknown status	01/02/2016	https://clinicaltrials.gov/study/NCT02701166	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	primary biliary cirrhosis	BEZAFIBRATE	targetBased	3	Unknown status	01/02/2016	https://clinicaltrials.gov/study/NCT02701166	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	primary biliary cirrhosis	BEZAFIBRATE	targetBased	3	Unknown status	01/02/2016	https://clinicaltrials.gov/study/NCT02701166	0.7	GoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	BOSUTINIB	targetBased	3	Not yet recruiting	01/05/2024	https://clinicaltrials.gov/study/NCT06423911	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	BOSUTINIB	targetBased	4	Recruiting	30/08/2022	https://clinicaltrials.gov/study/NCT04877522	1	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	BOSUTINIB	targetBased	3	Completed	15/07/2014	https://clinicaltrials.gov/study/NCT02130557	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	BOSUTINIB	targetBased	3	Active, not recruiting	29/11/2016	https://clinicaltrials.gov/study/NCT03106779	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	BOSUTINIB	targetBased	4	Terminated	07/11/2014	https://clinicaltrials.gov/study/NCT02228382	1	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	BOSUTINIB	targetBased	3	Completed	05/02/2008	https://clinicaltrials.gov/study/NCT00574873	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	BOSUTINIB	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203341lbl.pdf	1	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	BOSUTINIB	targetBased	3	Active, not recruiting	06/10/2021	https://clinicaltrials.gov/study/NCT04971226	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	BOSUTINIB	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adc84ad5-a04d-4fee-9ba8-91f7abd928e3	1	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	neoplasm	BOSUTINIB	targetBased	3			https://www.whocc.no/atc_ddd_index/?code=L01EA04	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	myeloid leukemia	BOSUTINIB	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/bosulif	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	non-small cell lung carcinoma	LOPERAMIDE	targetBased	3	Completed	01/04/2013	https://clinicaltrials.gov/study/NCT01814553	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	non-small cell lung carcinoma	LOPERAMIDE	targetBased	3	Completed	01/04/2013	https://clinicaltrials.gov/study/NCT01814553	0.7	GoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	POMALIDOMIDE	targetBased	3	Recruiting	15/12/2022	https://clinicaltrials.gov/study/NCT05438043	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	POMALIDOMIDE	targetBased	3	Active, not recruiting	14/10/2021	https://clinicaltrials.gov/study/NCT05083169	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	POMALIDOMIDE	targetBased	3	Active, not recruiting	23/06/2022	https://clinicaltrials.gov/study/NCT05405166	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	POMALIDOMIDE	targetBased	3	Active, not recruiting	04/01/2021	https://clinicaltrials.gov/study/NCT05236621	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	POMALIDOMIDE	targetBased	3	Recruiting	01/10/2020	https://clinicaltrials.gov/study/NCT04484623	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	POMALIDOMIDE	targetBased	3	Recruiting	22/01/2024	https://clinicaltrials.gov/study/NCT06208150	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	POMALIDOMIDE	targetBased	3	Active, not recruiting	02/04/2020	https://clinicaltrials.gov/study/NCT04162210	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	POMALIDOMIDE	targetBased	3	Completed	07/01/2013	https://clinicaltrials.gov/study/NCT01734928	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	POMALIDOMIDE	targetBased	3	Recruiting	04/10/2021	https://clinicaltrials.gov/study/NCT05020236	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	POMALIDOMIDE	targetBased	3	Completed	22/12/2016	https://clinicaltrials.gov/study/NCT02990338	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	POMALIDOMIDE	targetBased	3	Recruiting	27/03/2024	https://clinicaltrials.gov/study/NCT06464991	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	POMALIDOMIDE	targetBased	3	Recruiting	19/04/2022	https://clinicaltrials.gov/study/NCT05028348	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	POMALIDOMIDE	targetBased	3	Withdrawn	03/05/2024	https://clinicaltrials.gov/study/NCT06232707	0.7	LoF	protect	Business objectives have changed
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	POMALIDOMIDE	targetBased	4	Withdrawn	30/06/2022	https://clinicaltrials.gov/study/NCT05183139	1	LoF	protect	Business decision (no enrollment)
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	POMALIDOMIDE	targetBased	3	Recruiting	19/05/2024	https://clinicaltrials.gov/study/NCT06158841	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	POMALIDOMIDE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/imnovid	1	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	POMALIDOMIDE	targetBased	3	Active, not recruiting	12/06/2020	https://clinicaltrials.gov/study/NCT04181827	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	POMALIDOMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2b25ef01-5c9e-11e1-b86c-0800200c9a66	1	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	POMALIDOMIDE	targetBased	3	Unknown status	01/06/2017	https://clinicaltrials.gov/study/NCT03143049	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	POMALIDOMIDE	targetBased	3	Terminated	18/02/2016	https://clinicaltrials.gov/study/NCT03440411	0.7	LoF	protect	Low enrollment
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	POMALIDOMIDE	targetBased	3	Completed	11/03/2011	https://clinicaltrials.gov/study/NCT01311687	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	POMALIDOMIDE	targetBased	3	Recruiting	20/09/2022	https://clinicaltrials.gov/study/NCT05519085	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	POMALIDOMIDE	targetBased	3	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT01324947	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	POMALIDOMIDE	targetBased	3	Recruiting	08/02/2024	https://clinicaltrials.gov/study/NCT06152575	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	POMALIDOMIDE	targetBased	4	Not yet recruiting	01/12/2022	https://clinicaltrials.gov/study/NCT05555329	1	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	POMALIDOMIDE	targetBased	3	Active, not recruiting	16/04/2019	https://clinicaltrials.gov/study/NCT03651128	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	POMALIDOMIDE	targetBased	3	Terminated	19/10/2015	https://clinicaltrials.gov/study/NCT02576977	0.7	LoF	protect	The study was terminated early due to business reasons
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	POMALIDOMIDE	targetBased	3	Active, not recruiting	12/06/2017	https://clinicaltrials.gov/study/NCT03180736	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	POMALIDOMIDE	targetBased	4	Recruiting	26/07/2021	https://clinicaltrials.gov/study/NCT04989140	1	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	POMALIDOMIDE	targetBased	3	Recruiting	13/10/2022	https://clinicaltrials.gov/study/NCT05455320	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	POMALIDOMIDE	targetBased	3	Not yet recruiting	01/10/2024	https://clinicaltrials.gov/study/NCT06413498	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	POMALIDOMIDE	targetBased	3	Terminated	12/06/2017	https://clinicaltrials.gov/study/NCT03151811	0.35	LoF	protect	Sponsor assessed all endpoints and collected Overall Survival data for another two years following the primary completion date of 03Feb2021.
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	POMALIDOMIDE	targetBased	3	Recruiting	18/09/2023	https://clinicaltrials.gov/study/NCT05730036	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	POMALIDOMIDE	targetBased	3	Recruiting	29/03/2023	https://clinicaltrials.gov/study/NCT05572515	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	POMALIDOMIDE	targetBased	3	Completed	06/11/2012	https://clinicaltrials.gov/study/NCT01712789	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	POMALIDOMIDE	targetBased	3	Unknown status	01/09/2016	https://clinicaltrials.gov/study/NCT02916420	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	POMALIDOMIDE	targetBased	3	Recruiting	03/03/2023	https://clinicaltrials.gov/study/NCT05675319	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	POMALIDOMIDE	targetBased	3	Completed	10/08/2016	https://clinicaltrials.gov/study/NCT02726581	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	POMALIDOMIDE	targetBased	3	Active, not recruiting	22/10/2018	https://clinicaltrials.gov/study/NCT03539744	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	primary myelofibrosis	POMALIDOMIDE	targetBased	3	Completed	08/09/2010	https://clinicaltrials.gov/study/NCT01178281	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	polycythemia vera	POMALIDOMIDE	targetBased	3	Completed	27/10/2010	https://clinicaltrials.gov/study/NCT01243944	0.7	LoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	prostate cancer	CALCITRIOL	targetBased	3	Terminated	01/01/2006	https://clinicaltrials.gov/study/NCT00273338	0.7	GoF	protect	DSMB
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	Familial adenomatous polyposis	CALCITRIOL	targetBased	3	Terminated	01/06/2007	https://clinicaltrials.gov/study/NCT00486512	0.7	GoF	protect	The overall program was terminated
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	fibroma	CALCITRIOL	targetBased	3	Completed	05/09/2013	https://clinicaltrials.gov/study/NCT03140449	0.7	GoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	chronic lymphocytic leukemia	LENALIDOMIDE	targetBased	3	Completed	13/10/2009	https://clinicaltrials.gov/study/NCT00910910	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	chronic lymphocytic leukemia	LENALIDOMIDE	targetBased	3	Completed	20/07/2012	https://clinicaltrials.gov/study/NCT01556776	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	chronic lymphocytic leukemia	LENALIDOMIDE	targetBased	3	Completed	27/01/2009	https://clinicaltrials.gov/study/NCT00774345	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	melanoma	LENALIDOMIDE	targetBased	3	Completed	01/10/2002	https://clinicaltrials.gov/study/NCT00057616	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	LENALIDOMIDE	targetBased	3	Active, not recruiting	26/04/2019	https://clinicaltrials.gov/study/NCT03901963	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	LENALIDOMIDE	targetBased	3	Recruiting	10/11/2022	https://clinicaltrials.gov/study/NCT05623020	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	LENALIDOMIDE	targetBased	3	Recruiting	30/03/2022	https://clinicaltrials.gov/study/NCT05802992	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	LENALIDOMIDE	targetBased	3	Completed	01/11/2014	https://clinicaltrials.gov/study/NCT02406144	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	LENALIDOMIDE	targetBased	3	Active, not recruiting	01/02/2015	https://clinicaltrials.gov/study/NCT02252172	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	LENALIDOMIDE	targetBased	3	Completed	01/04/2009	https://clinicaltrials.gov/study/NCT00891384	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	LENALIDOMIDE	targetBased	3	Completed	01/01/2003	https://clinicaltrials.gov/study/NCT00424047	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	LENALIDOMIDE	targetBased	3	Active, not recruiting	16/06/2020	https://clinicaltrials.gov/study/NCT04270409	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	LENALIDOMIDE	targetBased	3	Active, not recruiting	01/07/2019	https://clinicaltrials.gov/study/NCT04096066	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	LENALIDOMIDE	targetBased	3	Active, not recruiting	01/10/2010	https://clinicaltrials.gov/study/NCT01208662	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	LENALIDOMIDE	targetBased	3	Not yet recruiting	01/10/2022	https://clinicaltrials.gov/study/NCT05558319	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	LENALIDOMIDE	targetBased	3	Terminated	01/02/2016	https://clinicaltrials.gov/study/NCT02516696	0.7	LoF	protect	low enrollment
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	LENALIDOMIDE	targetBased	3	Active, not recruiting	01/06/2007	https://clinicaltrials.gov/study/NCT00551928	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	LENALIDOMIDE	targetBased	3	Active, not recruiting	16/02/2022	https://clinicaltrials.gov/study/NCT03941860	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	LENALIDOMIDE	targetBased	3	Active, not recruiting	28/08/2018	https://clinicaltrials.gov/study/NCT03948035	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	LENALIDOMIDE	targetBased	3	Completed	01/04/2003	https://clinicaltrials.gov/study/NCT00622336	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	LENALIDOMIDE	targetBased	3	Active, not recruiting	01/07/2009	https://clinicaltrials.gov/study/NCT01091831	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	LENALIDOMIDE	targetBased	3	Completed	01/03/2015	https://clinicaltrials.gov/study/NCT02322320	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	LENALIDOMIDE	targetBased	3	Completed	29/04/2013	https://clinicaltrials.gov/study/NCT01850524	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	LENALIDOMIDE	targetBased	3	Completed	14/07/2010	https://clinicaltrials.gov/study/NCT01080391	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	LENALIDOMIDE	targetBased	3	Recruiting	19/10/2017	https://clinicaltrials.gov/study/NCT04287660	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	LENALIDOMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5fa97bf5-28a2-48f1-8955-f56012d296be	1	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	LENALIDOMIDE	targetBased	3	Recruiting	10/10/2023	https://clinicaltrials.gov/study/NCT05257083	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	LENALIDOMIDE	targetBased	3	Completed	01/03/2007	https://clinicaltrials.gov/study/NCT00478777	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	LENALIDOMIDE	targetBased	3	Active, not recruiting	23/05/2014	https://clinicaltrials.gov/study/NCT02076009	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	LENALIDOMIDE	targetBased	3	Completed	01/06/2015	https://clinicaltrials.gov/study/NCT02495922	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	LENALIDOMIDE	targetBased	3	Recruiting	14/04/2023	https://clinicaltrials.gov/study/NCT05804032	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	LENALIDOMIDE	targetBased	3	Completed	20/06/2011	https://clinicaltrials.gov/study/NCT01239797	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	LENALIDOMIDE	targetBased	3	Recruiting	25/10/2022	https://clinicaltrials.gov/study/NCT05552222	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	LENALIDOMIDE	targetBased	3	Active, not recruiting	18/10/2018	https://clinicaltrials.gov/study/NCT03617731	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	LENALIDOMIDE	targetBased	3	Active, not recruiting	01/04/2008	https://clinicaltrials.gov/study/NCT00644228	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	LENALIDOMIDE	targetBased	3	Active, not recruiting	26/04/2016	https://clinicaltrials.gov/study/NCT02659293	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	LENALIDOMIDE	targetBased	3	Active, not recruiting	03/11/2004	https://clinicaltrials.gov/study/NCT00098475	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	LENALIDOMIDE	targetBased	3	Completed	01/09/2013	https://clinicaltrials.gov/study/NCT01916252	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	LENALIDOMIDE	targetBased	3	Completed	01/01/2007	https://clinicaltrials.gov/study/NCT00405756	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	LENALIDOMIDE	targetBased	3	Active, not recruiting	22/10/2018	https://clinicaltrials.gov/study/NCT03742297	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	LENALIDOMIDE	targetBased	3	Recruiting	13/08/2019	https://clinicaltrials.gov/study/NCT04071457	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	LENALIDOMIDE	targetBased	3	Completed	21/08/2008	https://clinicaltrials.gov/study/NCT00689936	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	LENALIDOMIDE	targetBased	3	Completed	01/11/2004	https://clinicaltrials.gov/study/NCT00064038	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	LENALIDOMIDE	targetBased	3	Recruiting	25/03/2022	https://clinicaltrials.gov/study/NCT05317416	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	LENALIDOMIDE	targetBased	3	Completed	01/03/2010	https://clinicaltrials.gov/study/NCT01090089	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	LENALIDOMIDE	targetBased	3	Active, not recruiting	01/07/2014	https://clinicaltrials.gov/study/NCT02215980	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	LENALIDOMIDE	targetBased	4	Active, not recruiting	16/09/2019	https://clinicaltrials.gov/study/NCT03934684	1	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	LENALIDOMIDE	targetBased	3	Unknown status	01/05/2010	https://clinicaltrials.gov/study/NCT01554852	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	LENALIDOMIDE	targetBased	3	Active, not recruiting	25/09/2020	https://clinicaltrials.gov/study/NCT04483739	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	LENALIDOMIDE	targetBased	4	Withdrawn	30/06/2022	https://clinicaltrials.gov/study/NCT05183139	1	LoF	protect	Business decision (no enrollment)
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	LENALIDOMIDE	targetBased	3	Recruiting	10/04/2024	https://clinicaltrials.gov/study/NCT06182774	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	LENALIDOMIDE	targetBased	4	Active, not recruiting	01/01/2008	https://clinicaltrials.gov/study/NCT00777881	1	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	LENALIDOMIDE	targetBased	4	Completed	01/09/2012	https://clinicaltrials.gov/study/NCT01731886	1	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	LENALIDOMIDE	targetBased	3	Not yet recruiting	01/05/2024	https://clinicaltrials.gov/study/NCT06187441	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	LENALIDOMIDE	targetBased	3	Completed	28/04/2009	https://clinicaltrials.gov/study/NCT00928486	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	LENALIDOMIDE	targetBased	3	Recruiting	07/05/2019	https://clinicaltrials.gov/study/NCT03729804	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	LENALIDOMIDE	targetBased	3	Recruiting	08/09/2022	https://clinicaltrials.gov/study/NCT05243797	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	LENALIDOMIDE	targetBased	3	Recruiting	22/06/2023	https://clinicaltrials.gov/study/NCT05827016	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	LENALIDOMIDE	targetBased	3	Active, not recruiting	25/07/2019	https://clinicaltrials.gov/study/NCT03836014	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	LENALIDOMIDE	targetBased	3	Active, not recruiting	01/09/2015	https://clinicaltrials.gov/study/NCT02575144	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	LENALIDOMIDE	targetBased	3	Active, not recruiting	01/10/2009	https://clinicaltrials.gov/study/NCT01093196	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	LENALIDOMIDE	targetBased	3	Recruiting	15/12/2022	https://clinicaltrials.gov/study/NCT05438043	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	LENALIDOMIDE	targetBased	3	Active, not recruiting	01/01/2011	https://clinicaltrials.gov/study/NCT01208766	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	LENALIDOMIDE	targetBased	4	Recruiting	01/07/2022	https://clinicaltrials.gov/study/NCT05722405	1	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	LENALIDOMIDE	targetBased	3	Active, not recruiting	14/12/2018	https://clinicaltrials.gov/study/NCT03710603	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	LENALIDOMIDE	targetBased	3	Completed	01/09/2005	https://clinicaltrials.gov/study/NCT00179647	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	LENALIDOMIDE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/revlimid	1	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	LENALIDOMIDE	targetBased	3	Completed	01/08/2012	https://clinicaltrials.gov/study/NCT01564537	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	LENALIDOMIDE	targetBased	3	Completed	01/05/2010	https://clinicaltrials.gov/study/NCT01109004	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	LENALIDOMIDE	targetBased	3	Terminated	30/09/2013	https://clinicaltrials.gov/study/NCT01891643	0.7	LoF	protect	Insufficient enrollment
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	LENALIDOMIDE	targetBased	3	Active, not recruiting	16/04/2019	https://clinicaltrials.gov/study/NCT03651128	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	LENALIDOMIDE	targetBased	3	Recruiting	24/02/2021	https://clinicaltrials.gov/study/NCT04566328	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	LENALIDOMIDE	targetBased	3	Completed	01/01/2009	https://clinicaltrials.gov/study/NCT01530594	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	LENALIDOMIDE	targetBased	3	Active, not recruiting	01/05/2012	https://clinicaltrials.gov/study/NCT01685814	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	LENALIDOMIDE	targetBased	3	Recruiting	04/08/2020	https://clinicaltrials.gov/study/NCT03720041	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	LENALIDOMIDE	targetBased	4	Recruiting	03/01/2019	https://clinicaltrials.gov/study/NCT03829371	1	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	LENALIDOMIDE	targetBased	3	Completed	01/04/2010	https://clinicaltrials.gov/study/NCT01621672	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	LENALIDOMIDE	targetBased	4	Recruiting	03/01/2020	https://clinicaltrials.gov/study/NCT04217967	1	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	LENALIDOMIDE	targetBased	3	Completed	08/05/2019	https://clinicaltrials.gov/study/NCT03859427	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	LENALIDOMIDE	targetBased	3	Terminated	19/10/2015	https://clinicaltrials.gov/study/NCT02579863	0.7	LoF	protect	The study was terminated early due to business reasons
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	LENALIDOMIDE	targetBased	3	Active, not recruiting	29/02/2008	https://clinicaltrials.gov/study/NCT00602641	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	LENALIDOMIDE	targetBased	3	Recruiting	12/10/2023	https://clinicaltrials.gov/study/NCT05561387	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	LENALIDOMIDE	targetBased	4	Completed	18/02/2018	https://clinicaltrials.gov/study/NCT03416374	1	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	LENALIDOMIDE	targetBased	3	Active, not recruiting	06/12/2013	https://clinicaltrials.gov/study/NCT01863550	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	LENALIDOMIDE	targetBased	3	Recruiting	03/03/2023	https://clinicaltrials.gov/study/NCT05675319	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	LENALIDOMIDE	targetBased	3	Recruiting	16/10/2023	https://clinicaltrials.gov/study/NCT06045806	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	LENALIDOMIDE	targetBased	3	Completed	01/11/2006	https://clinicaltrials.gov/study/NCT00420849	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	LENALIDOMIDE	targetBased	3	Completed	27/03/2019	https://clinicaltrials.gov/study/NCT03952091	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	LENALIDOMIDE	targetBased	3	Recruiting	19/08/2021	https://clinicaltrials.gov/study/NCT04923893	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	LENALIDOMIDE	targetBased	3	Completed	01/10/2010	https://clinicaltrials.gov/study/NCT01191060	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	LENALIDOMIDE	targetBased	3	Active, not recruiting	06/11/2018	https://clinicaltrials.gov/study/NCT03652064	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	LENALIDOMIDE	targetBased	3	Active, not recruiting	17/10/2019	https://clinicaltrials.gov/study/NCT03993912	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	LENALIDOMIDE	targetBased	3	Terminated	01/09/2007	https://clinicaltrials.gov/study/NCT00522392	0.7	LoF	protect	Slow accrual
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	LENALIDOMIDE	targetBased	3	Completed	30/04/2014	https://clinicaltrials.gov/study/NCT02112175	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	LENALIDOMIDE	targetBased	4	Active, not recruiting	13/11/2017	https://clinicaltrials.gov/study/NCT03173092	1	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	LENALIDOMIDE	targetBased	3	Completed	01/06/2006	https://clinicaltrials.gov/study/NCT00430365	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	LENALIDOMIDE	targetBased	3	Active, not recruiting	07/12/2017	https://clinicaltrials.gov/study/NCT03319667	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	LENALIDOMIDE	targetBased	3	Active, not recruiting	17/07/2021	https://clinicaltrials.gov/study/NCT04751877	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	LENALIDOMIDE	targetBased	3	Completed	04/08/2011	https://clinicaltrials.gov/study/NCT01335399	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	LENALIDOMIDE	targetBased	3	Completed	01/01/2003	https://clinicaltrials.gov/study/NCT00056160	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	asymptomatic myeloma	LENALIDOMIDE	targetBased	3	Active, not recruiting	15/12/2004	https://clinicaltrials.gov/study/NCT00114101	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	asymptomatic myeloma	LENALIDOMIDE	targetBased	3	Recruiting	16/09/2019	https://clinicaltrials.gov/study/NCT03937635	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	prostate cancer	LENALIDOMIDE	targetBased	3	Completed	11/11/2009	https://clinicaltrials.gov/study/NCT00988208	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	follicular lymphoma	LENALIDOMIDE	targetBased	3	Recruiting	20/09/2022	https://clinicaltrials.gov/study/NCT05409066	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	follicular lymphoma	LENALIDOMIDE	targetBased	3	Recruiting	02/10/2023	https://clinicaltrials.gov/study/NCT05888493	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	follicular lymphoma	LENALIDOMIDE	targetBased	3	Completed	29/12/2011	https://clinicaltrials.gov/study/NCT01476787	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	follicular lymphoma	LENALIDOMIDE	targetBased	3	Recruiting	01/05/2024	https://clinicaltrials.gov/study/NCT06284122	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	follicular lymphoma	LENALIDOMIDE	targetBased	3	Not yet recruiting	29/03/2024	https://clinicaltrials.gov/study/NCT06313996	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	follicular lymphoma	LENALIDOMIDE	targetBased	3	Active, not recruiting	01/02/2012	https://clinicaltrials.gov/study/NCT01650701	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	follicular lymphoma	LENALIDOMIDE	targetBased	3	Active, not recruiting	15/04/2021	https://clinicaltrials.gov/study/NCT04680052	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	follicular lymphoma	LENALIDOMIDE	targetBased	3	Recruiting	10/03/2022	https://clinicaltrials.gov/study/NCT05100862	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	follicular lymphoma	LENALIDOMIDE	targetBased	3	Recruiting	05/02/2024	https://clinicaltrials.gov/study/NCT06191744	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	follicular lymphoma	LENALIDOMIDE	targetBased	3	Recruiting	11/06/2020	https://clinicaltrials.gov/study/NCT04224493	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	follicular lymphoma	LENALIDOMIDE	targetBased	3	Recruiting	27/10/2021	https://clinicaltrials.gov/study/NCT04712097	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	follicular lymphoma	LENALIDOMIDE	targetBased	3	Recruiting	12/09/2022	https://clinicaltrials.gov/study/NCT05371093	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	acute myeloid leukemia	LENALIDOMIDE	targetBased	4	Terminated	01/01/2011	https://clinicaltrials.gov/study/NCT01198054	1	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	acute myeloid leukemia	LENALIDOMIDE	targetBased	3	Recruiting	01/09/2020	https://clinicaltrials.gov/study/NCT04490707	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	non-Hodgkins lymphoma	LENALIDOMIDE	targetBased	3	Completed	21/11/2013	https://clinicaltrials.gov/study/NCT01938001	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	non-Hodgkins lymphoma	LENALIDOMIDE	targetBased	3	Active, not recruiting	01/04/2014	https://clinicaltrials.gov/study/NCT01996865	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	unspecified peripheral T-cell lymphoma	LENALIDOMIDE	targetBased	4	Recruiting	01/09/2019	https://clinicaltrials.gov/study/NCT04040491	1	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	plasmacytoma	LENALIDOMIDE	targetBased	3	Active, not recruiting	10/03/2017	https://clinicaltrials.gov/study/NCT02544308	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	plasmacytoma	LENALIDOMIDE	targetBased	3	Active, not recruiting	01/12/2015	https://clinicaltrials.gov/study/NCT02516423	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	plasma cell neoplasm	LENALIDOMIDE	targetBased	3	Completed	01/11/2004	https://clinicaltrials.gov/study/NCT00064038	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	myelodysplastic syndrome	LENALIDOMIDE	targetBased	3	Completed	01/01/2010	https://clinicaltrials.gov/study/NCT01243476	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	myelodysplastic syndrome	LENALIDOMIDE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/revlimid	1	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	myelodysplastic syndrome	LENALIDOMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5fa97bf5-28a2-48f1-8955-f56012d296be	1	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	myelodysplastic syndrome	LENALIDOMIDE	targetBased	3	Active, not recruiting	29/01/2009	https://clinicaltrials.gov/study/NCT00843882	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	myelodysplastic syndrome	LENALIDOMIDE	targetBased	4	Not yet recruiting	01/08/2023	https://clinicaltrials.gov/study/NCT06004765	1	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	myelodysplastic syndrome	LENALIDOMIDE	targetBased	3	Completed	01/07/2005	https://clinicaltrials.gov/study/NCT00179621	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	Mantle cell lymphoma	LENALIDOMIDE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/revlimid	1	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	Mantle cell lymphoma	LENALIDOMIDE	targetBased	3	Unknown status	01/05/2010	https://clinicaltrials.gov/study/NCT02354313	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	Mantle cell lymphoma	LENALIDOMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5fa97bf5-28a2-48f1-8955-f56012d296be	1	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	Mantle cell lymphoma	LENALIDOMIDE	targetBased	3	Active, not recruiting	01/11/2013	https://clinicaltrials.gov/study/NCT01865110	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	Mantle cell lymphoma	LENALIDOMIDE	targetBased	3	Terminated	01/04/2010	https://clinicaltrials.gov/study/NCT01021423	0.7	LoF	protect	Terminated by sponsor due to new unpublished data that rendered the current design of the study no longer clinically relevant. There were no safety concerns.
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	lymphoma	LENALIDOMIDE	targetBased	3	Terminated	01/07/2010	https://clinicaltrials.gov/study/NCT01098656	0.7	LoF	protect	recruitment prematurely halted following company's decision to stop financial support to the study
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	lymphoma	LENALIDOMIDE	targetBased	3	Recruiting	22/10/2023	https://clinicaltrials.gov/study/NCT06084936	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	lymphoma	LENALIDOMIDE	targetBased	4	Recruiting	01/04/2019	https://clinicaltrials.gov/study/NCT04038411	1	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	diffuse large B-cell lymphoma	LENALIDOMIDE	targetBased	3	Active, not recruiting	11/05/2021	https://clinicaltrials.gov/study/NCT04824092	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	diffuse large B-cell lymphoma	LENALIDOMIDE	targetBased	3	Active, not recruiting	20/08/2020	https://clinicaltrials.gov/study/NCT04404283	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	diffuse large B-cell lymphoma	LENALIDOMIDE	targetBased	3	Recruiting	23/12/2022	https://clinicaltrials.gov/study/NCT05429268	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	diffuse large B-cell lymphoma	LENALIDOMIDE	targetBased	3	Completed	01/08/2014	https://clinicaltrials.gov/study/NCT02128061	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	diffuse large B-cell lymphoma	LENALIDOMIDE	targetBased	3	Completed	17/02/2015	https://clinicaltrials.gov/study/NCT02285062	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	diffuse large B-cell lymphoma	LENALIDOMIDE	targetBased	3	Not yet recruiting	21/05/2024	https://clinicaltrials.gov/study/NCT06220032	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	diffuse large B-cell lymphoma	LENALIDOMIDE	targetBased	3	Completed	01/04/2009	https://clinicaltrials.gov/study/NCT01122472	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	diffuse large B-cell lymphoma	LENALIDOMIDE	targetBased	3	Recruiting	02/03/2022	https://clinicaltrials.gov/study/NCT05179733	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	diffuse large B-cell lymphoma	LENALIDOMIDE	targetBased	3	Recruiting	01/06/2022	https://clinicaltrials.gov/study/NCT05351346	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	marginal zone B-cell lymphoma	LENALIDOMIDE	targetBased	3	Recruiting	05/09/2023	https://clinicaltrials.gov/study/NCT06006117	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	marginal zone B-cell lymphoma	LENALIDOMIDE	targetBased	3	Recruiting	19/12/2023	https://clinicaltrials.gov/study/NCT06082102	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	polycythemia vera	LENALIDOMIDE	targetBased	3	Completed	27/10/2010	https://clinicaltrials.gov/study/NCT01243944	0.7	LoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	Endometrial Hyperplasia without Atypia	BAZEDOXIFENE	targetBased	3	Completed	01/09/2005	https://clinicaltrials.gov/study/NCT00242710	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Endometrial Hyperplasia without Atypia	BAZEDOXIFENE	targetBased	3	Completed	01/09/2005	https://clinicaltrials.gov/study/NCT00242710	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Endometrial Hyperplasia without Atypia	BAZEDOXIFENE	targetBased	3	Completed	01/09/2005	https://clinicaltrials.gov/study/NCT00242710	0.7		protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	melanoma	VINBLASTINE	targetBased	3	Completed	01/11/1995	https://clinicaltrials.gov/study/NCT00002882	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	ovarian cancer	VINBLASTINE	targetBased	3	Unknown status	01/05/2005	https://clinicaltrials.gov/study/NCT00274950	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	extragonadal germ cell tumor	VINBLASTINE	targetBased	3	Terminated	01/04/2004	https://clinicaltrials.gov/study/NCT00072215	0.7	LoF	protect	poor accrual
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	extragonadal germ cell tumor	VINBLASTINE	targetBased	3	Completed	01/02/1994	https://clinicaltrials.gov/study/NCT00002566	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	extragonadal germ cell tumor	VINBLASTINE	targetBased	3	Unknown status	01/05/2005	https://clinicaltrials.gov/study/NCT00274950	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Hodgkins lymphoma	VINBLASTINE	targetBased	3	Completed	01/03/2000	https://clinicaltrials.gov/study/NCT01251107	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Hodgkins lymphoma	VINBLASTINE	targetBased	4	Unknown status	01/05/2000	https://clinicaltrials.gov/study/NCT00188149	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Hodgkins lymphoma	VINBLASTINE	targetBased	3	Active, not recruiting	09/11/2012	https://clinicaltrials.gov/study/NCT01712490	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Hodgkins lymphoma	VINBLASTINE	targetBased	3	Unknown status	01/07/2011	https://clinicaltrials.gov/study/NCT00816959	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Hodgkins lymphoma	VINBLASTINE	targetBased	3	Active, not recruiting	29/08/2019	https://clinicaltrials.gov/study/NCT03907488	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Hodgkins lymphoma	VINBLASTINE	targetBased	3	Completed	13/01/2012	https://clinicaltrials.gov/study/NCT01356680	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Hodgkins lymphoma	VINBLASTINE	targetBased	3	Completed	01/11/2001	https://clinicaltrials.gov/study/NCT00038558	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Hodgkins lymphoma	VINBLASTINE	targetBased	3	Completed	25/01/1994	https://clinicaltrials.gov/study/NCT00002561	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Hodgkins lymphoma	VINBLASTINE	targetBased	3	Recruiting	01/02/2020	https://clinicaltrials.gov/study/NCT04638790	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Hodgkins lymphoma	VINBLASTINE	targetBased	4	Unknown status	01/08/2015	https://clinicaltrials.gov/study/NCT02526823	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Hodgkins lymphoma	VINBLASTINE	targetBased	3	Active, not recruiting	01/08/2017	https://clinicaltrials.gov/study/NCT03159897	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Hodgkins lymphoma	VINBLASTINE	targetBased	3	Completed	01/05/2011	https://clinicaltrials.gov/study/NCT01358747	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Hodgkins lymphoma	VINBLASTINE	targetBased	4	Recruiting	06/10/2017	https://clinicaltrials.gov/study/NCT03500133	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Hodgkins lymphoma	VINBLASTINE	targetBased	3	Recruiting	14/04/2022	https://clinicaltrials.gov/study/NCT04685616	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Hodgkins lymphoma	VINBLASTINE	targetBased	3	Withdrawn	01/05/2013	https://clinicaltrials.gov/study/NCT01652261	0.7	LoF	protect	Study closed due to lack of recruitment
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Hodgkins lymphoma	VINBLASTINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f073b58e-56d6-4c8d-a2ce-b37719402d77	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Hodgkins lymphoma	VINBLASTINE	targetBased	3	Completed	01/04/2000	https://clinicaltrials.gov/study/NCT00443677	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	leukemia	VINBLASTINE	targetBased	3	Withdrawn	01/08/2023	https://clinicaltrials.gov/study/NCT00488605	0.7	LoF	protect	This is a duplicate record and the sponsor has registered the study.
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	cutaneous melanoma	VINBLASTINE	targetBased	3	Completed	13/11/1997	https://clinicaltrials.gov/study/NCT00003027	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	cutaneous melanoma	VINBLASTINE	targetBased	3	Completed	01/08/2000	https://clinicaltrials.gov/study/NCT00006237	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	testicular neoplasm	VINBLASTINE	targetBased	3	Completed	01/02/1994	https://clinicaltrials.gov/study/NCT00002566	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	testicular neoplasm	VINBLASTINE	targetBased	3	Terminated	01/04/2004	https://clinicaltrials.gov/study/NCT00072215	0.7	LoF	protect	poor accrual
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoid neoplasm	VINBLASTINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f073b58e-56d6-4c8d-a2ce-b37719402d77	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	diffuse large B-cell lymphoma	VINBLASTINE	targetBased	3	Completed	01/01/2003	https://clinicaltrials.gov/study/NCT01148446	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-Hodgkins lymphoma	VINBLASTINE	targetBased	4	Unknown status	01/08/2015	https://clinicaltrials.gov/study/NCT02526823	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Langerhans Cell Histiocytosis	VINBLASTINE	targetBased	3	Recruiting	07/03/2016	https://clinicaltrials.gov/study/NCT02670707	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	renal pelvis/ureter urothelial carcinoma	VINBLASTINE	targetBased	3	Completed	03/12/1998	https://clinicaltrials.gov/study/NCT00003376	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	cervical cancer	VINBLASTINE	targetBased	3	Completed	01/12/1997	https://clinicaltrials.gov/study/NCT00003209	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	urinary bladder carcinoma	VINBLASTINE	targetBased	3	Completed	01/10/2001	https://clinicaltrials.gov/study/NCT00028756	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	childhood germ cell tumor	VINBLASTINE	targetBased	3	Unknown status	01/05/2005	https://clinicaltrials.gov/study/NCT00274950	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	unspecified peripheral T-cell lymphoma	VINBLASTINE	targetBased	3	Completed	01/01/1995	https://clinicaltrials.gov/study/NCT00970385	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	neoplasm	VINBLASTINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=L01CA01	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	prostate cancer	VINBLASTINE	targetBased	3	Completed	01/08/1996	https://clinicaltrials.gov/study/NCT00002855	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	prostate cancer	VINBLASTINE	targetBased	3	Terminated	01/04/2002	https://clinicaltrials.gov/study/NCT00024167	0.7	LoF	protect	Terminated due to slow accrual
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	prostate cancer	VINBLASTINE	targetBased	3	Completed	01/10/2002	https://clinicaltrials.gov/study/NCT00030654	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung cancer	VINBLASTINE	targetBased	3	Unknown status	01/05/1998	https://clinicaltrials.gov/study/NCT00004209	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung cancer	VINBLASTINE	targetBased	3	Unknown status	01/10/1995	https://clinicaltrials.gov/study/NCT00003240	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung cancer	VINBLASTINE	targetBased	3	Unknown status	01/01/1999	https://clinicaltrials.gov/study/NCT00004887	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung cancer	VINBLASTINE	targetBased	3	Completed	01/08/1997	https://clinicaltrials.gov/study/NCT00003159	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung cancer	VINBLASTINE	targetBased	3	Completed	01/02/1995	https://clinicaltrials.gov/study/NCT00002823	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung cancer	VINBLASTINE	targetBased	3	Completed	01/07/1994	https://clinicaltrials.gov/study/NCT01134861	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINBLASTINE	targetBased	3	Terminated	01/04/2000	https://clinicaltrials.gov/study/NCT00005090	0.7	LoF	protect	poor accrual
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINBLASTINE	targetBased	3	Active, not recruiting	01/09/1993	https://clinicaltrials.gov/study/NCT00379041	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINBLASTINE	targetBased	3	Active, not recruiting	01/10/1998	https://clinicaltrials.gov/study/NCT00005584	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINBLASTINE	targetBased	3	Completed	01/11/2003	https://clinicaltrials.gov/study/NCT00059839	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINBLASTINE	targetBased	3	Completed	26/11/1999	https://clinicaltrials.gov/study/NCT00006455	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINBLASTINE	targetBased	3	Completed	29/08/2008	https://clinicaltrials.gov/study/NCT00678327	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINBLASTINE	targetBased	3	Completed	01/08/2002	https://clinicaltrials.gov/study/NCT00049595	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINBLASTINE	targetBased	3	Completed	01/09/1992	https://clinicaltrials.gov/study/NCT00002495	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINBLASTINE	targetBased	3	Completed	01/05/1998	https://clinicaltrials.gov/study/NCT00264953	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINBLASTINE	targetBased	3	Unknown status	01/10/2001	https://clinicaltrials.gov/study/NCT00041210	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINBLASTINE	targetBased	4	Completed	01/11/2009	https://clinicaltrials.gov/study/NCT01088750	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINBLASTINE	targetBased	3	Active, not recruiting	01/09/1989	https://clinicaltrials.gov/study/NCT00002462	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINBLASTINE	targetBased	3	Completed	17/06/1999	https://clinicaltrials.gov/study/NCT00003389	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINBLASTINE	targetBased	3	Unknown status	01/10/2006	https://clinicaltrials.gov/study/NCT00433433	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINBLASTINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f073b58e-56d6-4c8d-a2ce-b37719402d77	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINBLASTINE	targetBased	3	Terminated	01/05/2008	https://clinicaltrials.gov/study/NCT00920153	0.7	LoF	protect	Other new drugs
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINBLASTINE	targetBased	3	Completed	01/06/1998	https://clinicaltrials.gov/study/NCT00003421	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINBLASTINE	targetBased	3	Completed	01/05/1998	https://clinicaltrials.gov/study/NCT00265018	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	urethra cancer	VINBLASTINE	targetBased	3	Completed	03/12/1998	https://clinicaltrials.gov/study/NCT00003376	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	skin cancer	VINBLASTINE	targetBased	3	Completed	01/11/1995	https://clinicaltrials.gov/study/NCT00002882	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	classic Hodgkin lymphoma	VINBLASTINE	targetBased	3	Active, not recruiting	29/08/2019	https://clinicaltrials.gov/study/NCT03907488	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	VINBLASTINE	targetBased	4	Completed	01/01/2017	https://clinicaltrials.gov/study/NCT03092986	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	urinary bladder cancer	VINBLASTINE	targetBased	3	Completed	03/12/1998	https://clinicaltrials.gov/study/NCT00003376	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	urinary bladder cancer	VINBLASTINE	targetBased	3	Terminated	01/08/1997	https://clinicaltrials.gov/study/NCT00005047	0.35	LoF	protect	Accrual was halted on the basis of the Data and Safety Monitoring Board review of a futility analysis.
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	urinary bladder cancer	VINBLASTINE	targetBased	3	Unknown status	01/02/2013	https://clinicaltrials.gov/study/NCT01812369	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	urinary bladder cancer	VINBLASTINE	targetBased	3	Completed	02/04/1999	https://clinicaltrials.gov/study/NCT00003701	0.7	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	cancer	BUPROPION	targetBased	3	Recruiting	27/06/2019	https://clinicaltrials.gov/study/NCT03996265	0.7	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	carcinoma	BUPROPION	targetBased	4	Recruiting	04/08/2020	https://clinicaltrials.gov/study/NCT04604509	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	lung cancer	BUPROPION	targetBased	3	Terminated	01/01/2002	https://clinicaltrials.gov/study/NCT00032084	0.7	LoF	protect	This study was closed early due to poor accrual
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	acute myeloid leukemia	NALBUPHINE	targetBased	3	Completed	01/02/2018	https://clinicaltrials.gov/study/NCT03825887	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	acute myeloid leukemia	NALBUPHINE	targetBased	3	Completed	01/02/2018	https://clinicaltrials.gov/study/NCT03825887	0.7	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	childhood acute lymphoblastic leukemia	NALBUPHINE	targetBased	4	Completed	25/03/2021	https://clinicaltrials.gov/study/NCT05176119	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	acute myeloid leukemia	NALBUPHINE	targetBased	3	Completed	01/02/2018	https://clinicaltrials.gov/study/NCT03825887	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	leukemia	NALBUPHINE	targetBased	3	Completed	01/02/2018	https://clinicaltrials.gov/study/NCT03825887	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	leukemia	NALBUPHINE	targetBased	3	Completed	01/02/2018	https://clinicaltrials.gov/study/NCT03825887	0.7	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	leukemia	NALBUPHINE	targetBased	3	Completed	01/02/2018	https://clinicaltrials.gov/study/NCT03825887	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	childhood acute lymphoblastic leukemia	NALBUPHINE	targetBased	4	Completed	25/03/2021	https://clinicaltrials.gov/study/NCT05176119	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	childhood acute lymphoblastic leukemia	NALBUPHINE	targetBased	4	Completed	25/03/2021	https://clinicaltrials.gov/study/NCT05176119	1	GoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	sarcoma	IMATINIB	targetBased	3	Completed	01/02/2004	https://clinicaltrials.gov/study/NCT00116935	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	sarcoma	IMATINIB	targetBased	3	Completed	01/05/2002	https://clinicaltrials.gov/study/NCT00367861	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	sarcoma	IMATINIB	targetBased	3	Active, not recruiting	01/05/2015	https://clinicaltrials.gov/study/NCT02413736	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	systemic mastocytosis	IMATINIB	targetBased	4	Completed	01/01/2011	https://clinicaltrials.gov/study/NCT01297777	1	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	IMATINIB	targetBased	4	Unknown status	01/02/2015	https://clinicaltrials.gov/study/NCT02317159	1	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	IMATINIB	targetBased	3	Unknown status	01/01/2004	https://clinicaltrials.gov/study/NCT00327262	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	IMATINIB	targetBased	3	Completed	05/02/2008	https://clinicaltrials.gov/study/NCT00574873	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	IMATINIB	targetBased	4	Completed	01/04/2005	https://clinicaltrials.gov/study/NCT00171899	1	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	IMATINIB	targetBased	3	Completed	01/06/2000	https://clinicaltrials.gov/study/NCT00333840	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	IMATINIB	targetBased	3	Completed	01/06/2014	https://clinicaltrials.gov/study/NCT02204644	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	IMATINIB	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0e9927ab-771e-4c2d-881e-7031c40bf205	1	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	IMATINIB	targetBased	3	Recruiting	19/06/2023	https://clinicaltrials.gov/study/NCT05413915	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	IMATINIB	targetBased	3	Completed	01/05/2009	https://clinicaltrials.gov/study/NCT00802841	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	IMATINIB	targetBased	3	Completed	01/04/2003	https://clinicaltrials.gov/study/NCT00050531	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	IMATINIB	targetBased	3	Terminated	01/06/2012	https://clinicaltrials.gov/study/NCT01650805	0.35	LoF	protect	Study terminated based on evaluation of safety data.
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	IMATINIB	targetBased	4	Recruiting	30/08/2022	https://clinicaltrials.gov/study/NCT04877522	1	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	IMATINIB	targetBased	3	Completed	01/04/2011	https://clinicaltrials.gov/study/NCT01275196	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	IMATINIB	targetBased	3	Active, not recruiting	01/04/2008	https://clinicaltrials.gov/study/NCT00718263	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	IMATINIB	targetBased	3	Terminated	01/06/2005	https://clinicaltrials.gov/study/NCT00124748	0.35	LoF	protect	This study was prematurely discontinued because no improvement was observed in the 800mg dose compared to 400mg dose
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	IMATINIB	targetBased	4	Completed	09/11/2011	https://clinicaltrials.gov/study/NCT01578213	1	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	IMATINIB	targetBased	3	Recruiting	10/06/2015	https://clinicaltrials.gov/study/NCT02326311	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	IMATINIB	targetBased	3	Completed	31/07/2007	https://clinicaltrials.gov/study/NCT00471497	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	IMATINIB	targetBased	4	Not yet recruiting	30/04/2022	https://clinicaltrials.gov/study/NCT05367765	1	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	IMATINIB	targetBased	3	Completed	01/09/2003	https://clinicaltrials.gov/study/NCT00219739	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	IMATINIB	targetBased	3	Completed	01/08/2008	https://clinicaltrials.gov/study/NCT01460693	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	IMATINIB	targetBased	3	Unknown status	01/02/2006	https://clinicaltrials.gov/study/NCT00297570	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	IMATINIB	targetBased	3	Unknown status	01/01/2009	https://clinicaltrials.gov/study/NCT01400074	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	IMATINIB	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=211ef2da-2868-4a77-8055-1cb2cd78e24b	1	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	IMATINIB	targetBased	3	Terminated	01/03/2014	https://clinicaltrials.gov/study/NCT02174445	0.7	LoF	protect	very slow recruitment rate and a lot of pat. didn't fulfil BCR-ABL requirements
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	IMATINIB	targetBased	4	Terminated	13/10/2014	https://clinicaltrials.gov/study/NCT02204722	1	LoF	protect	Sponsor's decision to halt the study.
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	IMATINIB	targetBased	4	Completed	01/07/2003	https://clinicaltrials.gov/study/NCT00390897	1	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	IMATINIB	targetBased	3	Completed	01/06/2004	https://clinicaltrials.gov/study/NCT00514488	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	IMATINIB	targetBased	3	Terminated	01/07/2009	https://clinicaltrials.gov/study/NCT01827930	0.7	LoF	protect	Difficulties of enrolment of Patient
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	IMATINIB	targetBased	3	Active, not recruiting	28/12/2018	https://clinicaltrials.gov/study/NCT03722420	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	IMATINIB	targetBased	3	Unknown status	01/05/2018	https://clinicaltrials.gov/study/NCT03515018	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	IMATINIB	targetBased	3	Completed	15/07/2014	https://clinicaltrials.gov/study/NCT02130557	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	IMATINIB	targetBased	3	Completed	01/11/2002	https://clinicaltrials.gov/study/NCT00237120	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	IMATINIB	targetBased	3	Active, not recruiting	06/10/2021	https://clinicaltrials.gov/study/NCT04971226	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	IMATINIB	targetBased	3	Completed	01/06/2009	https://clinicaltrials.gov/study/NCT00760877	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	IMATINIB	targetBased	4	Completed	01/07/2004	https://clinicaltrials.gov/study/NCT00845221	1	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	IMATINIB	targetBased	3	Completed	01/09/2007	https://clinicaltrials.gov/study/NCT00481247	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	IMATINIB	targetBased	4	Completed	01/10/2003	https://clinicaltrials.gov/study/NCT00081926	1	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	IMATINIB	targetBased	3	Completed	01/10/2012	https://clinicaltrials.gov/study/NCT01819389	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	acute lymphoblastic leukemia	IMATINIB	targetBased	3	Completed	08/07/2000	https://clinicaltrials.gov/study/NCT00137111	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	acute lymphoblastic leukemia	IMATINIB	targetBased	3	Active, not recruiting	04/10/2018	https://clinicaltrials.gov/study/NCT03589326	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	acute lymphoblastic leukemia	IMATINIB	targetBased	3	Recruiting	13/07/2020	https://clinicaltrials.gov/study/NCT04307576	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	acute lymphoblastic leukemia	IMATINIB	targetBased	3	Active, not recruiting	01/08/2016	https://clinicaltrials.gov/study/NCT02881086	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	acute lymphoblastic leukemia	IMATINIB	targetBased	3	Recruiting	08/09/2021	https://clinicaltrials.gov/study/NCT04722848	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	acute lymphoblastic leukemia	IMATINIB	targetBased	3	Recruiting	31/08/2023	https://clinicaltrials.gov/study/NCT06051409	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	acute lymphoblastic leukemia	IMATINIB	targetBased	4	Unknown status	01/01/2008	https://clinicaltrials.gov/study/NCT01491763	1	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	acute lymphoblastic leukemia	IMATINIB	targetBased	4	Unknown status	01/10/2008	https://clinicaltrials.gov/study/NCT02894645	1	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	lymphoblastic lymphoma	IMATINIB	targetBased	3	Active, not recruiting	01/08/2016	https://clinicaltrials.gov/study/NCT02881086	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	T-cell acute lymphoblastic leukemia	IMATINIB	targetBased	3	Recruiting	08/08/2017	https://clinicaltrials.gov/study/NCT03007147	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	childhood acute lymphoblastic leukemia	IMATINIB	targetBased	3	Completed	01/10/2002	https://clinicaltrials.gov/study/NCT00022737	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	glioblastoma multiforme	IMATINIB	targetBased	3	Completed	01/10/2004	https://clinicaltrials.gov/study/NCT00154375	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	neoplasm	IMATINIB	targetBased	3			https://www.whocc.no/atc_ddd_index/?code=L01EA01	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	lymphoid neoplasm	IMATINIB	targetBased	4	Recruiting	31/01/2016	https://clinicaltrials.gov/study/NCT03844360	1	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	adult acute lymphoblastic leukemia	IMATINIB	targetBased	3	Recruiting	01/04/2016	https://clinicaltrials.gov/study/NCT02611492	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	astrocytoma	IMATINIB	targetBased	3	Completed	01/10/2004	https://clinicaltrials.gov/study/NCT00154375	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	gastrointestinal stromal tumor	IMATINIB	targetBased	3	Terminated	01/01/2009	https://clinicaltrials.gov/study/NCT00812240	0.7	LoF	protect	Sponsor decision based on portfolio prioritization
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	gastrointestinal stromal tumor	IMATINIB	targetBased	3	Completed	01/06/2010	https://clinicaltrials.gov/study/NCT01151852	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	gastrointestinal stromal tumor	IMATINIB	targetBased	3	Completed	01/03/2007	https://clinicaltrials.gov/study/NCT00471328	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	gastrointestinal stromal tumor	IMATINIB	targetBased	3	Terminated	01/05/2009	https://clinicaltrials.gov/study/NCT00956072	0.7	LoF	protect	low accrual
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	gastrointestinal stromal tumor	IMATINIB	targetBased	3	Terminated	01/06/2007	https://clinicaltrials.gov/study/NCT00372567	0.7	LoF	protect	See termination reason in detailed description.
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	gastrointestinal stromal tumor	IMATINIB	targetBased	4	Active, not recruiting	26/03/2013	https://clinicaltrials.gov/study/NCT01742299	1	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	gastrointestinal stromal tumor	IMATINIB	targetBased	3	Terminated	01/04/2008	https://clinicaltrials.gov/study/NCT00324987	0.7	LoF	protect	The trial failed to accrue
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	gastrointestinal stromal tumor	IMATINIB	targetBased	4	Completed	01/10/2006	https://clinicaltrials.gov/study/NCT00510354	1	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	gastrointestinal stromal tumor	IMATINIB	targetBased	3	Terminated	01/06/2009	https://clinicaltrials.gov/study/NCT00751036	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	gastrointestinal stromal tumor	IMATINIB	targetBased	3	Terminated	01/12/2000	https://clinicaltrials.gov/study/NCT00009906	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	gastrointestinal stromal tumor	IMATINIB	targetBased	3	Completed	01/03/2009	https://clinicaltrials.gov/study/NCT00785785	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	gastrointestinal stromal tumor	IMATINIB	targetBased	3	Unknown status	01/01/2001	https://clinicaltrials.gov/study/NCT00685828	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	gastrointestinal stromal tumor	IMATINIB	targetBased	3	Completed	01/03/2004	https://clinicaltrials.gov/study/NCT00293124	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	gastrointestinal stromal tumor	IMATINIB	targetBased	3	Terminated	01/01/2010	https://clinicaltrials.gov/study/NCT01031628	0.7	LoF	protect	Lack of feasibility secondary to slow accrual
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	gastrointestinal stromal tumor	IMATINIB	targetBased	3	Completed	01/12/2004	https://clinicaltrials.gov/study/NCT00103168	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	gastrointestinal stromal tumor	IMATINIB	targetBased	3	Completed	24/12/2014	https://clinicaltrials.gov/study/NCT02260505	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	gastrointestinal stromal tumor	IMATINIB	targetBased	3	Completed	01/05/2002	https://clinicaltrials.gov/study/NCT00367861	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	gastrointestinal stromal tumor	IMATINIB	targetBased	4	Completed	01/07/2004	https://clinicaltrials.gov/study/NCT00171977	1	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	gastrointestinal stromal tumor	IMATINIB	targetBased	3	Completed	01/06/2002	https://clinicaltrials.gov/study/NCT00041197	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	breast cancer	IMATINIB	targetBased	4	Completed	01/06/2006	https://clinicaltrials.gov/study/NCT00372476	1	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	myeloid leukemia	IMATINIB	targetBased	4	Active, not recruiting	11/11/2016	https://clinicaltrials.gov/study/NCT02602314	1	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	myeloid leukemia	IMATINIB	targetBased	3	Terminated	01/10/2007	https://clinicaltrials.gov/study/NCT00519090	0.7	LoF	protect	This study was terminated due to limited enrollment.
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	mixed phenotype acute leukemia	IMATINIB	targetBased	3	Recruiting	08/08/2017	https://clinicaltrials.gov/study/NCT03007147	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	lymphoid leukemia	IMATINIB	targetBased	3	Completed	01/05/2006	https://clinicaltrials.gov/study/NCT00327678	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	leukemia	IMATINIB	targetBased	3	Completed	01/06/2000	https://clinicaltrials.gov/study/NCT00006343	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	leukemia	IMATINIB	targetBased	4	Recruiting	16/09/2021	https://clinicaltrials.gov/study/NCT05071482	1	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	leukemia	IMATINIB	targetBased	3	Terminated	01/04/2007	https://clinicaltrials.gov/study/NCT00362466	0.7	LoF	protect	Insufficient Enrollment
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	leukemia	IMATINIB	targetBased	3	Completed	01/06/2002	https://clinicaltrials.gov/study/NCT00055874	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	leukemia	IMATINIB	targetBased	3	Completed	07/05/1993	https://clinicaltrials.gov/study/NCT00002514	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	leukemia	IMATINIB	targetBased	3	Completed	17/07/2014	https://clinicaltrials.gov/study/NCT02272777	0.7	LoF	protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	head and neck malignant neoplasia	CAPSAICIN	targetBased	3	Completed	01/10/1998	https://clinicaltrials.gov/study/NCT00003610	0.7		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	breast cancer	CAPSAICIN	targetBased	3	Completed	19/03/2019	https://clinicaltrials.gov/study/NCT03794388	0.7		protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	neoplasm	REMIFENTANIL	targetBased	3	Completed	01/11/2006	https://clinicaltrials.gov/study/NCT00389883	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	neoplasm	REMIFENTANIL	targetBased	3	Completed	01/11/2006	https://clinicaltrials.gov/study/NCT00389883	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	neoplasm	REMIFENTANIL	targetBased	4	Completed	01/01/2015	https://clinicaltrials.gov/study/NCT02593942	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	neoplasm	REMIFENTANIL	targetBased	4	Completed	01/01/2015	https://clinicaltrials.gov/study/NCT02593942	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	lung cancer	REMIFENTANIL	targetBased	4	Unknown status	01/06/2011	https://clinicaltrials.gov/study/NCT01381627	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	lung cancer	REMIFENTANIL	targetBased	4	Unknown status	01/06/2011	https://clinicaltrials.gov/study/NCT01381627	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	ear neoplasm	REMIFENTANIL	targetBased	3	Completed	01/06/2009	https://clinicaltrials.gov/study/NCT02093143	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	ear neoplasm	REMIFENTANIL	targetBased	3	Completed	01/06/2009	https://clinicaltrials.gov/study/NCT02093143	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Nasal Cavity Polyp	REMIFENTANIL	targetBased	4	Completed	01/07/2015	https://clinicaltrials.gov/study/NCT02484859	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Nasal Cavity Polyp	REMIFENTANIL	targetBased	4	Completed	01/07/2015	https://clinicaltrials.gov/study/NCT02484859	1	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	pancreatic neoplasm	LEVODOPA	targetBased	4	Recruiting	01/02/2018	https://clinicaltrials.gov/study/NCT04357483	1	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	pancreatic neoplasm	LEVODOPA	targetBased	4	Recruiting	01/02/2018	https://clinicaltrials.gov/study/NCT04357483	1	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	pancreatic neoplasm	LEVODOPA	targetBased	4	Recruiting	01/02/2018	https://clinicaltrials.gov/study/NCT04357483	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	colorectal adenocarcinoma	CHOLECALCIFEROL	targetBased	3	Active, not recruiting	30/09/2019	https://clinicaltrials.gov/study/NCT04094688	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	prostate cancer	CHOLECALCIFEROL	targetBased	3	Recruiting	01/12/2009	https://clinicaltrials.gov/study/NCT00887432	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	melanoma	CHOLECALCIFEROL	targetBased	3	Terminated	01/05/2010	https://clinicaltrials.gov/study/NCT01264874	0.7	GoF	protect	poor accrual rate
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	colorectal adenoma	CHOLECALCIFEROL	targetBased	3	Active, not recruiting	01/06/2006	https://clinicaltrials.gov/study/NCT00399607	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	chronic lymphocytic leukemia	CHOLECALCIFEROL	targetBased	3	Terminated	01/01/2012	https://clinicaltrials.gov/study/NCT01518959	0.7	GoF	protect	Insufficient recruitment rate; technical issues with sample storage
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	prostate adenocarcinoma	CHOLECALCIFEROL	targetBased	3	Recruiting	01/12/2009	https://clinicaltrials.gov/study/NCT00887432	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	diffuse large B-cell lymphoma	CHOLECALCIFEROL	targetBased	3	Recruiting	23/03/2021	https://clinicaltrials.gov/study/NCT04442412	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	breast cancer	CHOLECALCIFEROL	targetBased	3	Unknown status	04/11/2016	https://clinicaltrials.gov/study/NCT02786875	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	breast cancer	CHOLECALCIFEROL	targetBased	3	Terminated	01/09/2007	https://clinicaltrials.gov/study/NCT01608451	0.7	GoF	protect	Slow accrual implies that clinical questions being questioned have lost its significance.
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	breast cancer	CHOLECALCIFEROL	targetBased	3	Completed	01/07/2011	https://clinicaltrials.gov/study/NCT01480869	0.7	GoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	adult T acute lymphoblastic leukemia	VINCRISTINE	targetBased	3	Active, not recruiting	04/10/2014	https://clinicaltrials.gov/study/NCT02112916	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	primitive neuroectodermal tumor	VINCRISTINE	targetBased	3	Active, not recruiting	06/08/2007	https://clinicaltrials.gov/study/NCT00336024	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	primitive neuroectodermal tumor	VINCRISTINE	targetBased	3	Completed	01/10/2000	https://clinicaltrials.gov/study/NCT00006461	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	retinoblastoma	VINCRISTINE	targetBased	3	Unknown status	01/01/2006	https://clinicaltrials.gov/study/NCT02137928	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	retinoblastoma	VINCRISTINE	targetBased	3	Active, not recruiting	04/02/2008	https://clinicaltrials.gov/study/NCT00554788	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	retinoblastoma	VINCRISTINE	targetBased	3	Active, not recruiting	01/08/2013	https://clinicaltrials.gov/study/NCT01906814	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	retinoblastoma	VINCRISTINE	targetBased	3	Active, not recruiting	07/04/2005	https://clinicaltrials.gov/study/NCT00186888	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	retinoblastoma	VINCRISTINE	targetBased	3	Completed	26/12/2005	https://clinicaltrials.gov/study/NCT00079417	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	retinoblastoma	VINCRISTINE	targetBased	3	Completed	16/04/2007	https://clinicaltrials.gov/study/NCT00072384	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	retinoblastoma	VINCRISTINE	targetBased	3	Completed	01/12/2005	https://clinicaltrials.gov/study/NCT00335738	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	low grade glioma	VINCRISTINE	targetBased	3	Recruiting	31/01/2020	https://clinicaltrials.gov/study/NCT04166409	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	low grade glioma	VINCRISTINE	targetBased	3	Unknown status	01/03/2015	https://clinicaltrials.gov/study/NCT02455245	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	follicular lymphoma	VINCRISTINE	targetBased	3	Completed	14/07/2014	https://clinicaltrials.gov/study/NCT02162771	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	follicular lymphoma	VINCRISTINE	targetBased	3	Unknown status	01/05/2013	https://clinicaltrials.gov/study/NCT01852435	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	follicular lymphoma	VINCRISTINE	targetBased	3	Completed	01/02/2000	https://clinicaltrials.gov/study/NCT00115700	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	follicular lymphoma	VINCRISTINE	targetBased	3	Completed	01/03/1998	https://clinicaltrials.gov/study/NCT00003204	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	follicular lymphoma	VINCRISTINE	targetBased	3	Not yet recruiting	29/03/2024	https://clinicaltrials.gov/study/NCT06313996	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	follicular lymphoma	VINCRISTINE	targetBased	3	Recruiting	12/12/2023	https://clinicaltrials.gov/study/NCT06091254	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	follicular lymphoma	VINCRISTINE	targetBased	3	Active, not recruiting	01/02/2012	https://clinicaltrials.gov/study/NCT01650701	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	follicular lymphoma	VINCRISTINE	targetBased	3	Recruiting	02/10/2023	https://clinicaltrials.gov/study/NCT05888493	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	follicular lymphoma	VINCRISTINE	targetBased	3	Recruiting	01/05/2024	https://clinicaltrials.gov/study/NCT06284122	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	follicular lymphoma	VINCRISTINE	targetBased	3	Terminated	13/08/2021	https://clinicaltrials.gov/study/NCT04745832	0.7	LoF	protect	Discontinuation of zandelisib program
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	follicular lymphoma	VINCRISTINE	targetBased	3	Terminated	01/11/2007	https://clinicaltrials.gov/study/NCT00562965	0.7	LoF	protect	See termination reason in detailed description.
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	follicular lymphoma	VINCRISTINE	targetBased	3	Completed	29/12/2011	https://clinicaltrials.gov/study/NCT01476787	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	follicular lymphoma	VINCRISTINE	targetBased	3	Unknown status	01/12/2005	https://clinicaltrials.gov/study/NCT00774826	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	follicular lymphoma	VINCRISTINE	targetBased	4	Completed	26/02/2019	https://clinicaltrials.gov/study/NCT03817853	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	follicular lymphoma	VINCRISTINE	targetBased	3	Recruiting	05/02/2024	https://clinicaltrials.gov/study/NCT06191744	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	follicular lymphoma	VINCRISTINE	targetBased	3	Recruiting	14/11/2023	https://clinicaltrials.gov/study/NCT06097364	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	follicular lymphoma	VINCRISTINE	targetBased	3	Recruiting	01/12/2021	https://clinicaltrials.gov/study/NCT05058404	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	follicular lymphoma	VINCRISTINE	targetBased	4	Recruiting	01/03/2021	https://clinicaltrials.gov/study/NCT04842318	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	follicular lymphoma	VINCRISTINE	targetBased	3	Unknown status	01/10/2009	https://clinicaltrials.gov/study/NCT01303887	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	follicular lymphoma	VINCRISTINE	targetBased	3	Terminated	01/10/2006	https://clinicaltrials.gov/study/NCT00384111	0.7	LoF	protect	Study was terminated early as per the Sponsor's decision.
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	follicular lymphoma	VINCRISTINE	targetBased	3	Completed	01/02/2007	https://clinicaltrials.gov/study/NCT00801281	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	follicular lymphoma	VINCRISTINE	targetBased	3	Recruiting	01/10/2015	https://clinicaltrials.gov/study/NCT02449252	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	follicular lymphoma	VINCRISTINE	targetBased	3	Recruiting	12/09/2022	https://clinicaltrials.gov/study/NCT05371093	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	neoplasm of mature B-cells	VINCRISTINE	targetBased	3	Completed	01/10/2015	https://clinicaltrials.gov/study/NCT02787239	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	neoplasm of mature B-cells	VINCRISTINE	targetBased	3	Terminated	26/07/2007	https://clinicaltrials.gov/study/NCT00486759	0.35	LoF	protect	Due to an unfavorable benefit/risk ratio.
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	neoplasm of mature B-cells	VINCRISTINE	targetBased	3	Recruiting	03/08/2017	https://clinicaltrials.gov/study/NCT03206671	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	ependymoma	VINCRISTINE	targetBased	3	Active, not recruiting	07/05/2010	https://clinicaltrials.gov/study/NCT01096368	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	gestational trophoblastic neoplasm	VINCRISTINE	targetBased	3	Recruiting	01/03/2016	https://clinicaltrials.gov/study/NCT02639650	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	mediastinal malignant lymphoma	VINCRISTINE	targetBased	3	Recruiting	01/04/2022	https://clinicaltrials.gov/study/NCT06188676	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	alveolar rhabdomyosarcoma	VINCRISTINE	targetBased	3	Completed	26/12/2006	https://clinicaltrials.gov/study/NCT00354835	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	alveolar rhabdomyosarcoma	VINCRISTINE	targetBased	3	Recruiting	14/09/2021	https://clinicaltrials.gov/study/NCT04994132	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	alveolar rhabdomyosarcoma	VINCRISTINE	targetBased	3	Recruiting	04/08/2022	https://clinicaltrials.gov/study/NCT05304585	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	alveolar rhabdomyosarcoma	VINCRISTINE	targetBased	3	Active, not recruiting	01/06/2016	https://clinicaltrials.gov/study/NCT02567435	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	mesothelioma	VINCRISTINE	targetBased	3	Completed	01/09/2003	https://clinicaltrials.gov/study/NCT00075699	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	adult acute lymphoblastic leukemia	VINCRISTINE	targetBased	4	Completed	01/04/1993	https://clinicaltrials.gov/study/NCT00199069	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	adult acute lymphoblastic leukemia	VINCRISTINE	targetBased	4	Completed	01/04/2003	https://clinicaltrials.gov/study/NCT00198991	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	adult acute lymphoblastic leukemia	VINCRISTINE	targetBased	3	Unknown status	01/06/2013	https://clinicaltrials.gov/study/NCT02072785	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	adult acute lymphoblastic leukemia	VINCRISTINE	targetBased	4	Completed	01/01/2003	https://clinicaltrials.gov/study/NCT00198978	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	adult acute lymphoblastic leukemia	VINCRISTINE	targetBased	4	Completed	01/02/1997	https://clinicaltrials.gov/study/NCT00199095	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	adult acute lymphoblastic leukemia	VINCRISTINE	targetBased	4	Completed	01/10/1999	https://clinicaltrials.gov/study/NCT00199056	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	adult acute lymphoblastic leukemia	VINCRISTINE	targetBased	4	Completed	01/04/2004	https://clinicaltrials.gov/study/NCT00199004	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	adult acute lymphoblastic leukemia	VINCRISTINE	targetBased	3	Recruiting	01/04/2016	https://clinicaltrials.gov/study/NCT02611492	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	T-lymphoblastic lymphoma	VINCRISTINE	targetBased	3	Active, not recruiting	22/01/2007	https://clinicaltrials.gov/study/NCT00408005	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	T-lymphoblastic lymphoma	VINCRISTINE	targetBased	3	Recruiting	06/02/2023	https://clinicaltrials.gov/study/NCT05681260	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoplasmacytic lymphoma	VINCRISTINE	targetBased	3	Completed	01/02/2007	https://clinicaltrials.gov/study/NCT00801281	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoblastic lymphoma	VINCRISTINE	targetBased	3	Active, not recruiting	01/08/2016	https://clinicaltrials.gov/study/NCT02881086	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoblastic lymphoma	VINCRISTINE	targetBased	3	Active, not recruiting	01/01/2016	https://clinicaltrials.gov/study/NCT02845882	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoblastic lymphoma	VINCRISTINE	targetBased	3	Recruiting	23/08/2019	https://clinicaltrials.gov/study/NCT04043494	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	adult T-cell leukemia/lymphoma	VINCRISTINE	targetBased	3	Completed	01/08/1998	https://clinicaltrials.gov/study/NCT00145002	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	adult T-cell leukemia/lymphoma	VINCRISTINE	targetBased	4	Completed		https://clinicaltrials.gov/study/NCT01418430	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	head and neck malignant neoplasia	VINCRISTINE	targetBased	3	Completed	01/01/1990	https://clinicaltrials.gov/study/NCT00002476	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	chronic lymphocytic leukemia	VINCRISTINE	targetBased	3	Completed	01/02/2007	https://clinicaltrials.gov/study/NCT00801281	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	chronic lymphocytic leukemia	VINCRISTINE	targetBased	3	Completed	01/03/1998	https://clinicaltrials.gov/study/NCT00003204	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	nodular sclerosis Hodgkin lymphoma	VINCRISTINE	targetBased	3	Completed	01/02/2006	https://clinicaltrials.gov/study/NCT00302003	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	soft tissue sarcoma	VINCRISTINE	targetBased	3	Completed	01/09/2002	https://clinicaltrials.gov/study/NCT00003958	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Hodgkins lymphoma	VINCRISTINE	targetBased	3	Completed	07/12/2009	https://clinicaltrials.gov/study/NCT01026220	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Hodgkins lymphoma	VINCRISTINE	targetBased	4	Unknown status	01/08/2015	https://clinicaltrials.gov/study/NCT02526823	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Hodgkins lymphoma	VINCRISTINE	targetBased	3	Completed	01/03/2000	https://clinicaltrials.gov/study/NCT01251107	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Hodgkins lymphoma	VINCRISTINE	targetBased	3	Unknown status	01/11/2009	https://clinicaltrials.gov/study/NCT00736320	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Hodgkins lymphoma	VINCRISTINE	targetBased	3	Recruiting	01/02/2020	https://clinicaltrials.gov/study/NCT04638790	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Hodgkins lymphoma	VINCRISTINE	targetBased	3	Active, not recruiting	19/03/2015	https://clinicaltrials.gov/study/NCT02166463	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Hodgkins lymphoma	VINCRISTINE	targetBased	3	Completed	13/01/2012	https://clinicaltrials.gov/study/NCT01356680	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	T-cell acute lymphoblastic leukemia	VINCRISTINE	targetBased	3	Recruiting	08/08/2017	https://clinicaltrials.gov/study/NCT03007147	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	T-cell acute lymphoblastic leukemia	VINCRISTINE	targetBased	3	Unknown status	01/01/2008	https://clinicaltrials.gov/study/NCT01788137	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	astrocytoma	VINCRISTINE	targetBased	3	Recruiting	31/01/2020	https://clinicaltrials.gov/study/NCT04166409	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	leukemia	VINCRISTINE	targetBased	3	Active, not recruiting	03/03/2017	https://clinicaltrials.gov/study/NCT03020030	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	leukemia	VINCRISTINE	targetBased	3	Withdrawn	01/10/1999	https://clinicaltrials.gov/study/NCT00019409	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	leukemia	VINCRISTINE	targetBased	3	Completed	01/12/1996	https://clinicaltrials.gov/study/NCT00002816	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	leukemia	VINCRISTINE	targetBased	3	Completed	01/07/2000	https://clinicaltrials.gov/study/NCT00430118	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	leukemia	VINCRISTINE	targetBased	3	Active, not recruiting	01/01/1996	https://clinicaltrials.gov/study/NCT00004034	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	leukemia	VINCRISTINE	targetBased	3	Completed	01/04/2000	https://clinicaltrials.gov/study/NCT00005585	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	leukemia	VINCRISTINE	targetBased	3	Unknown status	01/11/2002	https://clinicaltrials.gov/study/NCT00764907	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	leukemia	VINCRISTINE	targetBased	3	Completed	01/06/2000	https://clinicaltrials.gov/study/NCT00005945	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	leukemia	VINCRISTINE	targetBased	3	Active, not recruiting	17/12/2014	https://clinicaltrials.gov/study/NCT02101853	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	leukemia	VINCRISTINE	targetBased	3	Completed	01/04/2000	https://clinicaltrials.gov/study/NCT00005596	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	leukemia	VINCRISTINE	targetBased	3	Completed	01/05/2008	https://clinicaltrials.gov/study/NCT00707083	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	leukemia	VINCRISTINE	targetBased	3	Unknown status	01/01/1997	https://clinicaltrials.gov/study/NCT00003437	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	leukemia	VINCRISTINE	targetBased	3	Unknown status	01/12/1998	https://clinicaltrials.gov/study/NCT00003728	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	leukemia	VINCRISTINE	targetBased	3	Unknown status	01/12/2011	https://clinicaltrials.gov/study/NCT01516580	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	leukemia	VINCRISTINE	targetBased	3	Completed	01/09/1996	https://clinicaltrials.gov/study/NCT00002812	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	leukemia	VINCRISTINE	targetBased	3	Completed	07/05/1993	https://clinicaltrials.gov/study/NCT00002514	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	leukemia	VINCRISTINE	targetBased	3	Completed	01/06/2010	https://clinicaltrials.gov/study/NCT01117441	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	leukemia	VINCRISTINE	targetBased	3	Completed	01/03/1996	https://clinicaltrials.gov/study/NCT00002766	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	leukemia	VINCRISTINE	targetBased	3	Completed	01/05/1996	https://clinicaltrials.gov/study/NCT00002744	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	leukemia	VINCRISTINE	targetBased	3	Completed	01/09/2000	https://clinicaltrials.gov/study/NCT00005977	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	leukemia	VINCRISTINE	targetBased	3	Completed	01/10/2002	https://clinicaltrials.gov/study/NCT00967057	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	leukemia	VINCRISTINE	targetBased	3	Completed	01/04/2005	https://clinicaltrials.gov/study/NCT00400946	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	leukemia	VINCRISTINE	targetBased	3	Completed	01/03/2000	https://clinicaltrials.gov/study/NCT00005603	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	leukemia	VINCRISTINE	targetBased	3	Completed	01/05/1999	https://clinicaltrials.gov/study/NCT00015873	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	leukemia	VINCRISTINE	targetBased	3	Completed	01/06/2001	https://clinicaltrials.gov/study/NCT00002757	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	leukemia	VINCRISTINE	targetBased	3	Completed	01/08/1995	https://clinicaltrials.gov/study/NCT00002700	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	leukemia	VINCRISTINE	targetBased	3	Completed	01/10/1999	https://clinicaltrials.gov/study/NCT00004218	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	leukemia	VINCRISTINE	targetBased	3	Completed	01/09/2000	https://clinicaltrials.gov/study/NCT00613457	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	sarcoma	VINCRISTINE	targetBased	3	Completed	01/08/1997	https://clinicaltrials.gov/study/NCT00002995	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	sarcoma	VINCRISTINE	targetBased	3	Completed	01/07/2006	https://clinicaltrials.gov/study/NCT00354744	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	sarcoma	VINCRISTINE	targetBased	3	Withdrawn	01/12/2005	https://clinicaltrials.gov/study/NCT00334867	0.7	LoF	protect	withdrawn
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	sarcoma	VINCRISTINE	targetBased	3	Unknown status	01/02/2001	https://clinicaltrials.gov/study/NCT00020566	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	sarcoma	VINCRISTINE	targetBased	3	Completed	01/01/1995	https://clinicaltrials.gov/study/NCT00002898	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	sarcoma	VINCRISTINE	targetBased	3	Unknown status	01/07/1992	https://clinicaltrials.gov/study/NCT00002516	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	sarcoma	VINCRISTINE	targetBased	3	Completed	01/05/2001	https://clinicaltrials.gov/study/NCT00006734	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	sarcoma	VINCRISTINE	targetBased	3	Unknown status	01/06/2006	https://clinicaltrials.gov/study/NCT00379457	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	acute lymphoblastic leukemia	VINCRISTINE	targetBased	3	Completed	08/07/2000	https://clinicaltrials.gov/study/NCT00137111	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	acute lymphoblastic leukemia	VINCRISTINE	targetBased	3	Active, not recruiting	04/10/2018	https://clinicaltrials.gov/study/NCT03589326	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	acute lymphoblastic leukemia	VINCRISTINE	targetBased	3	Active, not recruiting	03/03/2017	https://clinicaltrials.gov/study/NCT03020030	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	acute lymphoblastic leukemia	VINCRISTINE	targetBased	3	Active, not recruiting	01/08/2016	https://clinicaltrials.gov/study/NCT02881086	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	acute lymphoblastic leukemia	VINCRISTINE	targetBased	3	Active, not recruiting	19/05/2014	https://clinicaltrials.gov/study/NCT02003222	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	acute lymphoblastic leukemia	VINCRISTINE	targetBased	3	Suspended	01/06/2017	https://clinicaltrials.gov/study/NCT03150693	0.35	LoF	protect	Unacceptable Toxicity
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	acute lymphoblastic leukemia	VINCRISTINE	targetBased	4	Completed	01/04/1995	https://clinicaltrials.gov/study/NCT00411541	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	acute lymphoblastic leukemia	VINCRISTINE	targetBased	3	Completed	01/09/2000	https://clinicaltrials.gov/study/NCT00165178	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	acute lymphoblastic leukemia	VINCRISTINE	targetBased	3	Not yet recruiting	22/07/2024	https://clinicaltrials.gov/study/NCT06124157	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	acute lymphoblastic leukemia	VINCRISTINE	targetBased	4	Unknown status	01/10/2008	https://clinicaltrials.gov/study/NCT02894645	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	acute lymphoblastic leukemia	VINCRISTINE	targetBased	3	Unknown status	01/09/2002	https://clinicaltrials.gov/study/NCT00131027	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	acute lymphoblastic leukemia	VINCRISTINE	targetBased	3	Completed	29/12/2003	https://clinicaltrials.gov/study/NCT00075725	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	acute lymphoblastic leukemia	VINCRISTINE	targetBased	4	Completed	01/01/2003	https://clinicaltrials.gov/study/NCT00853008	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	acute lymphoblastic leukemia	VINCRISTINE	targetBased	4	Recruiting	01/02/2012	https://clinicaltrials.gov/study/NCT01540812	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	acute lymphoblastic leukemia	VINCRISTINE	targetBased	4	Completed	01/06/1996	https://clinicaltrials.gov/study/NCT00494897	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	acute lymphoblastic leukemia	VINCRISTINE	targetBased	4	Completed	01/06/2005	https://clinicaltrials.gov/study/NCT00526409	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	acute lymphoblastic leukemia	VINCRISTINE	targetBased	3	Active, not recruiting	15/01/2008	https://clinicaltrials.gov/study/NCT00557193	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	acute lymphoblastic leukemia	VINCRISTINE	targetBased	3	Completed	29/10/2007	https://clinicaltrials.gov/study/NCT00549848	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	acute lymphoblastic leukemia	VINCRISTINE	targetBased	3	Completed	01/02/1997	https://clinicaltrials.gov/study/NCT00187083	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	acute lymphoblastic leukemia	VINCRISTINE	targetBased	4	Completed	01/06/2001	https://clinicaltrials.gov/study/NCT00526175	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	acute lymphoblastic leukemia	VINCRISTINE	targetBased	4	Completed	01/01/2000	https://clinicaltrials.gov/study/NCT00526305	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	acute lymphoblastic leukemia	VINCRISTINE	targetBased	4	Completed	01/12/2010	https://clinicaltrials.gov/study/NCT01358253	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	acute lymphoblastic leukemia	VINCRISTINE	targetBased	3	Recruiting	15/07/2018	https://clinicaltrials.gov/study/NCT03643276	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	acute lymphoblastic leukemia	VINCRISTINE	targetBased	4	Unknown status	01/05/2010	https://clinicaltrials.gov/study/NCT01358201	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	acute lymphoblastic leukemia	VINCRISTINE	targetBased	3	Terminated	01/03/2012	https://clinicaltrials.gov/study/NCT01439347	0.7	LoF	protect	Sponsor decision
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	acute lymphoblastic leukemia	VINCRISTINE	targetBased	4	Completed	01/01/2008	https://clinicaltrials.gov/study/NCT02036489	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	acute lymphoblastic leukemia	VINCRISTINE	targetBased	3	Recruiting	13/07/2020	https://clinicaltrials.gov/study/NCT04307576	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	acute lymphoblastic leukemia	VINCRISTINE	targetBased	3	Terminated	01/07/1998	https://clinicaltrials.gov/study/NCT00187005	0.35	LoF	protect	Toxicity
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	acute lymphoblastic leukemia	VINCRISTINE	targetBased	4	Unknown status	01/07/2008	https://clinicaltrials.gov/study/NCT00846703	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoid leukemia	VINCRISTINE	targetBased	3	Active, not recruiting	17/12/2014	https://clinicaltrials.gov/study/NCT02101853	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoid leukemia	VINCRISTINE	targetBased	3	Recruiting	25/01/2021	https://clinicaltrials.gov/study/NCT04530565	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoid leukemia	VINCRISTINE	targetBased	4	Completed	01/04/2004	https://clinicaltrials.gov/study/NCT00199017	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	ganglioneuroblastoma	VINCRISTINE	targetBased	3	Recruiting	19/04/2024	https://clinicaltrials.gov/study/NCT06172296	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	ganglioneuroblastoma	VINCRISTINE	targetBased	3	Active, not recruiting	14/05/2018	https://clinicaltrials.gov/study/NCT03126916	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	childhood B acute lymphoblastic leukemia	VINCRISTINE	targetBased	3	Completed	01/03/2007	https://clinicaltrials.gov/study/NCT00381680	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	childhood B acute lymphoblastic leukemia	VINCRISTINE	targetBased	3	Completed	11/04/2005	https://clinicaltrials.gov/study/NCT00103285	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	brain cancer	VINCRISTINE	targetBased	3	Terminated	01/11/2009	https://clinicaltrials.gov/study/NCT01014767	0.7	LoF	protect	PI departure from coordinating institution
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	adult malignant mesenchymoma	VINCRISTINE	targetBased	3	Completed	01/09/2002	https://clinicaltrials.gov/study/NCT00003958	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	colorectal cancer	VINCRISTINE	targetBased	3	Completed	01/09/1977	https://clinicaltrials.gov/study/NCT00427570	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Hepatoblastoma	VINCRISTINE	targetBased	3	Active, not recruiting	14/09/2009	https://clinicaltrials.gov/study/NCT00980460	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Hepatoblastoma	VINCRISTINE	targetBased	3	Completed	01/03/1999	https://clinicaltrials.gov/study/NCT00003994	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Hepatoblastoma	VINCRISTINE	targetBased	3	Active, not recruiting	24/08/2017	https://clinicaltrials.gov/study/NCT03017326	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Hepatoblastoma	VINCRISTINE	targetBased	3	Recruiting	01/03/2021	https://clinicaltrials.gov/study/NCT04478292	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	brain neoplasm	VINCRISTINE	targetBased	3	Completed	01/04/1997	https://clinicaltrials.gov/study/NCT00002944	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	brain neoplasm	VINCRISTINE	targetBased	3	Completed	01/12/1996	https://clinicaltrials.gov/study/NCT00002875	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Mantle cell lymphoma	VINCRISTINE	targetBased	3	Recruiting	01/07/2016	https://clinicaltrials.gov/study/NCT02858258	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Mantle cell lymphoma	VINCRISTINE	targetBased	4	Unknown status	01/01/2016	https://clinicaltrials.gov/study/NCT02858804	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Mantle cell lymphoma	VINCRISTINE	targetBased	3	Active, not recruiting	01/11/2013	https://clinicaltrials.gov/study/NCT01865110	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Mantle cell lymphoma	VINCRISTINE	targetBased	3	Recruiting	22/12/2021	https://clinicaltrials.gov/study/NCT05051891	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Mantle cell lymphoma	VINCRISTINE	targetBased	3	Completed	01/05/2008	https://clinicaltrials.gov/study/NCT00722137	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Mantle cell lymphoma	VINCRISTINE	targetBased	3	Unknown status	01/07/2004	https://clinicaltrials.gov/study/NCT00209222	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Mantle cell lymphoma	VINCRISTINE	targetBased	3	Completed	30/04/2009	https://clinicaltrials.gov/study/NCT00877006	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Mantle cell lymphoma	VINCRISTINE	targetBased	3	Unknown status	14/01/2004	https://clinicaltrials.gov/study/NCT00209209	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	plasma cell neoplasm	VINCRISTINE	targetBased	3	Completed	30/06/1997	https://clinicaltrials.gov/study/NCT00002878	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	cancer	VINCRISTINE	targetBased	4	Recruiting	20/04/2023	https://clinicaltrials.gov/study/NCT05844670	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	cancer	VINCRISTINE	targetBased	4	Unknown status	01/06/2004	https://clinicaltrials.gov/study/NCT00491946	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	carcinoma	VINCRISTINE	targetBased	3	Unknown status	01/12/1998	https://clinicaltrials.gov/study/NCT00022178	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	diffuse large B-cell lymphoma	VINCRISTINE	targetBased	3	Unknown status	27/07/2017	https://clinicaltrials.gov/study/NCT03018626	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	diffuse large B-cell lymphoma	VINCRISTINE	targetBased	3	Active, not recruiting	10/07/2017	https://clinicaltrials.gov/study/NCT03213977	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	diffuse large B-cell lymphoma	VINCRISTINE	targetBased	3	Recruiting	01/10/2015	https://clinicaltrials.gov/study/NCT02449265	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	diffuse large B-cell lymphoma	VINCRISTINE	targetBased	4	Active, not recruiting	14/06/2016	https://clinicaltrials.gov/study/NCT02752815	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	diffuse large B-cell lymphoma	VINCRISTINE	targetBased	3	Recruiting	01/06/2022	https://clinicaltrials.gov/study/NCT05351346	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	diffuse large B-cell lymphoma	VINCRISTINE	targetBased	3	Recruiting	13/12/2023	https://clinicaltrials.gov/study/NCT06091865	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	diffuse large B-cell lymphoma	VINCRISTINE	targetBased	3	Completed	01/05/2005	https://clinicaltrials.gov/study/NCT00355199	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	diffuse large B-cell lymphoma	VINCRISTINE	targetBased	3	Recruiting	10/02/2023	https://clinicaltrials.gov/study/NCT05605899	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	diffuse large B-cell lymphoma	VINCRISTINE	targetBased	3	Withdrawn	01/02/2014	https://clinicaltrials.gov/study/NCT02054559	0.35	LoF	protect	No consensus among trial centers regarding protocol
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	diffuse large B-cell lymphoma	VINCRISTINE	targetBased	3	Unknown status	01/06/2016	https://clinicaltrials.gov/study/NCT02772822	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	diffuse large B-cell lymphoma	VINCRISTINE	targetBased	3	Terminated	16/10/2001	https://clinicaltrials.gov/study/NCT00135499	0.7	LoF	protect	Recruitment too low
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	diffuse large B-cell lymphoma	VINCRISTINE	targetBased	3	Active, not recruiting	11/05/2021	https://clinicaltrials.gov/study/NCT04824092	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	diffuse large B-cell lymphoma	VINCRISTINE	targetBased	4	Unknown status	01/07/2017	https://clinicaltrials.gov/study/NCT03513601	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	diffuse large B-cell lymphoma	VINCRISTINE	targetBased	3	Completed	17/02/2015	https://clinicaltrials.gov/study/NCT02285062	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	diffuse large B-cell lymphoma	VINCRISTINE	targetBased	3	Recruiting	08/02/2023	https://clinicaltrials.gov/study/NCT05578976	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	diffuse large B-cell lymphoma	VINCRISTINE	targetBased	3	Unknown status	01/09/2015	https://clinicaltrials.gov/study/NCT02428751	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	diffuse large B-cell lymphoma	VINCRISTINE	targetBased	3	Recruiting	19/08/2020	https://clinicaltrials.gov/study/NCT04332822	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	diffuse large B-cell lymphoma	VINCRISTINE	targetBased	3	Completed	24/08/2012	https://clinicaltrials.gov/study/NCT01649856	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	diffuse large B-cell lymphoma	VINCRISTINE	targetBased	3	Unknown status	01/05/2013	https://clinicaltrials.gov/study/NCT01852435	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	diffuse large B-cell lymphoma	VINCRISTINE	targetBased	3	Recruiting	23/03/2021	https://clinicaltrials.gov/study/NCT04442412	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	diffuse large B-cell lymphoma	VINCRISTINE	targetBased	3	Recruiting	01/10/2015	https://clinicaltrials.gov/study/NCT02449278	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	diffuse large B-cell lymphoma	VINCRISTINE	targetBased	3	Completed	01/12/2015	https://clinicaltrials.gov/study/NCT02617485	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	diffuse large B-cell lymphoma	VINCRISTINE	targetBased	3	Terminated	01/09/2012	https://clinicaltrials.gov/study/NCT01659099	0.35	LoF	protect	experimental treatment not Superior to standard - no need to continue the follow-up
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	diffuse large B-cell lymphoma	VINCRISTINE	targetBased	3	Terminated	26/07/2011	https://clinicaltrials.gov/study/NCT01287741	0.7	LoF	protect	The study was closed by the Sponsor according to the protocol-specified minimum post-treatment follow-up period of 3 years.
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	diffuse large B-cell lymphoma	VINCRISTINE	targetBased	3	Active, not recruiting	21/05/2020	https://clinicaltrials.gov/study/NCT04231448	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	diffuse large B-cell lymphoma	VINCRISTINE	targetBased	3	Completed	01/01/2003	https://clinicaltrials.gov/study/NCT01148446	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	diffuse large B-cell lymphoma	VINCRISTINE	targetBased	3	Recruiting	02/03/2022	https://clinicaltrials.gov/study/NCT05179733	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	diffuse large B-cell lymphoma	VINCRISTINE	targetBased	3	Active, not recruiting	08/10/2020	https://clinicaltrials.gov/study/NCT04529772	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	diffuse large B-cell lymphoma	VINCRISTINE	targetBased	3	Completed	01/12/2012	https://clinicaltrials.gov/study/NCT01724021	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	diffuse large B-cell lymphoma	VINCRISTINE	targetBased	3	Active, not recruiting	16/11/2017	https://clinicaltrials.gov/study/NCT03274492	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	diffuse large B-cell lymphoma	VINCRISTINE	targetBased	3	Not yet recruiting	21/05/2024	https://clinicaltrials.gov/study/NCT06220032	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	diffuse large B-cell lymphoma	VINCRISTINE	targetBased	3	Completed	01/09/2006	https://clinicaltrials.gov/study/NCT01459887	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	diffuse large B-cell lymphoma	VINCRISTINE	targetBased	3	Recruiting	07/06/2023	https://clinicaltrials.gov/study/NCT05820841	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	diffuse large B-cell lymphoma	VINCRISTINE	targetBased	3	Recruiting	24/06/2024	https://clinicaltrials.gov/study/NCT06356129	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	diffuse large B-cell lymphoma	VINCRISTINE	targetBased	3	Completed	01/12/2010	https://clinicaltrials.gov/study/NCT01285765	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	diffuse large B-cell lymphoma	VINCRISTINE	targetBased	3	Recruiting	17/09/2021	https://clinicaltrials.gov/study/NCT05018520	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	diffuse large B-cell lymphoma	VINCRISTINE	targetBased	4	Unknown status	01/09/2012	https://clinicaltrials.gov/study/NCT01949818	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	diffuse large B-cell lymphoma	VINCRISTINE	targetBased	3	Completed	20/03/2018	https://clinicaltrials.gov/study/NCT03263026	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	diffuse large B-cell lymphoma	VINCRISTINE	targetBased	3	Recruiting	02/11/2022	https://clinicaltrials.gov/study/NCT05234684	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	diffuse large B-cell lymphoma	VINCRISTINE	targetBased	3	Recruiting	28/12/2018	https://clinicaltrials.gov/study/NCT03650933	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	diffuse large B-cell lymphoma	VINCRISTINE	targetBased	3	Completed	22/08/2016	https://clinicaltrials.gov/study/NCT02867566	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	rhabdomyosarcoma	VINCRISTINE	targetBased	3	Completed	01/09/2002	https://clinicaltrials.gov/study/NCT00003958	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	rhabdomyosarcoma	VINCRISTINE	targetBased	3	Terminated	01/07/1995	https://clinicaltrials.gov/study/NCT00162695	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	rhabdomyosarcoma	VINCRISTINE	targetBased	3	Completed	04/09/2004	https://clinicaltrials.gov/study/NCT00075582	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Central Nervous System Neoplasm	VINCRISTINE	targetBased	3	Unknown status	01/01/1997	https://clinicaltrials.gov/study/NCT00003015	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Central Nervous System Neoplasm	VINCRISTINE	targetBased	3	Completed	01/04/1992	https://clinicaltrials.gov/study/NCT00003859	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Central Nervous System Neoplasm	VINCRISTINE	targetBased	3	Unknown status	01/09/2003	https://clinicaltrials.gov/study/NCT00278278	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Central Nervous System Neoplasm	VINCRISTINE	targetBased	3	Completed	01/08/2003	https://clinicaltrials.gov/study/NCT00085202	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Central Nervous System Neoplasm	VINCRISTINE	targetBased	3	Completed	01/10/2002	https://clinicaltrials.gov/study/NCT00052455	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Central Nervous System Neoplasm	VINCRISTINE	targetBased	3	Completed	01/04/1997	https://clinicaltrials.gov/study/NCT00002944	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Central Nervous System Neoplasm	VINCRISTINE	targetBased	3	Unknown status	01/03/2004	https://clinicaltrials.gov/study/NCT00392886	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Central Nervous System Neoplasm	VINCRISTINE	targetBased	3	Unknown status	01/02/2003	https://clinicaltrials.gov/study/NCT00053872	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Central Nervous System Neoplasm	VINCRISTINE	targetBased	3	Completed	01/07/1994	https://clinicaltrials.gov/study/NCT00002569	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Central Nervous System Neoplasm	VINCRISTINE	targetBased	3	Recruiting	01/09/2009	https://clinicaltrials.gov/study/NCT00887146	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Central Nervous System Neoplasm	VINCRISTINE	targetBased	3	Completed	01/08/1996	https://clinicaltrials.gov/study/NCT00002840	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Ewing sarcoma	VINCRISTINE	targetBased	3	Completed	22/01/2009	https://clinicaltrials.gov/study/NCT02063022	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	undifferentiated high grade pleomorphic sarcoma of bone	VINCRISTINE	targetBased	3	Completed	01/01/1995	https://clinicaltrials.gov/study/NCT00002898	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-Hodgkins lymphoma	VINCRISTINE	targetBased	3	Completed	06/07/2011	https://clinicaltrials.gov/study/NCT01332968	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-Hodgkins lymphoma	VINCRISTINE	targetBased	3	Completed	01/07/2004	https://clinicaltrials.gov/study/NCT00088530	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-Hodgkins lymphoma	VINCRISTINE	targetBased	3	Completed	01/12/2012	https://clinicaltrials.gov/study/NCT01724021	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-Hodgkins lymphoma	VINCRISTINE	targetBased	3	Completed	01/07/2008	https://clinicaltrials.gov/study/NCT00719472	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-Hodgkins lymphoma	VINCRISTINE	targetBased	3	Unknown status	01/12/2011	https://clinicaltrials.gov/study/NCT01516580	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-Hodgkins lymphoma	VINCRISTINE	targetBased	3	Completed	15/02/2011	https://clinicaltrials.gov/study/NCT01200758	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-Hodgkins lymphoma	VINCRISTINE	targetBased	3	Terminated	01/02/1999	https://clinicaltrials.gov/study/NCT00133302	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-Hodgkins lymphoma	VINCRISTINE	targetBased	3	Completed	13/10/2015	https://clinicaltrials.gov/study/NCT02406092	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-Hodgkins lymphoma	VINCRISTINE	targetBased	3	Completed	30/04/2009	https://clinicaltrials.gov/study/NCT00877006	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-Hodgkins lymphoma	VINCRISTINE	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00000658	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-Hodgkins lymphoma	VINCRISTINE	targetBased	3	Completed	31/01/2013	https://clinicaltrials.gov/study/NCT01777152	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-Hodgkins lymphoma	VINCRISTINE	targetBased	3	Terminated	06/01/2016	https://clinicaltrials.gov/study/NCT02626455	0.35	LoF	protect	The study did not meet the primary endpoint. The addition of copanlisib to standard immunochemo therapy did not improve progression-free survival compared to the control arm. Base on the study results, company decided to terminate the study.
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-Hodgkins lymphoma	VINCRISTINE	targetBased	3	Terminated	01/07/2016	https://clinicaltrials.gov/study/NCT02703272	0.35	LoF	protect	IDMC recommended that enrolment be stoped, as the EFS hazard ratio and associated p-value crossed the futility boundary specified in protocol (July 2020).
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-Hodgkins lymphoma	VINCRISTINE	targetBased	4	Unknown status	01/08/2015	https://clinicaltrials.gov/study/NCT02526823	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	choroid plexus neoplasm	VINCRISTINE	targetBased	3	Terminated	02/09/2005	https://clinicaltrials.gov/study/NCT00500890	0.7	LoF	protect	PI has left the institution
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	choroid plexus neoplasm	VINCRISTINE	targetBased	3	Terminated	01/11/2009	https://clinicaltrials.gov/study/NCT01014767	0.7	LoF	protect	PI departure from coordinating institution
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Langerhans Cell Histiocytosis	VINCRISTINE	targetBased	3	Recruiting	01/07/2018	https://clinicaltrials.gov/study/NCT04773366	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	adult B acute lymphoblastic leukemia	VINCRISTINE	targetBased	3	Completed	29/12/2003	https://clinicaltrials.gov/study/NCT00075725	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	adult B acute lymphoblastic leukemia	VINCRISTINE	targetBased	3	Completed	21/07/2008	https://clinicaltrials.gov/study/NCT00671034	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	anaplastic ependymoma	VINCRISTINE	targetBased	3	Active, not recruiting	07/05/2010	https://clinicaltrials.gov/study/NCT01096368	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	cervical cancer	VINCRISTINE	targetBased	3	Completed	01/12/1996	https://clinicaltrials.gov/study/NCT00002536	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	unspecified peripheral T-cell lymphoma	VINCRISTINE	targetBased	3	Completed	01/01/2013	https://clinicaltrials.gov/study/NCT01796002	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	unspecified peripheral T-cell lymphoma	VINCRISTINE	targetBased	3	Unknown status	01/02/2017	https://clinicaltrials.gov/study/NCT03023358	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	unspecified peripheral T-cell lymphoma	VINCRISTINE	targetBased	4	Completed	01/08/2011	https://clinicaltrials.gov/study/NCT01664975	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	unspecified peripheral T-cell lymphoma	VINCRISTINE	targetBased	3	Enrolling by invitation	01/01/2023	https://clinicaltrials.gov/study/NCT05678933	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	unspecified peripheral T-cell lymphoma	VINCRISTINE	targetBased	3	Not yet recruiting	01/06/2018	https://clinicaltrials.gov/study/NCT03553537	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	unspecified peripheral T-cell lymphoma	VINCRISTINE	targetBased	3	Completed	01/01/1995	https://clinicaltrials.gov/study/NCT00970385	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	unspecified peripheral T-cell lymphoma	VINCRISTINE	targetBased	3	Recruiting	10/05/2019	https://clinicaltrials.gov/study/NCT03952572	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	unspecified peripheral T-cell lymphoma	VINCRISTINE	targetBased	3	Recruiting	04/10/2023	https://clinicaltrials.gov/study/NCT06072131	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	unspecified peripheral T-cell lymphoma	VINCRISTINE	targetBased	4	Unknown status	01/09/2018	https://clinicaltrials.gov/study/NCT03631862	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	kidney cancer	VINCRISTINE	targetBased	3	Unknown status	01/07/1993	https://clinicaltrials.gov/study/NCT00003804	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	kidney cancer	VINCRISTINE	targetBased	3	Unknown status	01/01/2001	https://clinicaltrials.gov/study/NCT00047138	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	kidney cancer	VINCRISTINE	targetBased	3	Completed	01/07/1995	https://clinicaltrials.gov/study/NCT00002611	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	kidney cancer	VINCRISTINE	targetBased	3	Completed	01/01/1996	https://clinicaltrials.gov/study/NCT00002610	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	small cell lung carcinoma	VINCRISTINE	targetBased	3	Completed	30/08/2016	https://clinicaltrials.gov/study/NCT02566993	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	neoplasm	VINCRISTINE	targetBased	3	Completed	10/02/2009	https://clinicaltrials.gov/study/NCT00653068	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	neoplasm	VINCRISTINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=L01CA02	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	childhood acute lymphoblastic leukemia	VINCRISTINE	targetBased	3	Completed	01/10/2002	https://clinicaltrials.gov/study/NCT00022737	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	kidney Wilms tumor	VINCRISTINE	targetBased	3	Active, not recruiting	26/02/2007	https://clinicaltrials.gov/study/NCT00379340	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Kaposi's sarcoma	VINCRISTINE	targetBased	3	Unknown status		https://clinicaltrials.gov/study/NCT00002318	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Kaposi's sarcoma	VINCRISTINE	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00002093	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Kaposi's sarcoma	VINCRISTINE	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00002105	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	medulloblastoma	VINCRISTINE	targetBased	3	Active, not recruiting	26/03/2007	https://clinicaltrials.gov/study/NCT00392327	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	medulloblastoma	VINCRISTINE	targetBased	3	Completed	01/10/2000	https://clinicaltrials.gov/study/NCT00006461	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	medulloblastoma	VINCRISTINE	targetBased	3	Active, not recruiting	01/04/2004	https://clinicaltrials.gov/study/NCT00085735	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	medulloblastoma	VINCRISTINE	targetBased	3	Active, not recruiting	06/08/2007	https://clinicaltrials.gov/study/NCT00336024	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	medulloblastoma	VINCRISTINE	targetBased	3	Suspended	20/02/2023	https://clinicaltrials.gov/study/NCT05382338	0.7	LoF	protect	Drug Supply Issues
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung cancer	VINCRISTINE	targetBased	3	Completed	01/01/1993	https://clinicaltrials.gov/study/NCT00003364	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung cancer	VINCRISTINE	targetBased	3	Completed	01/03/1996	https://clinicaltrials.gov/study/NCT00002822	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	mixed phenotype acute leukemia	VINCRISTINE	targetBased	3	Recruiting	08/08/2017	https://clinicaltrials.gov/study/NCT03007147	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	neuroblastoma	VINCRISTINE	targetBased	3	Active, not recruiting	14/05/2018	https://clinicaltrials.gov/study/NCT03126916	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	neuroblastoma	VINCRISTINE	targetBased	3	Recruiting	01/02/2002	https://clinicaltrials.gov/study/NCT01704716	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	neuroblastoma	VINCRISTINE	targetBased	3	Unknown status		https://clinicaltrials.gov/study/NCT00416676	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	neuroblastoma	VINCRISTINE	targetBased	3	Unknown status	01/03/1995	https://clinicaltrials.gov/study/NCT00276731	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	neuroblastoma	VINCRISTINE	targetBased	3	Unknown status		https://clinicaltrials.gov/study/NCT00417053	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	neuroblastoma	VINCRISTINE	targetBased	3	Completed	01/07/1990	https://clinicaltrials.gov/study/NCT00002802	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	neuroblastoma	VINCRISTINE	targetBased	3	Completed	01/12/2000	https://clinicaltrials.gov/study/NCT00025428	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	neuroblastoma	VINCRISTINE	targetBased	3	Recruiting	19/04/2024	https://clinicaltrials.gov/study/NCT06172296	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	neuroblastoma	VINCRISTINE	targetBased	3	Recruiting	05/11/2019	https://clinicaltrials.gov/study/NCT04221035	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	neuroblastoma	VINCRISTINE	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00365755	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	neuroblastoma	VINCRISTINE	targetBased	3	Unknown status	01/12/2001	https://clinicaltrials.gov/study/NCT00030719	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	neuroblastoma	VINCRISTINE	targetBased	3	Unknown status	01/10/2004	https://clinicaltrials.gov/study/NCT00410631	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	neuroblastoma	VINCRISTINE	targetBased	3	Completed	01/02/2001	https://clinicaltrials.gov/study/NCT00004188	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	neuroblastoma	VINCRISTINE	targetBased	3	Completed	05/11/2007	https://clinicaltrials.gov/study/NCT00567567	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	multiple myeloma	VINCRISTINE	targetBased	3	Completed	01/08/1998	https://clinicaltrials.gov/study/NCT00083551	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	multiple myeloma	VINCRISTINE	targetBased	3	Unknown status	01/09/1994	https://clinicaltrials.gov/study/NCT00002599	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	multiple myeloma	VINCRISTINE	targetBased	3	Terminated	01/06/2003	https://clinicaltrials.gov/study/NCT00215943	0.7	LoF	protect	Poor accrual, changes in management of newly diagnosed myeloma patients, new drugs/more effective regimens.
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	multiple myeloma	VINCRISTINE	targetBased	3	Completed	01/10/2000	https://clinicaltrials.gov/study/NCT00344422	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	multiple myeloma	VINCRISTINE	targetBased	3	Completed	30/06/1997	https://clinicaltrials.gov/study/NCT00002878	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	multiple myeloma	VINCRISTINE	targetBased	3	Completed	01/07/1994	https://clinicaltrials.gov/study/NCT00002556	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	multiple myeloma	VINCRISTINE	targetBased	3	Completed	01/10/1996	https://clinicaltrials.gov/study/NCT00006232	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	multiple myeloma	VINCRISTINE	targetBased	3	Completed	01/01/1994	https://clinicaltrials.gov/study/NCT00002548	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	multiple myeloma	VINCRISTINE	targetBased	3	Completed	01/03/2006	https://clinicaltrials.gov/study/NCT00461747	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	multiple myeloma	VINCRISTINE	targetBased	3	Unknown status	01/03/2001	https://clinicaltrials.gov/study/NCT00028886	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE	targetBased	3	Completed	16/03/1998	https://clinicaltrials.gov/study/NCT00577993	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE	targetBased	3	Unknown status	01/07/2001	https://clinicaltrials.gov/study/NCT00025636	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE	targetBased	3	Completed	01/03/1997	https://clinicaltrials.gov/study/NCT00005578	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE	targetBased	3	Completed	01/01/2001	https://clinicaltrials.gov/study/NCT00052936	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE	targetBased	3	Unknown status	01/06/1994	https://clinicaltrials.gov/study/NCT00003815	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE	targetBased	3	Completed	01/11/2005	https://clinicaltrials.gov/study/NCT00278408	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE	targetBased	3	Completed	01/09/2000	https://clinicaltrials.gov/study/NCT00005977	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE	targetBased	3	Unknown status	01/10/2001	https://clinicaltrials.gov/study/NCT00041210	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE	targetBased	3	Completed	01/01/2007	https://clinicaltrials.gov/study/NCT00433459	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE	targetBased	3	Completed	01/05/1999	https://clinicaltrials.gov/study/NCT00004179	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE	targetBased	3	Completed	01/12/1997	https://clinicaltrials.gov/study/NCT00003150	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE	targetBased	3	Completed	17/06/1999	https://clinicaltrials.gov/study/NCT00003389	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE	targetBased	3	Completed	30/10/1995	https://clinicaltrials.gov/study/NCT00002835	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE	targetBased	3	Completed	01/03/1996	https://clinicaltrials.gov/study/NCT00002766	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE	targetBased	3	Completed	01/01/1998	https://clinicaltrials.gov/study/NCT00005867	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE	targetBased	3	Completed	01/11/1992	https://clinicaltrials.gov/study/NCT00002576	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE	targetBased	3	Unknown status	01/02/2001	https://clinicaltrials.gov/study/NCT00028717	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE	targetBased	3	Completed	31/01/2013	https://clinicaltrials.gov/study/NCT01777152	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE	targetBased	3	Unknown status	01/01/1993	https://clinicaltrials.gov/study/NCT00003578	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE	targetBased	3	Completed	01/11/2007	https://clinicaltrials.gov/study/NCT00554164	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE	targetBased	3	Completed	01/02/1997	https://clinicaltrials.gov/study/NCT00003650	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE	targetBased	3	Completed	01/11/2011	https://clinicaltrials.gov/study/NCT01478542	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE	targetBased	3	Terminated	01/05/2015	https://clinicaltrials.gov/study/NCT02359162	0.7	LoF	protect	The study is out of date
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE	targetBased	3	Recruiting	01/10/2021	https://clinicaltrials.gov/study/NCT05075460	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE	targetBased	3	Completed	01/04/1997	https://clinicaltrials.gov/study/NCT00003215	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE	targetBased	3	Completed	01/10/1996	https://clinicaltrials.gov/study/NCT00002827	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE	targetBased	3	Terminated	01/09/2004	https://clinicaltrials.gov/study/NCT00275106	0.35	LoF	protect	Withdrawn due to an excess of toxic deaths
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE	targetBased	3	Completed	01/03/2009	https://clinicaltrials.gov/study/NCT00854568	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE	targetBased	3	Recruiting	05/10/2021	https://clinicaltrials.gov/study/NCT04759586	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE	targetBased	3	Completed	01/06/2000	https://clinicaltrials.gov/study/NCT00004228	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE	targetBased	3	Active, not recruiting	01/03/2001	https://clinicaltrials.gov/study/NCT00006721	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE	targetBased	3	Active, not recruiting	01/09/1993	https://clinicaltrials.gov/study/NCT00379041	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE	targetBased	3	Completed	01/06/2008	https://clinicaltrials.gov/study/NCT00646854	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE	targetBased	3	Recruiting	01/08/2018	https://clinicaltrials.gov/study/NCT03647072	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE	targetBased	3	Completed	01/06/2001	https://clinicaltrials.gov/study/NCT00002757	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE	targetBased	3	Completed	01/07/1997	https://clinicaltrials.gov/study/NCT00004031	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE	targetBased	3	Completed	08/05/2001	https://clinicaltrials.gov/study/NCT00064116	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE	targetBased	3	Completed	01/05/2005	https://clinicaltrials.gov/study/NCT00118209	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE	targetBased	3	Completed	03/09/2013	https://clinicaltrials.gov/study/NCT01855750	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE	targetBased	3	Active, not recruiting	01/09/1989	https://clinicaltrials.gov/study/NCT00002462	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE	targetBased	3	Completed	31/07/2013	https://clinicaltrials.gov/study/NCT01889069	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE	targetBased	3	Completed	01/04/2002	https://clinicaltrials.gov/study/NCT00053768	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE	targetBased	3	Unknown status	01/12/1998	https://clinicaltrials.gov/study/NCT00003728	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE	targetBased	3	Completed	01/01/1999	https://clinicaltrials.gov/study/NCT00265031	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE	targetBased	3	Unknown status	01/11/2000	https://clinicaltrials.gov/study/NCT00017290	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE	targetBased	3	Completed	01/08/2002	https://clinicaltrials.gov/study/NCT00049595	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE	targetBased	3	Completed	01/12/1994	https://clinicaltrials.gov/study/NCT00002618	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE	targetBased	3	Completed	01/05/1998	https://clinicaltrials.gov/study/NCT00264953	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE	targetBased	3	Completed	29/08/2008	https://clinicaltrials.gov/study/NCT00678327	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE	targetBased	3	Completed	01/11/2003	https://clinicaltrials.gov/study/NCT00059839	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE	targetBased	3	Completed	25/05/1994	https://clinicaltrials.gov/study/NCT00002565	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE	targetBased	3	Unknown status	01/01/1997	https://clinicaltrials.gov/study/NCT00002987	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE	targetBased	3	Terminated	01/05/2008	https://clinicaltrials.gov/study/NCT00920153	0.7	LoF	protect	Other new drugs
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE	targetBased	3	Unknown status	01/05/1995	https://clinicaltrials.gov/study/NCT00003423	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE	targetBased	3	Terminated	01/04/2005	https://clinicaltrials.gov/study/NCT00841945	0.7	LoF	protect	other drugs other studies
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE	targetBased	3	Suspended		https://clinicaltrials.gov/study/NCT00324831	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE	targetBased	3	Completed	01/06/1998	https://clinicaltrials.gov/study/NCT00003421	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE	targetBased	3	Completed	31/01/2014	https://clinicaltrials.gov/study/NCT01974440	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE	targetBased	3	Completed	01/11/2005	https://clinicaltrials.gov/study/NCT00278421	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE	targetBased	3	Completed	01/09/1999	https://clinicaltrials.gov/study/NCT00004112	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE	targetBased	3	Terminated	01/03/1997	https://clinicaltrials.gov/study/NCT00003152	0.7	LoF	protect	low accrual
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE	targetBased	3	Completed	01/01/1999	https://clinicaltrials.gov/study/NCT00003595	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE	targetBased	3	Completed	01/08/1995	https://clinicaltrials.gov/study/NCT00002700	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Wilms tumor	VINCRISTINE	targetBased	4	Not yet recruiting	01/06/2019	https://clinicaltrials.gov/study/NCT03892330	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	marginal zone B-cell lymphoma	VINCRISTINE	targetBased	3	Recruiting	05/09/2023	https://clinicaltrials.gov/study/NCT06006117	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	classic Hodgkin lymphoma	VINCRISTINE	targetBased	3	Completed	01/09/2002	https://clinicaltrials.gov/study/NCT00025259	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	classic Hodgkin lymphoma	VINCRISTINE	targetBased	3	Active, not recruiting	01/10/2015	https://clinicaltrials.gov/study/NCT02684708	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	classic Hodgkin lymphoma	VINCRISTINE	targetBased	3	Active, not recruiting	19/03/2015	https://clinicaltrials.gov/study/NCT02166463	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	classic Hodgkin lymphoma	VINCRISTINE	targetBased	3	Active, not recruiting	01/07/2016	https://clinicaltrials.gov/study/NCT02661503	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	childhood T acute lymphoblastic leukemia	VINCRISTINE	targetBased	3	Active, not recruiting	04/10/2014	https://clinicaltrials.gov/study/NCT02112916	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	childhood T acute lymphoblastic leukemia	VINCRISTINE	targetBased	3	Active, not recruiting	15/01/2008	https://clinicaltrials.gov/study/NCT00557193	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	acute myeloid leukemia	VINCRISTINE	targetBased	3	Completed	01/08/2002	https://clinicaltrials.gov/study/NCT00136084	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	embryonal rhabdomyosarcoma	VINCRISTINE	targetBased	3	Completed	26/12/2006	https://clinicaltrials.gov/study/NCT00354835	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	embryonal rhabdomyosarcoma	VINCRISTINE	targetBased	3	Recruiting	04/08/2022	https://clinicaltrials.gov/study/NCT05304585	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	embryonal rhabdomyosarcoma	VINCRISTINE	targetBased	3	Recruiting	14/09/2021	https://clinicaltrials.gov/study/NCT04994132	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	embryonal rhabdomyosarcoma	VINCRISTINE	targetBased	3	Active, not recruiting	01/06/2016	https://clinicaltrials.gov/study/NCT02567435	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	peritoneal neoplasm	PATUPILONE	targetBased	3	Completed	01/11/2005	https://clinicaltrials.gov/study/NCT00262990	0.7	GoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	ovarian cancer	PATUPILONE	targetBased	3	Completed	01/11/2005	https://clinicaltrials.gov/study/NCT00262990	0.7	GoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	fallopian tube cancer	PATUPILONE	targetBased	3	Completed	01/11/2005	https://clinicaltrials.gov/study/NCT00262990	0.7	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	breast cancer	RALOXIFENE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fcaaa6dc-74e8-4fb8-800c-5574bf0f8de9	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	LASOFOXIFENE	targetBased	3	Recruiting	31/10/2023	https://clinicaltrials.gov/study/NCT05696626	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	LASOFOXIFENE	targetBased	3	Recruiting	31/10/2023	https://clinicaltrials.gov/study/NCT05696626	0.7		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	breast cancer	LASOFOXIFENE	targetBased	3	Recruiting	31/10/2023	https://clinicaltrials.gov/study/NCT05696626	0.7		protect
HTS for Tumor Hsp90 Inhibitors	HSP90 known inhibitor displacement	HSP90AA1	Heat shock protein HSP 90-alpha	multiple myeloma	TANESPIMYCIN	targetBased	3	Completed	01/02/2008	https://clinicaltrials.gov/study/NCT00546780	0.7	LoF	protect
Luminescence-based primary biochemical high throughput screening assay to identify inhibitors of the Heat Shock Protein 90 (HSP90)	HSP90AA1	HSP90AA1	Full-length cDNA 5-PRIME end of clone CS0DN005YI08 of Adult brain of Homo sapiens , Heat shock protein HSP 90-alpha, Heat shock protein HSP 90-alpha	multiple myeloma	TANESPIMYCIN	targetBased	3	Completed	01/02/2008	https://clinicaltrials.gov/study/NCT00546780	0.7	LoF	protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	breast neoplasm	ISOFLURANE	targetBased	4	Completed	01/03/2007	https://clinicaltrials.gov/study/NCT00575354	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	breast neoplasm	ISOFLURANE	targetBased	4	Completed	01/03/2007	https://clinicaltrials.gov/study/NCT00575354	1		protect
Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3	HDAC3	HDAC3	Histone deacetylase 3	lymphoma	ROMIDEPSIN	targetBased	3	Withdrawn	01/09/2018	https://clinicaltrials.gov/study/NCT03355768	0.7	LoF	protect	Study was never opened due to lack of funding
Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3	HDAC3	HDAC3	Histone deacetylase 3	lymphoma	ROMIDEPSIN	targetBased	3	Active, not recruiting	06/11/2018	https://clinicaltrials.gov/study/NCT03703375	0.7	LoF	protect
Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3	HDAC3	HDAC3	Histone deacetylase 3	T-cell non-Hodgkin lymphoma	ROMIDEPSIN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03b39d40-90fe-11df-9de6-0002a5d5c51b	1	LoF	protect
Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3	HDAC3	HDAC3	Histone deacetylase 3	Cutaneous T-cell lymphoma	ROMIDEPSIN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03b39d40-90fe-11df-9de6-0002a5d5c51b	1	LoF	protect
Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3	HDAC3	HDAC3	Histone deacetylase 3	unspecified peripheral T-cell lymphoma	ROMIDEPSIN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03b39d40-90fe-11df-9de6-0002a5d5c51b	1	LoF	protect
Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3	HDAC3	HDAC3	Histone deacetylase 3	unspecified peripheral T-cell lymphoma	ROMIDEPSIN	targetBased	3	Completed	11/06/2012	https://clinicaltrials.gov/study/NCT01482962	0.7	LoF	protect
Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3	HDAC3	HDAC3	Histone deacetylase 3	unspecified peripheral T-cell lymphoma	ROMIDEPSIN	targetBased	3	Completed	01/01/2013	https://clinicaltrials.gov/study/NCT01796002	0.7	LoF	protect
Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3	HDAC3	HDAC3	Histone deacetylase 3	angioimmunoblastic T-cell lymphoma	ROMIDEPSIN	targetBased	3	Active, not recruiting	09/11/2018	https://clinicaltrials.gov/study/NCT03593018	0.7	LoF	protect
Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3	HDAC3	HDAC3	Histone deacetylase 3	neoplasm	ROMIDEPSIN	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=L01XH02	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Paraganglioma	LEVETIRACETAM	targetBased	4	Recruiting	01/02/2018	https://clinicaltrials.gov/study/NCT03048084	1	LoF	protect
qHTS assay for MDR1-selective chemotherapeutics: Primary screen using the drug-selected MDR subline cells KB-V1	MDR1-selective compounds	ABCB1	ATP-binding cassette, sub-family B , ATP-dependent translocase ABCB1	non-small cell lung carcinoma	TARIQUIDAR	targetBased	3	Terminated	01/06/2002	https://clinicaltrials.gov/study/NCT00042315	0.7	LoF	protect
qHTS assay for MDR1-selective chemotherapeutics: Primary screen using the parental adenocarcinoma cell KB-3-1	MDR1-selective compounds	ABCB1	ATP-binding cassette, sub-family B , ATP-dependent translocase ABCB1	non-small cell lung carcinoma	TARIQUIDAR	targetBased	3	Terminated	01/06/2002	https://clinicaltrials.gov/study/NCT00042315	0.7	LoF	protect
qHTS assay for MDR1-selective chemotherapeutics: Primary screen using the drug-selected MDR subline cells KB-V1	MDR1-selective compounds	ABCB1	ATP-binding cassette, sub-family B , ATP-dependent translocase ABCB1	non-small cell lung carcinoma	TARIQUIDAR	targetBased	3	Terminated	01/06/2002	https://clinicaltrials.gov/study/NCT00042302	0.7	LoF	protect
qHTS assay for MDR1-selective chemotherapeutics: Primary screen using the parental adenocarcinoma cell KB-3-1	MDR1-selective compounds	ABCB1	ATP-binding cassette, sub-family B , ATP-dependent translocase ABCB1	non-small cell lung carcinoma	TARIQUIDAR	targetBased	3	Terminated	01/06/2002	https://clinicaltrials.gov/study/NCT00042302	0.7	LoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	neoplasm	FULVESTRANT	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=L02BA03	1	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast neoplasm	FULVESTRANT	targetBased	3	Active, not recruiting	01/07/2022	https://clinicaltrials.gov/study/NCT05365178	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast neoplasm	FULVESTRANT	targetBased	3	Active, not recruiting	01/07/2022	https://clinicaltrials.gov/study/NCT05365178	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast neoplasm	FULVESTRANT	targetBased	3	Active, not recruiting	09/11/2017	https://clinicaltrials.gov/study/NCT03425838	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast neoplasm	FULVESTRANT	targetBased	3	Active, not recruiting	09/11/2017	https://clinicaltrials.gov/study/NCT03425838	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast neoplasm	FULVESTRANT	targetBased	3	Active, not recruiting	22/07/2014	https://clinicaltrials.gov/study/NCT02107703	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast neoplasm	FULVESTRANT	targetBased	3	Active, not recruiting	22/07/2014	https://clinicaltrials.gov/study/NCT02107703	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast neoplasm	FULVESTRANT	targetBased	4	Terminated	24/07/2017	https://clinicaltrials.gov/study/NCT03220178	1	LoF	protect	Due to COVID-19 pandemic, study cannot be finished in planned timeframe.
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast neoplasm	FULVESTRANT	targetBased	4	Terminated	24/07/2017	https://clinicaltrials.gov/study/NCT03220178	1	LoF	protect	Due to COVID-19 pandemic, study cannot be finished in planned timeframe.
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast neoplasm	FULVESTRANT	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/faslodex	1	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast neoplasm	FULVESTRANT	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/faslodex	1	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast neoplasm	FULVESTRANT	targetBased	3	Completed	20/12/2017	https://clinicaltrials.gov/study/NCT03447132	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast neoplasm	FULVESTRANT	targetBased	3	Completed	20/12/2017	https://clinicaltrials.gov/study/NCT03447132	0.7	LoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	breast carcinoma	FULVESTRANT	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=83d7a440-e904-4e36-afb5-cb02b1c919f7	1	LoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	breast carcinoma	FULVESTRANT	targetBased	3	Unknown status	01/12/2015	https://clinicaltrials.gov/study/NCT02404051	0.7	LoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	cancer	FULVESTRANT	targetBased	3	Recruiting	11/06/2020	https://clinicaltrials.gov/study/NCT04158362	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	HER2 Positive Breast Carcinoma	FULVESTRANT	targetBased	3	Completed	15/09/2006	https://clinicaltrials.gov/study/NCT00390455	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	HER2 Positive Breast Carcinoma	FULVESTRANT	targetBased	3	Completed	15/09/2006	https://clinicaltrials.gov/study/NCT00390455	0.7	LoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	HER2 Positive Breast Carcinoma	FULVESTRANT	targetBased	3	Completed	15/09/2006	https://clinicaltrials.gov/study/NCT00390455	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	neoplasm	FULVESTRANT	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=L02BA03	1	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	neoplasm	FULVESTRANT	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=L02BA03	1	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	cancer	FULVESTRANT	targetBased	3	Recruiting	11/06/2020	https://clinicaltrials.gov/study/NCT04158362	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	cancer	FULVESTRANT	targetBased	3	Recruiting	11/06/2020	https://clinicaltrials.gov/study/NCT04158362	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	invasive lobular carcinoma	FULVESTRANT	targetBased	3	Active, not recruiting	13/12/2013	https://clinicaltrials.gov/study/NCT01953588	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	invasive lobular carcinoma	FULVESTRANT	targetBased	3	Active, not recruiting	13/12/2013	https://clinicaltrials.gov/study/NCT01953588	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	invasive breast ductal carcinoma	FULVESTRANT	targetBased	3	Active, not recruiting	13/12/2013	https://clinicaltrials.gov/study/NCT01953588	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	invasive breast ductal carcinoma	FULVESTRANT	targetBased	3	Active, not recruiting	13/12/2013	https://clinicaltrials.gov/study/NCT01953588	0.7	LoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	breast neoplasm	FULVESTRANT	targetBased	3	Active, not recruiting	09/11/2017	https://clinicaltrials.gov/study/NCT03425838	0.7	LoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	breast neoplasm	FULVESTRANT	targetBased	3	Active, not recruiting	01/07/2022	https://clinicaltrials.gov/study/NCT05365178	0.7	LoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	breast neoplasm	FULVESTRANT	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/faslodex	1	LoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	breast neoplasm	FULVESTRANT	targetBased	3	Active, not recruiting	22/07/2014	https://clinicaltrials.gov/study/NCT02107703	0.7	LoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	breast neoplasm	FULVESTRANT	targetBased	4	Terminated	24/07/2017	https://clinicaltrials.gov/study/NCT03220178	1	LoF	protect	Due to COVID-19 pandemic, study cannot be finished in planned timeframe.
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	breast neoplasm	FULVESTRANT	targetBased	3	Completed	20/12/2017	https://clinicaltrials.gov/study/NCT03447132	0.7	LoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	invasive breast ductal carcinoma	FULVESTRANT	targetBased	3	Active, not recruiting	13/12/2013	https://clinicaltrials.gov/study/NCT01953588	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Terminated	09/04/2015	https://clinicaltrials.gov/study/NCT02340221	0.35	LoF	protect	The Sponsor discontinued the manufacturing and development of taselisib due to modest clinical benefit and limited tolerability.
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Terminated	09/04/2015	https://clinicaltrials.gov/study/NCT02340221	0.35	LoF	protect	The Sponsor discontinued the manufacturing and development of taselisib due to modest clinical benefit and limited tolerability.
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Completed	01/11/1998	https://clinicaltrials.gov/study/NCT00241449	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Completed	01/11/1998	https://clinicaltrials.gov/study/NCT00241449	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Completed	02/02/2018	https://clinicaltrials.gov/study/NCT03439046	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Completed	02/02/2018	https://clinicaltrials.gov/study/NCT03439046	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Active, not recruiting	14/09/2021	https://clinicaltrials.gov/study/NCT05063786	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Active, not recruiting	14/09/2021	https://clinicaltrials.gov/study/NCT05063786	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Recruiting	18/01/2022	https://clinicaltrials.gov/study/NCT05438810	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Recruiting	18/01/2022	https://clinicaltrials.gov/study/NCT05438810	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Terminated	03/10/2012	https://clinicaltrials.gov/study/NCT01633060	0.35	LoF	protect	Novartis decided not to pursue further development of buparlisib program (assessment of moderate PFS benefit with know, but manageable, buparlisib profile).
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Terminated	03/10/2012	https://clinicaltrials.gov/study/NCT01633060	0.35	LoF	protect	Novartis decided not to pursue further development of buparlisib program (assessment of moderate PFS benefit with know, but manageable, buparlisib profile).
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Completed	26/09/2013	https://clinicaltrials.gov/study/NCT01942135	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Completed	26/09/2013	https://clinicaltrials.gov/study/NCT01942135	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	4	Completed	29/05/2015	https://clinicaltrials.gov/study/NCT02447328	1	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	4	Completed	29/05/2015	https://clinicaltrials.gov/study/NCT02447328	1	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	4	Terminated	14/08/2019	https://clinicaltrials.gov/study/NCT04031885	1	LoF	protect	Business decision based on the inability to enroll subjects into the trial
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	4	Terminated	14/08/2019	https://clinicaltrials.gov/study/NCT04031885	1	LoF	protect	Business decision based on the inability to enroll subjects into the trial
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Completed	24/05/2018	https://clinicaltrials.gov/study/NCT03462251	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Completed	24/05/2018	https://clinicaltrials.gov/study/NCT03462251	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Terminated	11/04/2022	https://clinicaltrials.gov/study/NCT05065411	0.7	LoF	protect	Business decision
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Terminated	11/04/2022	https://clinicaltrials.gov/study/NCT05065411	0.7	LoF	protect	Business decision
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Unknown status	01/03/2004	https://clinicaltrials.gov/study/NCT00253422	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Unknown status	01/03/2004	https://clinicaltrials.gov/study/NCT00253422	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=99cf8b69-4c23-4886-80e9-b23e348b5bd7	1	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=99cf8b69-4c23-4886-80e9-b23e348b5bd7	1	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Completed	09/06/2015	https://clinicaltrials.gov/study/NCT02422615	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Completed	09/06/2015	https://clinicaltrials.gov/study/NCT02422615	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Active, not recruiting	25/05/2022	https://clinicaltrials.gov/study/NCT05433480	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Active, not recruiting	25/05/2022	https://clinicaltrials.gov/study/NCT05433480	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Completed	01/04/2004	https://clinicaltrials.gov/study/NCT00075764	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Completed	01/04/2004	https://clinicaltrials.gov/study/NCT00075764	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Active, not recruiting	16/04/2020	https://clinicaltrials.gov/study/NCT04305496	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Active, not recruiting	16/04/2020	https://clinicaltrials.gov/study/NCT04305496	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Recruiting	31/10/2023	https://clinicaltrials.gov/study/NCT05696626	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Recruiting	31/10/2023	https://clinicaltrials.gov/study/NCT05696626	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Recruiting	07/06/2023	https://clinicaltrials.gov/study/NCT05646862	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Recruiting	07/06/2023	https://clinicaltrials.gov/study/NCT05646862	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Recruiting	30/09/2022	https://clinicaltrials.gov/study/NCT05501886	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Recruiting	30/09/2022	https://clinicaltrials.gov/study/NCT05501886	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Terminated	01/11/2007	https://clinicaltrials.gov/study/NCT00543127	0.7	LoF	protect	Unjustified decision of company that funded the trial.
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Terminated	01/11/2007	https://clinicaltrials.gov/study/NCT00543127	0.7	LoF	protect	Unjustified decision of company that funded the trial.
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Recruiting	09/01/2024	https://clinicaltrials.gov/study/NCT06105632	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Recruiting	09/01/2024	https://clinicaltrials.gov/study/NCT06105632	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Active, not recruiting	22/03/2017	https://clinicaltrials.gov/study/NCT03079011	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Active, not recruiting	22/03/2017	https://clinicaltrials.gov/study/NCT03079011	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Completed	06/11/2007	https://clinicaltrials.gov/study/NCT00545077	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Completed	06/11/2007	https://clinicaltrials.gov/study/NCT00545077	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Active, not recruiting	13/02/2005	https://clinicaltrials.gov/study/NCT00099437	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Active, not recruiting	13/02/2005	https://clinicaltrials.gov/study/NCT00099437	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Not yet recruiting	18/04/2024	https://clinicaltrials.gov/study/NCT06380751	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Not yet recruiting	18/04/2024	https://clinicaltrials.gov/study/NCT06380751	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Active, not recruiting	16/11/2021	https://clinicaltrials.gov/study/NCT05077449	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Active, not recruiting	16/11/2021	https://clinicaltrials.gov/study/NCT05077449	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Not yet recruiting	01/07/2020	https://clinicaltrials.gov/study/NCT04337658	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Not yet recruiting	01/07/2020	https://clinicaltrials.gov/study/NCT04337658	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Recruiting	14/10/2020	https://clinicaltrials.gov/study/NCT04646759	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Recruiting	14/10/2020	https://clinicaltrials.gov/study/NCT04646759	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Recruiting	10/05/2021	https://clinicaltrials.gov/study/NCT04862663	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Recruiting	10/05/2021	https://clinicaltrials.gov/study/NCT04862663	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Completed	01/05/1997	https://clinicaltrials.gov/study/NCT00635713	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Completed	01/05/1997	https://clinicaltrials.gov/study/NCT00635713	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2fc17ba3-83c7-a2b4-8a75-6a0cb1e07682	1	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2fc17ba3-83c7-a2b4-8a75-6a0cb1e07682	1	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Terminated	15/11/2019	https://clinicaltrials.gov/study/NCT04060862	0.7	LoF	protect	The decision to not open the Phase III portion was based on a strategic sponsor decision and not driven by any safety concerns.
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Terminated	15/11/2019	https://clinicaltrials.gov/study/NCT04060862	0.7	LoF	protect	The decision to not open the Phase III portion was based on a strategic sponsor decision and not driven by any safety concerns.
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT01300351	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT01300351	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Active, not recruiting	13/12/2013	https://clinicaltrials.gov/study/NCT01953588	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Active, not recruiting	13/12/2013	https://clinicaltrials.gov/study/NCT01953588	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Active, not recruiting	05/12/2016	https://clinicaltrials.gov/study/NCT02763566	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Active, not recruiting	05/12/2016	https://clinicaltrials.gov/study/NCT02763566	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Active, not recruiting	21/06/2017	https://clinicaltrials.gov/study/NCT02947685	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Active, not recruiting	21/06/2017	https://clinicaltrials.gov/study/NCT02947685	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	4	Recruiting	27/04/2022	https://clinicaltrials.gov/study/NCT05362760	1	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	4	Recruiting	27/04/2022	https://clinicaltrials.gov/study/NCT05362760	1	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Unknown status	01/05/2008	https://clinicaltrials.gov/study/NCT00688194	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Unknown status	01/05/2008	https://clinicaltrials.gov/study/NCT00688194	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Active, not recruiting	13/06/2019	https://clinicaltrials.gov/study/NCT03927456	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Active, not recruiting	13/06/2019	https://clinicaltrials.gov/study/NCT03927456	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Recruiting	28/03/2022	https://clinicaltrials.gov/study/NCT05207709	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Recruiting	28/03/2022	https://clinicaltrials.gov/study/NCT05207709	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Active, not recruiting	17/10/2012	https://clinicaltrials.gov/study/NCT01602380	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Active, not recruiting	17/10/2012	https://clinicaltrials.gov/study/NCT01602380	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Recruiting	03/03/2023	https://clinicaltrials.gov/study/NCT05654623	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Recruiting	03/03/2023	https://clinicaltrials.gov/study/NCT05654623	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Active, not recruiting	27/01/2021	https://clinicaltrials.gov/study/NCT04650581	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Active, not recruiting	27/01/2021	https://clinicaltrials.gov/study/NCT04650581	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Completed	13/03/2014	https://clinicaltrials.gov/study/NCT02028507	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Completed	13/03/2014	https://clinicaltrials.gov/study/NCT02028507	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	4	Not yet recruiting	01/08/2018	https://clinicaltrials.gov/study/NCT03591549	1	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	4	Not yet recruiting	01/08/2018	https://clinicaltrials.gov/study/NCT03591549	1	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Recruiting	10/09/2021	https://clinicaltrials.gov/study/NCT05054751	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Recruiting	10/09/2021	https://clinicaltrials.gov/study/NCT05054751	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Recruiting	29/11/2021	https://clinicaltrials.gov/study/NCT05038735	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Recruiting	29/11/2021	https://clinicaltrials.gov/study/NCT05038735	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Recruiting	03/08/2022	https://clinicaltrials.gov/study/NCT05306340	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Recruiting	03/08/2022	https://clinicaltrials.gov/study/NCT05306340	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Completed	01/11/2005	https://clinicaltrials.gov/study/NCT00327769	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Completed	01/11/2005	https://clinicaltrials.gov/study/NCT00327769	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Completed	01/01/2004	https://clinicaltrials.gov/study/NCT00256698	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Completed	01/01/2004	https://clinicaltrials.gov/study/NCT00256698	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Recruiting	01/05/2018	https://clinicaltrials.gov/study/NCT04263298	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Recruiting	01/05/2018	https://clinicaltrials.gov/study/NCT04263298	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Completed	01/08/2003	https://clinicaltrials.gov/study/NCT00065325	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Completed	01/08/2003	https://clinicaltrials.gov/study/NCT00065325	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Terminated	01/05/2014	https://clinicaltrials.gov/study/NCT02137837	0.7	LoF	protect	lack of accrual
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Terminated	01/05/2014	https://clinicaltrials.gov/study/NCT02137837	0.7	LoF	protect	lack of accrual
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	4	Recruiting	09/08/2022	https://clinicaltrials.gov/study/NCT05631795	1	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	4	Recruiting	09/08/2022	https://clinicaltrials.gov/study/NCT05631795	1	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	4	Recruiting	01/03/2018	https://clinicaltrials.gov/study/NCT03355157	1	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	4	Recruiting	01/03/2018	https://clinicaltrials.gov/study/NCT03355157	1	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Completed	23/07/2015	https://clinicaltrials.gov/study/NCT02437318	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Completed	23/07/2015	https://clinicaltrials.gov/study/NCT02437318	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	4	Not yet recruiting	07/02/2022	https://clinicaltrials.gov/study/NCT05191914	1	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	4	Not yet recruiting	07/02/2022	https://clinicaltrials.gov/study/NCT05191914	1	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Terminated	01/11/2000	https://clinicaltrials.gov/study/NCT00010153	0.7	LoF	protect	low accrual
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Terminated	01/11/2000	https://clinicaltrials.gov/study/NCT00010153	0.7	LoF	protect	low accrual
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Unknown status	01/11/2007	https://clinicaltrials.gov/study/NCT02394496	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Unknown status	01/11/2007	https://clinicaltrials.gov/study/NCT02394496	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Completed	20/11/2019	https://clinicaltrials.gov/study/NCT04109066	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Completed	20/11/2019	https://clinicaltrials.gov/study/NCT04109066	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Completed	07/08/2012	https://clinicaltrials.gov/study/NCT01610284	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	FULVESTRANT	targetBased	3	Completed	07/08/2012	https://clinicaltrials.gov/study/NCT01610284	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast carcinoma	FULVESTRANT	targetBased	3	Unknown status	01/12/2015	https://clinicaltrials.gov/study/NCT02404051	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast carcinoma	FULVESTRANT	targetBased	3	Unknown status	01/12/2015	https://clinicaltrials.gov/study/NCT02404051	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast carcinoma	FULVESTRANT	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=83d7a440-e904-4e36-afb5-cb02b1c919f7	1	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast carcinoma	FULVESTRANT	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=83d7a440-e904-4e36-afb5-cb02b1c919f7	1	LoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	breast cancer	FULVESTRANT	targetBased	4	Not yet recruiting	07/02/2022	https://clinicaltrials.gov/study/NCT05191914	1	LoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	breast cancer	FULVESTRANT	targetBased	3	Terminated	09/04/2015	https://clinicaltrials.gov/study/NCT02340221	0.35	LoF	protect	The Sponsor discontinued the manufacturing and development of taselisib due to modest clinical benefit and limited tolerability.
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	breast cancer	FULVESTRANT	targetBased	3	Active, not recruiting	16/04/2020	https://clinicaltrials.gov/study/NCT04305496	0.7	LoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	breast cancer	FULVESTRANT	targetBased	3	Not yet recruiting	18/04/2024	https://clinicaltrials.gov/study/NCT06380751	0.7	LoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	breast cancer	FULVESTRANT	targetBased	3	Recruiting	18/01/2022	https://clinicaltrials.gov/study/NCT05438810	0.7	LoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	breast cancer	FULVESTRANT	targetBased	3	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT01300351	0.7	LoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	breast cancer	FULVESTRANT	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=99cf8b69-4c23-4886-80e9-b23e348b5bd7	1	LoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	breast cancer	FULVESTRANT	targetBased	3	Completed	01/11/1998	https://clinicaltrials.gov/study/NCT00241449	0.7	LoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	breast cancer	FULVESTRANT	targetBased	3	Recruiting	09/01/2024	https://clinicaltrials.gov/study/NCT06105632	0.7	LoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	breast cancer	FULVESTRANT	targetBased	4	Not yet recruiting	01/08/2018	https://clinicaltrials.gov/study/NCT03591549	1	LoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	breast cancer	FULVESTRANT	targetBased	3	Active, not recruiting	27/01/2021	https://clinicaltrials.gov/study/NCT04650581	0.7	LoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	breast cancer	FULVESTRANT	targetBased	3	Recruiting	28/03/2022	https://clinicaltrials.gov/study/NCT05207709	0.7	LoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	breast cancer	FULVESTRANT	targetBased	3	Completed	09/06/2015	https://clinicaltrials.gov/study/NCT02422615	0.7	LoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	breast cancer	FULVESTRANT	targetBased	3	Not yet recruiting	01/07/2020	https://clinicaltrials.gov/study/NCT04337658	0.7	LoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	breast cancer	FULVESTRANT	targetBased	3	Completed	23/07/2015	https://clinicaltrials.gov/study/NCT02437318	0.7	LoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	breast cancer	FULVESTRANT	targetBased	3	Completed	01/11/2005	https://clinicaltrials.gov/study/NCT00327769	0.7	LoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	breast cancer	FULVESTRANT	targetBased	3	Completed	07/08/2012	https://clinicaltrials.gov/study/NCT01610284	0.7	LoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	breast cancer	FULVESTRANT	targetBased	3	Completed	24/05/2018	https://clinicaltrials.gov/study/NCT03462251	0.7	LoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	breast cancer	FULVESTRANT	targetBased	3	Terminated	11/04/2022	https://clinicaltrials.gov/study/NCT05065411	0.7	LoF	protect	Business decision
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	breast cancer	FULVESTRANT	targetBased	3	Terminated	01/05/2014	https://clinicaltrials.gov/study/NCT02137837	0.7	LoF	protect	lack of accrual
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	breast cancer	FULVESTRANT	targetBased	3	Recruiting	10/05/2021	https://clinicaltrials.gov/study/NCT04862663	0.7	LoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	breast cancer	FULVESTRANT	targetBased	3	Recruiting	10/09/2021	https://clinicaltrials.gov/study/NCT05054751	0.7	LoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	breast cancer	FULVESTRANT	targetBased	3	Completed	01/08/2003	https://clinicaltrials.gov/study/NCT00065325	0.7	LoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	breast cancer	FULVESTRANT	targetBased	4	Recruiting	27/04/2022	https://clinicaltrials.gov/study/NCT05362760	1	LoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	breast cancer	FULVESTRANT	targetBased	3	Terminated	03/10/2012	https://clinicaltrials.gov/study/NCT01633060	0.35	LoF	protect	Novartis decided not to pursue further development of buparlisib program (assessment of moderate PFS benefit with know, but manageable, buparlisib profile).
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	breast cancer	FULVESTRANT	targetBased	3	Terminated	01/11/2007	https://clinicaltrials.gov/study/NCT00543127	0.7	LoF	protect	Unjustified decision of company that funded the trial.
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	breast cancer	FULVESTRANT	targetBased	3	Completed	13/03/2014	https://clinicaltrials.gov/study/NCT02028507	0.7	LoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	breast cancer	FULVESTRANT	targetBased	3	Active, not recruiting	21/06/2017	https://clinicaltrials.gov/study/NCT02947685	0.7	LoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	breast cancer	FULVESTRANT	targetBased	3	Recruiting	01/05/2018	https://clinicaltrials.gov/study/NCT04263298	0.7	LoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	breast cancer	FULVESTRANT	targetBased	3	Active, not recruiting	16/11/2021	https://clinicaltrials.gov/study/NCT05077449	0.7	LoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	breast cancer	FULVESTRANT	targetBased	4	Recruiting	01/03/2018	https://clinicaltrials.gov/study/NCT03355157	1	LoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	breast cancer	FULVESTRANT	targetBased	3	Recruiting	07/06/2023	https://clinicaltrials.gov/study/NCT05646862	0.7	LoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	breast cancer	FULVESTRANT	targetBased	3	Completed	01/04/2004	https://clinicaltrials.gov/study/NCT00075764	0.7	LoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	breast cancer	FULVESTRANT	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2fc17ba3-83c7-a2b4-8a75-6a0cb1e07682	1	LoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	breast cancer	FULVESTRANT	targetBased	3	Active, not recruiting	17/10/2012	https://clinicaltrials.gov/study/NCT01602380	0.7	LoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	breast cancer	FULVESTRANT	targetBased	3	Completed	01/05/1997	https://clinicaltrials.gov/study/NCT00635713	0.7	LoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	breast cancer	FULVESTRANT	targetBased	3	Completed	02/02/2018	https://clinicaltrials.gov/study/NCT03439046	0.7	LoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	breast cancer	FULVESTRANT	targetBased	3	Recruiting	29/11/2021	https://clinicaltrials.gov/study/NCT05038735	0.7	LoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	breast cancer	FULVESTRANT	targetBased	3	Active, not recruiting	13/06/2019	https://clinicaltrials.gov/study/NCT03927456	0.7	LoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	breast cancer	FULVESTRANT	targetBased	3	Recruiting	03/03/2023	https://clinicaltrials.gov/study/NCT05654623	0.7	LoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	breast cancer	FULVESTRANT	targetBased	3	Completed	06/11/2007	https://clinicaltrials.gov/study/NCT00545077	0.7	LoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	breast cancer	FULVESTRANT	targetBased	3	Unknown status	01/05/2008	https://clinicaltrials.gov/study/NCT00688194	0.7	LoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	breast cancer	FULVESTRANT	targetBased	4	Terminated	14/08/2019	https://clinicaltrials.gov/study/NCT04031885	1	LoF	protect	Business decision based on the inability to enroll subjects into the trial
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	breast cancer	FULVESTRANT	targetBased	3	Recruiting	14/10/2020	https://clinicaltrials.gov/study/NCT04646759	0.7	LoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	breast cancer	FULVESTRANT	targetBased	3	Unknown status	01/03/2004	https://clinicaltrials.gov/study/NCT00253422	0.7	LoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	breast cancer	FULVESTRANT	targetBased	3	Active, not recruiting	22/03/2017	https://clinicaltrials.gov/study/NCT03079011	0.7	LoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	breast cancer	FULVESTRANT	targetBased	3	Completed	26/09/2013	https://clinicaltrials.gov/study/NCT01942135	0.7	LoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	breast cancer	FULVESTRANT	targetBased	3	Completed	20/11/2019	https://clinicaltrials.gov/study/NCT04109066	0.7	LoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	breast cancer	FULVESTRANT	targetBased	3	Recruiting	03/08/2022	https://clinicaltrials.gov/study/NCT05306340	0.7	LoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	breast cancer	FULVESTRANT	targetBased	4	Completed	29/05/2015	https://clinicaltrials.gov/study/NCT02447328	1	LoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	breast cancer	FULVESTRANT	targetBased	3	Unknown status	01/11/2007	https://clinicaltrials.gov/study/NCT02394496	0.7	LoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	breast cancer	FULVESTRANT	targetBased	4	Recruiting	09/08/2022	https://clinicaltrials.gov/study/NCT05631795	1	LoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	breast cancer	FULVESTRANT	targetBased	3	Active, not recruiting	25/05/2022	https://clinicaltrials.gov/study/NCT05433480	0.7	LoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	breast cancer	FULVESTRANT	targetBased	3	Active, not recruiting	13/02/2005	https://clinicaltrials.gov/study/NCT00099437	0.7	LoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	breast cancer	FULVESTRANT	targetBased	3	Terminated	15/11/2019	https://clinicaltrials.gov/study/NCT04060862	0.7	LoF	protect	The decision to not open the Phase III portion was based on a strategic sponsor decision and not driven by any safety concerns.
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	breast cancer	FULVESTRANT	targetBased	3	Active, not recruiting	05/12/2016	https://clinicaltrials.gov/study/NCT02763566	0.7	LoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	breast cancer	FULVESTRANT	targetBased	3	Active, not recruiting	13/12/2013	https://clinicaltrials.gov/study/NCT01953588	0.7	LoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	breast cancer	FULVESTRANT	targetBased	3	Active, not recruiting	14/09/2021	https://clinicaltrials.gov/study/NCT05063786	0.7	LoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	breast cancer	FULVESTRANT	targetBased	3	Terminated	01/11/2000	https://clinicaltrials.gov/study/NCT00010153	0.7	LoF	protect	low accrual
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	breast cancer	FULVESTRANT	targetBased	3	Recruiting	30/09/2022	https://clinicaltrials.gov/study/NCT05501886	0.7	LoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	breast cancer	FULVESTRANT	targetBased	3	Recruiting	31/10/2023	https://clinicaltrials.gov/study/NCT05696626	0.7	LoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	breast cancer	FULVESTRANT	targetBased	3	Completed	01/01/2004	https://clinicaltrials.gov/study/NCT00256698	0.7	LoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	invasive lobular carcinoma	FULVESTRANT	targetBased	3	Active, not recruiting	13/12/2013	https://clinicaltrials.gov/study/NCT01953588	0.7	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	non-small cell lung carcinoma	MODAFINIL	targetBased	4	Completed	01/02/2009	https://clinicaltrials.gov/study/NCT00829322	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	Ewing sarcoma	MODAFINIL	targetBased	3	Terminated	21/08/2018	https://clinicaltrials.gov/study/NCT03495921	0.7	LoF	protect	Slow accrual and as a result, a strategic business decision was made to terminate enrollment.
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	brain neoplasm	MODAFINIL	targetBased	3	Terminated	01/02/2004	https://clinicaltrials.gov/study/NCT00418691	0.7	LoF	protect	Closed early due to slow accrual.
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	brain neoplasm	EPHEDRINE	targetBased	4	Completed	01/09/2015	https://clinicaltrials.gov/study/NCT02713087	1	GoF	protect
HTS for Tumor Hsp90 Inhibitors	HSP90 known inhibitor displacement	HSP90AA1	Heat shock protein HSP 90-alpha	gastrointestinal stromal tumor	RETASPIMYCIN HYDROCHLORIDE	targetBased	3	Terminated	01/08/2008	https://clinicaltrials.gov/study/NCT00688766	0.35	LoF	protect	Based on Independent Data Monitoring Committee (IDMC) recommendation.
Luminescence-based primary biochemical high throughput screening assay to identify inhibitors of the Heat Shock Protein 90 (HSP90)	HSP90AA1	HSP90AA1	Full-length cDNA 5-PRIME end of clone CS0DN005YI08 of Adult brain of Homo sapiens , Heat shock protein HSP 90-alpha, Heat shock protein HSP 90-alpha	gastrointestinal stromal tumor	RETASPIMYCIN HYDROCHLORIDE	targetBased	3	Terminated	01/08/2008	https://clinicaltrials.gov/study/NCT00688766	0.35	LoF	protect	Based on Independent Data Monitoring Committee (IDMC) recommendation.
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	ovarian cancer	VINBLASTINE SULFATE	targetBased	3	Unknown status	01/05/2005	https://clinicaltrials.gov/study/NCT00274950	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	extragonadal germ cell tumor	VINBLASTINE SULFATE	targetBased	3	Completed	01/02/1994	https://clinicaltrials.gov/study/NCT00002566	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	extragonadal germ cell tumor	VINBLASTINE SULFATE	targetBased	3	Unknown status	01/05/2005	https://clinicaltrials.gov/study/NCT00274950	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Hodgkins lymphoma	VINBLASTINE SULFATE	targetBased	3	Active, not recruiting	29/08/2019	https://clinicaltrials.gov/study/NCT03907488	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Hodgkins lymphoma	VINBLASTINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f073b58e-56d6-4c8d-a2ce-b37719402d77	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	testicular neoplasm	VINBLASTINE SULFATE	targetBased	3	Completed	01/02/1994	https://clinicaltrials.gov/study/NCT00002566	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoid neoplasm	VINBLASTINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f073b58e-56d6-4c8d-a2ce-b37719402d77	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	cervical cancer	VINBLASTINE SULFATE	targetBased	3	Completed	01/12/1997	https://clinicaltrials.gov/study/NCT00003209	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	urinary bladder carcinoma	VINBLASTINE SULFATE	targetBased	3	Completed	01/10/2001	https://clinicaltrials.gov/study/NCT00028756	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	childhood germ cell tumor	VINBLASTINE SULFATE	targetBased	3	Unknown status	01/05/2005	https://clinicaltrials.gov/study/NCT00274950	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	prostate cancer	VINBLASTINE SULFATE	targetBased	3	Completed	01/10/2002	https://clinicaltrials.gov/study/NCT00030654	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung cancer	VINBLASTINE SULFATE	targetBased	3	Unknown status	01/10/1995	https://clinicaltrials.gov/study/NCT00003240	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung cancer	VINBLASTINE SULFATE	targetBased	3	Completed	01/02/1995	https://clinicaltrials.gov/study/NCT00002823	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung cancer	VINBLASTINE SULFATE	targetBased	3	Unknown status	01/01/1999	https://clinicaltrials.gov/study/NCT00004887	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung cancer	VINBLASTINE SULFATE	targetBased	3	Completed	01/08/1997	https://clinicaltrials.gov/study/NCT00003159	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung cancer	VINBLASTINE SULFATE	targetBased	3	Unknown status	01/05/1998	https://clinicaltrials.gov/study/NCT00004209	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINBLASTINE SULFATE	targetBased	3	Active, not recruiting	01/09/1989	https://clinicaltrials.gov/study/NCT00002462	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINBLASTINE SULFATE	targetBased	3	Completed	01/11/2003	https://clinicaltrials.gov/study/NCT00059839	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINBLASTINE SULFATE	targetBased	3	Completed	01/08/2002	https://clinicaltrials.gov/study/NCT00049595	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINBLASTINE SULFATE	targetBased	3	Unknown status	01/10/2001	https://clinicaltrials.gov/study/NCT00041210	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINBLASTINE SULFATE	targetBased	3	Completed	26/11/1999	https://clinicaltrials.gov/study/NCT00006455	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINBLASTINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f073b58e-56d6-4c8d-a2ce-b37719402d77	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINBLASTINE SULFATE	targetBased	4	Completed	01/11/2009	https://clinicaltrials.gov/study/NCT01088750	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINBLASTINE SULFATE	targetBased	3	Active, not recruiting	01/09/1993	https://clinicaltrials.gov/study/NCT00379041	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINBLASTINE SULFATE	targetBased	3	Completed	01/06/1998	https://clinicaltrials.gov/study/NCT00003421	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINBLASTINE SULFATE	targetBased	3	Completed	29/08/2008	https://clinicaltrials.gov/study/NCT00678327	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINBLASTINE SULFATE	targetBased	3	Active, not recruiting	01/10/1998	https://clinicaltrials.gov/study/NCT00005584	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	classic Hodgkin lymphoma	VINBLASTINE SULFATE	targetBased	3	Active, not recruiting	29/08/2019	https://clinicaltrials.gov/study/NCT03907488	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	VINBLASTINE SULFATE	targetBased	4	Completed	01/01/2017	https://clinicaltrials.gov/study/NCT03092986	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	urinary bladder cancer	VINBLASTINE SULFATE	targetBased	3	Unknown status	01/02/2013	https://clinicaltrials.gov/study/NCT01812369	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	urinary bladder cancer	VINBLASTINE SULFATE	targetBased	3	Completed	02/04/1999	https://clinicaltrials.gov/study/NCT00003701	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	DASATINIB	targetBased	3	Terminated	03/08/2017	https://clinicaltrials.gov/study/NCT03079505	0.7	LoF	protect	Protocol Deviation
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	DASATINIB	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4764f37b-c9e6-4ede-bcc2-8a03b7c521df	1	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	DASATINIB	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0e7f054c-7a27-4192-bd1c-6115d8be858f	1	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	DASATINIB	targetBased	3	Completed	01/09/2007	https://clinicaltrials.gov/study/NCT00481247	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	DASATINIB	targetBased	4	Completed	01/12/2012	https://clinicaltrials.gov/study/NCT01660906	1	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	DASATINIB	targetBased	4	Completed	10/05/2016	https://clinicaltrials.gov/study/NCT04925141	1	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	DASATINIB	targetBased	4	Recruiting	01/07/2021	https://clinicaltrials.gov/study/NCT04933526	1	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	DASATINIB	targetBased	3	Completed	01/08/2016	https://clinicaltrials.gov/study/NCT02890784	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	DASATINIB	targetBased	3	Completed	01/07/2005	https://clinicaltrials.gov/study/NCT00123474	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	DASATINIB	targetBased	3	Recruiting	10/06/2015	https://clinicaltrials.gov/study/NCT02326311	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	DASATINIB	targetBased	4	Unknown status	01/04/2016	https://clinicaltrials.gov/study/NCT03216070	1	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	DASATINIB	targetBased	4	Recruiting	01/12/2019	https://clinicaltrials.gov/study/NCT04155411	1	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	DASATINIB	targetBased	3	Completed	01/08/2008	https://clinicaltrials.gov/study/NCT01460693	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	DASATINIB	targetBased	3	Completed	01/06/2005	https://clinicaltrials.gov/study/NCT00123487	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	DASATINIB	targetBased	4	Recruiting	30/08/2022	https://clinicaltrials.gov/study/NCT04877522	1	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	DASATINIB	targetBased	3	Active, not recruiting	06/10/2021	https://clinicaltrials.gov/study/NCT04971226	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	acute lymphoblastic leukemia	DASATINIB	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4764f37b-c9e6-4ede-bcc2-8a03b7c521df	1	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	acute lymphoblastic leukemia	DASATINIB	targetBased	3	Not yet recruiting	22/07/2024	https://clinicaltrials.gov/study/NCT06124157	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	acute lymphoblastic leukemia	DASATINIB	targetBased	4	Unknown status	01/03/2016	https://clinicaltrials.gov/study/NCT02690922	1	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	acute lymphoblastic leukemia	DASATINIB	targetBased	3	Completed	29/10/2007	https://clinicaltrials.gov/study/NCT00549848	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	acute lymphoblastic leukemia	DASATINIB	targetBased	3	Completed	01/06/2005	https://clinicaltrials.gov/study/NCT00123487	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	acute lymphoblastic leukemia	DASATINIB	targetBased	3	Active, not recruiting	03/03/2017	https://clinicaltrials.gov/study/NCT03020030	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	acute lymphoblastic leukemia	DASATINIB	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0e7f054c-7a27-4192-bd1c-6115d8be858f	1	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	neoplasm	DASATINIB	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=L01EA02	1	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	lymphoid neoplasm	DASATINIB	targetBased	4	Recruiting	31/01/2016	https://clinicaltrials.gov/study/NCT03844360	1	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	acute myeloid leukemia	DASATINIB	targetBased	3	Completed	01/07/2014	https://clinicaltrials.gov/study/NCT02013648	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	prostate adenocarcinoma	DASATINIB	targetBased	3	Completed	01/10/2008	https://clinicaltrials.gov/study/NCT00744497	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	lymphoid leukemia	DASATINIB	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/dasatinib-accordpharma	1	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	lymphoid leukemia	DASATINIB	targetBased	3	Recruiting	25/01/2021	https://clinicaltrials.gov/study/NCT04530565	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	leukemia	DASATINIB	targetBased	3	Terminated	01/04/2007	https://clinicaltrials.gov/study/NCT00362466	0.7	LoF	protect	Insufficient Enrollment
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	leukemia	DASATINIB	targetBased	3	Active, not recruiting	03/03/2017	https://clinicaltrials.gov/study/NCT03020030	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	multiple myeloma	DASATINIB	targetBased	4	Not yet recruiting	01/11/2023	https://clinicaltrials.gov/study/NCT05944783	1	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive	DASATINIB	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/dasatinib-accordpharma	1	LoF	protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	benign muscle neoplasm	VASOPRESSIN	targetBased	3	Completed	01/05/2013	https://clinicaltrials.gov/study/NCT01861015	0.7	GoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	glioblastoma multiforme	TOFACITINIB	targetBased	3	Recruiting	07/10/2022	https://clinicaltrials.gov/study/NCT05326464	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	head and neck malignant neoplasia	NOREPINEPHRINE	targetBased	4	Completed	01/06/2006	https://clinicaltrials.gov/study/NCT02241083	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast neoplasm	ARZOXIFENE	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00034125	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast neoplasm	ARZOXIFENE	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00034125	0.7		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	breast neoplasm	ARZOXIFENE	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00034125	0.7		protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		breast cancer	ESKETAMINE	targetBased	4	Recruiting	22/05/2023	https://clinicaltrials.gov/study/NCT05732064	1	LoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	benign muscle neoplasm	OXYTOCIN	targetBased	3	Recruiting	01/03/2024	https://clinicaltrials.gov/study/NCT06325501	0.7	GoF	protect
Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3	HDAC3	HDAC3	Histone deacetylase 3	lung cancer	TACEDINALINE	targetBased	3	Completed	01/12/1999	https://clinicaltrials.gov/study/NCT00005093	0.7	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	unspecified peripheral T-cell lymphoma	AZACITIDINE	targetBased	3	Enrolling by invitation	01/01/2023	https://clinicaltrials.gov/study/NCT05678933	0.7	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	chronic myelomonocytic leukemia	AZACITIDINE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/azacitidine-accord	1	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	chronic myelomonocytic leukemia	AZACITIDINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=55915b5d-0e85-4ede-ad4f-ac89670d8973	1	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	chronic myelomonocytic leukemia	AZACITIDINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=87f7a39d-06db-48ca-be21-9e8806608439	1	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	chronic myelomonocytic leukemia	AZACITIDINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3495a71a-cc04-4776-851f-f185956f32af	1	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	chronic myelomonocytic leukemia	AZACITIDINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=71d8d758-86c9-b571-aed1-719654fd4b82	1	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	chronic myelomonocytic leukemia	AZACITIDINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e437efe0-9c6a-4f87-b3b4-de90443b095f	1	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	diffuse large B-cell lymphoma	AZACITIDINE	targetBased	3	Terminated	16/12/2016	https://clinicaltrials.gov/study/NCT02951156	0.35	LoF	protect	Study was terminated due to closure of study arms following futility analysis and difficulty in enrolling participants due to evolving treatment landscape
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	neoplasm	AZACITIDINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=L01BC07	1	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	refractory anemia with excess blasts	AZACITIDINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=71d8d758-86c9-b571-aed1-719654fd4b82	1	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	refractory anemia with excess blasts	AZACITIDINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e437efe0-9c6a-4f87-b3b4-de90443b095f	1	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	refractory anemia with excess blasts	AZACITIDINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=55915b5d-0e85-4ede-ad4f-ac89670d8973	1	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	refractory anemia with excess blasts	AZACITIDINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3495a71a-cc04-4776-851f-f185956f32af	1	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	refractory anemia with excess blasts	AZACITIDINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=87f7a39d-06db-48ca-be21-9e8806608439	1	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	myelodysplastic syndrome	AZACITIDINE	targetBased	3	Recruiting	08/02/2021	https://clinicaltrials.gov/study/NCT04797780	0.7	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	myelodysplastic syndrome	AZACITIDINE	targetBased	4	Not yet recruiting	01/08/2023	https://clinicaltrials.gov/study/NCT06004765	1	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	myelodysplastic syndrome	AZACITIDINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=55915b5d-0e85-4ede-ad4f-ac89670d8973	1	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	myelodysplastic syndrome	AZACITIDINE	targetBased	3	Completed	01/04/2007	https://clinicaltrials.gov/study/NCT01186939	0.7	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	myelodysplastic syndrome	AZACITIDINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=71d8d758-86c9-b571-aed1-719654fd4b82	1	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	myelodysplastic syndrome	AZACITIDINE	targetBased	4	Completed	01/10/2010	https://clinicaltrials.gov/study/NCT01201811	1	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	myelodysplastic syndrome	AZACITIDINE	targetBased	3	Active, not recruiting	14/04/2013	https://clinicaltrials.gov/study/NCT04266301	0.7	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	myelodysplastic syndrome	AZACITIDINE	targetBased	3	Completed	11/01/2019	https://clinicaltrials.gov/study/NCT03745716	0.7	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	myelodysplastic syndrome	AZACITIDINE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/azacitidine-accord	1	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	myelodysplastic syndrome	AZACITIDINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3495a71a-cc04-4776-851f-f185956f32af	1	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	myelodysplastic syndrome	AZACITIDINE	targetBased	3	Terminated	09/09/2020	https://clinicaltrials.gov/study/NCT04313881	0.35	LoF	protect	Study discontinued due to futility based on a planned analysis
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	myelodysplastic syndrome	AZACITIDINE	targetBased	3	Recruiting	30/03/2023	https://clinicaltrials.gov/study/NCT05709093	0.7	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	myelodysplastic syndrome	AZACITIDINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e437efe0-9c6a-4f87-b3b4-de90443b095f	1	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	myelodysplastic syndrome	AZACITIDINE	targetBased	3	Not yet recruiting	30/12/2024	https://clinicaltrials.gov/study/NCT06465953	0.7	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	myelodysplastic syndrome	AZACITIDINE	targetBased	3	Completed	21/04/2009	https://clinicaltrials.gov/study/NCT00887068	0.7	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	myelodysplastic syndrome	AZACITIDINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=87f7a39d-06db-48ca-be21-9e8806608439	1	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	myelodysplastic syndrome	AZACITIDINE	targetBased	4	Terminated	01/11/2009	https://clinicaltrials.gov/study/NCT01011283	1	LoF	protect	The study was stopped due to insufficient enrollment.
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	myelodysplastic syndrome	AZACITIDINE	targetBased	3	Active, not recruiting	10/09/2020	https://clinicaltrials.gov/study/NCT04401748	0.7	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	myelodysplastic syndrome	AZACITIDINE	targetBased	3	Completed	01/11/2003	https://clinicaltrials.gov/study/NCT00071799	0.7	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	myelodysplastic syndrome	AZACITIDINE	targetBased	3	Completed	26/04/2013	https://clinicaltrials.gov/study/NCT01566695	0.7	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	acute myeloid leukemia	AZACITIDINE	targetBased	3	Recruiting	01/10/2022	https://clinicaltrials.gov/study/NCT05183035	0.7	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	acute myeloid leukemia	AZACITIDINE	targetBased	3	Active, not recruiting	24/09/2019	https://clinicaltrials.gov/study/NCT04090736	0.7	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	acute myeloid leukemia	AZACITIDINE	targetBased	3	Completed	21/04/2009	https://clinicaltrials.gov/study/NCT00887068	0.7	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	acute myeloid leukemia	AZACITIDINE	targetBased	3	Recruiting	03/03/2023	https://clinicaltrials.gov/study/NCT05586074	0.7	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	acute myeloid leukemia	AZACITIDINE	targetBased	3	Recruiting	01/03/2021	https://clinicaltrials.gov/study/NCT05264883	0.7	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	acute myeloid leukemia	AZACITIDINE	targetBased	3	Active, not recruiting	26/06/2017	https://clinicaltrials.gov/study/NCT03173248	0.7	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	acute myeloid leukemia	AZACITIDINE	targetBased	3	Completed	28/11/2010	https://clinicaltrials.gov/study/NCT05188326	0.7	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	acute myeloid leukemia	AZACITIDINE	targetBased	3	Recruiting	18/01/2024	https://clinicaltrials.gov/study/NCT06345365	0.7	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	acute myeloid leukemia	AZACITIDINE	targetBased	3	Withdrawn	01/04/2010	https://clinicaltrials.gov/study/NCT01067274	0.7	LoF	protect	Study abandoned
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	acute myeloid leukemia	AZACITIDINE	targetBased	3	Recruiting	14/06/2023	https://clinicaltrials.gov/study/NCT05907057	0.7	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	acute myeloid leukemia	AZACITIDINE	targetBased	3	Terminated	01/05/2016	https://clinicaltrials.gov/study/NCT02785900	0.35	LoF	protect	Due to safety; specifically a higher rate of deaths, including fatal infections, in the SGN33A arm versus the control arm
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	acute myeloid leukemia	AZACITIDINE	targetBased	3	Recruiting	13/01/2020	https://clinicaltrials.gov/study/NCT03765541	0.7	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	acute myeloid leukemia	AZACITIDINE	targetBased	3	Active, not recruiting	08/02/2021	https://clinicaltrials.gov/study/NCT04229979	0.7	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	acute myeloid leukemia	AZACITIDINE	targetBased	3	Completed	15/08/2019	https://clinicaltrials.gov/study/NCT03941964	0.7	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	acute myeloid leukemia	AZACITIDINE	targetBased	3	Active, not recruiting	20/10/2015	https://clinicaltrials.gov/study/NCT02421939	0.7	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	acute myeloid leukemia	AZACITIDINE	targetBased	3	Not yet recruiting	01/05/2024	https://clinicaltrials.gov/study/NCT06389292	0.7	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	acute myeloid leukemia	AZACITIDINE	targetBased	3	Active, not recruiting	24/04/2013	https://clinicaltrials.gov/study/NCT01757535	0.7	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	acute myeloid leukemia	AZACITIDINE	targetBased	3	Active, not recruiting	26/02/2020	https://clinicaltrials.gov/study/NCT04161885	0.7	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	acute myeloid leukemia	AZACITIDINE	targetBased	3	Completed	20/04/2018	https://clinicaltrials.gov/study/NCT03416179	0.7	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	acute myeloid leukemia	AZACITIDINE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/azacitidine-accord	1	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	acute myeloid leukemia	AZACITIDINE	targetBased	4	Not yet recruiting	01/06/2024	https://clinicaltrials.gov/study/NCT06370000	1	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	acute myeloid leukemia	AZACITIDINE	targetBased	3	Not yet recruiting	01/11/2023	https://clinicaltrials.gov/study/NCT06073730	0.7	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	acute myeloid leukemia	AZACITIDINE	targetBased	3	Completed	01/06/2010	https://clinicaltrials.gov/study/NCT01074047	0.7	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	acute myeloid leukemia	AZACITIDINE	targetBased	3	Recruiting	22/11/2019	https://clinicaltrials.gov/study/NCT03926624	0.7	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	acute myeloid leukemia	AZACITIDINE	targetBased	3	Terminated	23/06/2017	https://clinicaltrials.gov/study/NCT03151408	0.35	LoF	protect	The IDMC recommended to stop the study prematurely due to a lack of efficacy.
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	acute myeloid leukemia	AZACITIDINE	targetBased	3	Recruiting	01/09/2020	https://clinicaltrials.gov/study/NCT04490707	0.7	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	acute myeloid leukemia	AZACITIDINE	targetBased	3	Recruiting	31/10/2022	https://clinicaltrials.gov/study/NCT05654194	0.7	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	acute myeloid leukemia	AZACITIDINE	targetBased	3	Terminated	01/07/2021	https://clinicaltrials.gov/study/NCT04778397	0.35	LoF	protect	Study discontinued due to futility.
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	acute myeloid leukemia	AZACITIDINE	targetBased	3	Terminated	07/07/2022	https://clinicaltrials.gov/study/NCT05079230	0.35	LoF	protect	Study was terminated due to futility
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	lymphoma	AZACITIDINE	targetBased	3	Recruiting	01/10/2021	https://clinicaltrials.gov/study/NCT05075460	0.7	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	lymphoma	AZACITIDINE	targetBased	3	Active, not recruiting	06/11/2018	https://clinicaltrials.gov/study/NCT03703375	0.7	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	childhood acute myeloid leukemia	AZACITIDINE	targetBased	3	Active, not recruiting	01/08/2016	https://clinicaltrials.gov/study/NCT02752035	0.7	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	childhood acute myeloid leukemia	AZACITIDINE	targetBased	3	Active, not recruiting	02/02/2017	https://clinicaltrials.gov/study/NCT02993523	0.7	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	leukemia	AZACITIDINE	targetBased	3	Completed	30/12/2015	https://clinicaltrials.gov/study/NCT02577406	0.7	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	angioimmunoblastic T-cell lymphoma	AZACITIDINE	targetBased	3	Active, not recruiting	09/11/2018	https://clinicaltrials.gov/study/NCT03593018	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Genital neoplasm, female	HYDROMORPHONE	targetBased	4	Completed	09/07/2020	https://clinicaltrials.gov/study/NCT04258631	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Genital neoplasm, female	HYDROMORPHONE	targetBased	4	Completed	09/07/2020	https://clinicaltrials.gov/study/NCT04258631	1	GoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	soft tissue sarcoma	NILOTINIB	targetBased	3	Active, not recruiting	19/10/2019	https://clinicaltrials.gov/study/NCT03784014	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	NILOTINIB	targetBased	3	Completed	15/04/2013	https://clinicaltrials.gov/study/NCT01743989	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	NILOTINIB	targetBased	4	Terminated	01/03/2013	https://clinicaltrials.gov/study/NCT02086487	1	LoF	protect	Because of many unseen obstacles resulted in poor accrual, study is terminated.
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	NILOTINIB	targetBased	3	Terminated	17/12/2015	https://clinicaltrials.gov/study/NCT02115386	0.7	LoF	protect	Study was terminated by Novartis
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	NILOTINIB	targetBased	3	Recruiting	10/06/2015	https://clinicaltrials.gov/study/NCT02326311	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	NILOTINIB	targetBased	4	Terminated	21/10/2010	https://clinicaltrials.gov/study/NCT01131325	1	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	NILOTINIB	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6093952a-5248-45cb-ad17-33716a411146	1	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	NILOTINIB	targetBased	3	Terminated	31/12/2015	https://clinicaltrials.gov/study/NCT02627677	0.7	LoF	protect	The study was stopped due to operational feasibility and not due to any safety concerns
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	NILOTINIB	targetBased	4	Completed	01/11/2010	https://clinicaltrials.gov/study/NCT01227577	1	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	NILOTINIB	targetBased	4	Completed	01/12/2009	https://clinicaltrials.gov/study/NCT00980018	1	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	NILOTINIB	targetBased	3	Completed	01/10/2012	https://clinicaltrials.gov/study/NCT01819389	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	NILOTINIB	targetBased	4	Completed	01/02/2009	https://clinicaltrials.gov/study/NCT01206088	1	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	NILOTINIB	targetBased	3	Completed	01/01/2012	https://clinicaltrials.gov/study/NCT01535391	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	NILOTINIB	targetBased	3	Recruiting	21/11/2022	https://clinicaltrials.gov/study/NCT05456191	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	NILOTINIB	targetBased	4	Unknown status	01/04/2015	https://clinicaltrials.gov/study/NCT02389920	1	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	NILOTINIB	targetBased	4	Recruiting	30/08/2022	https://clinicaltrials.gov/study/NCT04877522	1	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	NILOTINIB	targetBased	3	Completed	01/01/2009	https://clinicaltrials.gov/study/NCT01126892	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	NILOTINIB	targetBased	3	Terminated	07/07/2014	https://clinicaltrials.gov/study/NCT02108951	0.7	LoF	protect	Study was terminated because of slow recruitment
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	NILOTINIB	targetBased	3	Unknown status	01/01/2009	https://clinicaltrials.gov/study/NCT01400074	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	NILOTINIB	targetBased	3	Completed	01/05/2009	https://clinicaltrials.gov/study/NCT00802841	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	NILOTINIB	targetBased	4	Completed	01/08/2008	https://clinicaltrials.gov/study/NCT00786812	1	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	NILOTINIB	targetBased	4	Withdrawn	01/02/2014	https://clinicaltrials.gov/study/NCT01605981	1	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	NILOTINIB	targetBased	3	Active, not recruiting	01/04/2008	https://clinicaltrials.gov/study/NCT00718263	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	NILOTINIB	targetBased	3	Completed	01/04/2011	https://clinicaltrials.gov/study/NCT01254188	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	NILOTINIB	targetBased	3	Active, not recruiting	06/10/2021	https://clinicaltrials.gov/study/NCT04971226	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	NILOTINIB	targetBased	4	Completed	18/02/2016	https://clinicaltrials.gov/study/NCT02546674	1	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	NILOTINIB	targetBased	3	Completed	01/04/2011	https://clinicaltrials.gov/study/NCT01275196	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	NILOTINIB	targetBased	4	Completed	01/05/2010	https://clinicaltrials.gov/study/NCT01061177	1	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	NILOTINIB	targetBased	3	Completed	01/06/2009	https://clinicaltrials.gov/study/NCT00760877	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	NILOTINIB	targetBased	3	Completed	31/07/2007	https://clinicaltrials.gov/study/NCT00471497	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	NILOTINIB	targetBased	3	Terminated	01/03/2014	https://clinicaltrials.gov/study/NCT02174445	0.7	LoF	protect	very slow recruitment rate and a lot of pat. didn't fulfil BCR-ABL requirements
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	NILOTINIB	targetBased	4	Completed	06/05/2013	https://clinicaltrials.gov/study/NCT03332511	1	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	NILOTINIB	targetBased	3	Recruiting	01/06/2019	https://clinicaltrials.gov/study/NCT03942094	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	NILOTINIB	targetBased	4	Completed	01/12/2008	https://clinicaltrials.gov/study/NCT01368523	1	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	NILOTINIB	targetBased	3	Unknown status	01/08/2014	https://clinicaltrials.gov/study/NCT02201459	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	NILOTINIB	targetBased	3	Terminated	03/08/2017	https://clinicaltrials.gov/study/NCT03079505	0.7	LoF	protect	Protocol Deviation
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	NILOTINIB	targetBased	4	Completed	01/12/2009	https://clinicaltrials.gov/study/NCT01043874	1	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	neoplasm	NILOTINIB	targetBased	3			https://www.whocc.no/atc_ddd_index/?code=L01EA03	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	adult acute lymphoblastic leukemia	NILOTINIB	targetBased	3	Recruiting	01/04/2016	https://clinicaltrials.gov/study/NCT02611492	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	gastrointestinal stromal tumor	NILOTINIB	targetBased	3	Completed	01/11/2008	https://clinicaltrials.gov/study/NCT01289028	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	gastrointestinal stromal tumor	NILOTINIB	targetBased	3	Completed	01/03/2007	https://clinicaltrials.gov/study/NCT00471328	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	gastrointestinal stromal tumor	NILOTINIB	targetBased	3	Terminated	01/06/2009	https://clinicaltrials.gov/study/NCT00751036	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	gastrointestinal stromal tumor	NILOTINIB	targetBased	4	Active, not recruiting	29/08/2008	https://clinicaltrials.gov/study/NCT00756509	1	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	gastrointestinal stromal tumor	NILOTINIB	targetBased	3	Completed	01/03/2009	https://clinicaltrials.gov/study/NCT00785785	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	myeloid leukemia	NILOTINIB	targetBased	4	Active, not recruiting	11/11/2016	https://clinicaltrials.gov/study/NCT02602314	1	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	myeloid leukemia	NILOTINIB	targetBased	3	Terminated	01/10/2007	https://clinicaltrials.gov/study/NCT00519090	0.7	LoF	protect	This study was terminated due to limited enrollment.
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	leukemia	NILOTINIB	targetBased	3	Completed	17/07/2014	https://clinicaltrials.gov/study/NCT02272777	0.7	LoF	protect
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of myeloid cell leukemia sequence 1 (MCL1) interactions with BIM-BH3 peptide.	MCL1	MCL1	Induced myeloid leukemia cell differentiation protein Mcl-1 , MCL1 apoptosis regulator, BCL2 family member, Myeloid cell leukemia ES variant	small cell lung carcinoma	OBATOCLAX	targetBased	3	Withdrawn	01/08/2012	https://clinicaltrials.gov/study/NCT01563601	0.7	LoF	protect	Business Decision
uHTS of Mcl-1/Bid interaction inhibitors	MCL1	MCL1	Induced myeloid leukemia cell differentiation protein Mcl-1 , MCL1 apoptosis regulator, BCL2 family member, Myeloid cell leukemia ES variant	small cell lung carcinoma	OBATOCLAX	targetBased	3	Withdrawn	01/08/2012	https://clinicaltrials.gov/study/NCT01563601	0.7	LoF	protect	Business Decision
uHTS of Mcl-1/Noxa interaction inhibitors	MCL1	MCL1	Induced myeloid leukemia cell differentiation protein Mcl-1 , MCL1 apoptosis regulator, BCL2 family member, Myeloid cell leukemia ES variant	small cell lung carcinoma	OBATOCLAX	targetBased	3	Withdrawn	01/08/2012	https://clinicaltrials.gov/study/NCT01563601	0.7	LoF	protect	Business Decision
Primary biochemical high throughput screening assay to identify inhibitors of BCL2-related protein, long isoform (BCLXL).	BCL2L1_modulators	BCL2L1	Bcl-2-like protein 1	small cell lung carcinoma	OBATOCLAX	targetBased	3	Withdrawn	01/08/2012	https://clinicaltrials.gov/study/NCT01563601	0.7	LoF	protect	Business Decision
Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bfl-1	BCL2A1_modulators	BCL2A1	Bcl-2-related protein A1	small cell lung carcinoma	OBATOCLAX	targetBased	3	Withdrawn	01/08/2012	https://clinicaltrials.gov/study/NCT01563601	0.7	LoF	protect	Business Decision
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	non-Hodgkins lymphoma	ERGOCALCIFEROL	targetBased	3	Completed	01/01/2006	https://clinicaltrials.gov/study/NCT00352846	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	prostate cancer	ERGOCALCIFEROL	targetBased	3	Completed	01/03/2006	https://clinicaltrials.gov/study/NCT00329797	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	prostate cancer	ERGOCALCIFEROL	targetBased	3	Completed	01/01/2004	https://clinicaltrials.gov/study/NCT00079001	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	cutaneous melanoma	ERGOCALCIFEROL	targetBased	3	Completed	01/12/2012	https://clinicaltrials.gov/study/NCT01748448	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	urothelial carcinoma	ERGOCALCIFEROL	targetBased	4	Completed	11/02/2020	https://clinicaltrials.gov/study/NCT04197089	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	metastatic malignant neoplasm	ERGOCALCIFEROL	targetBased	3	Completed	01/01/2004	https://clinicaltrials.gov/study/NCT00079001	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	breast neoplasm	ERGOCALCIFEROL	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00000611	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	lymphoma	ERGOCALCIFEROL	targetBased	3	Completed	01/02/2004	https://clinicaltrials.gov/study/NCT00452439	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	lymphoma	ERGOCALCIFEROL	targetBased	3	Completed	01/01/2006	https://clinicaltrials.gov/study/NCT00352846	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	leukemia	ERGOCALCIFEROL	targetBased	3	Completed	01/02/2004	https://clinicaltrials.gov/study/NCT00452439	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	breast cancer	ERGOCALCIFEROL	targetBased	3	Unknown status	01/07/2009	https://clinicaltrials.gov/study/NCT00944424	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	breast cancer	ERGOCALCIFEROL	targetBased	3	Completed	01/10/2010	https://clinicaltrials.gov/study/NCT01224678	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	colonic neoplasm	ERGOCALCIFEROL	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00000611	0.7	GoF	protect
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	THRB	Thyroid hormone receptor beta	differentiated thyroid carcinoma	LIOTHYRONINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=51452b31-ff68-4e0c-b982-c15502ebf1d3	1	GoF	protect
Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3	HDAC3	HDAC3	Histone deacetylase 3	T-cell non-Hodgkin lymphoma	BELINOSTAT	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2e8ef36b-71fa-4492-a16f-577d5f7d111d	1	LoF	protect
Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3	HDAC3	HDAC3	Histone deacetylase 3	unspecified peripheral T-cell lymphoma	BELINOSTAT	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=84b2e16e-f0d1-4757-8da8-79dfa83aab79	1	LoF	protect
Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3	HDAC3	HDAC3	Histone deacetylase 3	neoplasm	BELINOSTAT	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=L01XH04	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	urinary bladder cancer	ALVIMOPAN	targetBased	3	Recruiting	01/10/2018	https://clinicaltrials.gov/study/NCT03216525	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	urinary bladder cancer	ALVIMOPAN	targetBased	3	Recruiting	01/10/2018	https://clinicaltrials.gov/study/NCT03216525	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	peritoneum cancer	ALVIMOPAN	targetBased	3	Completed	01/01/2013	https://clinicaltrials.gov/study/NCT01704651	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	peritoneum cancer	ALVIMOPAN	targetBased	3	Completed	01/01/2013	https://clinicaltrials.gov/study/NCT01704651	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	ovarian cancer	ALVIMOPAN	targetBased	3	Completed	01/01/2013	https://clinicaltrials.gov/study/NCT01704651	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	ovarian cancer	ALVIMOPAN	targetBased	3	Completed	01/01/2013	https://clinicaltrials.gov/study/NCT01704651	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	fallopian tube cancer	ALVIMOPAN	targetBased	3	Completed	01/01/2013	https://clinicaltrials.gov/study/NCT01704651	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	fallopian tube cancer	ALVIMOPAN	targetBased	3	Completed	01/01/2013	https://clinicaltrials.gov/study/NCT01704651	0.7	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	cancer	BUPRENORPHINE	targetBased	4	Completed	01/04/2011	https://clinicaltrials.gov/study/NCT01809106	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer	BUPRENORPHINE	targetBased	4	Completed	01/04/2011	https://clinicaltrials.gov/study/NCT01809106	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer	BUPRENORPHINE	targetBased	4	Completed	01/04/2011	https://clinicaltrials.gov/study/NCT01809106	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hemangioma	nadolol	targetBased	3	Completed	01/09/2015	https://clinicaltrials.gov/study/NCT02505971	0.7	LoF	protect
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	THRB	Thyroid hormone receptor beta	thyroid cancer	LEVOTHYROXINE	targetBased	4	Terminated	01/02/2017	https://clinicaltrials.gov/study/NCT02946918	1	GoF	protect	Terminating study as sponsor has sold the drug to another company
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	THRB	Thyroid hormone receptor beta	thyroid cancer	LEVOTHYROXINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7a5a9e87-383a-4450-bf79-1f4f68655ace	1	GoF	protect
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	THRB	Thyroid hormone receptor beta	differentiated thyroid carcinoma	LEVOTHYROXINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=00a4fc0b-7162-455e-8ed3-56efdbbe182e	1	GoF	protect
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	THRB	Thyroid hormone receptor beta	differentiated thyroid carcinoma	LEVOTHYROXINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7a5a9e87-383a-4450-bf79-1f4f68655ace	1	GoF	protect
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	THRB	Thyroid hormone receptor beta	thyroid carcinoma	LEVOTHYROXINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f4d851f6-6bf5-4ed5-8d3a-1646773c4d40	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer	DIACETYLMORPHINE	targetBased	4	Completed	23/01/2017	https://clinicaltrials.gov/study/NCT02009306	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer	DIACETYLMORPHINE	targetBased	4	Completed	23/01/2017	https://clinicaltrials.gov/study/NCT02009306	1	GoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	sarcoma	IMATINIB MESYLATE	targetBased	3	Completed	01/02/2004	https://clinicaltrials.gov/study/NCT00116935	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	sarcoma	IMATINIB MESYLATE	targetBased	3	Completed	01/05/2002	https://clinicaltrials.gov/study/NCT00367861	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	systemic mastocytosis	IMATINIB MESYLATE	targetBased	4	Completed	01/01/2011	https://clinicaltrials.gov/study/NCT01297777	1	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	IMATINIB MESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=211ef2da-2868-4a77-8055-1cb2cd78e24b	1	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	IMATINIB MESYLATE	targetBased	3	Terminated	01/07/2009	https://clinicaltrials.gov/study/NCT01827930	0.7	LoF	protect	Difficulties of enrolment of Patient
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	IMATINIB MESYLATE	targetBased	4	Completed	01/07/2004	https://clinicaltrials.gov/study/NCT00845221	1	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	IMATINIB MESYLATE	targetBased	3	Terminated	01/06/2005	https://clinicaltrials.gov/study/NCT00124748	0.35	LoF	protect	This study was prematurely discontinued because no improvement was observed in the 800mg dose compared to 400mg dose
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	IMATINIB MESYLATE	targetBased	3	Completed	01/09/2003	https://clinicaltrials.gov/study/NCT00219739	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	IMATINIB MESYLATE	targetBased	3	Completed	01/06/2004	https://clinicaltrials.gov/study/NCT00514488	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	IMATINIB MESYLATE	targetBased	3	Completed	01/04/2003	https://clinicaltrials.gov/study/NCT00050531	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	IMATINIB MESYLATE	targetBased	3	Completed	01/06/2014	https://clinicaltrials.gov/study/NCT02204644	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	IMATINIB MESYLATE	targetBased	3	Unknown status	01/01/2009	https://clinicaltrials.gov/study/NCT01400074	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	IMATINIB MESYLATE	targetBased	4	Completed	01/10/2003	https://clinicaltrials.gov/study/NCT00081926	1	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	IMATINIB MESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0e9927ab-771e-4c2d-881e-7031c40bf205	1	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	IMATINIB MESYLATE	targetBased	4	Completed	09/11/2011	https://clinicaltrials.gov/study/NCT01578213	1	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	IMATINIB MESYLATE	targetBased	4	Completed	01/04/2005	https://clinicaltrials.gov/study/NCT00171899	1	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	IMATINIB MESYLATE	targetBased	4	Completed	01/07/2003	https://clinicaltrials.gov/study/NCT00390897	1	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	T-cell acute lymphoblastic leukemia	IMATINIB MESYLATE	targetBased	3	Recruiting	08/08/2017	https://clinicaltrials.gov/study/NCT03007147	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	childhood acute lymphoblastic leukemia	IMATINIB MESYLATE	targetBased	3	Completed	01/10/2002	https://clinicaltrials.gov/study/NCT00022737	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	glioblastoma multiforme	IMATINIB MESYLATE	targetBased	3	Completed	01/10/2004	https://clinicaltrials.gov/study/NCT00154375	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	astrocytoma	IMATINIB MESYLATE	targetBased	3	Completed	01/10/2004	https://clinicaltrials.gov/study/NCT00154375	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	gastrointestinal stromal tumor	IMATINIB MESYLATE	targetBased	3	Unknown status	01/01/2001	https://clinicaltrials.gov/study/NCT00685828	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	gastrointestinal stromal tumor	IMATINIB MESYLATE	targetBased	4	Completed	01/07/2004	https://clinicaltrials.gov/study/NCT00171977	1	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	gastrointestinal stromal tumor	IMATINIB MESYLATE	targetBased	3	Completed	01/12/2004	https://clinicaltrials.gov/study/NCT00103168	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	gastrointestinal stromal tumor	IMATINIB MESYLATE	targetBased	3	Completed	01/06/2002	https://clinicaltrials.gov/study/NCT00041197	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	gastrointestinal stromal tumor	IMATINIB MESYLATE	targetBased	3	Completed	01/03/2004	https://clinicaltrials.gov/study/NCT00293124	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	gastrointestinal stromal tumor	IMATINIB MESYLATE	targetBased	3	Completed	01/05/2002	https://clinicaltrials.gov/study/NCT00367861	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	gastrointestinal stromal tumor	IMATINIB MESYLATE	targetBased	4	Active, not recruiting	26/03/2013	https://clinicaltrials.gov/study/NCT01742299	1	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	gastrointestinal stromal tumor	IMATINIB MESYLATE	targetBased	3	Terminated	01/04/2008	https://clinicaltrials.gov/study/NCT00324987	0.7	LoF	protect	The trial failed to accrue
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	gastrointestinal stromal tumor	IMATINIB MESYLATE	targetBased	3	Terminated	01/01/2010	https://clinicaltrials.gov/study/NCT01031628	0.7	LoF	protect	Lack of feasibility secondary to slow accrual
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	gastrointestinal stromal tumor	IMATINIB MESYLATE	targetBased	4	Completed	01/10/2006	https://clinicaltrials.gov/study/NCT00510354	1	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	gastrointestinal stromal tumor	IMATINIB MESYLATE	targetBased	3	Terminated	01/12/2000	https://clinicaltrials.gov/study/NCT00009906	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	gastrointestinal stromal tumor	IMATINIB MESYLATE	targetBased	3	Terminated	01/06/2007	https://clinicaltrials.gov/study/NCT00372567	0.7	LoF	protect	See termination reason in detailed description.
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	gastrointestinal stromal tumor	IMATINIB MESYLATE	targetBased	3	Terminated	01/05/2009	https://clinicaltrials.gov/study/NCT00956072	0.7	LoF	protect	low accrual
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	mixed phenotype acute leukemia	IMATINIB MESYLATE	targetBased	3	Recruiting	08/08/2017	https://clinicaltrials.gov/study/NCT03007147	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	lymphoid leukemia	IMATINIB MESYLATE	targetBased	3	Completed	01/05/2006	https://clinicaltrials.gov/study/NCT00327678	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	leukemia	IMATINIB MESYLATE	targetBased	3	Completed	07/05/1993	https://clinicaltrials.gov/study/NCT00002514	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	leukemia	IMATINIB MESYLATE	targetBased	3	Completed	01/06/2002	https://clinicaltrials.gov/study/NCT00055874	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	leukemia	IMATINIB MESYLATE	targetBased	3	Completed	01/06/2000	https://clinicaltrials.gov/study/NCT00006343	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	adult T acute lymphoblastic leukemia	VINCRISTINE SULFATE	targetBased	3	Active, not recruiting	04/10/2014	https://clinicaltrials.gov/study/NCT02112916	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	primitive neuroectodermal tumor	VINCRISTINE SULFATE	targetBased	3	Active, not recruiting	06/08/2007	https://clinicaltrials.gov/study/NCT00336024	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	primitive neuroectodermal tumor	VINCRISTINE SULFATE	targetBased	3	Completed	01/10/2000	https://clinicaltrials.gov/study/NCT00006461	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	retinoblastoma	VINCRISTINE SULFATE	targetBased	3	Completed	01/12/2005	https://clinicaltrials.gov/study/NCT00335738	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	retinoblastoma	VINCRISTINE SULFATE	targetBased	3	Active, not recruiting	04/02/2008	https://clinicaltrials.gov/study/NCT00554788	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	retinoblastoma	VINCRISTINE SULFATE	targetBased	3	Completed	26/12/2005	https://clinicaltrials.gov/study/NCT00079417	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	retinoblastoma	VINCRISTINE SULFATE	targetBased	3	Completed	16/04/2007	https://clinicaltrials.gov/study/NCT00072384	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	low grade glioma	VINCRISTINE SULFATE	targetBased	3	Recruiting	31/01/2020	https://clinicaltrials.gov/study/NCT04166409	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	follicular lymphoma	VINCRISTINE SULFATE	targetBased	4	Recruiting	01/03/2021	https://clinicaltrials.gov/study/NCT04842318	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	follicular lymphoma	VINCRISTINE SULFATE	targetBased	3	Recruiting	02/10/2023	https://clinicaltrials.gov/study/NCT05888493	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	follicular lymphoma	VINCRISTINE SULFATE	targetBased	3	Completed	29/12/2011	https://clinicaltrials.gov/study/NCT01476787	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	follicular lymphoma	VINCRISTINE SULFATE	targetBased	3	Unknown status	01/12/2005	https://clinicaltrials.gov/study/NCT00774826	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	follicular lymphoma	VINCRISTINE SULFATE	targetBased	3	Completed	01/03/1998	https://clinicaltrials.gov/study/NCT00003204	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	follicular lymphoma	VINCRISTINE SULFATE	targetBased	3	Active, not recruiting	01/02/2012	https://clinicaltrials.gov/study/NCT01650701	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	follicular lymphoma	VINCRISTINE SULFATE	targetBased	3	Unknown status	01/05/2013	https://clinicaltrials.gov/study/NCT01852435	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	follicular lymphoma	VINCRISTINE SULFATE	targetBased	3	Recruiting	01/12/2021	https://clinicaltrials.gov/study/NCT05058404	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	follicular lymphoma	VINCRISTINE SULFATE	targetBased	3	Terminated	13/08/2021	https://clinicaltrials.gov/study/NCT04745832	0.7	LoF	protect	Discontinuation of zandelisib program
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	neoplasm of mature B-cells	VINCRISTINE SULFATE	targetBased	3	Completed	01/10/2015	https://clinicaltrials.gov/study/NCT02787239	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	neoplasm of mature B-cells	VINCRISTINE SULFATE	targetBased	3	Terminated	26/07/2007	https://clinicaltrials.gov/study/NCT00486759	0.35	LoF	protect	Due to an unfavorable benefit/risk ratio.
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	mediastinal malignant lymphoma	VINCRISTINE SULFATE	targetBased	3	Recruiting	01/04/2022	https://clinicaltrials.gov/study/NCT06188676	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	alveolar rhabdomyosarcoma	VINCRISTINE SULFATE	targetBased	3	Active, not recruiting	01/06/2016	https://clinicaltrials.gov/study/NCT02567435	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	alveolar rhabdomyosarcoma	VINCRISTINE SULFATE	targetBased	3	Recruiting	14/09/2021	https://clinicaltrials.gov/study/NCT04994132	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	alveolar rhabdomyosarcoma	VINCRISTINE SULFATE	targetBased	3	Completed	26/12/2006	https://clinicaltrials.gov/study/NCT00354835	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	mesothelioma	VINCRISTINE SULFATE	targetBased	3	Completed	01/09/2003	https://clinicaltrials.gov/study/NCT00075699	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	adult acute lymphoblastic leukemia	VINCRISTINE SULFATE	targetBased	3	Unknown status	01/06/2013	https://clinicaltrials.gov/study/NCT02072785	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	T-lymphoblastic lymphoma	VINCRISTINE SULFATE	targetBased	3	Active, not recruiting	22/01/2007	https://clinicaltrials.gov/study/NCT00408005	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	adult T-cell leukemia/lymphoma	VINCRISTINE SULFATE	targetBased	4	Completed		https://clinicaltrials.gov/study/NCT01418430	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	adult T-cell leukemia/lymphoma	VINCRISTINE SULFATE	targetBased	3	Completed	01/08/1998	https://clinicaltrials.gov/study/NCT00145002	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	head and neck malignant neoplasia	VINCRISTINE SULFATE	targetBased	3	Completed	01/01/1990	https://clinicaltrials.gov/study/NCT00002476	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	chronic lymphocytic leukemia	VINCRISTINE SULFATE	targetBased	3	Completed	01/03/1998	https://clinicaltrials.gov/study/NCT00003204	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	nodular sclerosis Hodgkin lymphoma	VINCRISTINE SULFATE	targetBased	3	Completed	01/02/2006	https://clinicaltrials.gov/study/NCT00302003	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	soft tissue sarcoma	VINCRISTINE SULFATE	targetBased	3	Completed	01/09/2002	https://clinicaltrials.gov/study/NCT00003958	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Hodgkins lymphoma	VINCRISTINE SULFATE	targetBased	3	Completed	07/12/2009	https://clinicaltrials.gov/study/NCT01026220	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Hodgkins lymphoma	VINCRISTINE SULFATE	targetBased	3	Active, not recruiting	19/03/2015	https://clinicaltrials.gov/study/NCT02166463	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Hodgkins lymphoma	VINCRISTINE SULFATE	targetBased	4	Unknown status	01/08/2015	https://clinicaltrials.gov/study/NCT02526823	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	T-cell acute lymphoblastic leukemia	VINCRISTINE SULFATE	targetBased	3	Recruiting	08/08/2017	https://clinicaltrials.gov/study/NCT03007147	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	T-cell acute lymphoblastic leukemia	VINCRISTINE SULFATE	targetBased	3	Unknown status	01/01/2008	https://clinicaltrials.gov/study/NCT01788137	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	astrocytoma	VINCRISTINE SULFATE	targetBased	3	Recruiting	31/01/2020	https://clinicaltrials.gov/study/NCT04166409	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	leukemia	VINCRISTINE SULFATE	targetBased	3	Completed	01/05/1999	https://clinicaltrials.gov/study/NCT00015873	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	leukemia	VINCRISTINE SULFATE	targetBased	3	Completed	01/03/2000	https://clinicaltrials.gov/study/NCT00005603	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	leukemia	VINCRISTINE SULFATE	targetBased	3	Completed	01/06/2010	https://clinicaltrials.gov/study/NCT01117441	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	leukemia	VINCRISTINE SULFATE	targetBased	3	Unknown status	01/01/1997	https://clinicaltrials.gov/study/NCT00003437	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	leukemia	VINCRISTINE SULFATE	targetBased	3	Completed	01/09/1996	https://clinicaltrials.gov/study/NCT00002812	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	leukemia	VINCRISTINE SULFATE	targetBased	3	Completed	07/05/1993	https://clinicaltrials.gov/study/NCT00002514	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	leukemia	VINCRISTINE SULFATE	targetBased	3	Active, not recruiting	17/12/2014	https://clinicaltrials.gov/study/NCT02101853	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	leukemia	VINCRISTINE SULFATE	targetBased	3	Completed	01/10/1999	https://clinicaltrials.gov/study/NCT00004218	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	leukemia	VINCRISTINE SULFATE	targetBased	3	Withdrawn	01/10/1999	https://clinicaltrials.gov/study/NCT00019409	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	leukemia	VINCRISTINE SULFATE	targetBased	3	Completed	01/08/1995	https://clinicaltrials.gov/study/NCT00002700	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	leukemia	VINCRISTINE SULFATE	targetBased	3	Completed	01/04/2000	https://clinicaltrials.gov/study/NCT00005585	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	leukemia	VINCRISTINE SULFATE	targetBased	3	Completed	01/06/2001	https://clinicaltrials.gov/study/NCT00002757	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	leukemia	VINCRISTINE SULFATE	targetBased	3	Completed	01/04/2000	https://clinicaltrials.gov/study/NCT00005596	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	leukemia	VINCRISTINE SULFATE	targetBased	3	Completed	01/05/2008	https://clinicaltrials.gov/study/NCT00707083	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	leukemia	VINCRISTINE SULFATE	targetBased	3	Completed	01/10/2002	https://clinicaltrials.gov/study/NCT00967057	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	leukemia	VINCRISTINE SULFATE	targetBased	3	Completed	01/04/2005	https://clinicaltrials.gov/study/NCT00400946	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	leukemia	VINCRISTINE SULFATE	targetBased	3	Completed	01/05/1996	https://clinicaltrials.gov/study/NCT00002744	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	leukemia	VINCRISTINE SULFATE	targetBased	3	Completed	01/12/1996	https://clinicaltrials.gov/study/NCT00002816	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	leukemia	VINCRISTINE SULFATE	targetBased	3	Completed	01/03/1996	https://clinicaltrials.gov/study/NCT00002766	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	leukemia	VINCRISTINE SULFATE	targetBased	3	Completed	01/07/2000	https://clinicaltrials.gov/study/NCT00430118	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	leukemia	VINCRISTINE SULFATE	targetBased	3	Unknown status	01/11/2002	https://clinicaltrials.gov/study/NCT00764907	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	leukemia	VINCRISTINE SULFATE	targetBased	3	Unknown status	01/12/1998	https://clinicaltrials.gov/study/NCT00003728	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	leukemia	VINCRISTINE SULFATE	targetBased	3	Completed	01/06/2000	https://clinicaltrials.gov/study/NCT00005945	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	leukemia	VINCRISTINE SULFATE	targetBased	3	Completed	01/09/2000	https://clinicaltrials.gov/study/NCT00005977	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	leukemia	VINCRISTINE SULFATE	targetBased	3	Active, not recruiting	01/01/1996	https://clinicaltrials.gov/study/NCT00004034	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	sarcoma	VINCRISTINE SULFATE	targetBased	3	Unknown status	01/06/2006	https://clinicaltrials.gov/study/NCT00379457	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	sarcoma	VINCRISTINE SULFATE	targetBased	3	Unknown status	01/07/1992	https://clinicaltrials.gov/study/NCT00002516	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	sarcoma	VINCRISTINE SULFATE	targetBased	3	Completed	01/07/2006	https://clinicaltrials.gov/study/NCT00354744	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	sarcoma	VINCRISTINE SULFATE	targetBased	3	Unknown status	01/02/2001	https://clinicaltrials.gov/study/NCT00020566	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	sarcoma	VINCRISTINE SULFATE	targetBased	3	Completed	01/05/2001	https://clinicaltrials.gov/study/NCT00006734	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	sarcoma	VINCRISTINE SULFATE	targetBased	3	Completed	01/01/1995	https://clinicaltrials.gov/study/NCT00002898	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	sarcoma	VINCRISTINE SULFATE	targetBased	3	Withdrawn	01/12/2005	https://clinicaltrials.gov/study/NCT00334867	0.7	LoF	protect	withdrawn
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	sarcoma	VINCRISTINE SULFATE	targetBased	3	Completed	01/08/1997	https://clinicaltrials.gov/study/NCT00002995	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	acute lymphoblastic leukemia	VINCRISTINE SULFATE	targetBased	3	Active, not recruiting	15/01/2008	https://clinicaltrials.gov/study/NCT00557193	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	acute lymphoblastic leukemia	VINCRISTINE SULFATE	targetBased	3	Terminated	01/03/2012	https://clinicaltrials.gov/study/NCT01439347	0.7	LoF	protect	Sponsor decision
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	acute lymphoblastic leukemia	VINCRISTINE SULFATE	targetBased	3	Active, not recruiting	19/05/2014	https://clinicaltrials.gov/study/NCT02003222	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	acute lymphoblastic leukemia	VINCRISTINE SULFATE	targetBased	3	Completed	29/12/2003	https://clinicaltrials.gov/study/NCT00075725	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	acute lymphoblastic leukemia	VINCRISTINE SULFATE	targetBased	3	Suspended	01/06/2017	https://clinicaltrials.gov/study/NCT03150693	0.35	LoF	protect	Unacceptable Toxicity
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoid leukemia	VINCRISTINE SULFATE	targetBased	3	Active, not recruiting	17/12/2014	https://clinicaltrials.gov/study/NCT02101853	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoid leukemia	VINCRISTINE SULFATE	targetBased	3	Recruiting	25/01/2021	https://clinicaltrials.gov/study/NCT04530565	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	ganglioneuroblastoma	VINCRISTINE SULFATE	targetBased	3	Active, not recruiting	14/05/2018	https://clinicaltrials.gov/study/NCT03126916	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	childhood B acute lymphoblastic leukemia	VINCRISTINE SULFATE	targetBased	3	Completed	11/04/2005	https://clinicaltrials.gov/study/NCT00103285	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	childhood B acute lymphoblastic leukemia	VINCRISTINE SULFATE	targetBased	3	Completed	01/03/2007	https://clinicaltrials.gov/study/NCT00381680	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	adult malignant mesenchymoma	VINCRISTINE SULFATE	targetBased	3	Completed	01/09/2002	https://clinicaltrials.gov/study/NCT00003958	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	colorectal cancer	VINCRISTINE SULFATE	targetBased	3	Completed	01/09/1977	https://clinicaltrials.gov/study/NCT00427570	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Hepatoblastoma	VINCRISTINE SULFATE	targetBased	3	Completed	01/03/1999	https://clinicaltrials.gov/study/NCT00003994	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Hepatoblastoma	VINCRISTINE SULFATE	targetBased	3	Active, not recruiting	14/09/2009	https://clinicaltrials.gov/study/NCT00980460	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	brain neoplasm	VINCRISTINE SULFATE	targetBased	3	Completed	01/04/1997	https://clinicaltrials.gov/study/NCT00002944	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	brain neoplasm	VINCRISTINE SULFATE	targetBased	3	Completed	01/12/1996	https://clinicaltrials.gov/study/NCT00002875	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Mantle cell lymphoma	VINCRISTINE SULFATE	targetBased	3	Recruiting	01/07/2016	https://clinicaltrials.gov/study/NCT02858258	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Mantle cell lymphoma	VINCRISTINE SULFATE	targetBased	3	Active, not recruiting	01/11/2013	https://clinicaltrials.gov/study/NCT01865110	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Mantle cell lymphoma	VINCRISTINE SULFATE	targetBased	3	Recruiting	22/12/2021	https://clinicaltrials.gov/study/NCT05051891	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	plasma cell neoplasm	VINCRISTINE SULFATE	targetBased	3	Completed	30/06/1997	https://clinicaltrials.gov/study/NCT00002878	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	carcinoma	VINCRISTINE SULFATE	targetBased	3	Unknown status	01/12/1998	https://clinicaltrials.gov/study/NCT00022178	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	diffuse large B-cell lymphoma	VINCRISTINE SULFATE	targetBased	4	Unknown status	01/07/2017	https://clinicaltrials.gov/study/NCT03513601	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	diffuse large B-cell lymphoma	VINCRISTINE SULFATE	targetBased	3	Completed	20/03/2018	https://clinicaltrials.gov/study/NCT03263026	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	diffuse large B-cell lymphoma	VINCRISTINE SULFATE	targetBased	3	Recruiting	19/08/2020	https://clinicaltrials.gov/study/NCT04332822	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	diffuse large B-cell lymphoma	VINCRISTINE SULFATE	targetBased	3	Recruiting	17/09/2021	https://clinicaltrials.gov/study/NCT05018520	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	diffuse large B-cell lymphoma	VINCRISTINE SULFATE	targetBased	3	Completed	24/08/2012	https://clinicaltrials.gov/study/NCT01649856	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	diffuse large B-cell lymphoma	VINCRISTINE SULFATE	targetBased	3	Completed	01/12/2010	https://clinicaltrials.gov/study/NCT01285765	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	diffuse large B-cell lymphoma	VINCRISTINE SULFATE	targetBased	3	Completed	01/09/2006	https://clinicaltrials.gov/study/NCT01459887	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	diffuse large B-cell lymphoma	VINCRISTINE SULFATE	targetBased	3	Completed	01/05/2005	https://clinicaltrials.gov/study/NCT00355199	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	diffuse large B-cell lymphoma	VINCRISTINE SULFATE	targetBased	3	Withdrawn	01/02/2014	https://clinicaltrials.gov/study/NCT02054559	0.35	LoF	protect	No consensus among trial centers regarding protocol
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	diffuse large B-cell lymphoma	VINCRISTINE SULFATE	targetBased	3	Completed	01/12/2012	https://clinicaltrials.gov/study/NCT01724021	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	diffuse large B-cell lymphoma	VINCRISTINE SULFATE	targetBased	3	Unknown status	01/05/2013	https://clinicaltrials.gov/study/NCT01852435	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	diffuse large B-cell lymphoma	VINCRISTINE SULFATE	targetBased	3	Recruiting	07/06/2023	https://clinicaltrials.gov/study/NCT05820841	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	diffuse large B-cell lymphoma	VINCRISTINE SULFATE	targetBased	3	Active, not recruiting	10/07/2017	https://clinicaltrials.gov/study/NCT03213977	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	diffuse large B-cell lymphoma	VINCRISTINE SULFATE	targetBased	3	Recruiting	28/12/2018	https://clinicaltrials.gov/study/NCT03650933	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	diffuse large B-cell lymphoma	VINCRISTINE SULFATE	targetBased	3	Recruiting	02/03/2022	https://clinicaltrials.gov/study/NCT05179733	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	diffuse large B-cell lymphoma	VINCRISTINE SULFATE	targetBased	3	Active, not recruiting	21/05/2020	https://clinicaltrials.gov/study/NCT04231448	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	diffuse large B-cell lymphoma	VINCRISTINE SULFATE	targetBased	3	Unknown status	01/06/2016	https://clinicaltrials.gov/study/NCT02772822	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	diffuse large B-cell lymphoma	VINCRISTINE SULFATE	targetBased	4	Unknown status	01/09/2012	https://clinicaltrials.gov/study/NCT01949818	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	diffuse large B-cell lymphoma	VINCRISTINE SULFATE	targetBased	3	Recruiting	23/03/2021	https://clinicaltrials.gov/study/NCT04442412	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	diffuse large B-cell lymphoma	VINCRISTINE SULFATE	targetBased	3	Recruiting	02/11/2022	https://clinicaltrials.gov/study/NCT05234684	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	diffuse large B-cell lymphoma	VINCRISTINE SULFATE	targetBased	3	Completed	22/08/2016	https://clinicaltrials.gov/study/NCT02867566	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	rhabdomyosarcoma	VINCRISTINE SULFATE	targetBased	3	Completed	04/09/2004	https://clinicaltrials.gov/study/NCT00075582	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	rhabdomyosarcoma	VINCRISTINE SULFATE	targetBased	3	Terminated	01/07/1995	https://clinicaltrials.gov/study/NCT00162695	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	rhabdomyosarcoma	VINCRISTINE SULFATE	targetBased	3	Completed	01/09/2002	https://clinicaltrials.gov/study/NCT00003958	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Central Nervous System Neoplasm	VINCRISTINE SULFATE	targetBased	3	Unknown status	01/02/2003	https://clinicaltrials.gov/study/NCT00053872	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Central Nervous System Neoplasm	VINCRISTINE SULFATE	targetBased	3	Completed	01/04/1992	https://clinicaltrials.gov/study/NCT00003859	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Central Nervous System Neoplasm	VINCRISTINE SULFATE	targetBased	3	Unknown status	01/09/2003	https://clinicaltrials.gov/study/NCT00278278	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Central Nervous System Neoplasm	VINCRISTINE SULFATE	targetBased	3	Completed	01/08/1996	https://clinicaltrials.gov/study/NCT00002840	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Central Nervous System Neoplasm	VINCRISTINE SULFATE	targetBased	3	Unknown status	01/03/2004	https://clinicaltrials.gov/study/NCT00392886	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Central Nervous System Neoplasm	VINCRISTINE SULFATE	targetBased	3	Completed	01/04/1997	https://clinicaltrials.gov/study/NCT00002944	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Central Nervous System Neoplasm	VINCRISTINE SULFATE	targetBased	3	Completed	01/10/2002	https://clinicaltrials.gov/study/NCT00052455	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Central Nervous System Neoplasm	VINCRISTINE SULFATE	targetBased	3	Unknown status	01/01/1997	https://clinicaltrials.gov/study/NCT00003015	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Central Nervous System Neoplasm	VINCRISTINE SULFATE	targetBased	3	Completed	01/07/1994	https://clinicaltrials.gov/study/NCT00002569	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	undifferentiated high grade pleomorphic sarcoma of bone	VINCRISTINE SULFATE	targetBased	3	Completed	01/01/1995	https://clinicaltrials.gov/study/NCT00002898	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-Hodgkins lymphoma	VINCRISTINE SULFATE	targetBased	3	Completed	01/12/2012	https://clinicaltrials.gov/study/NCT01724021	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-Hodgkins lymphoma	VINCRISTINE SULFATE	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00000658	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-Hodgkins lymphoma	VINCRISTINE SULFATE	targetBased	3	Terminated	01/02/1999	https://clinicaltrials.gov/study/NCT00133302	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-Hodgkins lymphoma	VINCRISTINE SULFATE	targetBased	4	Unknown status	01/08/2015	https://clinicaltrials.gov/study/NCT02526823	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-Hodgkins lymphoma	VINCRISTINE SULFATE	targetBased	3	Completed	01/07/2008	https://clinicaltrials.gov/study/NCT00719472	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	adult B acute lymphoblastic leukemia	VINCRISTINE SULFATE	targetBased	3	Completed	21/07/2008	https://clinicaltrials.gov/study/NCT00671034	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	adult B acute lymphoblastic leukemia	VINCRISTINE SULFATE	targetBased	3	Completed	29/12/2003	https://clinicaltrials.gov/study/NCT00075725	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	cervical cancer	VINCRISTINE SULFATE	targetBased	3	Completed	01/12/1996	https://clinicaltrials.gov/study/NCT00002536	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	unspecified peripheral T-cell lymphoma	VINCRISTINE SULFATE	targetBased	3	Completed	01/01/2013	https://clinicaltrials.gov/study/NCT01796002	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	unspecified peripheral T-cell lymphoma	VINCRISTINE SULFATE	targetBased	4	Completed	01/08/2011	https://clinicaltrials.gov/study/NCT01664975	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	unspecified peripheral T-cell lymphoma	VINCRISTINE SULFATE	targetBased	3	Recruiting	04/10/2023	https://clinicaltrials.gov/study/NCT06072131	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	unspecified peripheral T-cell lymphoma	VINCRISTINE SULFATE	targetBased	4	Unknown status	01/09/2018	https://clinicaltrials.gov/study/NCT03631862	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	unspecified peripheral T-cell lymphoma	VINCRISTINE SULFATE	targetBased	3	Completed	01/01/1995	https://clinicaltrials.gov/study/NCT00970385	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	kidney cancer	VINCRISTINE SULFATE	targetBased	3	Unknown status	01/01/2001	https://clinicaltrials.gov/study/NCT00047138	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	kidney cancer	VINCRISTINE SULFATE	targetBased	3	Completed	01/07/1995	https://clinicaltrials.gov/study/NCT00002611	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	kidney cancer	VINCRISTINE SULFATE	targetBased	3	Unknown status	01/07/1993	https://clinicaltrials.gov/study/NCT00003804	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	kidney cancer	VINCRISTINE SULFATE	targetBased	3	Completed	01/01/1996	https://clinicaltrials.gov/study/NCT00002610	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	neoplasm	VINCRISTINE SULFATE	targetBased	3	Completed	10/02/2009	https://clinicaltrials.gov/study/NCT00653068	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	childhood acute lymphoblastic leukemia	VINCRISTINE SULFATE	targetBased	3	Completed	01/10/2002	https://clinicaltrials.gov/study/NCT00022737	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	kidney Wilms tumor	VINCRISTINE SULFATE	targetBased	3	Active, not recruiting	26/02/2007	https://clinicaltrials.gov/study/NCT00379340	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Kaposi's sarcoma	VINCRISTINE SULFATE	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00002105	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Kaposi's sarcoma	VINCRISTINE SULFATE	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00002093	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Kaposi's sarcoma	VINCRISTINE SULFATE	targetBased	3	Unknown status		https://clinicaltrials.gov/study/NCT00002318	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	medulloblastoma	VINCRISTINE SULFATE	targetBased	3	Active, not recruiting	26/03/2007	https://clinicaltrials.gov/study/NCT00392327	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	medulloblastoma	VINCRISTINE SULFATE	targetBased	3	Active, not recruiting	06/08/2007	https://clinicaltrials.gov/study/NCT00336024	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	medulloblastoma	VINCRISTINE SULFATE	targetBased	3	Completed	01/10/2000	https://clinicaltrials.gov/study/NCT00006461	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	medulloblastoma	VINCRISTINE SULFATE	targetBased	3	Active, not recruiting	01/04/2004	https://clinicaltrials.gov/study/NCT00085735	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung cancer	VINCRISTINE SULFATE	targetBased	3	Completed	01/03/1996	https://clinicaltrials.gov/study/NCT00002822	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung cancer	VINCRISTINE SULFATE	targetBased	3	Completed	01/01/1993	https://clinicaltrials.gov/study/NCT00003364	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	mixed phenotype acute leukemia	VINCRISTINE SULFATE	targetBased	3	Recruiting	08/08/2017	https://clinicaltrials.gov/study/NCT03007147	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	neuroblastoma	VINCRISTINE SULFATE	targetBased	3	Unknown status	01/03/1995	https://clinicaltrials.gov/study/NCT00276731	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	neuroblastoma	VINCRISTINE SULFATE	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00365755	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	neuroblastoma	VINCRISTINE SULFATE	targetBased	3	Unknown status		https://clinicaltrials.gov/study/NCT00416676	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	neuroblastoma	VINCRISTINE SULFATE	targetBased	3	Completed	01/02/2001	https://clinicaltrials.gov/study/NCT00004188	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	neuroblastoma	VINCRISTINE SULFATE	targetBased	3	Completed	01/07/1990	https://clinicaltrials.gov/study/NCT00002802	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	neuroblastoma	VINCRISTINE SULFATE	targetBased	3	Unknown status		https://clinicaltrials.gov/study/NCT00417053	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	neuroblastoma	VINCRISTINE SULFATE	targetBased	3	Completed	05/11/2007	https://clinicaltrials.gov/study/NCT00567567	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	neuroblastoma	VINCRISTINE SULFATE	targetBased	3	Completed	01/12/2000	https://clinicaltrials.gov/study/NCT00025428	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	neuroblastoma	VINCRISTINE SULFATE	targetBased	3	Active, not recruiting	14/05/2018	https://clinicaltrials.gov/study/NCT03126916	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	neuroblastoma	VINCRISTINE SULFATE	targetBased	3	Unknown status	01/12/2001	https://clinicaltrials.gov/study/NCT00030719	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	neuroblastoma	VINCRISTINE SULFATE	targetBased	3	Unknown status	01/10/2004	https://clinicaltrials.gov/study/NCT00410631	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	multiple myeloma	VINCRISTINE SULFATE	targetBased	3	Unknown status	01/09/1994	https://clinicaltrials.gov/study/NCT00002599	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	multiple myeloma	VINCRISTINE SULFATE	targetBased	3	Completed	30/06/1997	https://clinicaltrials.gov/study/NCT00002878	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	multiple myeloma	VINCRISTINE SULFATE	targetBased	3	Completed	01/01/1994	https://clinicaltrials.gov/study/NCT00002548	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	multiple myeloma	VINCRISTINE SULFATE	targetBased	3	Unknown status	01/03/2001	https://clinicaltrials.gov/study/NCT00028886	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	multiple myeloma	VINCRISTINE SULFATE	targetBased	3	Completed	01/10/1996	https://clinicaltrials.gov/study/NCT00006232	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	multiple myeloma	VINCRISTINE SULFATE	targetBased	3	Completed	01/07/1994	https://clinicaltrials.gov/study/NCT00002556	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE SULFATE	targetBased	3	Completed	01/08/1995	https://clinicaltrials.gov/study/NCT00002700	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE SULFATE	targetBased	3	Unknown status	01/02/2001	https://clinicaltrials.gov/study/NCT00028717	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE SULFATE	targetBased	3	Completed	01/11/2005	https://clinicaltrials.gov/study/NCT00278408	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE SULFATE	targetBased	3	Completed	01/05/1999	https://clinicaltrials.gov/study/NCT00004179	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE SULFATE	targetBased	3	Completed	01/01/1998	https://clinicaltrials.gov/study/NCT00005867	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE SULFATE	targetBased	3	Completed	29/08/2008	https://clinicaltrials.gov/study/NCT00678327	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE SULFATE	targetBased	3	Completed	01/06/2008	https://clinicaltrials.gov/study/NCT00646854	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE SULFATE	targetBased	3	Unknown status	01/05/1995	https://clinicaltrials.gov/study/NCT00003423	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE SULFATE	targetBased	3	Completed	08/05/2001	https://clinicaltrials.gov/study/NCT00064116	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE SULFATE	targetBased	3	Unknown status	01/07/2001	https://clinicaltrials.gov/study/NCT00025636	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE SULFATE	targetBased	3	Completed	01/09/1999	https://clinicaltrials.gov/study/NCT00004112	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE SULFATE	targetBased	3	Completed	01/06/1998	https://clinicaltrials.gov/study/NCT00003421	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE SULFATE	targetBased	3	Completed	25/05/1994	https://clinicaltrials.gov/study/NCT00002565	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE SULFATE	targetBased	3	Completed	01/11/1992	https://clinicaltrials.gov/study/NCT00002576	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE SULFATE	targetBased	3	Completed	01/03/2009	https://clinicaltrials.gov/study/NCT00854568	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE SULFATE	targetBased	3	Unknown status	01/01/1997	https://clinicaltrials.gov/study/NCT00002987	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE SULFATE	targetBased	3	Completed	01/09/2000	https://clinicaltrials.gov/study/NCT00005977	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE SULFATE	targetBased	3	Completed	01/06/2001	https://clinicaltrials.gov/study/NCT00002757	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE SULFATE	targetBased	3	Completed	01/04/1997	https://clinicaltrials.gov/study/NCT00003215	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE SULFATE	targetBased	3	Completed	01/11/2003	https://clinicaltrials.gov/study/NCT00059839	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE SULFATE	targetBased	3	Recruiting	05/10/2021	https://clinicaltrials.gov/study/NCT04759586	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE SULFATE	targetBased	3	Terminated	01/09/2004	https://clinicaltrials.gov/study/NCT00275106	0.35	LoF	protect	Withdrawn due to an excess of toxic deaths
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE SULFATE	targetBased	3	Completed	01/10/1996	https://clinicaltrials.gov/study/NCT00002827	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE SULFATE	targetBased	3	Terminated	01/03/1997	https://clinicaltrials.gov/study/NCT00003152	0.7	LoF	protect	low accrual
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE SULFATE	targetBased	3	Completed	01/12/1994	https://clinicaltrials.gov/study/NCT00002618	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE SULFATE	targetBased	3	Completed	01/06/2000	https://clinicaltrials.gov/study/NCT00004228	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE SULFATE	targetBased	3	Completed	01/01/2007	https://clinicaltrials.gov/study/NCT00433459	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE SULFATE	targetBased	3	Completed	01/03/1996	https://clinicaltrials.gov/study/NCT00002766	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE SULFATE	targetBased	3	Recruiting	01/10/2021	https://clinicaltrials.gov/study/NCT05075460	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE SULFATE	targetBased	3	Unknown status	01/01/1993	https://clinicaltrials.gov/study/NCT00003578	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE SULFATE	targetBased	3	Completed	01/02/1997	https://clinicaltrials.gov/study/NCT00003650	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE SULFATE	targetBased	3	Unknown status	01/10/2001	https://clinicaltrials.gov/study/NCT00041210	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE SULFATE	targetBased	3	Recruiting	01/08/2018	https://clinicaltrials.gov/study/NCT03647072	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE SULFATE	targetBased	3	Completed	01/03/1997	https://clinicaltrials.gov/study/NCT00005578	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE SULFATE	targetBased	3	Completed	01/01/1999	https://clinicaltrials.gov/study/NCT00003595	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE SULFATE	targetBased	3	Completed	01/01/2001	https://clinicaltrials.gov/study/NCT00052936	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE SULFATE	targetBased	3	Completed	01/08/2002	https://clinicaltrials.gov/study/NCT00049595	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE SULFATE	targetBased	3	Active, not recruiting	01/09/1989	https://clinicaltrials.gov/study/NCT00002462	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE SULFATE	targetBased	3	Completed	01/12/1997	https://clinicaltrials.gov/study/NCT00003150	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE SULFATE	targetBased	3	Unknown status	01/12/1998	https://clinicaltrials.gov/study/NCT00003728	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE SULFATE	targetBased	3	Terminated	01/05/2008	https://clinicaltrials.gov/study/NCT00920153	0.7	LoF	protect	Other new drugs
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE SULFATE	targetBased	3	Unknown status	01/06/1994	https://clinicaltrials.gov/study/NCT00003815	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE SULFATE	targetBased	3	Completed	01/11/2007	https://clinicaltrials.gov/study/NCT00554164	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE SULFATE	targetBased	3	Active, not recruiting	01/09/1993	https://clinicaltrials.gov/study/NCT00379041	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE SULFATE	targetBased	3	Completed	30/10/1995	https://clinicaltrials.gov/study/NCT00002835	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE SULFATE	targetBased	3	Completed	01/07/1997	https://clinicaltrials.gov/study/NCT00004031	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE SULFATE	targetBased	3	Unknown status	01/11/2000	https://clinicaltrials.gov/study/NCT00017290	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE SULFATE	targetBased	3	Completed	01/11/2005	https://clinicaltrials.gov/study/NCT00278421	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINCRISTINE SULFATE	targetBased	3	Completed	01/04/2002	https://clinicaltrials.gov/study/NCT00053768	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	marginal zone B-cell lymphoma	VINCRISTINE SULFATE	targetBased	3	Recruiting	05/09/2023	https://clinicaltrials.gov/study/NCT06006117	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	classic Hodgkin lymphoma	VINCRISTINE SULFATE	targetBased	3	Active, not recruiting	19/03/2015	https://clinicaltrials.gov/study/NCT02166463	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	classic Hodgkin lymphoma	VINCRISTINE SULFATE	targetBased	3	Completed	01/09/2002	https://clinicaltrials.gov/study/NCT00025259	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	childhood T acute lymphoblastic leukemia	VINCRISTINE SULFATE	targetBased	3	Active, not recruiting	04/10/2014	https://clinicaltrials.gov/study/NCT02112916	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	childhood T acute lymphoblastic leukemia	VINCRISTINE SULFATE	targetBased	3	Active, not recruiting	15/01/2008	https://clinicaltrials.gov/study/NCT00557193	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	embryonal rhabdomyosarcoma	VINCRISTINE SULFATE	targetBased	3	Active, not recruiting	01/06/2016	https://clinicaltrials.gov/study/NCT02567435	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	embryonal rhabdomyosarcoma	VINCRISTINE SULFATE	targetBased	3	Completed	26/12/2006	https://clinicaltrials.gov/study/NCT00354835	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	embryonal rhabdomyosarcoma	VINCRISTINE SULFATE	targetBased	3	Recruiting	14/09/2021	https://clinicaltrials.gov/study/NCT04994132	0.7	LoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	neoplasm	TOREMIFENE	targetBased	3			https://www.whocc.no/atc_ddd_index/?code=L02BA02	0.7		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	prostate intraepithelial neoplasia	TOREMIFENE	targetBased	3	Completed	01/01/2005	https://clinicaltrials.gov/study/NCT00106691	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast neoplasm	TOREMIFENE	targetBased	3	Terminated	01/12/2004	https://clinicaltrials.gov/study/NCT00097344	0.35		protect	Identical study Biomed 777-CLP-029 did not meet superiority endpoint
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast neoplasm	TOREMIFENE	targetBased	3	Terminated	01/12/2004	https://clinicaltrials.gov/study/NCT00097344	0.35		protect	Identical study Biomed 777-CLP-029 did not meet superiority endpoint
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast neoplasm	TOREMIFENE	targetBased	3	Terminated	01/11/2005	https://clinicaltrials.gov/study/NCT00267553	0.35		protect	This was a follow-on study to Biomed 777-CLP-029 which did not meet superiority endpoint
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast neoplasm	TOREMIFENE	targetBased	3	Terminated	01/11/2005	https://clinicaltrials.gov/study/NCT00267553	0.35		protect	This was a follow-on study to Biomed 777-CLP-029 which did not meet superiority endpoint
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast neoplasm	TOREMIFENE	targetBased	3	Completed	01/06/2002	https://clinicaltrials.gov/study/NCT00044291	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast neoplasm	TOREMIFENE	targetBased	3	Completed	01/06/2002	https://clinicaltrials.gov/study/NCT00044291	0.7		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	breast carcinoma	TOREMIFENE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a6ff9761-7442-4bff-9e50-858c03e27fd0	1		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	breast carcinoma	TOREMIFENE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2cab8dd1-3a10-48e6-86ce-0e5275ed49e5	1		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	breast carcinoma in situ	TOREMIFENE	targetBased	4	Withdrawn	01/09/2018	https://clinicaltrials.gov/study/NCT03238703	1		protect	Administrative closure based on sponsor recommendation, prior to subject enrollment
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	neoplasm	TOREMIFENE	targetBased	3			https://www.whocc.no/atc_ddd_index/?code=L02BA02	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	neoplasm	TOREMIFENE	targetBased	3			https://www.whocc.no/atc_ddd_index/?code=L02BA02	0.7		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	breast neoplasm	TOREMIFENE	targetBased	3	Completed	01/06/2002	https://clinicaltrials.gov/study/NCT00044291	0.7		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	breast neoplasm	TOREMIFENE	targetBased	3	Terminated	01/12/2004	https://clinicaltrials.gov/study/NCT00097344	0.35		protect	Identical study Biomed 777-CLP-029 did not meet superiority endpoint
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	breast neoplasm	TOREMIFENE	targetBased	3	Terminated	01/11/2005	https://clinicaltrials.gov/study/NCT00267553	0.35		protect	This was a follow-on study to Biomed 777-CLP-029 which did not meet superiority endpoint
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast carcinoma in situ	TOREMIFENE	targetBased	4	Withdrawn	01/09/2018	https://clinicaltrials.gov/study/NCT03238703	1		protect	Administrative closure based on sponsor recommendation, prior to subject enrollment
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast carcinoma in situ	TOREMIFENE	targetBased	4	Withdrawn	01/09/2018	https://clinicaltrials.gov/study/NCT03238703	1		protect	Administrative closure based on sponsor recommendation, prior to subject enrollment
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TOREMIFENE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0b3ebaa6-9cbe-405e-8f14-14ce8dcd2a68	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TOREMIFENE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0b3ebaa6-9cbe-405e-8f14-14ce8dcd2a68	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TOREMIFENE	targetBased	3	Completed	01/05/1993	https://clinicaltrials.gov/study/NCT00002529	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TOREMIFENE	targetBased	3	Completed	01/05/1993	https://clinicaltrials.gov/study/NCT00002529	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TOREMIFENE	targetBased	4	Unknown status	01/11/2014	https://clinicaltrials.gov/study/NCT02089854	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TOREMIFENE	targetBased	4	Unknown status	01/11/2014	https://clinicaltrials.gov/study/NCT02089854	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TOREMIFENE	targetBased	4	Completed	01/12/2014	https://clinicaltrials.gov/study/NCT02344940	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TOREMIFENE	targetBased	4	Completed	01/12/2014	https://clinicaltrials.gov/study/NCT02344940	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TOREMIFENE	targetBased	3	Terminated	01/10/2000	https://clinicaltrials.gov/study/NCT00010322	0.7		protect	Withdrawn due to change in standard of care - new protocol required
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TOREMIFENE	targetBased	3	Terminated	01/10/2000	https://clinicaltrials.gov/study/NCT00010322	0.7		protect	Withdrawn due to change in standard of care - new protocol required
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TOREMIFENE	targetBased	3	Recruiting	01/06/2023	https://clinicaltrials.gov/study/NCT05891093	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TOREMIFENE	targetBased	3	Recruiting	01/06/2023	https://clinicaltrials.gov/study/NCT05891093	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TOREMIFENE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2cab8dd1-3a10-48e6-86ce-0e5275ed49e5	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TOREMIFENE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2cab8dd1-3a10-48e6-86ce-0e5275ed49e5	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TOREMIFENE	targetBased	3	Recruiting	01/03/2014	https://clinicaltrials.gov/study/NCT02097459	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TOREMIFENE	targetBased	3	Recruiting	01/03/2014	https://clinicaltrials.gov/study/NCT02097459	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TOREMIFENE	targetBased	3	Recruiting	01/11/2017	https://clinicaltrials.gov/study/NCT03351062	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TOREMIFENE	targetBased	3	Recruiting	01/11/2017	https://clinicaltrials.gov/study/NCT03351062	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast carcinoma	TOREMIFENE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a6ff9761-7442-4bff-9e50-858c03e27fd0	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast carcinoma	TOREMIFENE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a6ff9761-7442-4bff-9e50-858c03e27fd0	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast carcinoma	TOREMIFENE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2cab8dd1-3a10-48e6-86ce-0e5275ed49e5	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast carcinoma	TOREMIFENE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2cab8dd1-3a10-48e6-86ce-0e5275ed49e5	1		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	breast cancer	TOREMIFENE	targetBased	4	Unknown status	01/11/2014	https://clinicaltrials.gov/study/NCT02089854	1		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	breast cancer	TOREMIFENE	targetBased	3	Terminated	01/10/2000	https://clinicaltrials.gov/study/NCT00010322	0.7		protect	Withdrawn due to change in standard of care - new protocol required
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	breast cancer	TOREMIFENE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2cab8dd1-3a10-48e6-86ce-0e5275ed49e5	1		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	breast cancer	TOREMIFENE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0b3ebaa6-9cbe-405e-8f14-14ce8dcd2a68	1		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	breast cancer	TOREMIFENE	targetBased	3	Recruiting	01/03/2014	https://clinicaltrials.gov/study/NCT02097459	0.7		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	breast cancer	TOREMIFENE	targetBased	3	Recruiting	01/11/2017	https://clinicaltrials.gov/study/NCT03351062	0.7		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	breast cancer	TOREMIFENE	targetBased	4	Completed	01/12/2014	https://clinicaltrials.gov/study/NCT02344940	1		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	breast cancer	TOREMIFENE	targetBased	3	Recruiting	01/06/2023	https://clinicaltrials.gov/study/NCT05891093	0.7		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	breast cancer	TOREMIFENE	targetBased	3	Completed	01/05/1993	https://clinicaltrials.gov/study/NCT00002529	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	prostate intraepithelial neoplasia	TOREMIFENE	targetBased	3	Completed	01/01/2005	https://clinicaltrials.gov/study/NCT00106691	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	prostate intraepithelial neoplasia	TOREMIFENE	targetBased	3	Completed	01/01/2005	https://clinicaltrials.gov/study/NCT00106691	0.7		protect
Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3	HDAC3	HDAC3	Histone deacetylase 3	multiple myeloma	PANOBINOSTAT	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/farydak	1	LoF	protect
Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3	HDAC3	HDAC3	Histone deacetylase 3	multiple myeloma	PANOBINOSTAT	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7774972a-eeaa-4b9a-9e56-3fc1b968e86a	1	LoF	protect
Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3	HDAC3	HDAC3	Histone deacetylase 3	multiple myeloma	PANOBINOSTAT	targetBased	3	Completed	21/12/2009	https://clinicaltrials.gov/study/NCT01023308	0.7	LoF	protect
Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3	HDAC3	HDAC3	Histone deacetylase 3	Hodgkins lymphoma	PANOBINOSTAT	targetBased	3	Completed	01/06/2010	https://clinicaltrials.gov/study/NCT01034163	0.7	LoF	protect
Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3	HDAC3	HDAC3	Histone deacetylase 3	primary myelofibrosis	PANOBINOSTAT	targetBased	4	Recruiting	05/03/2015	https://clinicaltrials.gov/study/NCT02386800	1	LoF	protect
Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3	HDAC3	HDAC3	Histone deacetylase 3	neoplasm	PANOBINOSTAT	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=L01XH03	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hemangioma	PROPRANOLOL HYDROCHLORIDE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/hemangiol	1	LoF	protect
Primary biochemical high throughput screening assay to identify inhibitors of BCL2-related protein, long isoform (BCLXL).	BCL2L1_modulators	BCL2L1	Bcl-2-like protein 1	primary myelofibrosis	NAVITOCLAX	targetBased	3	Active, not recruiting	29/09/2020	https://clinicaltrials.gov/study/NCT04472598	0.7	LoF	protect
Primary biochemical high throughput screening assay to identify inhibitors of BCL2-related protein, long isoform (BCLXL).	BCL2L1_modulators	BCL2L1	Bcl-2-like protein 1	primary myelofibrosis	NAVITOCLAX	targetBased	3	Active, not recruiting	31/08/2020	https://clinicaltrials.gov/study/NCT04468984	0.7	LoF	protect
qHTS assay for MDR1-selective chemotherapeutics: Primary screen using the drug-selected MDR subline cells KB-V1	MDR1-selective compounds	ABCB1	ATP-binding cassette, sub-family B , ATP-dependent translocase ABCB1	myelodysplastic syndrome	ZOSUQUIDAR	targetBased	3	Completed	17/09/2002	https://clinicaltrials.gov/study/NCT00046930	0.7	LoF	protect
qHTS assay for MDR1-selective chemotherapeutics: Primary screen using the parental adenocarcinoma cell KB-3-1	MDR1-selective compounds	ABCB1	ATP-binding cassette, sub-family B , ATP-dependent translocase ABCB1	myelodysplastic syndrome	ZOSUQUIDAR	targetBased	3	Completed	17/09/2002	https://clinicaltrials.gov/study/NCT00046930	0.7	LoF	protect
qHTS assay for MDR1-selective chemotherapeutics: Primary screen using the drug-selected MDR subline cells KB-V1	MDR1-selective compounds	ABCB1	ATP-binding cassette, sub-family B , ATP-dependent translocase ABCB1	leukemia	ZOSUQUIDAR	targetBased	3	Completed	17/09/2002	https://clinicaltrials.gov/study/NCT00046930	0.7	LoF	protect
qHTS assay for MDR1-selective chemotherapeutics: Primary screen using the parental adenocarcinoma cell KB-3-1	MDR1-selective compounds	ABCB1	ATP-binding cassette, sub-family B , ATP-dependent translocase ABCB1	leukemia	ZOSUQUIDAR	targetBased	3	Completed	17/09/2002	https://clinicaltrials.gov/study/NCT00046930	0.7	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	cancer	BUPROPION HYDROCHLORIDE	targetBased	3	Recruiting	27/06/2019	https://clinicaltrials.gov/study/NCT03996265	0.7	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	carcinoma	BUPROPION HYDROCHLORIDE	targetBased	4	Recruiting	04/08/2020	https://clinicaltrials.gov/study/NCT04604509	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	lung cancer	BUPROPION HYDROCHLORIDE	targetBased	3	Terminated	01/01/2002	https://clinicaltrials.gov/study/NCT00032084	0.7	LoF	protect	This study was closed early due to poor accrual
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		cancer	KETAMINE HYDROCHLORIDE	targetBased	3	Unknown status	01/04/2009	https://clinicaltrials.gov/study/NCT01316744	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	squamous cell carcinoma	VINORELBINE	targetBased	3	Completed	01/05/2003	https://clinicaltrials.gov/study/NCT00064077	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	VINORELBINE	targetBased	3	Completed	01/08/2001	https://clinicaltrials.gov/study/NCT00146549	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	VINORELBINE	targetBased	3	Completed	01/10/2009	https://clinicaltrials.gov/study/NCT01007942	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	VINORELBINE	targetBased	3	Unknown status	01/08/2015	https://clinicaltrials.gov/study/NCT02514681	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	VINORELBINE	targetBased	3	Not yet recruiting	01/03/2021	https://clinicaltrials.gov/study/NCT04665986	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	VINORELBINE	targetBased	4	Recruiting	10/11/2017	https://clinicaltrials.gov/study/NCT03270007	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	VINORELBINE	targetBased	3	Completed	08/05/2019	https://clinicaltrials.gov/study/NCT03901339	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	VINORELBINE	targetBased	3	Unknown status	01/05/2005	https://clinicaltrials.gov/study/NCT00430001	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	VINORELBINE	targetBased	3	Completed	01/04/2002	https://clinicaltrials.gov/study/NCT00431106	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	VINORELBINE	targetBased	3	Active, not recruiting	14/09/2021	https://clinicaltrials.gov/study/NCT05063786	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	VINORELBINE	targetBased	4	Recruiting	01/03/2018	https://clinicaltrials.gov/study/NCT03355157	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	VINORELBINE	targetBased	3	Completed	07/11/2017	https://clinicaltrials.gov/study/NCT02574455	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	VINORELBINE	targetBased	3	Completed	29/05/2008	https://clinicaltrials.gov/study/NCT00776724	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	VINORELBINE	targetBased	3	Completed	01/02/2009	https://clinicaltrials.gov/study/NCT00868634	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	VINORELBINE	targetBased	3	Terminated	24/02/2016	https://clinicaltrials.gov/study/NCT02730091	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	VINORELBINE	targetBased	4	Recruiting	04/01/2021	https://clinicaltrials.gov/study/NCT05131841	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	VINORELBINE	targetBased	3	Completed	26/09/2013	https://clinicaltrials.gov/study/NCT02225470	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	VINORELBINE	targetBased	3	Recruiting	24/04/2024	https://clinicaltrials.gov/study/NCT06343948	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	VINORELBINE	targetBased	3	Withdrawn	01/01/2019	https://clinicaltrials.gov/study/NCT03811418	0.7	LoF	protect	Study approved with treatment regimen based on current guidelines. However, reimbursement of IMP was not feasible.
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	VINORELBINE	targetBased	3	Active, not recruiting	18/10/2021	https://clinicaltrials.gov/study/NCT05104866	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	VINORELBINE	targetBased	3	Terminated	17/01/2022	https://clinicaltrials.gov/study/NCT05134194	0.7	LoF	protect	Sponsor R \& D Strategy Adjustment\]
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	VINORELBINE	targetBased	3	Recruiting	30/10/2023	https://clinicaltrials.gov/study/NCT06143553	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	VINORELBINE	targetBased	3	Not yet recruiting	01/07/2023	https://clinicaltrials.gov/study/NCT05901935	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	VINORELBINE	targetBased	3	Not yet recruiting	01/12/2023	https://clinicaltrials.gov/study/NCT06079983	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	VINORELBINE	targetBased	3	Completed	13/10/2015	https://clinicaltrials.gov/study/NCT02555657	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	VINORELBINE	targetBased	3	Completed	16/05/2018	https://clinicaltrials.gov/study/NCT06107790	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	VINORELBINE	targetBased	3	Completed	01/12/2004	https://clinicaltrials.gov/study/NCT00103233	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	VINORELBINE	targetBased	3	Recruiting	15/01/2024	https://clinicaltrials.gov/study/NCT06268652	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	VINORELBINE	targetBased	3	Not yet recruiting	01/02/2024	https://clinicaltrials.gov/study/NCT06255392	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	VINORELBINE	targetBased	3	Recruiting	03/07/2018	https://clinicaltrials.gov/study/NCT04307147	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	VINORELBINE	targetBased	3	Not yet recruiting	16/07/2024	https://clinicaltrials.gov/study/NCT06435429	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	VINORELBINE	targetBased	3	Recruiting	29/09/2020	https://clinicaltrials.gov/study/NCT04400695	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	VINORELBINE	targetBased	4	Completed	01/06/2006	https://clinicaltrials.gov/study/NCT00372476	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	alveolar rhabdomyosarcoma	VINORELBINE	targetBased	3	Active, not recruiting	01/06/2016	https://clinicaltrials.gov/study/NCT02567435	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	alveolar rhabdomyosarcoma	VINORELBINE	targetBased	3	Recruiting	14/09/2021	https://clinicaltrials.gov/study/NCT04994132	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	mesothelioma	VINORELBINE	targetBased	3	Completed	01/09/2003	https://clinicaltrials.gov/study/NCT00075699	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	adenosquamous lung carcinoma	VINORELBINE	targetBased	3	Completed	01/03/2000	https://clinicaltrials.gov/study/NCT00005838	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	nodular sclerosis Hodgkin lymphoma	VINORELBINE	targetBased	3	Completed	01/02/2006	https://clinicaltrials.gov/study/NCT00302003	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	malignant pleural mesothelioma	VINORELBINE	targetBased	3	Completed	12/09/2017	https://clinicaltrials.gov/study/NCT02991482	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Hodgkins lymphoma	VINORELBINE	targetBased	3	Completed	07/12/2009	https://clinicaltrials.gov/study/NCT01026220	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	sarcoma	VINORELBINE	targetBased	3	Unknown status	01/06/2006	https://clinicaltrials.gov/study/NCT00379457	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung adenocarcinoma	VINORELBINE	targetBased	3	Completed	01/03/2000	https://clinicaltrials.gov/study/NCT00005838	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast neoplasm	VINORELBINE	targetBased	3	Completed	22/06/2010	https://clinicaltrials.gov/study/NCT01125566	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast carcinoma	VINORELBINE	targetBased	3	Recruiting	15/01/2024	https://clinicaltrials.gov/study/NCT06268652	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	cervical squamous cell carcinoma	VINORELBINE	targetBased	3	Completed	01/05/2003	https://clinicaltrials.gov/study/NCT00064077	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	cervical adenocarcinoma	VINORELBINE	targetBased	3	Completed	01/05/2003	https://clinicaltrials.gov/study/NCT00064077	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	carcinoma	VINORELBINE	targetBased	3	Unknown status	01/07/2010	https://clinicaltrials.gov/study/NCT01126138	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-Hodgkins lymphoma	VINORELBINE	targetBased	3	Completed	01/07/2004	https://clinicaltrials.gov/study/NCT00088530	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	cervical cancer	VINORELBINE	targetBased	3	Withdrawn	02/08/2021	https://clinicaltrials.gov/study/NCT04943627	0.7	LoF	protect	Strategic Business Decision
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	cervical cancer	VINORELBINE	targetBased	3	Active, not recruiting	22/02/2021	https://clinicaltrials.gov/study/NCT04697628	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	cervical cancer	VINORELBINE	targetBased	3	Not yet recruiting	05/07/2024	https://clinicaltrials.gov/study/NCT06459180	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	cervical cancer	VINORELBINE	targetBased	3	Completed	01/05/2003	https://clinicaltrials.gov/study/NCT00064077	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	neoplasm	VINORELBINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=L01CA04	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	triple-negative breast cancer	VINORELBINE	targetBased	3	Not yet recruiting	01/05/2024	https://clinicaltrials.gov/study/NCT06382142	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	triple-negative breast cancer	VINORELBINE	targetBased	3	Recruiting	25/04/2023	https://clinicaltrials.gov/study/NCT05806060	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung cancer	VINORELBINE	targetBased	3	Unknown status	01/11/1998	https://clinicaltrials.gov/study/NCT00004100	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung cancer	VINORELBINE	targetBased	3	Unknown status	01/07/1998	https://clinicaltrials.gov/study/NCT00003447	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung cancer	VINORELBINE	targetBased	3	Completed	01/03/2000	https://clinicaltrials.gov/study/NCT00005838	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung cancer	VINORELBINE	targetBased	3	Completed	01/06/1999	https://clinicaltrials.gov/study/NCT00148291	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung cancer	VINORELBINE	targetBased	3	Withdrawn	01/11/2002	https://clinicaltrials.gov/study/NCT00055887	0.7	LoF	protect	Study never started. No patients were enrolled.
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung cancer	VINORELBINE	targetBased	3	Terminated	01/01/2003	https://clinicaltrials.gov/study/NCT00054197	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung cancer	VINORELBINE	targetBased	3	Terminated	01/03/2009	https://clinicaltrials.gov/study/NCT00863512	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung cancer	VINORELBINE	targetBased	3	Terminated	01/01/2016	https://clinicaltrials.gov/study/NCT02644252	0.7	LoF	protect	The trial was ended prematurely because of a poor accrual rate
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung cancer	VINORELBINE	targetBased	3	Completed	01/07/2000	https://clinicaltrials.gov/study/NCT00017459	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung cancer	VINORELBINE	targetBased	3	Unknown status	01/10/1995	https://clinicaltrials.gov/study/NCT00003240	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung cancer	VINORELBINE	targetBased	3	Completed	01/06/2004	https://clinicaltrials.gov/study/NCT00193362	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung cancer	VINORELBINE	targetBased	3	Completed	01/02/1995	https://clinicaltrials.gov/study/NCT00002823	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung cancer	VINORELBINE	targetBased	3	Completed	07/07/1994	https://clinicaltrials.gov/study/NCT00002583	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung cancer	VINORELBINE	targetBased	3	Completed	01/08/1997	https://clinicaltrials.gov/study/NCT00003159	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung cancer	VINORELBINE	targetBased	3	Completed	01/12/2005	https://clinicaltrials.gov/study/NCT00309972	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung cancer	VINORELBINE	targetBased	3	Completed	01/03/2001	https://clinicaltrials.gov/study/NCT00079287	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	esophageal squamous cell carcinoma	VINORELBINE	targetBased	3	Active, not recruiting	01/07/2015	https://clinicaltrials.gov/study/NCT02465736	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINORELBINE	targetBased	3	Terminated	01/05/2008	https://clinicaltrials.gov/study/NCT00920153	0.7	LoF	protect	Other new drugs
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	classic Hodgkin lymphoma	VINORELBINE	targetBased	3	Withdrawn	10/08/2023	https://clinicaltrials.gov/study/NCT05711628	0.7	LoF	protect	Other - Protocol moved to Withdrawn
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	VINORELBINE	targetBased	3	Unknown status	31/08/2018	https://clinicaltrials.gov/study/NCT03656393	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	VINORELBINE	targetBased	3	Unknown status	01/10/2016	https://clinicaltrials.gov/study/NCT02579564	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	VINORELBINE	targetBased	4	Completed	01/02/2007	https://clinicaltrials.gov/study/NCT01196078	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	VINORELBINE	targetBased	3	Completed	01/09/2007	https://clinicaltrials.gov/study/NCT00737867	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	VINORELBINE	targetBased	4	Active, not recruiting	01/02/2023	https://clinicaltrials.gov/study/NCT05583188	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	VINORELBINE	targetBased	3	Completed	09/12/2011	https://clinicaltrials.gov/study/NCT01454934	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	VINORELBINE	targetBased	3	Completed	01/04/2004	https://clinicaltrials.gov/study/NCT00441740	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	VINORELBINE	targetBased	3	Terminated	01/05/2005	https://clinicaltrials.gov/study/NCT00345059	0.7	LoF	protect	slow accrual
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	VINORELBINE	targetBased	3	Completed	01/05/2007	https://clinicaltrials.gov/study/NCT00499109	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	VINORELBINE	targetBased	3	Completed	01/03/2006	https://clinicaltrials.gov/study/NCT00298415	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	VINORELBINE	targetBased	3	Active, not recruiting	16/08/2018	https://clinicaltrials.gov/study/NCT03456076	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	VINORELBINE	targetBased	3	Completed	01/06/2002	https://clinicaltrials.gov/study/NCT00148395	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	VINORELBINE	targetBased	3	Recruiting	10/04/2018	https://clinicaltrials.gov/study/NCT03381066	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	VINORELBINE	targetBased	3	Completed	13/01/2015	https://clinicaltrials.gov/study/NCT02352948	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	VINORELBINE	targetBased	3	Terminated	01/06/2002	https://clinicaltrials.gov/study/NCT00042315	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	VINORELBINE	targetBased	3	Completed	11/09/2017	https://clinicaltrials.gov/study/NCT03191786	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	VINORELBINE	targetBased	3	Completed	01/04/2005	https://clinicaltrials.gov/study/NCT00683514	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	VINORELBINE	targetBased	3	Active, not recruiting	31/10/2015	https://clinicaltrials.gov/study/NCT02486718	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	VINORELBINE	targetBased	3	Not yet recruiting	01/10/2022	https://clinicaltrials.gov/study/NCT05487391	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	VINORELBINE	targetBased	4	Completed	01/08/2010	https://clinicaltrials.gov/study/NCT02497118	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	VINORELBINE	targetBased	3	Withdrawn	01/06/2016	https://clinicaltrials.gov/study/NCT02795884	0.7	LoF	protect	Because of reconsideration of using erlotinib(EGFR Tyrosine kinase inhibitor) as adjuvant aim
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	VINORELBINE	targetBased	3	Completed	01/01/2003	https://clinicaltrials.gov/study/NCT00441922	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	VINORELBINE	targetBased	3	Active, not recruiting	04/03/2017	https://clinicaltrials.gov/study/NCT02998528	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	VINORELBINE	targetBased	3	Active, not recruiting	01/06/2007	https://clinicaltrials.gov/study/NCT00324805	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	VINORELBINE	targetBased	3	Unknown status	19/09/2011	https://clinicaltrials.gov/study/NCT01405079	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	VINORELBINE	targetBased	3	Unknown status		https://clinicaltrials.gov/study/NCT00265694	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	VINORELBINE	targetBased	3	Completed	01/09/2008	https://clinicaltrials.gov/study/NCT00686959	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	VINORELBINE	targetBased	3	Terminated	01/11/2016	https://clinicaltrials.gov/study/NCT02974426	0.7	LoF	protect	Enrollment was delayed and the number of eligible patients significantly declined with the use of neoadjuvant or adjuvant ICIs and TKIs therapies. Thus, this trial was closed due to insufficient accrual.
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	VINORELBINE	targetBased	4	Completed	01/10/2012	https://clinicaltrials.gov/study/NCT01848613	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	VINORELBINE	targetBased	3	Completed	01/10/2004	https://clinicaltrials.gov/study/NCT00148798	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung carcinoma	VINORELBINE	targetBased	3	Unknown status	01/10/2014	https://clinicaltrials.gov/study/NCT02281708	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	embryonal rhabdomyosarcoma	VINORELBINE	targetBased	3	Active, not recruiting	01/06/2016	https://clinicaltrials.gov/study/NCT02567435	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	embryonal rhabdomyosarcoma	VINORELBINE	targetBased	3	Recruiting	14/09/2021	https://clinicaltrials.gov/study/NCT04994132	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	squamous cell carcinoma	VINORELBINE TARTRATE	targetBased	3	Completed	01/05/2003	https://clinicaltrials.gov/study/NCT00064077	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	VINORELBINE TARTRATE	targetBased	3	Recruiting	29/09/2020	https://clinicaltrials.gov/study/NCT04400695	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	VINORELBINE TARTRATE	targetBased	3	Completed	01/12/2004	https://clinicaltrials.gov/study/NCT00103233	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	VINORELBINE TARTRATE	targetBased	3	Completed	26/09/2013	https://clinicaltrials.gov/study/NCT02225470	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	VINORELBINE TARTRATE	targetBased	3	Not yet recruiting	01/12/2023	https://clinicaltrials.gov/study/NCT06079983	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	VINORELBINE TARTRATE	targetBased	3	Not yet recruiting	01/02/2024	https://clinicaltrials.gov/study/NCT06255392	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	VINORELBINE TARTRATE	targetBased	3	Not yet recruiting	01/03/2021	https://clinicaltrials.gov/study/NCT04665986	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	VINORELBINE TARTRATE	targetBased	3	Recruiting	30/10/2023	https://clinicaltrials.gov/study/NCT06143553	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	VINORELBINE TARTRATE	targetBased	3	Not yet recruiting	01/07/2023	https://clinicaltrials.gov/study/NCT05901935	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	alveolar rhabdomyosarcoma	VINORELBINE TARTRATE	targetBased	3	Recruiting	14/09/2021	https://clinicaltrials.gov/study/NCT04994132	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	mesothelioma	VINORELBINE TARTRATE	targetBased	3	Completed	01/09/2003	https://clinicaltrials.gov/study/NCT00075699	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	adenosquamous lung carcinoma	VINORELBINE TARTRATE	targetBased	3	Completed	01/03/2000	https://clinicaltrials.gov/study/NCT00005838	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	nodular sclerosis Hodgkin lymphoma	VINORELBINE TARTRATE	targetBased	3	Completed	01/02/2006	https://clinicaltrials.gov/study/NCT00302003	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Hodgkins lymphoma	VINORELBINE TARTRATE	targetBased	3	Completed	07/12/2009	https://clinicaltrials.gov/study/NCT01026220	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	sarcoma	VINORELBINE TARTRATE	targetBased	3	Unknown status	01/06/2006	https://clinicaltrials.gov/study/NCT00379457	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung adenocarcinoma	VINORELBINE TARTRATE	targetBased	3	Completed	01/03/2000	https://clinicaltrials.gov/study/NCT00005838	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	cervical squamous cell carcinoma	VINORELBINE TARTRATE	targetBased	3	Completed	01/05/2003	https://clinicaltrials.gov/study/NCT00064077	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	cervical adenocarcinoma	VINORELBINE TARTRATE	targetBased	3	Completed	01/05/2003	https://clinicaltrials.gov/study/NCT00064077	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-Hodgkins lymphoma	VINORELBINE TARTRATE	targetBased	3	Completed	01/07/2004	https://clinicaltrials.gov/study/NCT00088530	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	cervical cancer	VINORELBINE TARTRATE	targetBased	3	Completed	01/05/2003	https://clinicaltrials.gov/study/NCT00064077	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung cancer	VINORELBINE TARTRATE	targetBased	3	Unknown status	01/10/1995	https://clinicaltrials.gov/study/NCT00003240	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung cancer	VINORELBINE TARTRATE	targetBased	3	Terminated	01/01/2003	https://clinicaltrials.gov/study/NCT00054197	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung cancer	VINORELBINE TARTRATE	targetBased	3	Unknown status	01/07/1998	https://clinicaltrials.gov/study/NCT00003447	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung cancer	VINORELBINE TARTRATE	targetBased	3	Completed	01/02/1995	https://clinicaltrials.gov/study/NCT00002823	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung cancer	VINORELBINE TARTRATE	targetBased	3	Unknown status	01/11/1998	https://clinicaltrials.gov/study/NCT00004100	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung cancer	VINORELBINE TARTRATE	targetBased	3	Completed	07/07/1994	https://clinicaltrials.gov/study/NCT00002583	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung cancer	VINORELBINE TARTRATE	targetBased	3	Terminated	01/03/2009	https://clinicaltrials.gov/study/NCT00863512	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung cancer	VINORELBINE TARTRATE	targetBased	3	Withdrawn	01/11/2002	https://clinicaltrials.gov/study/NCT00055887	0.7	LoF	protect	Study never started. No patients were enrolled.
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung cancer	VINORELBINE TARTRATE	targetBased	3	Completed	01/03/2001	https://clinicaltrials.gov/study/NCT00079287	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung cancer	VINORELBINE TARTRATE	targetBased	3	Completed	01/08/1997	https://clinicaltrials.gov/study/NCT00003159	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung cancer	VINORELBINE TARTRATE	targetBased	3	Completed	01/07/2000	https://clinicaltrials.gov/study/NCT00017459	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung cancer	VINORELBINE TARTRATE	targetBased	3	Completed	01/03/2000	https://clinicaltrials.gov/study/NCT00005838	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	VINORELBINE TARTRATE	targetBased	3	Terminated	01/05/2008	https://clinicaltrials.gov/study/NCT00920153	0.7	LoF	protect	Other new drugs
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	VINORELBINE TARTRATE	targetBased	3	Active, not recruiting	01/06/2007	https://clinicaltrials.gov/study/NCT00324805	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	VINORELBINE TARTRATE	targetBased	3	Completed	01/03/2006	https://clinicaltrials.gov/study/NCT00298415	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	VINORELBINE TARTRATE	targetBased	3	Not yet recruiting	01/10/2022	https://clinicaltrials.gov/study/NCT05487391	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	VINORELBINE TARTRATE	targetBased	3	Completed	01/06/2002	https://clinicaltrials.gov/study/NCT00148395	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	VINORELBINE TARTRATE	targetBased	3	Completed	01/10/2004	https://clinicaltrials.gov/study/NCT00148798	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	embryonal rhabdomyosarcoma	VINORELBINE TARTRATE	targetBased	3	Recruiting	14/09/2021	https://clinicaltrials.gov/study/NCT04994132	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	sarcoma	OMBRABULIN	targetBased	3	Completed	01/06/2008	https://clinicaltrials.gov/study/NCT00699517	0.7	LoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	prostate cancer	ESTRAMUSTINE PHOSPHATE	targetBased	3	Completed	08/10/2003	https://clinicaltrials.gov/study/NCT00027859	0.7		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	prostate cancer	ESTRAMUSTINE PHOSPHATE	targetBased	3	Completed	01/01/2000	https://clinicaltrials.gov/study/NCT00004054	0.7		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	prostate cancer	ESTRAMUSTINE PHOSPHATE	targetBased	3	Completed	14/11/2002	https://clinicaltrials.gov/study/NCT00055731	0.7		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	prostate cancer	ESTRAMUSTINE PHOSPHATE	targetBased	3	Terminated	01/04/2002	https://clinicaltrials.gov/study/NCT00024167	0.7		protect	Terminated due to slow accrual
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	prostate cancer	ESTRAMUSTINE PHOSPHATE	targetBased	3	Completed	01/08/1996	https://clinicaltrials.gov/study/NCT00002855	0.7		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	prostate cancer	ESTRAMUSTINE PHOSPHATE	targetBased	3	Completed	01/10/2002	https://clinicaltrials.gov/study/NCT00030654	0.7		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	carcinoma	ESTRAMUSTINE PHOSPHATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a9b01bc6-95ac-46f9-befa-d845a74d53c1	1		protect
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	MTOR	Serine/threonine-protein kinase mTOR	breast cancer	GEDATOLISIB	pathwayBased	3	Recruiting	30/09/2022	https://clinicaltrials.gov/study/NCT05501886	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	childhood T acute lymphoblastic leukemia	LESTAURTINIB	targetBased	3	Active, not recruiting	15/01/2008	https://clinicaltrials.gov/study/NCT00557193	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	acute lymphoblastic leukemia	LESTAURTINIB	targetBased	3	Active, not recruiting	15/01/2008	https://clinicaltrials.gov/study/NCT00557193	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	primary myelofibrosis	MOMELOTINIB	targetBased	3	Completed	06/12/2013	https://clinicaltrials.gov/study/NCT01969838	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	primary myelofibrosis	MOMELOTINIB	targetBased	3	Completed	19/06/2014	https://clinicaltrials.gov/study/NCT02101268	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	primary myelofibrosis	MOMELOTINIB	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216873s000lbl.pdf	1	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	pancreatic ductal adenocarcinoma	MOMELOTINIB	targetBased	3	Terminated	02/06/2014	https://clinicaltrials.gov/study/NCT02101021	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	polycythemia vera	MOMELOTINIB	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216873s000lbl.pdf	1	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	essential thrombocythemia	MOMELOTINIB	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216873s000lbl.pdf	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PLINABULIN	targetBased	3	Completed	01/12/2015	https://clinicaltrials.gov/study/NCT02504489	0.7	LoF	protect
qHTS assay for MDR1-selective chemotherapeutics: Primary screen using the drug-selected MDR subline cells KB-V1	MDR1-selective compounds	ABCB1	ATP-binding cassette, sub-family B , ATP-dependent translocase ABCB1	plasma cell neoplasm	VALSPODAR	targetBased	3	Completed	30/06/1997	https://clinicaltrials.gov/study/NCT00002878	0.7	LoF	protect
qHTS assay for MDR1-selective chemotherapeutics: Primary screen using the parental adenocarcinoma cell KB-3-1	MDR1-selective compounds	ABCB1	ATP-binding cassette, sub-family B , ATP-dependent translocase ABCB1	plasma cell neoplasm	VALSPODAR	targetBased	3	Completed	30/06/1997	https://clinicaltrials.gov/study/NCT00002878	0.7	LoF	protect
qHTS assay for MDR1-selective chemotherapeutics: Primary screen using the drug-selected MDR subline cells KB-V1	MDR1-selective compounds	ABCB1	ATP-binding cassette, sub-family B , ATP-dependent translocase ABCB1	acute megakaryoblastic leukaemia	VALSPODAR	targetBased	3	Completed	01/01/1998	https://clinicaltrials.gov/study/NCT00003190	0.7	LoF	protect
qHTS assay for MDR1-selective chemotherapeutics: Primary screen using the parental adenocarcinoma cell KB-3-1	MDR1-selective compounds	ABCB1	ATP-binding cassette, sub-family B , ATP-dependent translocase ABCB1	acute megakaryoblastic leukaemia	VALSPODAR	targetBased	3	Completed	01/01/1998	https://clinicaltrials.gov/study/NCT00003190	0.7	LoF	protect
qHTS assay for MDR1-selective chemotherapeutics: Primary screen using the drug-selected MDR subline cells KB-V1	MDR1-selective compounds	ABCB1	ATP-binding cassette, sub-family B , ATP-dependent translocase ABCB1	acute megakaryoblastic leukaemia	VALSPODAR	targetBased	3	Completed	01/11/2000	https://clinicaltrials.gov/study/NCT00006363	0.7	LoF	protect
qHTS assay for MDR1-selective chemotherapeutics: Primary screen using the parental adenocarcinoma cell KB-3-1	MDR1-selective compounds	ABCB1	ATP-binding cassette, sub-family B , ATP-dependent translocase ABCB1	acute megakaryoblastic leukaemia	VALSPODAR	targetBased	3	Completed	01/11/2000	https://clinicaltrials.gov/study/NCT00006363	0.7	LoF	protect
qHTS assay for MDR1-selective chemotherapeutics: Primary screen using the drug-selected MDR subline cells KB-V1	MDR1-selective compounds	ABCB1	ATP-binding cassette, sub-family B , ATP-dependent translocase ABCB1	acute myelomonocytic leukemia	VALSPODAR	targetBased	3	Completed	01/01/1998	https://clinicaltrials.gov/study/NCT00003190	0.7	LoF	protect
qHTS assay for MDR1-selective chemotherapeutics: Primary screen using the parental adenocarcinoma cell KB-3-1	MDR1-selective compounds	ABCB1	ATP-binding cassette, sub-family B , ATP-dependent translocase ABCB1	acute myelomonocytic leukemia	VALSPODAR	targetBased	3	Completed	01/01/1998	https://clinicaltrials.gov/study/NCT00003190	0.7	LoF	protect
qHTS assay for MDR1-selective chemotherapeutics: Primary screen using the drug-selected MDR subline cells KB-V1	MDR1-selective compounds	ABCB1	ATP-binding cassette, sub-family B , ATP-dependent translocase ABCB1	acute myelomonocytic leukemia	VALSPODAR	targetBased	3	Completed	01/11/2000	https://clinicaltrials.gov/study/NCT00006363	0.7	LoF	protect
qHTS assay for MDR1-selective chemotherapeutics: Primary screen using the parental adenocarcinoma cell KB-3-1	MDR1-selective compounds	ABCB1	ATP-binding cassette, sub-family B , ATP-dependent translocase ABCB1	acute myelomonocytic leukemia	VALSPODAR	targetBased	3	Completed	01/11/2000	https://clinicaltrials.gov/study/NCT00006363	0.7	LoF	protect
qHTS assay for MDR1-selective chemotherapeutics: Primary screen using the drug-selected MDR subline cells KB-V1	MDR1-selective compounds	ABCB1	ATP-binding cassette, sub-family B , ATP-dependent translocase ABCB1	myelodysplastic syndrome	VALSPODAR	targetBased	3	Completed	01/12/1998	https://clinicaltrials.gov/study/NCT00005823	0.7	LoF	protect
qHTS assay for MDR1-selective chemotherapeutics: Primary screen using the parental adenocarcinoma cell KB-3-1	MDR1-selective compounds	ABCB1	ATP-binding cassette, sub-family B , ATP-dependent translocase ABCB1	myelodysplastic syndrome	VALSPODAR	targetBased	3	Completed	01/12/1998	https://clinicaltrials.gov/study/NCT00005823	0.7	LoF	protect
qHTS assay for MDR1-selective chemotherapeutics: Primary screen using the drug-selected MDR subline cells KB-V1	MDR1-selective compounds	ABCB1	ATP-binding cassette, sub-family B , ATP-dependent translocase ABCB1	myelodysplastic syndrome	VALSPODAR	targetBased	3	Completed	01/11/2000	https://clinicaltrials.gov/study/NCT00006363	0.7	LoF	protect
qHTS assay for MDR1-selective chemotherapeutics: Primary screen using the parental adenocarcinoma cell KB-3-1	MDR1-selective compounds	ABCB1	ATP-binding cassette, sub-family B , ATP-dependent translocase ABCB1	myelodysplastic syndrome	VALSPODAR	targetBased	3	Completed	01/11/2000	https://clinicaltrials.gov/study/NCT00006363	0.7	LoF	protect
qHTS assay for MDR1-selective chemotherapeutics: Primary screen using the drug-selected MDR subline cells KB-V1	MDR1-selective compounds	ABCB1	ATP-binding cassette, sub-family B , ATP-dependent translocase ABCB1	acute myeloblastic leukemia with maturation	VALSPODAR	targetBased	3	Completed	01/01/1998	https://clinicaltrials.gov/study/NCT00003190	0.7	LoF	protect
qHTS assay for MDR1-selective chemotherapeutics: Primary screen using the parental adenocarcinoma cell KB-3-1	MDR1-selective compounds	ABCB1	ATP-binding cassette, sub-family B , ATP-dependent translocase ABCB1	acute myeloblastic leukemia with maturation	VALSPODAR	targetBased	3	Completed	01/01/1998	https://clinicaltrials.gov/study/NCT00003190	0.7	LoF	protect
qHTS assay for MDR1-selective chemotherapeutics: Primary screen using the drug-selected MDR subline cells KB-V1	MDR1-selective compounds	ABCB1	ATP-binding cassette, sub-family B , ATP-dependent translocase ABCB1	acute myeloid leukemia	VALSPODAR	targetBased	3	Completed	01/11/2000	https://clinicaltrials.gov/study/NCT00006363	0.7	LoF	protect
qHTS assay for MDR1-selective chemotherapeutics: Primary screen using the parental adenocarcinoma cell KB-3-1	MDR1-selective compounds	ABCB1	ATP-binding cassette, sub-family B , ATP-dependent translocase ABCB1	acute myeloid leukemia	VALSPODAR	targetBased	3	Completed	01/11/2000	https://clinicaltrials.gov/study/NCT00006363	0.7	LoF	protect
qHTS assay for MDR1-selective chemotherapeutics: Primary screen using the drug-selected MDR subline cells KB-V1	MDR1-selective compounds	ABCB1	ATP-binding cassette, sub-family B , ATP-dependent translocase ABCB1	acute myeloblastic leukemia without maturation	VALSPODAR	targetBased	3	Completed	01/01/1998	https://clinicaltrials.gov/study/NCT00003190	0.7	LoF	protect
qHTS assay for MDR1-selective chemotherapeutics: Primary screen using the parental adenocarcinoma cell KB-3-1	MDR1-selective compounds	ABCB1	ATP-binding cassette, sub-family B , ATP-dependent translocase ABCB1	acute myeloblastic leukemia without maturation	VALSPODAR	targetBased	3	Completed	01/01/1998	https://clinicaltrials.gov/study/NCT00003190	0.7	LoF	protect
qHTS assay for MDR1-selective chemotherapeutics: Primary screen using the drug-selected MDR subline cells KB-V1	MDR1-selective compounds	ABCB1	ATP-binding cassette, sub-family B , ATP-dependent translocase ABCB1	acute myeloblastic leukemia without maturation	VALSPODAR	targetBased	3	Completed	01/11/2000	https://clinicaltrials.gov/study/NCT00006363	0.7	LoF	protect
qHTS assay for MDR1-selective chemotherapeutics: Primary screen using the parental adenocarcinoma cell KB-3-1	MDR1-selective compounds	ABCB1	ATP-binding cassette, sub-family B , ATP-dependent translocase ABCB1	acute myeloblastic leukemia without maturation	VALSPODAR	targetBased	3	Completed	01/11/2000	https://clinicaltrials.gov/study/NCT00006363	0.7	LoF	protect
qHTS assay for MDR1-selective chemotherapeutics: Primary screen using the drug-selected MDR subline cells KB-V1	MDR1-selective compounds	ABCB1	ATP-binding cassette, sub-family B , ATP-dependent translocase ABCB1	acute basophilic leukemia	VALSPODAR	targetBased	3	Completed	01/11/2000	https://clinicaltrials.gov/study/NCT00006363	0.7	LoF	protect
qHTS assay for MDR1-selective chemotherapeutics: Primary screen using the parental adenocarcinoma cell KB-3-1	MDR1-selective compounds	ABCB1	ATP-binding cassette, sub-family B , ATP-dependent translocase ABCB1	acute basophilic leukemia	VALSPODAR	targetBased	3	Completed	01/11/2000	https://clinicaltrials.gov/study/NCT00006363	0.7	LoF	protect
qHTS assay for MDR1-selective chemotherapeutics: Primary screen using the drug-selected MDR subline cells KB-V1	MDR1-selective compounds	ABCB1	ATP-binding cassette, sub-family B , ATP-dependent translocase ABCB1	childhood acute myeloid leukemia with maturation	VALSPODAR	targetBased	3	Completed	01/11/2000	https://clinicaltrials.gov/study/NCT00006363	0.7	LoF	protect
qHTS assay for MDR1-selective chemotherapeutics: Primary screen using the parental adenocarcinoma cell KB-3-1	MDR1-selective compounds	ABCB1	ATP-binding cassette, sub-family B , ATP-dependent translocase ABCB1	childhood acute myeloid leukemia with maturation	VALSPODAR	targetBased	3	Completed	01/11/2000	https://clinicaltrials.gov/study/NCT00006363	0.7	LoF	protect
qHTS assay for MDR1-selective chemotherapeutics: Primary screen using the drug-selected MDR subline cells KB-V1	MDR1-selective compounds	ABCB1	ATP-binding cassette, sub-family B , ATP-dependent translocase ABCB1	childhood acute myeloid leukemia	VALSPODAR	targetBased	3	Completed	01/11/2000	https://clinicaltrials.gov/study/NCT00006363	0.7	LoF	protect
qHTS assay for MDR1-selective chemotherapeutics: Primary screen using the parental adenocarcinoma cell KB-3-1	MDR1-selective compounds	ABCB1	ATP-binding cassette, sub-family B , ATP-dependent translocase ABCB1	childhood acute myeloid leukemia	VALSPODAR	targetBased	3	Completed	01/11/2000	https://clinicaltrials.gov/study/NCT00006363	0.7	LoF	protect
qHTS assay for MDR1-selective chemotherapeutics: Primary screen using the drug-selected MDR subline cells KB-V1	MDR1-selective compounds	ABCB1	ATP-binding cassette, sub-family B , ATP-dependent translocase ABCB1	myeloproliferative disorder	VALSPODAR	targetBased	3	Completed	01/12/1998	https://clinicaltrials.gov/study/NCT00005823	0.7	LoF	protect
qHTS assay for MDR1-selective chemotherapeutics: Primary screen using the parental adenocarcinoma cell KB-3-1	MDR1-selective compounds	ABCB1	ATP-binding cassette, sub-family B , ATP-dependent translocase ABCB1	myeloproliferative disorder	VALSPODAR	targetBased	3	Completed	01/12/1998	https://clinicaltrials.gov/study/NCT00005823	0.7	LoF	protect
qHTS assay for MDR1-selective chemotherapeutics: Primary screen using the drug-selected MDR subline cells KB-V1	MDR1-selective compounds	ABCB1	ATP-binding cassette, sub-family B , ATP-dependent translocase ABCB1	leukemia	VALSPODAR	targetBased	3	Completed	01/12/1998	https://clinicaltrials.gov/study/NCT00005823	0.7	LoF	protect
qHTS assay for MDR1-selective chemotherapeutics: Primary screen using the parental adenocarcinoma cell KB-3-1	MDR1-selective compounds	ABCB1	ATP-binding cassette, sub-family B , ATP-dependent translocase ABCB1	leukemia	VALSPODAR	targetBased	3	Completed	01/12/1998	https://clinicaltrials.gov/study/NCT00005823	0.7	LoF	protect
qHTS assay for MDR1-selective chemotherapeutics: Primary screen using the drug-selected MDR subline cells KB-V1	MDR1-selective compounds	ABCB1	ATP-binding cassette, sub-family B , ATP-dependent translocase ABCB1	acute erythroleukemia	VALSPODAR	targetBased	3	Completed	01/11/2000	https://clinicaltrials.gov/study/NCT00006363	0.7	LoF	protect
qHTS assay for MDR1-selective chemotherapeutics: Primary screen using the parental adenocarcinoma cell KB-3-1	MDR1-selective compounds	ABCB1	ATP-binding cassette, sub-family B , ATP-dependent translocase ABCB1	acute erythroleukemia	VALSPODAR	targetBased	3	Completed	01/11/2000	https://clinicaltrials.gov/study/NCT00006363	0.7	LoF	protect
qHTS assay for MDR1-selective chemotherapeutics: Primary screen using the drug-selected MDR subline cells KB-V1	MDR1-selective compounds	ABCB1	ATP-binding cassette, sub-family B , ATP-dependent translocase ABCB1	acute erythroleukemia	VALSPODAR	targetBased	3	Completed	01/01/1998	https://clinicaltrials.gov/study/NCT00003190	0.7	LoF	protect
qHTS assay for MDR1-selective chemotherapeutics: Primary screen using the parental adenocarcinoma cell KB-3-1	MDR1-selective compounds	ABCB1	ATP-binding cassette, sub-family B , ATP-dependent translocase ABCB1	acute erythroleukemia	VALSPODAR	targetBased	3	Completed	01/01/1998	https://clinicaltrials.gov/study/NCT00003190	0.7	LoF	protect
qHTS assay for MDR1-selective chemotherapeutics: Primary screen using the drug-selected MDR subline cells KB-V1	MDR1-selective compounds	ABCB1	ATP-binding cassette, sub-family B , ATP-dependent translocase ABCB1	multiple myeloma	VALSPODAR	targetBased	3	Completed	30/06/1997	https://clinicaltrials.gov/study/NCT00002878	0.7	LoF	protect
qHTS assay for MDR1-selective chemotherapeutics: Primary screen using the parental adenocarcinoma cell KB-3-1	MDR1-selective compounds	ABCB1	ATP-binding cassette, sub-family B , ATP-dependent translocase ABCB1	multiple myeloma	VALSPODAR	targetBased	3	Completed	30/06/1997	https://clinicaltrials.gov/study/NCT00002878	0.7	LoF	protect
qHTS assay for MDR1-selective chemotherapeutics: Primary screen using the drug-selected MDR subline cells KB-V1	MDR1-selective compounds	ABCB1	ATP-binding cassette, sub-family B , ATP-dependent translocase ABCB1	acute monocytic leukemia	VALSPODAR	targetBased	3	Completed	01/01/1998	https://clinicaltrials.gov/study/NCT00003190	0.7	LoF	protect
qHTS assay for MDR1-selective chemotherapeutics: Primary screen using the parental adenocarcinoma cell KB-3-1	MDR1-selective compounds	ABCB1	ATP-binding cassette, sub-family B , ATP-dependent translocase ABCB1	acute monocytic leukemia	VALSPODAR	targetBased	3	Completed	01/01/1998	https://clinicaltrials.gov/study/NCT00003190	0.7	LoF	protect
qHTS assay for MDR1-selective chemotherapeutics: Primary screen using the drug-selected MDR subline cells KB-V1	MDR1-selective compounds	ABCB1	ATP-binding cassette, sub-family B , ATP-dependent translocase ABCB1	acute monocytic leukemia	VALSPODAR	targetBased	3	Completed	01/11/2000	https://clinicaltrials.gov/study/NCT00006363	0.7	LoF	protect
qHTS assay for MDR1-selective chemotherapeutics: Primary screen using the parental adenocarcinoma cell KB-3-1	MDR1-selective compounds	ABCB1	ATP-binding cassette, sub-family B , ATP-dependent translocase ABCB1	acute monocytic leukemia	VALSPODAR	targetBased	3	Completed	01/11/2000	https://clinicaltrials.gov/study/NCT00006363	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	PONATINIB	targetBased	3	Terminated	31/12/2015	https://clinicaltrials.gov/study/NCT02627677	0.7	LoF	protect	The study was stopped due to operational feasibility and not due to any safety concerns
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	PONATINIB	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=16d804b6-4957-43ee-b18c-3b36ec37c5ac	1	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	PONATINIB	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=807f988e-117b-4497-934d-73aa78baac71	1	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	PONATINIB	targetBased	3	Terminated	01/06/2012	https://clinicaltrials.gov/study/NCT01650805	0.35	LoF	protect	Study terminated based on evaluation of safety data.
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	acute lymphoblastic leukemia	PONATINIB	targetBased	3	Active, not recruiting	04/10/2018	https://clinicaltrials.gov/study/NCT03589326	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	acute lymphoblastic leukemia	PONATINIB	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=807f988e-117b-4497-934d-73aa78baac71	1	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	acute lymphoblastic leukemia	PONATINIB	targetBased	3	Recruiting	08/09/2021	https://clinicaltrials.gov/study/NCT04722848	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	neoplasm	PONATINIB	targetBased	3			https://www.whocc.no/atc_ddd_index/?code=L01EA05	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	lymphoid leukemia	PONATINIB	targetBased	3	Recruiting	25/01/2021	https://clinicaltrials.gov/study/NCT04530565	0.7	LoF	protect
HTS for Tumor Hsp90 Inhibitors	HSP90 known inhibitor displacement	HSP90AA1	Heat shock protein HSP 90-alpha	gastrointestinal stromal tumor	RETASPIMYCIN	targetBased	3	Terminated	01/08/2008	https://clinicaltrials.gov/study/NCT00688766	0.35	LoF	protect	Based on Independent Data Monitoring Committee (IDMC) recommendation.
Luminescence-based primary biochemical high throughput screening assay to identify inhibitors of the Heat Shock Protein 90 (HSP90)	HSP90AA1	HSP90AA1	Full-length cDNA 5-PRIME end of clone CS0DN005YI08 of Adult brain of Homo sapiens , Heat shock protein HSP 90-alpha, Heat shock protein HSP 90-alpha	gastrointestinal stromal tumor	RETASPIMYCIN	targetBased	3	Terminated	01/08/2008	https://clinicaltrials.gov/study/NCT00688766	0.35	LoF	protect	Based on Independent Data Monitoring Committee (IDMC) recommendation.
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pancreatic carcinoma	METHYLNALTREXONE	targetBased	3	Withdrawn	03/02/2020	https://clinicaltrials.gov/study/NCT04151719	0.7	LoF	protect	Due to pandemic challenges and consideration of a different study design in the future.
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pancreatic carcinoma	METHYLNALTREXONE	targetBased	3	Withdrawn	03/02/2020	https://clinicaltrials.gov/study/NCT04151719	0.7	LoF	protect	Due to pandemic challenges and consideration of a different study design in the future.
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	head and neck squamous cell carcinoma	METHYLNALTREXONE	targetBased	4	Recruiting	10/01/2024	https://clinicaltrials.gov/study/NCT06162377	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	head and neck squamous cell carcinoma	METHYLNALTREXONE	targetBased	4	Recruiting	10/01/2024	https://clinicaltrials.gov/study/NCT06162377	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	head and neck malignant neoplasia	PILOCARPINE HYDROCHLORIDE	targetBased	3	Completed	01/04/2002	https://clinicaltrials.gov/study/NCT00168181	0.7	GoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	head and neck malignant neoplasia	PILOCARPINE HYDROCHLORIDE	targetBased	3	Completed	01/04/2002	https://clinicaltrials.gov/study/NCT00168181	0.7	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	head and neck malignant neoplasia	PILOCARPINE HYDROCHLORIDE	targetBased	3	Completed	01/04/2002	https://clinicaltrials.gov/study/NCT00168181	0.7	GoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	head and neck malignant neoplasia	PILOCARPINE HYDROCHLORIDE	targetBased	3	Completed	01/04/2002	https://clinicaltrials.gov/study/NCT00168181	0.7	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	head and neck malignant neoplasia	PILOCARPINE HYDROCHLORIDE	targetBased	3	Completed	01/04/2002	https://clinicaltrials.gov/study/NCT00168181	0.7	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	adenoma	BROMOCRIPTINE MESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fc2a08dd-4fb6-4ac4-9082-f99552fae25c	1	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	adenoma	BROMOCRIPTINE MESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fc2a08dd-4fb6-4ac4-9082-f99552fae25c	1	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	adenoma	BROMOCRIPTINE MESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fc2a08dd-4fb6-4ac4-9082-f99552fae25c	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	adenoma	BROMOCRIPTINE MESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fc2a08dd-4fb6-4ac4-9082-f99552fae25c	1	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	adenoma	BROMOCRIPTINE MESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fc2a08dd-4fb6-4ac4-9082-f99552fae25c	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	adenoma	BROMOCRIPTINE MESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fc2a08dd-4fb6-4ac4-9082-f99552fae25c	1	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	adenoma	BROMOCRIPTINE MESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fc2a08dd-4fb6-4ac4-9082-f99552fae25c	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	adenoma	BROMOCRIPTINE MESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fc2a08dd-4fb6-4ac4-9082-f99552fae25c	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	adenoma	BROMOCRIPTINE MESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fc2a08dd-4fb6-4ac4-9082-f99552fae25c	1	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	neoplasm	DIETHYLSTILBESTROL DIPHOSPHATE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=L02AA04	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	neoplasm	DIETHYLSTILBESTROL DIPHOSPHATE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=L02AA04	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	neoplasm	DIETHYLSTILBESTROL DIPHOSPHATE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=L02AA04	1	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	breast carcinoma	TOREMIFENE CITRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2cab8dd1-3a10-48e6-86ce-0e5275ed49e5	1		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	breast carcinoma	TOREMIFENE CITRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a6ff9761-7442-4bff-9e50-858c03e27fd0	1		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	breast carcinoma in situ	TOREMIFENE CITRATE	targetBased	4	Withdrawn	01/09/2018	https://clinicaltrials.gov/study/NCT03238703	1		protect	Administrative closure based on sponsor recommendation, prior to subject enrollment
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast carcinoma in situ	TOREMIFENE CITRATE	targetBased	4	Withdrawn	01/09/2018	https://clinicaltrials.gov/study/NCT03238703	1		protect	Administrative closure based on sponsor recommendation, prior to subject enrollment
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast carcinoma in situ	TOREMIFENE CITRATE	targetBased	4	Withdrawn	01/09/2018	https://clinicaltrials.gov/study/NCT03238703	1		protect	Administrative closure based on sponsor recommendation, prior to subject enrollment
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TOREMIFENE CITRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2cab8dd1-3a10-48e6-86ce-0e5275ed49e5	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TOREMIFENE CITRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2cab8dd1-3a10-48e6-86ce-0e5275ed49e5	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TOREMIFENE CITRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0b3ebaa6-9cbe-405e-8f14-14ce8dcd2a68	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	TOREMIFENE CITRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0b3ebaa6-9cbe-405e-8f14-14ce8dcd2a68	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast carcinoma	TOREMIFENE CITRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a6ff9761-7442-4bff-9e50-858c03e27fd0	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast carcinoma	TOREMIFENE CITRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a6ff9761-7442-4bff-9e50-858c03e27fd0	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast carcinoma	TOREMIFENE CITRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2cab8dd1-3a10-48e6-86ce-0e5275ed49e5	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast carcinoma	TOREMIFENE CITRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2cab8dd1-3a10-48e6-86ce-0e5275ed49e5	1		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	breast cancer	TOREMIFENE CITRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2cab8dd1-3a10-48e6-86ce-0e5275ed49e5	1		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	breast cancer	TOREMIFENE CITRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0b3ebaa6-9cbe-405e-8f14-14ce8dcd2a68	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	Pituitary Gland Adenoma	SEVOFLURANE	targetBased	4	Recruiting	03/05/2023	https://clinicaltrials.gov/study/NCT05822817	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	hepatocellular carcinoma	SEVOFLURANE	targetBased	4	Recruiting	26/04/2022	https://clinicaltrials.gov/study/NCT05331911	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	breast neoplasm	SEVOFLURANE	targetBased	4	Completed	01/03/2007	https://clinicaltrials.gov/study/NCT00575354	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	cancer	SEVOFLURANE	targetBased	3	Withdrawn	01/11/2007	https://clinicaltrials.gov/study/NCT00531349	0.7		protect	Lack of study population
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	cancer	SEVOFLURANE	targetBased	4	Recruiting	11/01/2021	https://clinicaltrials.gov/study/NCT04475705	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	esophageal cancer	SEVOFLURANE	targetBased	3	Recruiting	15/08/2020	https://clinicaltrials.gov/study/NCT04513808	0.7		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	ovarian cancer	SEVOFLURANE	targetBased	4	Recruiting	23/11/2022	https://clinicaltrials.gov/study/NCT05606692	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	female breast carcinoma	SEVOFLURANE	targetBased	4	Completed	01/03/2014	https://clinicaltrials.gov/study/NCT02005770	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	Pituitary Gland Adenoma	SEVOFLURANE	targetBased	4	Recruiting	03/05/2023	https://clinicaltrials.gov/study/NCT05822817	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	female breast carcinoma	SEVOFLURANE	targetBased	4	Completed	01/03/2014	https://clinicaltrials.gov/study/NCT02005770	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	neoplasm	SEVOFLURANE	targetBased	4	Recruiting	11/01/2021	https://clinicaltrials.gov/study/NCT04475705	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	neoplasm	SEVOFLURANE	targetBased	4	Completed	01/04/2015	https://clinicaltrials.gov/study/NCT02660411	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	brain neoplasm	SEVOFLURANE	targetBased	4	Recruiting	18/02/2022	https://clinicaltrials.gov/study/NCT05141877	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	esophageal cancer	SEVOFLURANE	targetBased	3	Recruiting	15/08/2020	https://clinicaltrials.gov/study/NCT04513808	0.7		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	brain neoplasm	SEVOFLURANE	targetBased	4	Recruiting	18/02/2022	https://clinicaltrials.gov/study/NCT05141877	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	kidney cancer	SEVOFLURANE	targetBased	4	Completed	14/05/2018	https://clinicaltrials.gov/study/NCT03514550	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	carcinoma	SEVOFLURANE	targetBased	4	Recruiting	11/01/2021	https://clinicaltrials.gov/study/NCT04475705	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	cancer	SEVOFLURANE	targetBased	3	Withdrawn	01/11/2007	https://clinicaltrials.gov/study/NCT00531349	0.7		protect	Lack of study population
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	cancer	SEVOFLURANE	targetBased	4	Recruiting	11/01/2021	https://clinicaltrials.gov/study/NCT04475705	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	neoplasm	SEVOFLURANE	targetBased	4	Completed	01/04/2015	https://clinicaltrials.gov/study/NCT02660411	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	neoplasm	SEVOFLURANE	targetBased	4	Recruiting	11/01/2021	https://clinicaltrials.gov/study/NCT04475705	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	kidney cancer	SEVOFLURANE	targetBased	4	Completed	14/05/2018	https://clinicaltrials.gov/study/NCT03514550	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	carcinoma	SEVOFLURANE	targetBased	4	Recruiting	11/01/2021	https://clinicaltrials.gov/study/NCT04475705	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	breast neoplasm	SEVOFLURANE	targetBased	4	Completed	01/03/2007	https://clinicaltrials.gov/study/NCT00575354	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	hepatocellular carcinoma	SEVOFLURANE	targetBased	4	Recruiting	26/04/2022	https://clinicaltrials.gov/study/NCT05331911	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	lung cancer	SEVOFLURANE	targetBased	4	Recruiting	27/12/2022	https://clinicaltrials.gov/study/NCT05663242	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	lung cancer	SEVOFLURANE	targetBased	4	Recruiting	27/12/2022	https://clinicaltrials.gov/study/NCT05663242	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	ovarian cancer	SEVOFLURANE	targetBased	4	Recruiting	23/11/2022	https://clinicaltrials.gov/study/NCT05606692	1		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	prostate cancer	ESTRAMUSTINE PHOSPHATE SODIUM	targetBased	3	Completed	14/11/2002	https://clinicaltrials.gov/study/NCT00055731	0.7		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	prostate cancer	ESTRAMUSTINE PHOSPHATE SODIUM	targetBased	3	Completed	08/10/2003	https://clinicaltrials.gov/study/NCT00027859	0.7		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	prostate cancer	ESTRAMUSTINE PHOSPHATE SODIUM	targetBased	3	Completed	01/10/2002	https://clinicaltrials.gov/study/NCT00030654	0.7		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	prostate cancer	ESTRAMUSTINE PHOSPHATE SODIUM	targetBased	3	Terminated	01/04/2002	https://clinicaltrials.gov/study/NCT00024167	0.7		protect	Terminated due to slow accrual
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	prostate cancer	ESTRAMUSTINE PHOSPHATE SODIUM	targetBased	3	Completed	01/08/1996	https://clinicaltrials.gov/study/NCT00002855	0.7		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	prostate cancer	ESTRAMUSTINE PHOSPHATE SODIUM	targetBased	3	Completed	01/01/2000	https://clinicaltrials.gov/study/NCT00004054	0.7		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	carcinoma	ESTRAMUSTINE PHOSPHATE SODIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a9b01bc6-95ac-46f9-befa-d845a74d53c1	1		protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	small cell carcinoma	GUANIDINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=903fbd33-e5d9-41fb-9414-7bd6f42a8593	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	small cell carcinoma	GUANIDINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=903fbd33-e5d9-41fb-9414-7bd6f42a8593	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	small cell carcinoma	GUANIDINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=903fbd33-e5d9-41fb-9414-7bd6f42a8593	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	small cell carcinoma	GUANIDINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=903fbd33-e5d9-41fb-9414-7bd6f42a8593	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	small cell carcinoma	GUANIDINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=903fbd33-e5d9-41fb-9414-7bd6f42a8593	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	small cell carcinoma	GUANIDINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=903fbd33-e5d9-41fb-9414-7bd6f42a8593	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	small cell carcinoma	GUANIDINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=903fbd33-e5d9-41fb-9414-7bd6f42a8593	1	LoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	hepatocellular carcinoma	CHLOROTRIANISENE	targetBased	4	Unknown status	01/04/2010	https://clinicaltrials.gov/study/NCT01102335	1		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	hepatocellular carcinoma	CHLOROTRIANISENE	targetBased	4	Completed	01/04/2011	https://clinicaltrials.gov/study/NCT01332669	1		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	hepatocellular carcinoma	CHLOROTRIANISENE	targetBased	3	Unknown status	01/08/2016	https://clinicaltrials.gov/study/NCT02856126	0.7		protect
qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium	IMPA1	IMPA1	Inositol monophosphatase 1	osteosarcoma	LITHIUM CARBONATE	targetBased	4	Recruiting	01/01/2013	https://clinicaltrials.gov/study/NCT01669369	1	LoF	protect
Luminescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha	GSK3A	GSK3A	Glycogen synthase kinase-3 alpha	osteosarcoma	LITHIUM CARBONATE	targetBased	4	Recruiting	01/01/2013	https://clinicaltrials.gov/study/NCT01669369	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hemangioma	TIMOLOL MALEATE	targetBased	4	Recruiting	01/10/2019	https://clinicaltrials.gov/study/NCT04288700	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hemangioma	TIMOLOL MALEATE	targetBased	3	Completed	01/09/2012	https://clinicaltrials.gov/study/NCT01685398	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	cancer	METOCLOPRAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=94e5acdf-f19c-749a-e053-2995a90ae451	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	cancer	METOCLOPRAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=94e5acdf-f19c-749a-e053-2995a90ae451	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	cancer	METOCLOPRAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=94e5acdf-f19c-749a-e053-2995a90ae451	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	cancer	METOCLOPRAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=94e5acdf-f19c-749a-e053-2995a90ae451	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	cancer	METOCLOPRAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=94e5acdf-f19c-749a-e053-2995a90ae451	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	cancer	METOCLOPRAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=94e5acdf-f19c-749a-e053-2995a90ae451	1	LoF	protect
qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS	TXNRD1	TXNRD1	Thioredoxin reductase 1, cytoplasmic	myelodysplastic syndrome	ARSENIC TRIOXIDE	targetBased	3	Withdrawn	20/03/2018	https://clinicaltrials.gov/study/NCT03377725	0.7	LoF	protect	No patient was involved.
qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS	TXNRD1	TXNRD1	Thioredoxin reductase 1, cytoplasmic	acute promyelocytic leukemia	ARSENIC TRIOXIDE	targetBased	4	Completed	01/09/2011	https://clinicaltrials.gov/study/NCT02200978	1	LoF	protect
qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS	TXNRD1	TXNRD1	Thioredoxin reductase 1, cytoplasmic	acute promyelocytic leukemia	ARSENIC TRIOXIDE	targetBased	4	Completed	01/07/2007	https://clinicaltrials.gov/study/NCT00504764	1	LoF	protect
qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS	TXNRD1	TXNRD1	Thioredoxin reductase 1, cytoplasmic	acute promyelocytic leukemia	ARSENIC TRIOXIDE	targetBased	3	Unknown status	01/10/2006	https://clinicaltrials.gov/study/NCT00378365	0.7	LoF	protect
qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS	TXNRD1	TXNRD1	Thioredoxin reductase 1, cytoplasmic	acute promyelocytic leukemia	ARSENIC TRIOXIDE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/arsenic-trioxide-mylan	1	LoF	protect
qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS	TXNRD1	TXNRD1	Thioredoxin reductase 1, cytoplasmic	acute promyelocytic leukemia	ARSENIC TRIOXIDE	targetBased	3	Active, not recruiting	01/06/2016	https://clinicaltrials.gov/study/NCT02688140	0.7	LoF	protect
qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS	TXNRD1	TXNRD1	Thioredoxin reductase 1, cytoplasmic	acute promyelocytic leukemia	ARSENIC TRIOXIDE	targetBased	3	Unknown status	01/09/2016	https://clinicaltrials.gov/study/NCT02899169	0.7	LoF	protect
qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS	TXNRD1	TXNRD1	Thioredoxin reductase 1, cytoplasmic	acute promyelocytic leukemia	ARSENIC TRIOXIDE	targetBased	4	Unknown status	01/01/2005	https://clinicaltrials.gov/study/NCT00196768	1	LoF	protect
qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS	TXNRD1	TXNRD1	Thioredoxin reductase 1, cytoplasmic	acute promyelocytic leukemia	ARSENIC TRIOXIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dec51fab-3784-deb7-752f-2d4d5692a20f	1	LoF	protect
qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS	TXNRD1	TXNRD1	Thioredoxin reductase 1, cytoplasmic	acute promyelocytic leukemia	ARSENIC TRIOXIDE	targetBased	3	Completed	09/03/2009	https://clinicaltrials.gov/study/NCT00866918	0.7	LoF	protect
qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS	TXNRD1	TXNRD1	Thioredoxin reductase 1, cytoplasmic	acute promyelocytic leukemia	ARSENIC TRIOXIDE	targetBased	3	Completed	01/06/1999	https://clinicaltrials.gov/study/NCT00003934	0.7	LoF	protect
qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS	TXNRD1	TXNRD1	Thioredoxin reductase 1, cytoplasmic	leukemia	ARSENIC TRIOXIDE	targetBased	3	Completed	01/08/2007	https://clinicaltrials.gov/study/NCT00482833	0.7	LoF	protect
qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS	TXNRD1	TXNRD1	Thioredoxin reductase 1, cytoplasmic	neoplasm	ARSENIC TRIOXIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=L01XX27	1	LoF	protect
qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS	TXNRD1	TXNRD1	Thioredoxin reductase 1, cytoplasmic	acute myeloid leukemia	ARSENIC TRIOXIDE	targetBased	3	Terminated	01/10/2007	https://clinicaltrials.gov/study/NCT00513305	0.7	LoF	protect	Study has been stopped by sponsor decision
qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS	TXNRD1	TXNRD1	Thioredoxin reductase 1, cytoplasmic	myeloid neoplasm	ARSENIC TRIOXIDE	targetBased	3	Completed	09/03/2009	https://clinicaltrials.gov/study/NCT00866918	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	urinary bladder cancer	GLYCOPYRROLATE	targetBased	4	Completed	18/09/2017	https://clinicaltrials.gov/study/NCT03138967	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	urinary bladder cancer	GLYCOPYRROLATE	targetBased	4	Completed	18/09/2017	https://clinicaltrials.gov/study/NCT03138967	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	urinary bladder cancer	GLYCOPYRROLATE	targetBased	4	Completed	18/09/2017	https://clinicaltrials.gov/study/NCT03138967	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	urinary bladder cancer	GLYCOPYRROLATE	targetBased	4	Completed	18/09/2017	https://clinicaltrials.gov/study/NCT03138967	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	urinary bladder cancer	GLYCOPYRROLATE	targetBased	4	Completed	18/09/2017	https://clinicaltrials.gov/study/NCT03138967	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	hypothalamic neoplasm	CABERGOLINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=74b61e8a-7ae9-4996-85ec-df23c56de16f	1	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	hypothalamic neoplasm	CABERGOLINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=74b61e8a-7ae9-4996-85ec-df23c56de16f	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	hypothalamic neoplasm	CABERGOLINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=74b61e8a-7ae9-4996-85ec-df23c56de16f	1	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	hypothalamic neoplasm	CABERGOLINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=74b61e8a-7ae9-4996-85ec-df23c56de16f	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	hypothalamic neoplasm	CABERGOLINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=74b61e8a-7ae9-4996-85ec-df23c56de16f	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	hypothalamic neoplasm	CABERGOLINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=74b61e8a-7ae9-4996-85ec-df23c56de16f	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	non-functioning pituitary adenoma	CABERGOLINE	targetBased	3	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT03271918	0.7	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	non-functioning pituitary adenoma	CABERGOLINE	targetBased	3	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT03271918	0.7	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	non-functioning pituitary adenoma	CABERGOLINE	targetBased	3	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT03271918	0.7	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	non-functioning pituitary adenoma	CABERGOLINE	targetBased	3	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT03271918	0.7	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	non-functioning pituitary adenoma	CABERGOLINE	targetBased	3	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT03271918	0.7	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	non-functioning pituitary adenoma	CABERGOLINE	targetBased	3	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT03271918	0.7	GoF	protect
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	THRB	Thyroid hormone receptor beta	differentiated thyroid carcinoma	LIOTHYRONINE SODIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=51452b31-ff68-4e0c-b982-c15502ebf1d3	1	GoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	unspecified peripheral T-cell lymphoma	DECITABINE	targetBased	3	Not yet recruiting	01/06/2018	https://clinicaltrials.gov/study/NCT03553537	0.7	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	myeloproliferative disorder	DECITABINE	targetBased	3	Unknown status	01/05/2002	https://clinicaltrials.gov/study/NCT00043134	0.7	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	chronic myelomonocytic leukemia	DECITABINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=99cea19b-cabf-8a6d-b2ef-f04920952b93	1	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	chronic myelomonocytic leukemia	DECITABINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=deb4a13c-855b-4372-9778-6e81da598df6	1	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	chronic myelomonocytic leukemia	DECITABINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c155d6ba-9a16-406c-919e-65a149689ab9	1	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	chronic myelomonocytic leukemia	DECITABINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0b9599e8-9018-42ee-b247-e2a944c36510	1	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	chronic myelomonocytic leukemia	DECITABINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4e1f4eb4-19b2-eee8-3402-bd2ccf622791	1	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	chronic myelomonocytic leukemia	DECITABINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=acaf6e50-7cd3-4431-98ef-d1c07e3ed8c2	1	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	chronic myelomonocytic leukemia	DECITABINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=358764ca-4c69-d516-af0c-bf8a348d26ca	1	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	diffuse large B-cell lymphoma	DECITABINE	targetBased	3	Recruiting	01/06/2022	https://clinicaltrials.gov/study/NCT05351346	0.7	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	diffuse large B-cell lymphoma	DECITABINE	targetBased	4	Unknown status	01/06/2018	https://clinicaltrials.gov/study/NCT03579082	1	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	neoplasm	DECITABINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=L01BC08	1	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	refractory anemia with excess blasts	DECITABINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c155d6ba-9a16-406c-919e-65a149689ab9	1	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	refractory anemia with excess blasts	DECITABINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4e1f4eb4-19b2-eee8-3402-bd2ccf622791	1	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	refractory anemia with excess blasts	DECITABINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=99cea19b-cabf-8a6d-b2ef-f04920952b93	1	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	refractory anemia with excess blasts	DECITABINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=358764ca-4c69-d516-af0c-bf8a348d26ca	1	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	refractory anemia with excess blasts	DECITABINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0b9599e8-9018-42ee-b247-e2a944c36510	1	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	refractory anemia with excess blasts	DECITABINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=deb4a13c-855b-4372-9778-6e81da598df6	1	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	refractory anemia with excess blasts	DECITABINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=acaf6e50-7cd3-4431-98ef-d1c07e3ed8c2	1	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	T-lymphoblastic lymphoma	DECITABINE	targetBased	4	Unknown status	01/06/2018	https://clinicaltrials.gov/study/NCT03558412	1	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	myelodysplastic syndrome	DECITABINE	targetBased	3	Unknown status	01/05/2002	https://clinicaltrials.gov/study/NCT00043134	0.7	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	myelodysplastic syndrome	DECITABINE	targetBased	3	Completed	14/10/2014	https://clinicaltrials.gov/study/NCT02214407	0.7	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	myelodysplastic syndrome	DECITABINE	targetBased	3	Completed	01/08/2009	https://clinicaltrials.gov/study/NCT01751867	0.7	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	myelodysplastic syndrome	DECITABINE	targetBased	4	Unknown status	01/09/2009	https://clinicaltrials.gov/study/NCT01806116	1	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	myelodysplastic syndrome	DECITABINE	targetBased	3	Completed	15/02/2018	https://clinicaltrials.gov/study/NCT03306264	0.7	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	myelodysplastic syndrome	DECITABINE	targetBased	3	Withdrawn	20/03/2018	https://clinicaltrials.gov/study/NCT03377725	0.7	LoF	protect	No patient was involved.
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	myelodysplastic syndrome	DECITABINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4e1f4eb4-19b2-eee8-3402-bd2ccf622791	1	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	myelodysplastic syndrome	DECITABINE	targetBased	3	Completed	01/04/2001	https://clinicaltrials.gov/study/NCT00043381	0.7	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	myelodysplastic syndrome	DECITABINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=99cea19b-cabf-8a6d-b2ef-f04920952b93	1	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	myelodysplastic syndrome	DECITABINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=deb4a13c-855b-4372-9778-6e81da598df6	1	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	myelodysplastic syndrome	DECITABINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c155d6ba-9a16-406c-919e-65a149689ab9	1	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	myelodysplastic syndrome	DECITABINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=acaf6e50-7cd3-4431-98ef-d1c07e3ed8c2	1	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	myelodysplastic syndrome	DECITABINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0b9599e8-9018-42ee-b247-e2a944c36510	1	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	myelodysplastic syndrome	DECITABINE	targetBased	4	Unknown status	01/03/2013	https://clinicaltrials.gov/study/NCT02013102	1	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	myelodysplastic syndrome	DECITABINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=358764ca-4c69-d516-af0c-bf8a348d26ca	1	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	myelodysplastic syndrome	DECITABINE	targetBased	4	Terminated	01/11/2009	https://clinicaltrials.gov/study/NCT01011283	1	LoF	protect	The study was stopped due to insufficient enrollment.
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	myelodysplastic syndrome	DECITABINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=91a0f80b-f865-4d06-a40d-4d148d99ee71	1	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	acute myeloid leukemia	DECITABINE	targetBased	3	Recruiting	03/03/2023	https://clinicaltrials.gov/study/NCT05586074	0.7	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	acute myeloid leukemia	DECITABINE	targetBased	3	Completed	15/08/2019	https://clinicaltrials.gov/study/NCT03941964	0.7	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	acute myeloid leukemia	DECITABINE	targetBased	3	Completed	01/11/2005	https://clinicaltrials.gov/study/NCT00260832	0.7	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	acute myeloid leukemia	DECITABINE	targetBased	3	Active, not recruiting	28/11/2014	https://clinicaltrials.gov/study/NCT02172872	0.7	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	acute myeloid leukemia	DECITABINE	targetBased	3	Recruiting	01/04/2019	https://clinicaltrials.gov/study/NCT04083911	0.7	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	acute myeloid leukemia	DECITABINE	targetBased	3	Not yet recruiting	01/11/2023	https://clinicaltrials.gov/study/NCT06073730	0.7	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	acute myeloid leukemia	DECITABINE	targetBased	3	Recruiting	22/11/2019	https://clinicaltrials.gov/study/NCT03926624	0.7	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	acute myeloid leukemia	DECITABINE	targetBased	3	Unknown status	01/05/2012	https://clinicaltrials.gov/study/NCT01633099	0.7	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	acute myeloid leukemia	DECITABINE	targetBased	3	Unknown status	01/12/2016	https://clinicaltrials.gov/study/NCT02985372	0.7	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	acute myeloid leukemia	DECITABINE	targetBased	3	Completed	15/02/2018	https://clinicaltrials.gov/study/NCT03306264	0.7	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	acute myeloid leukemia	DECITABINE	targetBased	3	Not yet recruiting	01/06/2024	https://clinicaltrials.gov/study/NCT06297772	0.7	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	acute myeloid leukemia	DECITABINE	targetBased	3	Terminated	01/05/2016	https://clinicaltrials.gov/study/NCT02785900	0.35	LoF	protect	Due to safety; specifically a higher rate of deaths, including fatal infections, in the SGN33A arm versus the control arm
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	acute myeloid leukemia	DECITABINE	targetBased	3	Recruiting	01/03/2021	https://clinicaltrials.gov/study/NCT05264883	0.7	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	acute myeloid leukemia	DECITABINE	targetBased	3	Active, not recruiting	01/03/2022	https://clinicaltrials.gov/study/NCT05177731	0.7	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	acute myeloid leukemia	DECITABINE	targetBased	4	Unknown status	01/09/2009	https://clinicaltrials.gov/study/NCT01806116	1	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	acute myeloid leukemia	DECITABINE	targetBased	3	Active, not recruiting	08/02/2021	https://clinicaltrials.gov/study/NCT04229979	0.7	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	acute myeloid leukemia	DECITABINE	targetBased	3	Recruiting	21/01/2022	https://clinicaltrials.gov/study/NCT05382390	0.7	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	acute myeloid leukemia	DECITABINE	targetBased	4	Active, not recruiting	01/01/2017	https://clinicaltrials.gov/study/NCT03026842	1	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	acute myeloid leukemia	DECITABINE	targetBased	3	Completed	01/10/2011	https://clinicaltrials.gov/study/NCT01303796	0.7	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	myeloid leukemia	DECITABINE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/dacogen	1	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	cancer	DECITABINE	targetBased	3	Recruiting	21/01/2020	https://clinicaltrials.gov/study/NCT04292769	0.7	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	leukemia	DECITABINE	targetBased	3	Unknown status	01/05/2002	https://clinicaltrials.gov/study/NCT00043134	0.7	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	leukemia	DECITABINE	targetBased	3	Recruiting	01/01/2011	https://clinicaltrials.gov/study/NCT01041703	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	acute myeloid leukemia	NALBUPHINE HYDROCHLORIDE	targetBased	3	Completed	01/02/2018	https://clinicaltrials.gov/study/NCT03825887	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	acute myeloid leukemia	NALBUPHINE HYDROCHLORIDE	targetBased	3	Completed	01/02/2018	https://clinicaltrials.gov/study/NCT03825887	0.7	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	childhood acute lymphoblastic leukemia	NALBUPHINE HYDROCHLORIDE	targetBased	4	Completed	25/03/2021	https://clinicaltrials.gov/study/NCT05176119	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	acute myeloid leukemia	NALBUPHINE HYDROCHLORIDE	targetBased	3	Completed	01/02/2018	https://clinicaltrials.gov/study/NCT03825887	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	leukemia	NALBUPHINE HYDROCHLORIDE	targetBased	3	Completed	01/02/2018	https://clinicaltrials.gov/study/NCT03825887	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	leukemia	NALBUPHINE HYDROCHLORIDE	targetBased	3	Completed	01/02/2018	https://clinicaltrials.gov/study/NCT03825887	0.7	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	leukemia	NALBUPHINE HYDROCHLORIDE	targetBased	3	Completed	01/02/2018	https://clinicaltrials.gov/study/NCT03825887	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	childhood acute lymphoblastic leukemia	NALBUPHINE HYDROCHLORIDE	targetBased	4	Completed	25/03/2021	https://clinicaltrials.gov/study/NCT05176119	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	childhood acute lymphoblastic leukemia	NALBUPHINE HYDROCHLORIDE	targetBased	4	Completed	25/03/2021	https://clinicaltrials.gov/study/NCT05176119	1	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	urinary bladder cancer	GLYCOPYRRONIUM	targetBased	4	Completed	18/09/2017	https://clinicaltrials.gov/study/NCT03138967	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	urinary bladder cancer	GLYCOPYRRONIUM	targetBased	4	Completed	18/09/2017	https://clinicaltrials.gov/study/NCT03138967	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	urinary bladder cancer	GLYCOPYRRONIUM	targetBased	4	Completed	18/09/2017	https://clinicaltrials.gov/study/NCT03138967	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	urinary bladder cancer	GLYCOPYRRONIUM	targetBased	4	Completed	18/09/2017	https://clinicaltrials.gov/study/NCT03138967	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	urinary bladder cancer	GLYCOPYRRONIUM	targetBased	4	Completed	18/09/2017	https://clinicaltrials.gov/study/NCT03138967	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	urinary bladder cancer	GLYCOPYRRONIUM	targetBased	4	Completed	18/09/2017	https://clinicaltrials.gov/study/NCT03138967	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	urinary bladder cancer	GLYCOPYRRONIUM	targetBased	4	Completed	18/09/2017	https://clinicaltrials.gov/study/NCT03138967	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	urinary bladder cancer	GLYCOPYRRONIUM	targetBased	4	Completed	18/09/2017	https://clinicaltrials.gov/study/NCT03138967	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	urinary bladder cancer	GLYCOPYRRONIUM	targetBased	4	Completed	18/09/2017	https://clinicaltrials.gov/study/NCT03138967	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	urinary bladder cancer	GLYCOPYRRONIUM	targetBased	4	Completed	18/09/2017	https://clinicaltrials.gov/study/NCT03138967	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	urinary bladder cancer	GLYCOPYRRONIUM	targetBased	4	Completed	18/09/2017	https://clinicaltrials.gov/study/NCT03138967	1	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	neoplasm	POLYESTRADIOL PHOSPHATE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=L02AA02	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	neoplasm	POLYESTRADIOL PHOSPHATE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=L02AA02	1	GoF	protect
Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	TSHR	Thyrotropin receptor	head and neck malignant neoplasia	THYROTROPIN	targetBased	3	Active, not recruiting	01/11/2006	https://clinicaltrials.gov/study/NCT00415233	0.7	GoF	protect
Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	TSHR	Thyrotropin receptor	head and neck malignant neoplasia	THYROTROPIN	targetBased	3	Active, not recruiting	01/11/2006	https://clinicaltrials.gov/study/NCT00415233	0.7	GoF	protect
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor	TSHR	TSHR	Thyrotropin receptor	head and neck malignant neoplasia	THYROTROPIN	targetBased	3	Active, not recruiting	01/11/2006	https://clinicaltrials.gov/study/NCT00415233	0.7	GoF	protect
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293	TSHR	TSHR	Thyrotropin receptor	head and neck malignant neoplasia	THYROTROPIN	targetBased	3	Active, not recruiting	01/11/2006	https://clinicaltrials.gov/study/NCT00415233	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	ESTROGENS, ESTERIFIED	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e0141598-0bb2-4cf0-c9b8-6867b34bbb17	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	ESTROGENS, ESTERIFIED	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e0141598-0bb2-4cf0-c9b8-6867b34bbb17	1	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	breast cancer	ESTROGENS, ESTERIFIED	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e0141598-0bb2-4cf0-c9b8-6867b34bbb17	1	GoF	protect
Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	TSHR	Thyrotropin receptor	thyroid cancer	THYROTROPIN ALFA	targetBased	3	Completed	10/09/2021	https://clinicaltrials.gov/study/NCT04971473	0.7	GoF	protect
Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	TSHR	Thyrotropin receptor	thyroid cancer	THYROTROPIN ALFA	targetBased	3	Completed	10/09/2021	https://clinicaltrials.gov/study/NCT04971473	0.7	GoF	protect
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor	TSHR	TSHR	Thyrotropin receptor	thyroid cancer	THYROTROPIN ALFA	targetBased	3	Completed	10/09/2021	https://clinicaltrials.gov/study/NCT04971473	0.7	GoF	protect
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293	TSHR	TSHR	Thyrotropin receptor	thyroid cancer	THYROTROPIN ALFA	targetBased	3	Completed	10/09/2021	https://clinicaltrials.gov/study/NCT04971473	0.7	GoF	protect
Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	TSHR	Thyrotropin receptor	thyroid cancer	THYROTROPIN ALFA	targetBased	4	Completed	01/02/2008	https://clinicaltrials.gov/study/NCT00604318	1	GoF	protect
Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	TSHR	Thyrotropin receptor	thyroid cancer	THYROTROPIN ALFA	targetBased	4	Completed	01/02/2008	https://clinicaltrials.gov/study/NCT00604318	1	GoF	protect
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor	TSHR	TSHR	Thyrotropin receptor	thyroid cancer	THYROTROPIN ALFA	targetBased	4	Completed	01/02/2008	https://clinicaltrials.gov/study/NCT00604318	1	GoF	protect
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293	TSHR	TSHR	Thyrotropin receptor	thyroid cancer	THYROTROPIN ALFA	targetBased	4	Completed	01/02/2008	https://clinicaltrials.gov/study/NCT00604318	1	GoF	protect
Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	TSHR	Thyrotropin receptor	thyroid cancer	THYROTROPIN ALFA	targetBased	3	Recruiting	06/10/2021	https://clinicaltrials.gov/study/NCT04964284	0.7	GoF	protect
Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	TSHR	Thyrotropin receptor	thyroid cancer	THYROTROPIN ALFA	targetBased	3	Recruiting	06/10/2021	https://clinicaltrials.gov/study/NCT04964284	0.7	GoF	protect
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor	TSHR	TSHR	Thyrotropin receptor	thyroid cancer	THYROTROPIN ALFA	targetBased	3	Recruiting	06/10/2021	https://clinicaltrials.gov/study/NCT04964284	0.7	GoF	protect
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293	TSHR	TSHR	Thyrotropin receptor	thyroid cancer	THYROTROPIN ALFA	targetBased	3	Recruiting	06/10/2021	https://clinicaltrials.gov/study/NCT04964284	0.7	GoF	protect
Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	TSHR	Thyrotropin receptor	thyroid cancer	THYROTROPIN ALFA	targetBased	3	Completed	01/05/2006	https://clinicaltrials.gov/study/NCT00295763	0.7	GoF	protect
Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	TSHR	Thyrotropin receptor	thyroid cancer	THYROTROPIN ALFA	targetBased	3	Completed	01/05/2006	https://clinicaltrials.gov/study/NCT00295763	0.7	GoF	protect
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor	TSHR	TSHR	Thyrotropin receptor	thyroid cancer	THYROTROPIN ALFA	targetBased	3	Completed	01/05/2006	https://clinicaltrials.gov/study/NCT00295763	0.7	GoF	protect
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293	TSHR	TSHR	Thyrotropin receptor	thyroid cancer	THYROTROPIN ALFA	targetBased	3	Completed	01/05/2006	https://clinicaltrials.gov/study/NCT00295763	0.7	GoF	protect
Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	TSHR	Thyrotropin receptor	thyroid cancer	THYROTROPIN ALFA	targetBased	3	Unknown status	01/02/2007	https://clinicaltrials.gov/study/NCT00435851	0.7	GoF	protect
Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	TSHR	Thyrotropin receptor	thyroid cancer	THYROTROPIN ALFA	targetBased	3	Unknown status	01/02/2007	https://clinicaltrials.gov/study/NCT00435851	0.7	GoF	protect
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor	TSHR	TSHR	Thyrotropin receptor	thyroid cancer	THYROTROPIN ALFA	targetBased	3	Unknown status	01/02/2007	https://clinicaltrials.gov/study/NCT00435851	0.7	GoF	protect
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293	TSHR	TSHR	Thyrotropin receptor	thyroid cancer	THYROTROPIN ALFA	targetBased	3	Unknown status	01/02/2007	https://clinicaltrials.gov/study/NCT00435851	0.7	GoF	protect
Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	TSHR	Thyrotropin receptor	thyroid cancer	THYROTROPIN ALFA	targetBased	3	Active, not recruiting	13/05/2013	https://clinicaltrials.gov/study/NCT01837745	0.7	GoF	protect
Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	TSHR	Thyrotropin receptor	thyroid cancer	THYROTROPIN ALFA	targetBased	3	Active, not recruiting	13/05/2013	https://clinicaltrials.gov/study/NCT01837745	0.7	GoF	protect
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor	TSHR	TSHR	Thyrotropin receptor	thyroid cancer	THYROTROPIN ALFA	targetBased	3	Active, not recruiting	13/05/2013	https://clinicaltrials.gov/study/NCT01837745	0.7	GoF	protect
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293	TSHR	TSHR	Thyrotropin receptor	thyroid cancer	THYROTROPIN ALFA	targetBased	3	Active, not recruiting	13/05/2013	https://clinicaltrials.gov/study/NCT01837745	0.7	GoF	protect
Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	TSHR	Thyrotropin receptor	thyroid neoplasm	THYROTROPIN ALFA	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/thyrogen	1	GoF	protect
Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	TSHR	Thyrotropin receptor	thyroid neoplasm	THYROTROPIN ALFA	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/thyrogen	1	GoF	protect
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor	TSHR	TSHR	Thyrotropin receptor	thyroid neoplasm	THYROTROPIN ALFA	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/thyrogen	1	GoF	protect
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293	TSHR	TSHR	Thyrotropin receptor	thyroid neoplasm	THYROTROPIN ALFA	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/thyrogen	1	GoF	protect
Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	TSHR	Thyrotropin receptor	thyroid neoplasm	THYROTROPIN ALFA	targetBased	4	Completed	01/12/1997	https://clinicaltrials.gov/study/NCT00001730	1	GoF	protect
Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	TSHR	Thyrotropin receptor	thyroid neoplasm	THYROTROPIN ALFA	targetBased	4	Completed	01/12/1997	https://clinicaltrials.gov/study/NCT00001730	1	GoF	protect
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor	TSHR	TSHR	Thyrotropin receptor	thyroid neoplasm	THYROTROPIN ALFA	targetBased	4	Completed	01/12/1997	https://clinicaltrials.gov/study/NCT00001730	1	GoF	protect
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293	TSHR	TSHR	Thyrotropin receptor	thyroid neoplasm	THYROTROPIN ALFA	targetBased	4	Completed	01/12/1997	https://clinicaltrials.gov/study/NCT00001730	1	GoF	protect
Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	TSHR	Thyrotropin receptor	thyroid neoplasm	THYROTROPIN ALFA	targetBased	3	Completed	01/12/2001	https://clinicaltrials.gov/study/NCT00196729	0.7	GoF	protect
Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	TSHR	Thyrotropin receptor	thyroid neoplasm	THYROTROPIN ALFA	targetBased	3	Completed	01/12/2001	https://clinicaltrials.gov/study/NCT00196729	0.7	GoF	protect
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor	TSHR	TSHR	Thyrotropin receptor	thyroid neoplasm	THYROTROPIN ALFA	targetBased	3	Completed	01/12/2001	https://clinicaltrials.gov/study/NCT00196729	0.7	GoF	protect
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293	TSHR	TSHR	Thyrotropin receptor	thyroid neoplasm	THYROTROPIN ALFA	targetBased	3	Completed	01/12/2001	https://clinicaltrials.gov/study/NCT00196729	0.7	GoF	protect
Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	TSHR	Thyrotropin receptor	thyroid carcinoma	THYROTROPIN ALFA	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b52dfa36-f90b-4e19-9b5e-26db9d04df2b	1	GoF	protect
Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	TSHR	Thyrotropin receptor	thyroid carcinoma	THYROTROPIN ALFA	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b52dfa36-f90b-4e19-9b5e-26db9d04df2b	1	GoF	protect
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor	TSHR	TSHR	Thyrotropin receptor	thyroid carcinoma	THYROTROPIN ALFA	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b52dfa36-f90b-4e19-9b5e-26db9d04df2b	1	GoF	protect
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293	TSHR	TSHR	Thyrotropin receptor	thyroid carcinoma	THYROTROPIN ALFA	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b52dfa36-f90b-4e19-9b5e-26db9d04df2b	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	endometrial cancer	ESTROGENS, CONJUGATED	targetBased	3	Terminated	01/06/1997	https://clinicaltrials.gov/study/NCT00002976	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	endometrial cancer	ESTROGENS, CONJUGATED	targetBased	3	Terminated	01/06/1997	https://clinicaltrials.gov/study/NCT00002976	0.7	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	Endometrial Hyperplasia without Atypia	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/09/2005	https://clinicaltrials.gov/study/NCT00242710	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast neoplasm	ESTROGENS, CONJUGATED	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00000611	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast neoplasm	ESTROGENS, CONJUGATED	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00000611	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	colonic neoplasm	ESTROGENS, CONJUGATED	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00000611	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	colonic neoplasm	ESTROGENS, CONJUGATED	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00000611	0.7	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	endometrial cancer	ESTROGENS, CONJUGATED	targetBased	3	Terminated	01/06/1997	https://clinicaltrials.gov/study/NCT00002976	0.7	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	colonic neoplasm	ESTROGENS, CONJUGATED	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00000611	0.7	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	breast neoplasm	ESTROGENS, CONJUGATED	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00000611	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	ESTROGENS, CONJUGATED	targetBased	3	Terminated	01/07/2005	https://clinicaltrials.gov/study/NCT00193726	0.7	GoF	protect	The accrual was very slow and there were many competing studies ongoing/initiated .
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	ESTROGENS, CONJUGATED	targetBased	3	Terminated	01/07/2005	https://clinicaltrials.gov/study/NCT00193726	0.7	GoF	protect	The accrual was very slow and there were many competing studies ongoing/initiated .
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	ESTROGENS, CONJUGATED	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=751b6213-92d8-40f8-a2d5-83e8dad086dd	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	ESTROGENS, CONJUGATED	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=751b6213-92d8-40f8-a2d5-83e8dad086dd	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Endometrial Hyperplasia without Atypia	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/09/2005	https://clinicaltrials.gov/study/NCT00242710	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Endometrial Hyperplasia without Atypia	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/09/2005	https://clinicaltrials.gov/study/NCT00242710	0.7	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	breast cancer	ESTROGENS, CONJUGATED	targetBased	3	Terminated	01/07/2005	https://clinicaltrials.gov/study/NCT00193726	0.7	GoF	protect	The accrual was very slow and there were many competing studies ongoing/initiated .
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	breast cancer	ESTROGENS, CONJUGATED	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=751b6213-92d8-40f8-a2d5-83e8dad086dd	1	GoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	NILOTINIB HYDROCHLORIDE MONOHYDRATE	targetBased	3	Terminated	03/08/2017	https://clinicaltrials.gov/study/NCT03079505	0.7	LoF	protect	Protocol Deviation
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	NILOTINIB HYDROCHLORIDE MONOHYDRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6093952a-5248-45cb-ad17-33716a411146	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	prostate adenocarcinoma	CABAZITAXEL	targetBased	3	Active, not recruiting	01/12/2013	https://clinicaltrials.gov/study/NCT01952223	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	prostate adenocarcinoma	CABAZITAXEL	targetBased	3	Completed	01/01/2007	https://clinicaltrials.gov/study/NCT00417079	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	neoplasm	CABAZITAXEL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=L01CD04	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	prostate cancer	CABAZITAXEL	targetBased	4	Completed	01/07/2014	https://clinicaltrials.gov/study/NCT02074137	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	prostate cancer	CABAZITAXEL	targetBased	4	Completed	09/11/2015	https://clinicaltrials.gov/study/NCT02485691	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	prostate cancer	CABAZITAXEL	targetBased	3	Completed	01/04/2011	https://clinicaltrials.gov/study/NCT01308580	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	prostate cancer	CABAZITAXEL	targetBased	3	Unknown status	22/05/2014	https://clinicaltrials.gov/study/NCT02044354	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	prostate cancer	CABAZITAXEL	targetBased	3	Active, not recruiting	01/12/2013	https://clinicaltrials.gov/study/NCT01952223	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	prostate cancer	CABAZITAXEL	targetBased	4	Completed	01/04/2015	https://clinicaltrials.gov/study/NCT02441894	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	prostate cancer	CABAZITAXEL	targetBased	3	Completed	01/08/2012	https://clinicaltrials.gov/study/NCT01578655	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	prostate cancer	CABAZITAXEL	targetBased	3	Terminated	01/03/2010	https://clinicaltrials.gov/study/NCT01083615	0.7	LoF	protect	Unable to enroll due to criteria for stable baseline pain
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	prostate cancer	CABAZITAXEL	targetBased	3	Completed	05/05/2011	https://clinicaltrials.gov/study/NCT01308567	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	prostate cancer	CABAZITAXEL	targetBased	4	Completed	01/07/2012	https://clinicaltrials.gov/study/NCT01649635	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	prostate cancer	CABAZITAXEL	targetBased	3	Completed	05/05/2017	https://clinicaltrials.gov/study/NCT02961257	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	prostate cancer	CABAZITAXEL	targetBased	3	Completed	01/12/2010	https://clinicaltrials.gov/study/NCT01254279	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	prostate cancer	CABAZITAXEL	targetBased	3	Unknown status	01/11/2012	https://clinicaltrials.gov/study/NCT01978873	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	prostate cancer	CABAZITAXEL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de3d9c26-572b-4ea4-9b2d-dd58a2b3e8fa	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	prostate cancer	CABAZITAXEL	targetBased	3	Recruiting	01/02/2019	https://clinicaltrials.gov/study/NCT03903835	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	prostate neoplasm	CABAZITAXEL	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/cabazitaxel-accord	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	IXABEPILONE	targetBased	3	Recruiting	28/07/2023	https://clinicaltrials.gov/study/NCT05894239	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	IXABEPILONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=241f0b1e-8b95-470d-876f-bf1804daaf18	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	IXABEPILONE	targetBased	3	Completed	01/12/2008	https://clinicaltrials.gov/study/NCT00789581	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	IXABEPILONE	targetBased	3	Completed	01/11/2003	https://clinicaltrials.gov/study/NCT00082433	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	IXABEPILONE	targetBased	3	Completed	01/09/2003	https://clinicaltrials.gov/study/NCT00080301	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	IXABEPILONE	targetBased	3	Completed	01/09/2006	https://clinicaltrials.gov/study/NCT00448591	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	IXABEPILONE	targetBased	3	Completed	01/09/2007	https://clinicaltrials.gov/study/NCT00630032	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast carcinoma	IXABEPILONE	targetBased	3	Completed	13/10/2008	https://clinicaltrials.gov/study/NCT00785291	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast carcinoma	IXABEPILONE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022065lbl.pdf	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	endometrial cancer	IXABEPILONE	targetBased	3	Terminated	01/08/2009	https://clinicaltrials.gov/study/NCT00883116	0.7	LoF	protect	Interim analysis results showed that ixabepilone did not improve survival compared with control chemotherapies.
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	cancer	IXABEPILONE	targetBased	3	Completed	01/11/2003	https://clinicaltrials.gov/study/NCT00082433	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	neoplasm	IXABEPILONE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=L01DC04	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pancreatic carcinoma	METHYLNALTREXONE BROMIDE	targetBased	3	Withdrawn	03/02/2020	https://clinicaltrials.gov/study/NCT04151719	0.7	LoF	protect	Due to pandemic challenges and consideration of a different study design in the future.
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pancreatic carcinoma	METHYLNALTREXONE BROMIDE	targetBased	3	Withdrawn	03/02/2020	https://clinicaltrials.gov/study/NCT04151719	0.7	LoF	protect	Due to pandemic challenges and consideration of a different study design in the future.
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	neoplasm	TAPENTADOL	targetBased	3	Completed	01/08/2010	https://clinicaltrials.gov/study/NCT01309386	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	neoplasm	TAPENTADOL	targetBased	3	Completed	01/08/2010	https://clinicaltrials.gov/study/NCT01309386	0.7	GoF	protect
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	Interleukin-1 beta	pancreatic carcinoma	CANAKINUMAB	pathwayBased	3	Active, not recruiting	31/01/2020	https://clinicaltrials.gov/study/NCT04229004	0.7	LoF	protect
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	Interleukin-1 beta	pancreatic adenocarcinoma	CANAKINUMAB	pathwayBased	3	Active, not recruiting	31/01/2020	https://clinicaltrials.gov/study/NCT04229004	0.7	LoF	protect
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	Interleukin-1 beta	non-small cell lung carcinoma	CANAKINUMAB	pathwayBased	3	Terminated	16/03/2018	https://clinicaltrials.gov/study/NCT03447769	0.35	LoF	protect	Upon review of the primary analysis results, the benefit-risk was assessed by the Steering Committee Members with the decision that the study will be closed. No new safety signals were observed for canakinumab.
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	Interleukin-1 beta	non-small cell lung carcinoma	CANAKINUMAB	pathwayBased	3	Terminated	23/01/2019	https://clinicaltrials.gov/study/NCT03626545	0.35	LoF	protect	The study was early terminated due to the lack of efficacy of study treatment observed in the analysis of the primary endpoint of the randomized part
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	Interleukin-1 beta	non-small cell lung carcinoma	CANAKINUMAB	pathwayBased	3	Active, not recruiting	21/12/2018	https://clinicaltrials.gov/study/NCT03631199	0.7	LoF	protect
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	Interleukin-1 beta	lung cancer	CANAKINUMAB	pathwayBased	3	Terminated	03/02/2022	https://clinicaltrials.gov/study/NCT05725343	0.7	LoF	protect	Novartis has decided to terminate the trial due to the recent results made available from the Novartis CANOPY A study (CACZ885T2301), this decision is not related to any safety data for Canakinumab
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	thyroid cancer	FOSBRETABULIN	targetBased	3	Withdrawn	01/03/2015	https://clinicaltrials.gov/study/NCT01701349	0.7	LoF	protect	Expected inability to recruit study participants in a reasonable amount of time.
Fluorescence polarization assay for PLK1 inhibitors	PLK1	PLK1	Serine/threonine-protein kinase PLK1	acute myeloid leukemia	VOLASERTIB	targetBased	3	Completed	29/01/2013	https://clinicaltrials.gov/study/NCT01721876	0.7	LoF	protect
qHTS for Inhibitors of PLK1-PDB (polo-like kinase 1 - polo-box domain): Primary Screen	PLK1	PLK1	Serine/threonine-protein kinase PLK1	acute myeloid leukemia	VOLASERTIB	targetBased	3	Completed	29/01/2013	https://clinicaltrials.gov/study/NCT01721876	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer	TRAMADOL	targetBased	3	Completed	20/11/2020	https://clinicaltrials.gov/study/NCT04613830	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer	TRAMADOL	targetBased	3	Completed	20/11/2020	https://clinicaltrials.gov/study/NCT04613830	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer	TRAMADOL	targetBased	4	Completed	01/07/2004	https://clinicaltrials.gov/study/NCT01968018	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer	TRAMADOL	targetBased	4	Completed	01/07/2004	https://clinicaltrials.gov/study/NCT01968018	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	brain neoplasm	TRAMADOL	targetBased	4	Completed	01/03/2016	https://clinicaltrials.gov/study/NCT02964416	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	brain neoplasm	TRAMADOL	targetBased	4	Completed	01/03/2016	https://clinicaltrials.gov/study/NCT02964416	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Nasal Cavity Polyp	TRAMADOL	targetBased	4	Completed	01/07/2015	https://clinicaltrials.gov/study/NCT02484859	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Nasal Cavity Polyp	TRAMADOL	targetBased	4	Completed	01/07/2015	https://clinicaltrials.gov/study/NCT02484859	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer	TRAMADOL HYDROCHLORIDE	targetBased	3	Completed	20/11/2020	https://clinicaltrials.gov/study/NCT04613830	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer	TRAMADOL HYDROCHLORIDE	targetBased	3	Completed	20/11/2020	https://clinicaltrials.gov/study/NCT04613830	0.7	GoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	primary myelofibrosis	FEDRATINIB	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212327s000lbl.pdf	1	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	primary myelofibrosis	FEDRATINIB	targetBased	3	Completed	27/03/2019	https://clinicaltrials.gov/study/NCT03755518	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	primary myelofibrosis	FEDRATINIB	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/inrebic	1	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	myeloproliferative disorder	FEDRATINIB	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/inrebic	1	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	neoplasm	FEDRATINIB	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=L01EJ02	1	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	neoplasm	FEDRATINIB	targetBased	3	Completed	01/12/2011	https://clinicaltrials.gov/study/NCT01437787	0.7	LoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	metastatic colorectal cancer	XALIPRODEN	targetBased	3	Completed	01/12/2005	https://clinicaltrials.gov/study/NCT00305188	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	metastatic colorectal cancer	XALIPRODEN	targetBased	3	Completed	01/12/2005	https://clinicaltrials.gov/study/NCT00305188	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	colorectal neoplasm	XALIPRODEN	targetBased	3	Terminated	01/01/2008	https://clinicaltrials.gov/study/NCT00603577	0.7	GoF	protect	development of product discontinued
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	colorectal neoplasm	XALIPRODEN	targetBased	3	Terminated	01/01/2008	https://clinicaltrials.gov/study/NCT00603577	0.7	GoF	protect	development of product discontinued
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	ERIBULIN MESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=31ce4750-ded5-4a0b-95e9-f229fa6bc822	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	ERIBULIN MESYLATE	targetBased	3	Not yet recruiting	01/12/2023	https://clinicaltrials.gov/study/NCT06079983	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	ERIBULIN MESYLATE	targetBased	3	Completed	01/11/2006	https://clinicaltrials.gov/study/NCT00388726	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	ERIBULIN MESYLATE	targetBased	4	Completed	01/06/2013	https://clinicaltrials.gov/study/NCT01961544	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	ERIBULIN MESYLATE	targetBased	3	Completed	20/09/2006	https://clinicaltrials.gov/study/NCT00337103	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	ERIBULIN MESYLATE	targetBased	3	Not yet recruiting	01/02/2024	https://clinicaltrials.gov/study/NCT06255392	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	ERIBULIN MESYLATE	targetBased	4	Completed	01/05/2014	https://clinicaltrials.gov/study/NCT02864030	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	ERIBULIN MESYLATE	targetBased	3	Recruiting	16/05/2022	https://clinicaltrials.gov/study/NCT05374512	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	ERIBULIN MESYLATE	targetBased	3	Recruiting	30/10/2023	https://clinicaltrials.gov/study/NCT06143553	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	ERIBULIN MESYLATE	targetBased	3	Completed	26/09/2013	https://clinicaltrials.gov/study/NCT02225470	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	liposarcoma	ERIBULIN MESYLATE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/halaven	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	soft tissue sarcoma	ERIBULIN MESYLATE	targetBased	3	Completed	10/03/2011	https://clinicaltrials.gov/study/NCT01327885	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast neoplasm	ERIBULIN MESYLATE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/halaven	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast neoplasm	ERIBULIN MESYLATE	targetBased	4	Completed	28/03/2018	https://clinicaltrials.gov/study/NCT03583944	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast carcinoma	ERIBULIN MESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=31ce4750-ded5-4a0b-95e9-f229fa6bc822	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast carcinoma	ERIBULIN MESYLATE	targetBased	3	Suspended	17/01/2014	https://clinicaltrials.gov/study/NCT02037529	0.7	LoF	protect	Total enrollment number is being lowered
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	bladder transitional cell carcinoma	ERIBULIN MESYLATE	targetBased	3	Recruiting	28/06/2021	https://clinicaltrials.gov/study/NCT04579224	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	ureter urothelial carcinoma	ERIBULIN MESYLATE	targetBased	3	Recruiting	28/06/2021	https://clinicaltrials.gov/study/NCT04579224	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	triple-negative breast cancer	ERIBULIN MESYLATE	targetBased	3	Recruiting	25/04/2023	https://clinicaltrials.gov/study/NCT05806060	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	triple-negative breast cancer	ERIBULIN MESYLATE	targetBased	3	Recruiting	17/03/2023	https://clinicaltrials.gov/study/NCT05760378	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	transitional cell carcinoma of kidney	ERIBULIN MESYLATE	targetBased	3	Recruiting	28/06/2021	https://clinicaltrials.gov/study/NCT04579224	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast adenocarcinoma	ERIBULIN MESYLATE	targetBased	3	Suspended	17/01/2014	https://clinicaltrials.gov/study/NCT02037529	0.7	LoF	protect	Total enrollment number is being lowered
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	ERIBULIN	targetBased	3	Terminated	17/01/2022	https://clinicaltrials.gov/study/NCT05134194	0.7	LoF	protect	Sponsor R \& D Strategy Adjustment\]
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	ERIBULIN	targetBased	3	Completed	20/09/2006	https://clinicaltrials.gov/study/NCT00337103	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	ERIBULIN	targetBased	3	Completed	01/11/2006	https://clinicaltrials.gov/study/NCT00388726	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	ERIBULIN	targetBased	3	Active, not recruiting	14/09/2021	https://clinicaltrials.gov/study/NCT05063786	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	ERIBULIN	targetBased	3	Recruiting	30/06/2023	https://clinicaltrials.gov/study/NCT05814354	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	ERIBULIN	targetBased	3	Active, not recruiting	27/12/2018	https://clinicaltrials.gov/study/NCT03734029	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	ERIBULIN	targetBased	3	Unknown status	01/08/2015	https://clinicaltrials.gov/study/NCT02514681	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	ERIBULIN	targetBased	3	Active, not recruiting	18/10/2021	https://clinicaltrials.gov/study/NCT05104866	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	ERIBULIN	targetBased	3	Recruiting	28/08/2017	https://clinicaltrials.gov/study/NCT03264547	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	ERIBULIN	targetBased	3	Completed	13/10/2015	https://clinicaltrials.gov/study/NCT02555657	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	ERIBULIN	targetBased	4	Completed	01/06/2013	https://clinicaltrials.gov/study/NCT01961544	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	ERIBULIN	targetBased	3	Recruiting	30/10/2023	https://clinicaltrials.gov/study/NCT06143553	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	ERIBULIN	targetBased	3	Completed	08/05/2019	https://clinicaltrials.gov/study/NCT03901339	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	ERIBULIN	targetBased	4	Recruiting	11/03/2021	https://clinicaltrials.gov/study/NCT05033769	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	ERIBULIN	targetBased	3	Recruiting	24/04/2024	https://clinicaltrials.gov/study/NCT06343948	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	ERIBULIN	targetBased	3	Terminated	30/05/2019	https://clinicaltrials.gov/study/NCT03786094	0.35	LoF	protect	The study was halted early due to failure to meet the primary endpoint.
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	ERIBULIN	targetBased	3	Not yet recruiting	01/12/2023	https://clinicaltrials.gov/study/NCT06079983	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	ERIBULIN	targetBased	4	Completed	01/05/2014	https://clinicaltrials.gov/study/NCT02864030	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	ERIBULIN	targetBased	3	Completed	26/09/2013	https://clinicaltrials.gov/study/NCT02225470	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	ERIBULIN	targetBased	3	Not yet recruiting	01/02/2024	https://clinicaltrials.gov/study/NCT06255392	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	ERIBULIN	targetBased	3	Recruiting	16/05/2022	https://clinicaltrials.gov/study/NCT05374512	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	ERIBULIN	targetBased	3	Not yet recruiting	16/07/2024	https://clinicaltrials.gov/study/NCT06435429	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	ERIBULIN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=31ce4750-ded5-4a0b-95e9-f229fa6bc822	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	ERIBULIN	targetBased	3	Recruiting	15/01/2024	https://clinicaltrials.gov/study/NCT06268652	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	ERIBULIN	targetBased	3	Completed	07/11/2017	https://clinicaltrials.gov/study/NCT02574455	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	liposarcoma	ERIBULIN	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/halaven	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	soft tissue sarcoma	ERIBULIN	targetBased	3	Completed	10/03/2011	https://clinicaltrials.gov/study/NCT01327885	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	sarcoma	ERIBULIN	targetBased	3	Recruiting	01/06/2024	https://clinicaltrials.gov/study/NCT06263231	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast neoplasm	ERIBULIN	targetBased	4	Completed	28/03/2018	https://clinicaltrials.gov/study/NCT03583944	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast neoplasm	ERIBULIN	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/halaven	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast neoplasm	ERIBULIN	targetBased	4	Recruiting	11/03/2021	https://clinicaltrials.gov/study/NCT05033769	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast carcinoma	ERIBULIN	targetBased	3	Recruiting	15/01/2024	https://clinicaltrials.gov/study/NCT06268652	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast carcinoma	ERIBULIN	targetBased	3	Suspended	17/01/2014	https://clinicaltrials.gov/study/NCT02037529	0.7	LoF	protect	Total enrollment number is being lowered
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast carcinoma	ERIBULIN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=31ce4750-ded5-4a0b-95e9-f229fa6bc822	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	bladder transitional cell carcinoma	ERIBULIN	targetBased	3	Recruiting	28/06/2021	https://clinicaltrials.gov/study/NCT04579224	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	ureter urothelial carcinoma	ERIBULIN	targetBased	3	Recruiting	28/06/2021	https://clinicaltrials.gov/study/NCT04579224	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	neoplasm	ERIBULIN	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=L01XX41	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	triple-negative breast cancer	ERIBULIN	targetBased	3	Recruiting	25/04/2023	https://clinicaltrials.gov/study/NCT05806060	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	triple-negative breast cancer	ERIBULIN	targetBased	3	Not yet recruiting	01/05/2024	https://clinicaltrials.gov/study/NCT06382142	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	triple-negative breast cancer	ERIBULIN	targetBased	3	Recruiting	17/03/2023	https://clinicaltrials.gov/study/NCT05760378	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	transitional cell carcinoma of kidney	ERIBULIN	targetBased	3	Recruiting	28/06/2021	https://clinicaltrials.gov/study/NCT04579224	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast adenocarcinoma	ERIBULIN	targetBased	3	Suspended	17/01/2014	https://clinicaltrials.gov/study/NCT02037529	0.7	LoF	protect	Total enrollment number is being lowered
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	ERIBULIN	targetBased	3	Completed	09/12/2011	https://clinicaltrials.gov/study/NCT01454934	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Hodgkins lymphoma	BRENTUXIMAB VEDOTIN	targetBased	3	Active, not recruiting	29/08/2019	https://clinicaltrials.gov/study/NCT03907488	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Hodgkins lymphoma	BRENTUXIMAB VEDOTIN	targetBased	4	Completed	14/03/2014	https://clinicaltrials.gov/study/NCT01990534	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Hodgkins lymphoma	BRENTUXIMAB VEDOTIN	targetBased	3	Completed	30/04/2010	https://clinicaltrials.gov/study/NCT01100502	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Hodgkins lymphoma	BRENTUXIMAB VEDOTIN	targetBased	3	Active, not recruiting	19/03/2015	https://clinicaltrials.gov/study/NCT02166463	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Hodgkins lymphoma	BRENTUXIMAB VEDOTIN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3904f8dd-1aef-3490-e48f-bd55f32ed67f	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Hodgkins lymphoma	BRENTUXIMAB VEDOTIN	targetBased	3	Recruiting	14/04/2022	https://clinicaltrials.gov/study/NCT04685616	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Hodgkins lymphoma	BRENTUXIMAB VEDOTIN	targetBased	3	Active, not recruiting	23/05/2016	https://clinicaltrials.gov/study/NCT02684292	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Hodgkins lymphoma	BRENTUXIMAB VEDOTIN	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/adcetris	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Hodgkins lymphoma	BRENTUXIMAB VEDOTIN	targetBased	3	Terminated	26/06/2017	https://clinicaltrials.gov/study/NCT03138499	0.7	LoF	protect	Insufficient enrollment.
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Hodgkins lymphoma	BRENTUXIMAB VEDOTIN	targetBased	3	Active, not recruiting	09/11/2012	https://clinicaltrials.gov/study/NCT01712490	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	anaplastic large cell lymphoma	BRENTUXIMAB VEDOTIN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3904f8dd-1aef-3490-e48f-bd55f32ed67f	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	anaplastic large cell lymphoma	BRENTUXIMAB VEDOTIN	targetBased	3	Completed	11/06/2012	https://clinicaltrials.gov/study/NCT01578499	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	diffuse large B-cell lymphoma	BRENTUXIMAB VEDOTIN	targetBased	3	Active, not recruiting	20/08/2020	https://clinicaltrials.gov/study/NCT04404283	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	diffuse large B-cell lymphoma	BRENTUXIMAB VEDOTIN	targetBased	3	Not yet recruiting	01/01/2024	https://clinicaltrials.gov/study/NCT06186986	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	mycosis fungoides	BRENTUXIMAB VEDOTIN	targetBased	3	Completed	11/06/2012	https://clinicaltrials.gov/study/NCT01578499	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-Hodgkins lymphoma	BRENTUXIMAB VEDOTIN	targetBased	3	Completed	31/01/2013	https://clinicaltrials.gov/study/NCT01777152	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-Hodgkins lymphoma	BRENTUXIMAB VEDOTIN	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/adcetris	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	neoplasm	BRENTUXIMAB VEDOTIN	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=L01FX05	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Cutaneous T-cell lymphoma	BRENTUXIMAB VEDOTIN	targetBased	3	Completed	11/06/2012	https://clinicaltrials.gov/study/NCT01578499	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	BRENTUXIMAB VEDOTIN	targetBased	4	Active, not recruiting	30/01/2014	https://clinicaltrials.gov/study/NCT01909934	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	BRENTUXIMAB VEDOTIN	targetBased	3	Completed	31/01/2013	https://clinicaltrials.gov/study/NCT01777152	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lymphoma	BRENTUXIMAB VEDOTIN	targetBased	4	Active, not recruiting	20/07/2023	https://clinicaltrials.gov/study/NCT05442554	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	classic Hodgkin lymphoma	BRENTUXIMAB VEDOTIN	targetBased	3	Withdrawn	10/08/2023	https://clinicaltrials.gov/study/NCT05711628	0.7	LoF	protect	Other - Protocol moved to Withdrawn
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	classic Hodgkin lymphoma	BRENTUXIMAB VEDOTIN	targetBased	3	Active, not recruiting	01/07/2016	https://clinicaltrials.gov/study/NCT02661503	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	classic Hodgkin lymphoma	BRENTUXIMAB VEDOTIN	targetBased	3	Active, not recruiting	19/03/2015	https://clinicaltrials.gov/study/NCT02166463	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	classic Hodgkin lymphoma	BRENTUXIMAB VEDOTIN	targetBased	3	Active, not recruiting	29/08/2019	https://clinicaltrials.gov/study/NCT03907488	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	TRASTUZUMAB EMTANSINE	targetBased	3	Recruiting	01/01/2021	https://clinicaltrials.gov/study/NCT05429684	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	TRASTUZUMAB EMTANSINE	targetBased	3	Active, not recruiting	03/04/2013	https://clinicaltrials.gov/study/NCT01772472	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	TRASTUZUMAB EMTANSINE	targetBased	3	Recruiting	04/05/2021	https://clinicaltrials.gov/study/NCT04873362	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	TRASTUZUMAB EMTANSINE	targetBased	3	Completed	01/09/2011	https://clinicaltrials.gov/study/NCT01419197	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	TRASTUZUMAB EMTANSINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=23f3c1f4-0fc8-4804-a9e3-04cf25dd302e	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	TRASTUZUMAB EMTANSINE	targetBased	3	Completed	01/02/2009	https://clinicaltrials.gov/study/NCT00829166	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	TRASTUZUMAB EMTANSINE	targetBased	3	Terminated	01/06/2014	https://clinicaltrials.gov/study/NCT02144012	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	TRASTUZUMAB EMTANSINE	targetBased	3	Completed	24/04/2017	https://clinicaltrials.gov/study/NCT03084939	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	TRASTUZUMAB EMTANSINE	targetBased	3	Active, not recruiting	07/06/2021	https://clinicaltrials.gov/study/NCT04740918	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	TRASTUZUMAB EMTANSINE	targetBased	3	Active, not recruiting	09/08/2018	https://clinicaltrials.gov/study/NCT03529110	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	TRASTUZUMAB EMTANSINE	targetBased	3	Recruiting	28/03/2023	https://clinicaltrials.gov/study/NCT05755048	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	TRASTUZUMAB EMTANSINE	targetBased	3	Completed	31/01/2014	https://clinicaltrials.gov/study/NCT01966471	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	TRASTUZUMAB EMTANSINE	targetBased	4	Completed	01/11/2016	https://clinicaltrials.gov/study/NCT02658734	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	TRASTUZUMAB EMTANSINE	targetBased	3	Completed	11/01/2019	https://clinicaltrials.gov/study/NCT03726879	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	TRASTUZUMAB EMTANSINE	targetBased	3	Completed	27/11/2012	https://clinicaltrials.gov/study/NCT01702571	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	TRASTUZUMAB EMTANSINE	targetBased	3	Active, not recruiting	04/12/2020	https://clinicaltrials.gov/study/NCT04622319	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	TRASTUZUMAB EMTANSINE	targetBased	3	Completed	31/07/2010	https://clinicaltrials.gov/study/NCT01120184	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	TRASTUZUMAB EMTANSINE	targetBased	3	Not yet recruiting	01/11/2023	https://clinicaltrials.gov/study/NCT06126640	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	TRASTUZUMAB EMTANSINE	targetBased	3	Recruiting	29/01/2024	https://clinicaltrials.gov/study/NCT06265428	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	inflammatory breast carcinoma	TRASTUZUMAB EMTANSINE	targetBased	3	Active, not recruiting	05/07/2022	https://clinicaltrials.gov/study/NCT05415215	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast neoplasm	TRASTUZUMAB EMTANSINE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/kadcyla	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast neoplasm	TRASTUZUMAB EMTANSINE	targetBased	3	Completed	25/06/2014	https://clinicaltrials.gov/study/NCT02131064	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast carcinoma	TRASTUZUMAB EMTANSINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=23f3c1f4-0fc8-4804-a9e3-04cf25dd302e	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	HER2 Positive Breast Carcinoma	TRASTUZUMAB EMTANSINE	targetBased	3	Recruiting	06/01/2021	https://clinicaltrials.gov/study/NCT04457596	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	neoplasm	TRASTUZUMAB EMTANSINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=L01FD03	1	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	primary myelofibrosis	RUXOLITINIB	targetBased	4	Recruiting	05/03/2015	https://clinicaltrials.gov/study/NCT02386800	1	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	primary myelofibrosis	RUXOLITINIB	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1c82580-87ae-11e0-bc84-0002a5d5c51b	1	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	primary myelofibrosis	RUXOLITINIB	targetBased	3	Active, not recruiting	31/08/2020	https://clinicaltrials.gov/study/NCT04468984	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	primary myelofibrosis	RUXOLITINIB	targetBased	4	Completed	01/05/2012	https://clinicaltrials.gov/study/NCT01558739	1	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	primary myelofibrosis	RUXOLITINIB	targetBased	3	Completed	06/12/2013	https://clinicaltrials.gov/study/NCT01969838	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	primary myelofibrosis	RUXOLITINIB	targetBased	3	Active, not recruiting	29/09/2020	https://clinicaltrials.gov/study/NCT04472598	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	primary myelofibrosis	RUXOLITINIB	targetBased	3	Completed	01/04/2014	https://clinicaltrials.gov/study/NCT02087059	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	pancreatic carcinoma	RUXOLITINIB	targetBased	3	Terminated	01/06/2014	https://clinicaltrials.gov/study/NCT02119663	0.35	LoF	protect	The safety committee found no safety issues but recommended halting the study based on a lack of efficacy in a similar trial. The sponsor terminated the trial.
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	pancreatic carcinoma	RUXOLITINIB	targetBased	3	Terminated	01/03/2014	https://clinicaltrials.gov/study/NCT02117479	0.35	LoF	protect	The study was terminated early based on the results of the planned interim analysis.
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	myeloproliferative disorder	RUXOLITINIB	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/jakavi	1	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	myeloproliferative disorder	RUXOLITINIB	targetBased	3	Completed	01/08/2009	https://clinicaltrials.gov/study/NCT00952289	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	neoplasm	RUXOLITINIB	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=L01EJ01	1	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	polycythemia vera	RUXOLITINIB	targetBased	3	Recruiting	25/10/2019	https://clinicaltrials.gov/study/NCT04116502	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	polycythemia vera	RUXOLITINIB	targetBased	3	Completed	27/10/2010	https://clinicaltrials.gov/study/NCT01243944	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	polycythemia vera	RUXOLITINIB	targetBased	3	Completed	21/11/2014	https://clinicaltrials.gov/study/NCT02292446	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	polycythemia vera	RUXOLITINIB	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1c82580-87ae-11e0-bc84-0002a5d5c51b	1	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	polycythemia vera	RUXOLITINIB	targetBased	3	Completed	01/06/2012	https://clinicaltrials.gov/study/NCT01632904	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	polycythemia vera	RUXOLITINIB	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/jakavi	1	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	polycythemia vera	RUXOLITINIB	targetBased	3	Completed	25/03/2014	https://clinicaltrials.gov/study/NCT02038036	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	essential thrombocythemia	RUXOLITINIB	targetBased	3	Recruiting	31/12/2023	https://clinicaltrials.gov/study/NCT06079879	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	primary myelofibrosis	RUXOLITINIB PHOSPHATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1c82580-87ae-11e0-bc84-0002a5d5c51b	1	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	myeloproliferative disorder	RUXOLITINIB PHOSPHATE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/jakavi	1	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	polycythemia vera	RUXOLITINIB PHOSPHATE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/jakavi	1	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	polycythemia vera	RUXOLITINIB PHOSPHATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1c82580-87ae-11e0-bc84-0002a5d5c51b	1	LoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	hepatocellular carcinoma	SEOCALCITOL	targetBased	3	Terminated	01/11/1999	https://clinicaltrials.gov/study/NCT00051545	0.7	GoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	esophageal cancer	REGORAFENIB	targetBased	3	Active, not recruiting	01/06/2021	https://clinicaltrials.gov/study/NCT04879368	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	esophageal cancer	REGORAFENIB	targetBased	3	Unknown status	01/11/2016	https://clinicaltrials.gov/study/NCT02773524	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	neoplasm	REGORAFENIB	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=L01EX05	1	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	colorectal neoplasm	REGORAFENIB	targetBased	3	Completed	01/04/2012	https://clinicaltrials.gov/study/NCT01584830	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	colorectal neoplasm	REGORAFENIB	targetBased	3	Active, not recruiting	28/04/2022	https://clinicaltrials.gov/study/NCT05328908	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	colorectal neoplasm	REGORAFENIB	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/stivarga	1	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	colorectal neoplasm	REGORAFENIB	targetBased	3	Terminated	02/12/2013	https://clinicaltrials.gov/study/NCT01939223	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	colorectal neoplasm	REGORAFENIB	targetBased	3	Active, not recruiting	29/03/2021	https://clinicaltrials.gov/study/NCT04776148	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	hepatocellular carcinoma	REGORAFENIB	targetBased	3	Recruiting	11/10/2023	https://clinicaltrials.gov/study/NCT04777851	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	hepatocellular carcinoma	REGORAFENIB	targetBased	3	Terminated	26/09/2021	https://clinicaltrials.gov/study/NCT04985136	0.7	LoF	protect	Sponsor R & D Strategy Adjustment
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	hepatocellular carcinoma	REGORAFENIB	targetBased	3	Completed	14/05/2013	https://clinicaltrials.gov/study/NCT01774344	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	gastrointestinal stromal tumor	REGORAFENIB	targetBased	3	Completed	26/03/2018	https://clinicaltrials.gov/study/NCT03465722	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	gastrointestinal stromal tumor	REGORAFENIB	targetBased	3	Completed	04/01/2011	https://clinicaltrials.gov/study/NCT01271712	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	colorectal cancer	REGORAFENIB	targetBased	3	Recruiting	07/09/2022	https://clinicaltrials.gov/study/NCT05425940	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	colorectal cancer	REGORAFENIB	targetBased	3	Recruiting	01/03/2024	https://clinicaltrials.gov/study/NCT06199973	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	colorectal cancer	REGORAFENIB	targetBased	3	Active, not recruiting	10/11/2021	https://clinicaltrials.gov/study/NCT05064059	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	colorectal cancer	REGORAFENIB	targetBased	3	Completed	05/07/2016	https://clinicaltrials.gov/study/NCT02788279	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	colorectal cancer	REGORAFENIB	targetBased	3	Active, not recruiting	19/04/2022	https://clinicaltrials.gov/study/NCT05198934	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	colorectal cancer	REGORAFENIB	targetBased	3	Active, not recruiting	14/06/2022	https://clinicaltrials.gov/study/NCT05600309	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	colorectal cancer	REGORAFENIB	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=824f19c9-0546-4a8a-8d8f-c4055c04f7c7	1	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	malignant colon neoplasm	REGORAFENIB	targetBased	3	Terminated	01/06/2016	https://clinicaltrials.gov/study/NCT02664077	0.7	LoF	protect	Due to the significantly lower than expected accrual it was impossible to evaluate the endpoint in a timely fashion.
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	metastatic colorectal cancer	REGORAFENIB	targetBased	3	Completed	01/04/2010	https://clinicaltrials.gov/study/NCT01103323	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	metastatic colorectal cancer	REGORAFENIB	targetBased	3	Active, not recruiting	01/03/2015	https://clinicaltrials.gov/study/NCT02934529	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	metastatic colorectal cancer	REGORAFENIB	targetBased	3	Withdrawn	01/06/2013	https://clinicaltrials.gov/study/NCT01786538	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	metastatic colorectal cancer	REGORAFENIB	targetBased	3	Recruiting	28/03/2019	https://clinicaltrials.gov/study/NCT03829462	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	metastatic colorectal cancer	REGORAFENIB	targetBased	4	Completed	30/07/2018	https://clinicaltrials.gov/study/NCT03564938	1	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	metastatic colorectal cancer	REGORAFENIB	targetBased	3	Recruiting	10/06/2023	https://clinicaltrials.gov/study/NCT05794971	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	metastatic colorectal cancer	REGORAFENIB	targetBased	4	Recruiting	22/10/2021	https://clinicaltrials.gov/study/NCT04874207	1	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	primary myelofibrosis	PACRITINIB	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/208712s000lbl.pdf	1	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	neoplasm	PACRITINIB	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=L01EJ03	1	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	polycythemia vera	PACRITINIB	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/208712s000lbl.pdf	1	LoF	protect
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	THRB	Thyroid hormone receptor beta	thyroid cancer	LEVOTHYROXINE SODIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7a5a9e87-383a-4450-bf79-1f4f68655ace	1	GoF	protect
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	THRB	Thyroid hormone receptor beta	differentiated thyroid carcinoma	LEVOTHYROXINE SODIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=00a4fc0b-7162-455e-8ed3-56efdbbe182e	1	GoF	protect
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	THRB	Thyroid hormone receptor beta	differentiated thyroid carcinoma	LEVOTHYROXINE SODIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7a5a9e87-383a-4450-bf79-1f4f68655ace	1	GoF	protect
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	THRB	Thyroid hormone receptor beta	thyroid carcinoma	LEVOTHYROXINE SODIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f4d851f6-6bf5-4ed5-8d3a-1646773c4d40	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	idiopathic pulmonary fibrosis	MORPHINE SULFATE	targetBased	3	Completed	17/12/2020	https://clinicaltrials.gov/study/NCT04429516	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	idiopathic pulmonary fibrosis	MORPHINE SULFATE	targetBased	3	Completed	17/12/2020	https://clinicaltrials.gov/study/NCT04429516	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer	MORPHINE SULFATE	targetBased	4	Completed	20/03/2020	https://clinicaltrials.gov/study/NCT04316871	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer	MORPHINE SULFATE	targetBased	4	Completed	20/03/2020	https://clinicaltrials.gov/study/NCT04316871	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer	MORPHINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c6e2b3fd-691b-4f1f-94a4-ede191e0de78	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer	MORPHINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c6e2b3fd-691b-4f1f-94a4-ede191e0de78	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer	MORPHINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cadc3fdb-8edc-44cd-aaea-89e68aaf9a04	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer	MORPHINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cadc3fdb-8edc-44cd-aaea-89e68aaf9a04	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer	MORPHINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e360d6b6-d9ef-487d-bf14-fcbbee8beb29	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer	MORPHINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e360d6b6-d9ef-487d-bf14-fcbbee8beb29	1	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	non-small cell lung carcinoma	AGATOLIMOD	targetBased	3	Terminated	01/11/2005	https://clinicaltrials.gov/study/NCT00254904	0.7	GoF	protect	See Termination Reason in Detailed Description
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	non-small cell lung carcinoma	AGATOLIMOD SODIUM	targetBased	3	Terminated	01/11/2005	https://clinicaltrials.gov/study/NCT00254904	0.7	GoF	protect	See Termination Reason in Detailed Description
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	MTOR	Serine/threonine-protein kinase mTOR	bone sarcoma	RIDAFOROLIMUS	pathwayBased	3	Completed	01/10/2007	https://clinicaltrials.gov/study/NCT00538239	0.7	LoF	protect
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	MTOR	Serine/threonine-protein kinase mTOR	neoplasm	RIDAFOROLIMUS	pathwayBased	3			https://www.whocc.no/atc_ddd_index/?code=L01EG03	0.7	LoF	protect
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	MTOR	Serine/threonine-protein kinase mTOR	soft tissue sarcoma	RIDAFOROLIMUS	pathwayBased	3	Completed	01/10/2007	https://clinicaltrials.gov/study/NCT00538239	0.7	LoF	protect
Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3	HDAC3	HDAC3	Histone deacetylase 3	renal cell carcinoma	ABEXINOSTAT	targetBased	3	Recruiting	17/07/2018	https://clinicaltrials.gov/study/NCT03592472	0.7	LoF	protect
HTS for Tumor Hsp90 Inhibitors	HSP90 known inhibitor displacement	HSP90AA1	Heat shock protein HSP 90-alpha	non-small cell lung carcinoma	GANETESPIB	targetBased	3	Terminated	01/04/2013	https://clinicaltrials.gov/study/NCT01798485	0.35	LoF	protect	The study was stopped after the first Interim Analysis due to futility.
Luminescence-based primary biochemical high throughput screening assay to identify inhibitors of the Heat Shock Protein 90 (HSP90)	HSP90AA1	HSP90AA1	Full-length cDNA 5-PRIME end of clone CS0DN005YI08 of Adult brain of Homo sapiens , Heat shock protein HSP 90-alpha, Heat shock protein HSP 90-alpha	non-small cell lung carcinoma	GANETESPIB	targetBased	3	Terminated	01/04/2013	https://clinicaltrials.gov/study/NCT01798485	0.35	LoF	protect	The study was stopped after the first Interim Analysis due to futility.
HTS for Tumor Hsp90 Inhibitors	HSP90 known inhibitor displacement	HSP90AA1	Heat shock protein HSP 90-alpha	lung adenocarcinoma	GANETESPIB	targetBased	3	Terminated	01/04/2013	https://clinicaltrials.gov/study/NCT01798485	0.35	LoF	protect	The study was stopped after the first Interim Analysis due to futility.
Luminescence-based primary biochemical high throughput screening assay to identify inhibitors of the Heat Shock Protein 90 (HSP90)	HSP90AA1	HSP90AA1	Full-length cDNA 5-PRIME end of clone CS0DN005YI08 of Adult brain of Homo sapiens , Heat shock protein HSP 90-alpha, Heat shock protein HSP 90-alpha	lung adenocarcinoma	GANETESPIB	targetBased	3	Terminated	01/04/2013	https://clinicaltrials.gov/study/NCT01798485	0.35	LoF	protect	The study was stopped after the first Interim Analysis due to futility.
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	PONATINIB HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=807f988e-117b-4497-934d-73aa78baac71	1	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	PONATINIB HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=16d804b6-4957-43ee-b18c-3b36ec37c5ac	1	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	acute lymphoblastic leukemia	PONATINIB HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=807f988e-117b-4497-934d-73aa78baac71	1	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	lymphoid leukemia	PONATINIB HYDROCHLORIDE	targetBased	3	Recruiting	25/01/2021	https://clinicaltrials.gov/study/NCT04530565	0.7	LoF	protect
uHTS luminescence assay for the identification of compounds that inhibit NOD2	NOD2	NOD2	Nucleotide-binding oligomerization domain-containing protein 2	neoplasm	MIFAMURTIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=L03AX15	1		protect
uHTS luminescence assay for the identification of compounds that inhibit NOD2	NOD2	NOD2	Nucleotide-binding oligomerization domain-containing protein 2	bone osteosarcoma	MIFAMURTIDE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/mepact	1		protect
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of myeloid cell leukemia sequence 1 (MCL1) interactions with BIM-BH3 peptide.	MCL1	MCL1	Induced myeloid leukemia cell differentiation protein Mcl-1 , MCL1 apoptosis regulator, BCL2 family member, Myeloid cell leukemia ES variant	small cell lung carcinoma	OBATOCLAX MESYLATE	targetBased	3	Withdrawn	01/08/2012	https://clinicaltrials.gov/study/NCT01563601	0.7	LoF	protect	Business Decision
uHTS of Mcl-1/Bid interaction inhibitors	MCL1	MCL1	Induced myeloid leukemia cell differentiation protein Mcl-1 , MCL1 apoptosis regulator, BCL2 family member, Myeloid cell leukemia ES variant	small cell lung carcinoma	OBATOCLAX MESYLATE	targetBased	3	Withdrawn	01/08/2012	https://clinicaltrials.gov/study/NCT01563601	0.7	LoF	protect	Business Decision
uHTS of Mcl-1/Noxa interaction inhibitors	MCL1	MCL1	Induced myeloid leukemia cell differentiation protein Mcl-1 , MCL1 apoptosis regulator, BCL2 family member, Myeloid cell leukemia ES variant	small cell lung carcinoma	OBATOCLAX MESYLATE	targetBased	3	Withdrawn	01/08/2012	https://clinicaltrials.gov/study/NCT01563601	0.7	LoF	protect	Business Decision
Primary biochemical high throughput screening assay to identify inhibitors of BCL2-related protein, long isoform (BCLXL).	BCL2L1_modulators	BCL2L1	Bcl-2-like protein 1	small cell lung carcinoma	OBATOCLAX MESYLATE	targetBased	3	Withdrawn	01/08/2012	https://clinicaltrials.gov/study/NCT01563601	0.7	LoF	protect	Business Decision
Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bfl-1	BCL2A1_modulators	BCL2A1	Bcl-2-related protein A1	small cell lung carcinoma	OBATOCLAX MESYLATE	targetBased	3	Withdrawn	01/08/2012	https://clinicaltrials.gov/study/NCT01563601	0.7	LoF	protect	Business Decision
qHTS assay for re-activators of p53 using a Luc reporter	TP53	TP53	Cellular tumor antigen p53, Cellular tumor antigen p53	neoplasm	CONTUSUGENE LADENOVEC	pathwayBased	4	Unknown status	01/05/2009	https://clinicaltrials.gov/study/NCT00902122	1		protect
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	TP53	Cellular tumor antigen p53	neoplasm	CONTUSUGENE LADENOVEC	targetBased	4	Unknown status	01/05/2009	https://clinicaltrials.gov/study/NCT00902122	1		protect
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	TP53	Cellular tumor antigen p53	neoplasm	CONTUSUGENE LADENOVEC	targetBased	4	Unknown status	01/05/2009	https://clinicaltrials.gov/study/NCT00902122	1		protect
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	TP53	Cellular tumor antigen p53	neoplasm	CONTUSUGENE LADENOVEC	targetBased	4	Unknown status	01/05/2009	https://clinicaltrials.gov/study/NCT00902122	1		protect
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	TP53	Cellular tumor antigen p53	neoplasm	CONTUSUGENE LADENOVEC	targetBased	4	Unknown status	01/05/2009	https://clinicaltrials.gov/study/NCT00902122	1		protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	ovarian mucinous adenocarcinoma	PACLITAXEL POLIGLUMEX	targetBased	3	Unknown status	21/03/2005	https://clinicaltrials.gov/study/NCT00108745	0.7	GoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	ovarian serous adenocarcinoma	PACLITAXEL POLIGLUMEX	targetBased	3	Unknown status	21/03/2005	https://clinicaltrials.gov/study/NCT00108745	0.7	GoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Fallopian Tube Serous Adenocarcinoma	PACLITAXEL POLIGLUMEX	targetBased	3	Unknown status	21/03/2005	https://clinicaltrials.gov/study/NCT00108745	0.7	GoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Malignant Ovarian Brenner Tumor	PACLITAXEL POLIGLUMEX	targetBased	3	Unknown status	21/03/2005	https://clinicaltrials.gov/study/NCT00108745	0.7	GoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	ovarian clear cell adenocarcinoma	PACLITAXEL POLIGLUMEX	targetBased	3	Unknown status	21/03/2005	https://clinicaltrials.gov/study/NCT00108745	0.7	GoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Primary Peritoneal Serous Adenocarcinoma	PACLITAXEL POLIGLUMEX	targetBased	3	Unknown status	21/03/2005	https://clinicaltrials.gov/study/NCT00108745	0.7	GoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	primary peritoneal carcinoma	PACLITAXEL POLIGLUMEX	targetBased	3	Unknown status	21/03/2005	https://clinicaltrials.gov/study/NCT00108745	0.7	GoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	neoplasm	PACLITAXEL POLIGLUMEX	targetBased	3			https://www.whocc.no/atc_ddd_index/?code=L01CD03	0.7	GoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Ovarian Transitional Cell Carcinoma	PACLITAXEL POLIGLUMEX	targetBased	3	Unknown status	21/03/2005	https://clinicaltrials.gov/study/NCT00108745	0.7	GoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung cancer	PACLITAXEL POLIGLUMEX	targetBased	3	Terminated	01/01/2003	https://clinicaltrials.gov/study/NCT00054210	0.7	GoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung cancer	PACLITAXEL POLIGLUMEX	targetBased	3	Terminated	01/01/2003	https://clinicaltrials.gov/study/NCT00054184	0.7	GoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung cancer	PACLITAXEL POLIGLUMEX	targetBased	3	Terminated	01/01/2003	https://clinicaltrials.gov/study/NCT00054197	0.7	GoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung cancer	PACLITAXEL POLIGLUMEX	targetBased	3	Terminated	01/08/2007	https://clinicaltrials.gov/study/NCT00551733	0.7	GoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	undifferentiated carcinoma	PACLITAXEL POLIGLUMEX	targetBased	3	Unknown status	21/03/2005	https://clinicaltrials.gov/study/NCT00108745	0.7	GoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL POLIGLUMEX	targetBased	3	Terminated	01/12/2005	https://clinicaltrials.gov/study/NCT00269828	0.7	GoF	protect
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	FGB	Fibrinogen beta chain [Cleaved into: Fibrinopeptide B; Fibrinogen beta chain]	pancreatic carcinoma	FIBRINOGEN, HUMAN	targetBased	4	Unknown status	27/02/2017	https://clinicaltrials.gov/study/NCT03269955	1		protect
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	FGB	Fibrinogen beta chain [Cleaved into: Fibrinopeptide B; Fibrinogen beta chain]	pancreatic carcinoma	FIBRINOGEN, HUMAN	targetBased	4	Unknown status	27/02/2017	https://clinicaltrials.gov/study/NCT03269955	1		protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	VINFLUNINE	targetBased	3	Completed	01/07/2009	https://clinicaltrials.gov/study/NCT01091168	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	VINFLUNINE	targetBased	3	Completed	01/05/2009	https://clinicaltrials.gov/study/NCT01095003	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	VINFLUNINE	targetBased	3	Completed	01/09/2013	https://clinicaltrials.gov/study/NCT01953003	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	urothelial carcinoma	VINFLUNINE	targetBased	3	Completed	01/07/2005	https://clinicaltrials.gov/study/NCT00315237	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	urogenital neoplasm	VINFLUNINE	targetBased	3	Active, not recruiting	13/01/2021	https://clinicaltrials.gov/study/NCT04527991	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	urogenital neoplasm	VINFLUNINE	targetBased	3	Completed	22/10/2014	https://clinicaltrials.gov/study/NCT02256436	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	cancer	VINFLUNINE	targetBased	3	Active, not recruiting	23/03/2018	https://clinicaltrials.gov/study/NCT03390504	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	neoplasm	VINFLUNINE	targetBased	3			https://www.whocc.no/atc_ddd_index/?code=L01CA05	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	bladder tumor	VINFLUNINE	targetBased	3	Completed	01/07/2005	https://clinicaltrials.gov/study/NCT00315237	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	head and neck carcinoma	VINFLUNINE	targetBased	3	Completed	25/04/2014	https://clinicaltrials.gov/study/NCT02347332	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	urinary bladder cancer	VINFLUNINE	targetBased	3	Completed	13/01/2015	https://clinicaltrials.gov/study/NCT02302807	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	urinary bladder cancer	VINFLUNINE	targetBased	3	Completed	01/07/2005	https://clinicaltrials.gov/study/NCT00315237	0.7	LoF	protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	cirrhosis of liver	TERLIPRESSIN	targetBased	4	Not yet recruiting	01/06/2020	https://clinicaltrials.gov/study/NCT04353193	1		protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	cirrhosis of liver	TERLIPRESSIN	targetBased	4	Completed	01/09/2006	https://clinicaltrials.gov/study/NCT00966355	1		protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	cirrhosis of liver	TERLIPRESSIN	targetBased	3	Completed	01/11/2009	https://clinicaltrials.gov/study/NCT00986817	0.7		protect
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	AKT1	RAC-alpha serine/threonine-protein kinase	cancer	IPATASERTIB	targetBased	3	Recruiting	01/06/2023	https://clinicaltrials.gov/study/NCT05862285	0.7	LoF	protect
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	AKT1	RAC-alpha serine/threonine-protein kinase	triple-negative breast cancer	IPATASERTIB	targetBased	3	Completed	25/11/2019	https://clinicaltrials.gov/study/NCT04177108	0.7	LoF	protect
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	AKT1	RAC-alpha serine/threonine-protein kinase	metastatic prostate cancer	IPATASERTIB	targetBased	3	Completed	30/06/2017	https://clinicaltrials.gov/study/NCT03072238	0.7	LoF	protect
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	AKT1	RAC-alpha serine/threonine-protein kinase	breast cancer	IPATASERTIB	targetBased	3	Terminated	15/11/2019	https://clinicaltrials.gov/study/NCT04060862	0.7	LoF	protect	The decision to not open the Phase III portion was based on a strategic sponsor decision and not driven by any safety concerns.
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	AKT1	RAC-alpha serine/threonine-protein kinase	breast cancer	IPATASERTIB	targetBased	3	Active, not recruiting	27/01/2021	https://clinicaltrials.gov/study/NCT04650581	0.7	LoF	protect
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	AKT1	RAC-alpha serine/threonine-protein kinase	breast cancer	IPATASERTIB	targetBased	3	Completed	06/01/2018	https://clinicaltrials.gov/study/NCT03337724	0.7	LoF	protect
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	AKT1	RAC-alpha serine/threonine-protein kinase	breast cancer	AFURESERTIB	targetBased	3	Recruiting	18/02/2022	https://clinicaltrials.gov/study/NCT04851613	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	OLVEREMBATINIB	targetBased	3	Not yet recruiting	01/05/2024	https://clinicaltrials.gov/study/NCT06423911	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	OLVEREMBATINIB	targetBased	3	Recruiting	01/07/2022	https://clinicaltrials.gov/study/NCT05311943	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	acute lymphoblastic leukemia	OLVEREMBATINIB	targetBased	3	Recruiting	31/08/2023	https://clinicaltrials.gov/study/NCT06051409	0.7	LoF	protect
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	AKT1	RAC-alpha serine/threonine-protein kinase	prostate cancer	CAPIVASERTIB	targetBased	3	Active, not recruiting	13/07/2020	https://clinicaltrials.gov/study/NCT04493853	0.7	LoF	protect
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	AKT1	RAC-alpha serine/threonine-protein kinase	prostate cancer	CAPIVASERTIB	targetBased	3	Recruiting	25/03/2022	https://clinicaltrials.gov/study/NCT05348577	0.7	LoF	protect
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	AKT1	RAC-alpha serine/threonine-protein kinase	breast neoplasm	CAPIVASERTIB	targetBased	3	Active, not recruiting	25/06/2019	https://clinicaltrials.gov/study/NCT03997123	0.7	LoF	protect
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	AKT1	RAC-alpha serine/threonine-protein kinase	breast cancer	CAPIVASERTIB	targetBased	3	Recruiting	10/05/2021	https://clinicaltrials.gov/study/NCT04862663	0.7	LoF	protect
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	AKT1	RAC-alpha serine/threonine-protein kinase	breast cancer	CAPIVASERTIB	targetBased	3	Active, not recruiting	16/04/2020	https://clinicaltrials.gov/study/NCT04305496	0.7	LoF	protect
E3 Ligase HTS_1536	MDM2	MDM2	E3 ubiquitin-protein ligase Mdm2	acute myeloid leukemia	IDASANUTLIN	targetBased	3	Terminated	30/12/2015	https://clinicaltrials.gov/study/NCT02545283	0.35	LoF	protect	The study was stopped for futility based on efficacy results at the interim analysis; no unexpected safety findings were observed.
qHTS assay for re-activators of p53 using a Luc reporter	TP53	TP53	Cellular tumor antigen p53, Cellular tumor antigen p53	acute myeloid leukemia	IDASANUTLIN	pathwayBased	3	Terminated	30/12/2015	https://clinicaltrials.gov/study/NCT02545283	0.35	LoF	protect	The study was stopped for futility based on efficacy results at the interim analysis; no unexpected safety findings were observed.
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	TP53	Cellular tumor antigen p53	acute myeloid leukemia	IDASANUTLIN	targetBased	3	Terminated	30/12/2015	https://clinicaltrials.gov/study/NCT02545283	0.35	LoF	protect	The study was stopped for futility based on efficacy results at the interim analysis; no unexpected safety findings were observed.
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	TP53	Cellular tumor antigen p53	acute myeloid leukemia	IDASANUTLIN	targetBased	3	Terminated	30/12/2015	https://clinicaltrials.gov/study/NCT02545283	0.35	LoF	protect	The study was stopped for futility based on efficacy results at the interim analysis; no unexpected safety findings were observed.
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	TP53	Cellular tumor antigen p53	acute myeloid leukemia	IDASANUTLIN	targetBased	3	Terminated	30/12/2015	https://clinicaltrials.gov/study/NCT02545283	0.35	LoF	protect	The study was stopped for futility based on efficacy results at the interim analysis; no unexpected safety findings were observed.
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	TP53	Cellular tumor antigen p53	acute myeloid leukemia	IDASANUTLIN	targetBased	3	Terminated	30/12/2015	https://clinicaltrials.gov/study/NCT02545283	0.35	LoF	protect	The study was stopped for futility based on efficacy results at the interim analysis; no unexpected safety findings were observed.
qHTS for Inhibitors of TGF-b	TGFB1	TGFB1	HSPC193, Mothers against decapentaplegic homolog 3	myeloproliferative disorder	LUSPATERCEPT	pathwayBased	3	Recruiting	12/08/2019	https://clinicaltrials.gov/study/NCT04064060	0.7	LoF	protect
qHTS for Inhibitors of TGF-b	TGFB1	TGFB1	HSPC193, Mothers against decapentaplegic homolog 3	myelodysplastic syndrome	LUSPATERCEPT	pathwayBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/reblozyl	1	LoF	protect
qHTS for Inhibitors of TGF-b	TGFB1	TGFB1	HSPC193, Mothers against decapentaplegic homolog 3	myelodysplastic syndrome	LUSPATERCEPT	pathwayBased	3	Recruiting	05/10/2023	https://clinicaltrials.gov/study/NCT06045689	0.7	LoF	protect
qHTS for Inhibitors of TGF-b	TGFB1	TGFB1	HSPC193, Mothers against decapentaplegic homolog 3	myelodysplastic syndrome	LUSPATERCEPT	pathwayBased	3	Completed	09/02/2016	https://clinicaltrials.gov/study/NCT02631070	0.7	LoF	protect
qHTS for Inhibitors of TGF-b	TGFB1	TGFB1	HSPC193, Mothers against decapentaplegic homolog 3	myelodysplastic syndrome	LUSPATERCEPT	pathwayBased	3	Recruiting	27/10/2021	https://clinicaltrials.gov/study/NCT05181592	0.7	LoF	protect
qHTS for Inhibitors of TGF-b	TGFB1	TGFB1	HSPC193, Mothers against decapentaplegic homolog 3	myelodysplastic syndrome	LUSPATERCEPT	pathwayBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=82f4d266-3f52-41eb-86ba-0abf3cf468e8	1	LoF	protect
qHTS for Inhibitors of TGF-b	TGFB1	TGFB1	HSPC193, Mothers against decapentaplegic homolog 3	myelodysplastic syndrome	LUSPATERCEPT	pathwayBased	3	Active, not recruiting	02/01/2019	https://clinicaltrials.gov/study/NCT03682536	0.7	LoF	protect
qHTS for Inhibitors of TGF-b	TGFB1	TGFB1	HSPC193, Mothers against decapentaplegic homolog 3	myelodysplastic syndrome	LUSPATERCEPT	pathwayBased	4	Not yet recruiting	01/08/2023	https://clinicaltrials.gov/study/NCT06006949	1	LoF	protect
qHTS for Inhibitors of TGF-b	TGFB1	TGFB1	HSPC193, Mothers against decapentaplegic homolog 3	myelodysplastic syndrome	LUSPATERCEPT	pathwayBased	3	Recruiting	24/10/2023	https://clinicaltrials.gov/study/NCT05949684	0.7	LoF	protect
qHTS for Inhibitors of TGF-b	TGFB1	TGFB1	HSPC193, Mothers against decapentaplegic homolog 3	myelodysplastic syndrome	LUSPATERCEPT	pathwayBased	3	Recruiting	12/08/2019	https://clinicaltrials.gov/study/NCT04064060	0.7	LoF	protect
Primary biochemical high-throughput screening assay for inhibitors of Focal Adhesion Kinase (FAK)	PTK2	PTK2	Focal adhesion kinase 1	ovarian cancer	DEFACTINIB	targetBased	3	Recruiting	18/03/2024	https://clinicaltrials.gov/study/NCT06072781	0.7	LoF	protect
Antagonist identification of Pyk2 oligomerization: high-throughput screening cellular assay	Pyk2	PTK2B	Protein tyrosine kinase 2 beta	ovarian cancer	DEFACTINIB	targetBased	3	Recruiting	18/03/2024	https://clinicaltrials.gov/study/NCT06072781	0.7	LoF	protect
qHTS assay for re-activators of p53 using a Luc reporter	TP53	TP53	Cellular tumor antigen p53, Cellular tumor antigen p53	myelodysplastic syndrome	EPRENETAPOPT	pathwayBased	3	Completed	11/01/2019	https://clinicaltrials.gov/study/NCT03745716	0.7	GoF	protect
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	TP53	Cellular tumor antigen p53	myelodysplastic syndrome	EPRENETAPOPT	targetBased	3	Completed	11/01/2019	https://clinicaltrials.gov/study/NCT03745716	0.7	GoF	protect
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	TP53	Cellular tumor antigen p53	myelodysplastic syndrome	EPRENETAPOPT	targetBased	3	Completed	11/01/2019	https://clinicaltrials.gov/study/NCT03745716	0.7	GoF	protect
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	TP53	Cellular tumor antigen p53	myelodysplastic syndrome	EPRENETAPOPT	targetBased	3	Completed	11/01/2019	https://clinicaltrials.gov/study/NCT03745716	0.7	GoF	protect
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	TP53	Cellular tumor antigen p53	myelodysplastic syndrome	EPRENETAPOPT	targetBased	3	Completed	11/01/2019	https://clinicaltrials.gov/study/NCT03745716	0.7	GoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	diffuse large B-cell lymphoma	POLATUZUMAB VEDOTIN	targetBased	3	Active, not recruiting	07/02/2020	https://clinicaltrials.gov/study/NCT04182204	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	diffuse large B-cell lymphoma	POLATUZUMAB VEDOTIN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=20a16ab2-f338-4abb-9dcd-254bd949a2bc	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	diffuse large B-cell lymphoma	POLATUZUMAB VEDOTIN	targetBased	3	Recruiting	18/09/2023	https://clinicaltrials.gov/study/NCT06047080	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	diffuse large B-cell lymphoma	POLATUZUMAB VEDOTIN	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761121s000lbl.pdf	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	diffuse large B-cell lymphoma	POLATUZUMAB VEDOTIN	targetBased	3	Terminated	10/07/2020	https://clinicaltrials.gov/study/NCT04236141	0.7	LoF	protect	Sponsor's decision, no safety concerns
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	diffuse large B-cell lymphoma	POLATUZUMAB VEDOTIN	targetBased	3	Recruiting	30/04/2021	https://clinicaltrials.gov/study/NCT04833114	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	diffuse large B-cell lymphoma	POLATUZUMAB VEDOTIN	targetBased	3	Active, not recruiting	16/11/2017	https://clinicaltrials.gov/study/NCT03274492	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-Hodgkins lymphoma	POLATUZUMAB VEDOTIN	targetBased	3	Recruiting	25/04/2022	https://clinicaltrials.gov/study/NCT05171647	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	neoplasm	POLATUZUMAB VEDOTIN	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=L01FX14	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	B-cell neoplasm	POLATUZUMAB VEDOTIN	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/polivy	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Transitional Cell Carcinoma	ENFORTUMAB VEDOTIN	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/padcev	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	cancer	ENFORTUMAB VEDOTIN	targetBased	3	Active, not recruiting	30/03/2020	https://clinicaltrials.gov/study/NCT04223856	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	cancer	ENFORTUMAB VEDOTIN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b5631d3e-4604-4363-8f20-11dfc5a4a8ed	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	neoplasm	ENFORTUMAB VEDOTIN	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=L01FX13	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	benign urinary system neoplasm	ENFORTUMAB VEDOTIN	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/padcev	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	urinary bladder cancer	ENFORTUMAB VEDOTIN	targetBased	3	Active, not recruiting	24/07/2019	https://clinicaltrials.gov/study/NCT03924895	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	urinary bladder cancer	ENFORTUMAB VEDOTIN	targetBased	3	Recruiting	05/08/2021	https://clinicaltrials.gov/study/NCT04960709	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	urinary bladder cancer	ENFORTUMAB VEDOTIN	targetBased	3	Active, not recruiting	21/04/2021	https://clinicaltrials.gov/study/NCT04700124	0.7	LoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	benign muscle neoplasm	CARBETOCIN	targetBased	4	Completed	15/07/2020	https://clinicaltrials.gov/study/NCT04482959	1	GoF	protect
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2_inhibitors	EZH2	Histone-lysine N-methyltransferase EZH2	follicular lymphoma	TAZEMETOSTAT	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7db07b5f-4e22-467c-9c0a-f830b08dbb1d	1	LoF	protect
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2_inhibitors	EZH2	Histone-lysine N-methyltransferase EZH2	follicular lymphoma	TAZEMETOSTAT	targetBased	3	Recruiting	11/06/2020	https://clinicaltrials.gov/study/NCT04224493	0.7	LoF	protect
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2_inhibitors	EZH2	Histone-lysine N-methyltransferase EZH2	sarcoma	TAZEMETOSTAT	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211723s000lbl.pdf	1	LoF	protect
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2_inhibitors	EZH2	Histone-lysine N-methyltransferase EZH2	neoplasm	TAZEMETOSTAT	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=L01XX72	1	LoF	protect
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2_inhibitors	EZH2	Histone-lysine N-methyltransferase EZH2	epithelioid sarcoma	TAZEMETOSTAT	targetBased	3	Recruiting	19/12/2019	https://clinicaltrials.gov/study/NCT04204941	0.7	LoF	protect
qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS	TXNRD1	TXNRD1	Thioredoxin reductase 1, cytoplasmic	metastatic malignant neoplasm	MOTEXAFIN GADOLINIUM	targetBased	3	Completed	01/08/1998	https://clinicaltrials.gov/study/NCT00003563	0.7	LoF	protect
qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS	TXNRD1	TXNRD1	Thioredoxin reductase 1, cytoplasmic	brain neoplasm	MOTEXAFIN GADOLINIUM	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00054795	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	peritoneal neoplasm	MIRVETUXIMAB SORAVTANSINE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761310s000lbl.pdf	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	malignant epithelial tumor of ovary	MIRVETUXIMAB SORAVTANSINE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761310s000lbl.pdf	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	fallopian tube neoplasm	MIRVETUXIMAB SORAVTANSINE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761310s000lbl.pdf	1	LoF	protect
Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3	HDAC3	HDAC3	Histone deacetylase 3	multiple myeloma	PANOBINOSTAT LACTATE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/farydak	1	LoF	protect
Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3	HDAC3	HDAC3	Histone deacetylase 3	multiple myeloma	PANOBINOSTAT LACTATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7774972a-eeaa-4b9a-9e56-3fc1b968e86a	1	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	FLUMATINIB	targetBased	4	Not yet recruiting	30/04/2022	https://clinicaltrials.gov/study/NCT05367765	1	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	FLUMATINIB	targetBased	4	Recruiting	23/11/2021	https://clinicaltrials.gov/study/NCT05353205	1	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	FLUMATINIB	targetBased	3	Completed	01/06/2014	https://clinicaltrials.gov/study/NCT02204644	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	FLUMATINIB	targetBased	4	Recruiting	01/07/2021	https://clinicaltrials.gov/study/NCT04933526	1	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	FLUMATINIB	targetBased	4	Recruiting	01/01/2021	https://clinicaltrials.gov/study/NCT04677439	1	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	acute lymphoblastic leukemia	FLUMATINIB	targetBased	3	Recruiting	01/03/2020	https://clinicaltrials.gov/study/NCT04375683	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	leukemia	FLUMATINIB	targetBased	4	Recruiting	16/09/2021	https://clinicaltrials.gov/study/NCT05071482	1	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	acute myeloid leukemia	SKLB1028	targetBased	3	Recruiting	24/03/2021	https://clinicaltrials.gov/study/NCT04716114	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	marginal zone B-cell lymphoma	UMBRALISIB	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213176s000lbl.pdf	1	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic lymphocytic leukemia	UMBRALISIB	targetBased	3	Terminated	19/11/2015	https://clinicaltrials.gov/study/NCT02612311	0.7	LoF	protect	Strategic/Business decision
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	neoplasm	UMBRALISIB	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=L01EX25	1	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	follicular lymphoma	UMBRALISIB	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2cdecefe-c9e4-4af3-bbaa-a1111c768d29	1	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	follicular lymphoma	UMBRALISIB	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213176s000lbl.pdf	1	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	marginal zone B-cell lymphoma	UMBRALISIB TOSYLATE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213176s000lbl.pdf	1	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic lymphocytic leukemia	UMBRALISIB TOSYLATE	targetBased	3	Terminated	19/11/2015	https://clinicaltrials.gov/study/NCT02612311	0.7	LoF	protect	Strategic/Business decision
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	follicular lymphoma	UMBRALISIB TOSYLATE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213176s000lbl.pdf	1	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	follicular lymphoma	UMBRALISIB TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2cdecefe-c9e4-4af3-bbaa-a1111c768d29	1	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	IBERDOMIDE	targetBased	3	Recruiting	05/04/2024	https://clinicaltrials.gov/study/NCT06216158	0.7		protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	IBERDOMIDE	targetBased	3	Recruiting	22/06/2023	https://clinicaltrials.gov/study/NCT05827016	0.7		protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	IBERDOMIDE	targetBased	3	Recruiting	23/06/2022	https://clinicaltrials.gov/study/NCT04975997	0.7		protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	multiple myeloma	IBERDOMIDE	targetBased	3	Not yet recruiting	01/10/2022	https://clinicaltrials.gov/study/NCT05558319	0.7		protect
Identification of agents that induce E-selectin on human endothelial cells Measured in Cell-Based System Using Imaging - 2152-01_Activator_SinglePoint_HTS_Activity	SELE	SELE	E-selectin	acute myeloid leukemia	UPROLESELAN	targetBased	3	Active, not recruiting	15/10/2018	https://clinicaltrials.gov/study/NCT03616470	0.7	LoF	protect
Primary HTS assay for chemical inhibitors of TNF alpha stimulated E-Selectin expression	E-selectinExpression	SELE	E-Selectin	acute myeloid leukemia	UPROLESELAN	targetBased	3	Active, not recruiting	15/10/2018	https://clinicaltrials.gov/study/NCT03616470	0.7	LoF	protect
Identification of agents that induce E-selectin on human endothelial cells Measured in Cell-Based System Using Imaging - 2152-01_Activator_SinglePoint_HTS_Activity	SELE	SELE	E-selectin	acute myeloid leukemia	UPROLESELAN	targetBased	3	Recruiting	18/10/2021	https://clinicaltrials.gov/study/NCT05054543	0.7	LoF	protect
Primary HTS assay for chemical inhibitors of TNF alpha stimulated E-Selectin expression	E-selectinExpression	SELE	E-Selectin	acute myeloid leukemia	UPROLESELAN	targetBased	3	Recruiting	18/10/2021	https://clinicaltrials.gov/study/NCT05054543	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	TELISOTUZUMAB VEDOTIN	targetBased	3	Recruiting	25/03/2022	https://clinicaltrials.gov/study/NCT04928846	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	TELISOTUZUMAB VEDOTIN	targetBased	3	Withdrawn	31/05/2024	https://clinicaltrials.gov/study/NCT06093503	0.7	LoF	protect	Strategic considerations
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	ASCIMINIB	targetBased	3	Active, not recruiting	25/05/2021	https://clinicaltrials.gov/study/NCT04666259	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	ASCIMINIB	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215358s000Orig1lbl.pdf	1	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	ASCIMINIB	targetBased	3	Active, not recruiting	29/11/2016	https://clinicaltrials.gov/study/NCT03106779	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	ASCIMINIB	targetBased	3	Active, not recruiting	06/10/2021	https://clinicaltrials.gov/study/NCT04971226	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	ASCIMINIB	targetBased	3	Recruiting	21/11/2022	https://clinicaltrials.gov/study/NCT05456191	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	ASCIMINIB	targetBased	3	Recruiting	19/06/2023	https://clinicaltrials.gov/study/NCT05413915	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	ASCIMINIB	targetBased	4	Recruiting	30/08/2022	https://clinicaltrials.gov/study/NCT04877522	1	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	ASCIMINIB	targetBased	3	Active, not recruiting	13/10/2021	https://clinicaltrials.gov/study/NCT04948333	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	neoplasm	ASCIMINIB	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=L01EA06	1	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive	ASCIMINIB	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/scemblix	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	breast cancer	LAROTAXEL	targetBased	3	Completed	01/04/2004	https://clinicaltrials.gov/study/NCT00081796	0.7	GoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	pancreatic neoplasm	LAROTAXEL	targetBased	3	Completed	01/12/2006	https://clinicaltrials.gov/study/NCT00417209	0.7	GoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	bladder tumor	LAROTAXEL	targetBased	3	Completed	01/02/2008	https://clinicaltrials.gov/study/NCT00625664	0.7	GoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	primary myelofibrosis	FEDRATINIB HYDROCHLORIDE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212327s000lbl.pdf	1	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	primary myelofibrosis	FEDRATINIB HYDROCHLORIDE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/inrebic	1	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	myeloproliferative disorder	FEDRATINIB HYDROCHLORIDE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/inrebic	1	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	ASCIMINIB HYDROCHLORIDE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215358s000Orig1lbl.pdf	1	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive	ASCIMINIB HYDROCHLORIDE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/scemblix	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	PACLITAXEL DOCOSAHEXAENOIC ACID	targetBased	3	Completed	01/11/2005	https://clinicaltrials.gov/study/NCT00243867	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast neoplasm	ELACESTRANT	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217639s000lbl.pdf	1	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast neoplasm	ELACESTRANT	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217639s000lbl.pdf	1	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	male breast carcinoma	ELACESTRANT	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217639s000lbl.pdf	1	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	male breast carcinoma	ELACESTRANT	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217639s000lbl.pdf	1	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	ELACESTRANT	targetBased	3	Active, not recruiting	10/05/2019	https://clinicaltrials.gov/study/NCT03778931	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	ELACESTRANT	targetBased	3	Active, not recruiting	10/05/2019	https://clinicaltrials.gov/study/NCT03778931	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	ELACESTRANT	targetBased	3	Recruiting	15/12/2023	https://clinicaltrials.gov/study/NCT05512364	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	ELACESTRANT	targetBased	3	Recruiting	15/12/2023	https://clinicaltrials.gov/study/NCT05512364	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	RADOTINIB	targetBased	3	Active, not recruiting	28/12/2018	https://clinicaltrials.gov/study/NCT03722420	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia	RADOTINIB	targetBased	3	Recruiting	25/06/2018	https://clinicaltrials.gov/study/NCT03459534	0.7	LoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	primary biliary cirrhosis	SAROGLITAZAR	targetBased	3	Not yet recruiting	15/06/2024	https://clinicaltrials.gov/study/NCT06427395	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	primary biliary cirrhosis	SAROGLITAZAR	targetBased	3	Not yet recruiting	15/06/2024	https://clinicaltrials.gov/study/NCT06427395	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	primary biliary cirrhosis	SAROGLITAZAR	targetBased	3	Not yet recruiting	15/06/2024	https://clinicaltrials.gov/study/NCT06427395	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	primary biliary cirrhosis	SAROGLITAZAR	targetBased	3	Not yet recruiting	15/06/2024	https://clinicaltrials.gov/study/NCT06427395	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	primary biliary cirrhosis	SAROGLITAZAR	targetBased	3	Not yet recruiting	15/06/2024	https://clinicaltrials.gov/study/NCT06427395	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	primary biliary cirrhosis	SAROGLITAZAR	targetBased	3	Not yet recruiting	15/06/2024	https://clinicaltrials.gov/study/NCT06427395	0.7	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	metastatic melanoma	TILSOTOLIMOD	targetBased	3	Terminated	30/05/2018	https://clinicaltrials.gov/study/NCT03445533	0.35	GoF	protect	Lack of Efficacy
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	cervical cancer	TISOTUMAB VEDOTIN	targetBased	3	Active, not recruiting	22/02/2021	https://clinicaltrials.gov/study/NCT04697628	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	cervical cancer	TISOTUMAB VEDOTIN	targetBased	3	Not yet recruiting	05/07/2024	https://clinicaltrials.gov/study/NCT06459180	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	cervical cancer	TISOTUMAB VEDOTIN	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761208Orig1s000lbledt.pdf	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	neoplasm	TISOTUMAB VEDOTIN	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=L01FX23	1	LoF	protect
qHTS for Inhibitors of TGF-b	TGFB1	TGFB1	HSPC193, Mothers against decapentaplegic homolog 3	non-small cell lung carcinoma	BINTRAFUSP ALFA	pathwayBased	3	Active, not recruiting	01/10/2018	https://clinicaltrials.gov/study/NCT03631706	0.7		protect
qHTS for Inhibitors of TGF-b	TGFB1	TGFB1	HSPC193, Mothers against decapentaplegic homolog 3	lung cancer	BINTRAFUSP ALFA	pathwayBased	3	Active, not recruiting	01/12/2021	https://clinicaltrials.gov/study/NCT05061823	0.7		protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	non-small cell lung carcinoma	TUSAMITAMAB RAVTANSINE	targetBased	3	Active, not recruiting	06/02/2020	https://clinicaltrials.gov/study/NCT04154956	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	neoplasm	BELANTAMAB MAFODOTIN	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=L01FX15	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	multiple myeloma	BELANTAMAB MAFODOTIN	targetBased	3	Terminated	21/12/2020	https://clinicaltrials.gov/study/NCT04549363	0.7	LoF	protect	The study has been terminated for reasons pertaining to feasibility
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	multiple myeloma	BELANTAMAB MAFODOTIN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=16a160a4-3ec0-4ddf-99ce-05912dd3382d	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	multiple myeloma	BELANTAMAB MAFODOTIN	targetBased	3	Withdrawn	20/10/2022	https://clinicaltrials.gov/study/NCT05461209	0.7	LoF	protect	Business Decision
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	multiple myeloma	BELANTAMAB MAFODOTIN	targetBased	3	Active, not recruiting	07/05/2020	https://clinicaltrials.gov/study/NCT04246047	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	multiple myeloma	BELANTAMAB MAFODOTIN	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761158s000lbl.pdf	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	multiple myeloma	BELANTAMAB MAFODOTIN	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/blenrep	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	multiple myeloma	BELANTAMAB MAFODOTIN	targetBased	3	Recruiting	01/10/2020	https://clinicaltrials.gov/study/NCT04484623	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	multiple myeloma	BELANTAMAB MAFODOTIN	targetBased	3	Active, not recruiting	02/04/2020	https://clinicaltrials.gov/study/NCT04162210	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	AMCENESTRANT	targetBased	3	Terminated	17/02/2022	https://clinicaltrials.gov/study/NCT05128773	0.7	LoF	protect	Sponsor decision to prematurely stop the study, not linked to any safety concern
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	AMCENESTRANT	targetBased	3	Terminated	17/02/2022	https://clinicaltrials.gov/study/NCT05128773	0.7	LoF	protect	Sponsor decision to prematurely stop the study, not linked to any safety concern
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	AMCENESTRANT	targetBased	3	Terminated	14/10/2020	https://clinicaltrials.gov/study/NCT04478266	0.7	LoF	protect	The study was terminated based on the review by an independent data monitoring committee of the prespecified interim analysis of the Phase 3 AMEERA-5 efficacy data. No new safety signals were observed.
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	AMCENESTRANT	targetBased	3	Terminated	14/10/2020	https://clinicaltrials.gov/study/NCT04478266	0.7	LoF	protect	The study was terminated based on the review by an independent data monitoring committee of the prespecified interim analysis of the Phase 3 AMEERA-5 efficacy data. No new safety signals were observed.
uHTS identification of HIF-2a Inhibitors in a luminesence assay	HIF-2a_inhibitors	EPAS1	Endothelial PAS domain-containing protein 1	hemangioblastoma	BELZUTIFAN	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215383s000lbl.pdf	1	LoF	protect
uHTS identification of HIF-2a Inhibitors in a luminesence assay	HIF-2a_inhibitors	EPAS1	Endothelial PAS domain-containing protein 1	neoplasm	BELZUTIFAN	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=L01XX74	1	LoF	protect
uHTS identification of HIF-2a Inhibitors in a luminesence assay	HIF-2a_inhibitors	EPAS1	Endothelial PAS domain-containing protein 1	renal cell carcinoma	BELZUTIFAN	targetBased	3	Active, not recruiting	14/04/2021	https://clinicaltrials.gov/study/NCT04736706	0.7	LoF	protect
uHTS identification of HIF-2a Inhibitors in a luminesence assay	HIF-2a_inhibitors	EPAS1	Endothelial PAS domain-containing protein 1	renal cell carcinoma	BELZUTIFAN	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215383s000lbl.pdf	1	LoF	protect
uHTS identification of HIF-2a Inhibitors in a luminesence assay	HIF-2a_inhibitors	EPAS1	Endothelial PAS domain-containing protein 1	renal cell carcinoma	BELZUTIFAN	targetBased	3	Active, not recruiting	27/07/2022	https://clinicaltrials.gov/study/NCT05899049	0.7	LoF	protect
uHTS identification of HIF-2a Inhibitors in a luminesence assay	HIF-2a_inhibitors	EPAS1	Endothelial PAS domain-containing protein 1	renal cell carcinoma	BELZUTIFAN	targetBased	3	Active, not recruiting	25/02/2021	https://clinicaltrials.gov/study/NCT04586231	0.7	LoF	protect
uHTS identification of HIF-2a Inhibitors in a luminesence assay	HIF-2a_inhibitors	EPAS1	Endothelial PAS domain-containing protein 1	renal cell carcinoma	BELZUTIFAN	targetBased	3	Active, not recruiting	27/02/2020	https://clinicaltrials.gov/study/NCT04195750	0.7	LoF	protect
uHTS identification of HIF-2a Inhibitors in a luminesence assay	HIF-2a_inhibitors	EPAS1	Endothelial PAS domain-containing protein 1	renal cell carcinoma	BELZUTIFAN	targetBased	3	Active, not recruiting	15/03/2022	https://clinicaltrials.gov/study/NCT05239728	0.7	LoF	protect
uHTS identification of HIF-2a Inhibitors in a luminesence assay	HIF-2a_inhibitors	EPAS1	Endothelial PAS domain-containing protein 1	pancreatic neuroendocrine tumor	BELZUTIFAN	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215383s000lbl.pdf	1	LoF	protect
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2_inhibitors	EZH2	Histone-lysine N-methyltransferase EZH2	follicular lymphoma	TAZEMETOSTAT HYDROBROMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7db07b5f-4e22-467c-9c0a-f830b08dbb1d	1	LoF	protect
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2_inhibitors	EZH2	Histone-lysine N-methyltransferase EZH2	sarcoma	TAZEMETOSTAT HYDROBROMIDE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211723s000lbl.pdf	1	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast neoplasm	ELACESTRANT HYDROCHLORIDE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217639s000lbl.pdf	1	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast neoplasm	ELACESTRANT HYDROCHLORIDE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217639s000lbl.pdf	1	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	male breast carcinoma	ELACESTRANT HYDROCHLORIDE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217639s000lbl.pdf	1	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	male breast carcinoma	ELACESTRANT HYDROCHLORIDE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217639s000lbl.pdf	1	LoF	protect
qHTS assay for MDR1-selective chemotherapeutics: Primary screen using the drug-selected MDR subline cells KB-V1	MDR1-selective compounds	ABCB1	ATP-binding cassette, sub-family B , ATP-dependent translocase ABCB1	breast cancer	ENCEQUIDAR	targetBased	3	Completed	02/12/2015	https://clinicaltrials.gov/study/NCT02594371	0.7	LoF	protect
qHTS assay for MDR1-selective chemotherapeutics: Primary screen using the parental adenocarcinoma cell KB-3-1	MDR1-selective compounds	ABCB1	ATP-binding cassette, sub-family B , ATP-dependent translocase ABCB1	breast cancer	ENCEQUIDAR	targetBased	3	Completed	02/12/2015	https://clinicaltrials.gov/study/NCT02594371	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	GIREDESTRANT	targetBased	3	Recruiting	03/08/2022	https://clinicaltrials.gov/study/NCT05306340	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	GIREDESTRANT	targetBased	3	Recruiting	03/08/2022	https://clinicaltrials.gov/study/NCT05306340	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	GIREDESTRANT	targetBased	3	Active, not recruiting	09/10/2020	https://clinicaltrials.gov/study/NCT04546009	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	GIREDESTRANT	targetBased	3	Active, not recruiting	09/10/2020	https://clinicaltrials.gov/study/NCT04546009	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	GIREDESTRANT	targetBased	3	Recruiting	27/08/2021	https://clinicaltrials.gov/study/NCT04961996	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	GIREDESTRANT	targetBased	3	Recruiting	27/08/2021	https://clinicaltrials.gov/study/NCT04961996	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	GIREDESTRANT	targetBased	3	Recruiting	04/07/2022	https://clinicaltrials.gov/study/NCT05296798	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	GIREDESTRANT	targetBased	3	Recruiting	04/07/2022	https://clinicaltrials.gov/study/NCT05296798	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	CAMIZESTRANT	targetBased	3	Recruiting	31/03/2023	https://clinicaltrials.gov/study/NCT05774951	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	CAMIZESTRANT	targetBased	3	Recruiting	31/03/2023	https://clinicaltrials.gov/study/NCT05774951	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	CAMIZESTRANT	targetBased	3	Active, not recruiting	28/01/2021	https://clinicaltrials.gov/study/NCT04711252	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	CAMIZESTRANT	targetBased	3	Active, not recruiting	28/01/2021	https://clinicaltrials.gov/study/NCT04711252	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	CAMIZESTRANT	targetBased	3	Not yet recruiting	18/04/2024	https://clinicaltrials.gov/study/NCT06380751	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	CAMIZESTRANT	targetBased	3	Not yet recruiting	18/04/2024	https://clinicaltrials.gov/study/NCT06380751	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	CAMIZESTRANT	targetBased	3	Recruiting	05/10/2023	https://clinicaltrials.gov/study/NCT05952557	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	CAMIZESTRANT	targetBased	3	Recruiting	05/10/2023	https://clinicaltrials.gov/study/NCT05952557	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	CAMIZESTRANT	targetBased	3	Recruiting	30/06/2021	https://clinicaltrials.gov/study/NCT04964934	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	breast cancer	CAMIZESTRANT	targetBased	3	Recruiting	30/06/2021	https://clinicaltrials.gov/study/NCT04964934	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	primary myelofibrosis	PACRITINIB CITRATE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/208712s000lbl.pdf	1	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	polycythemia vera	PACRITINIB CITRATE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/208712s000lbl.pdf	1	LoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	childhood acute lymphoblastic leukemia		targetBased	4	Completed	25/03/2018	https://clinicaltrials.gov/study/NCT03318393	1	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia		targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203341lbl.pdf	1	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic myelogenous leukemia		targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adc84ad5-a04d-4fee-9ba8-91f7abd928e3	1	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	myeloid leukemia		targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/bosulif	1	LoF	protect

Partner with DrTarget for AI-Optimized Screening

We welcome collaborations with biotech companies, research institutions, and pharmaceutical partners looking to leverage AI for drug discovery. Get in touch to explore custom screening solutions and accelerate your research.

drTarget portfolio target-disease associations for cancer

DrTarget’s AI-Driven Insights for Cancer Research

Our AI-powered approach enables:

✔ Target identification for novel drug discovery✔ Drug repurposing opportunities for existing therapies✔ Pathway and biomarker analysis for precision oncology

By integrating AI-driven virtual screening and multi-source validation, we provide actionable insights to accelerate cancer research and therapeutic innovation.

Check best scored target-disease associations in table:

Some of these associations have also gone through clinical trials, as those in the graph below.

Partner with DrTarget for AI-Optimized Screening

We welcome collaborations with biotech companies, research institutions, and pharmaceutical partners looking to leverage AI for drug discovery. Get in touch to explore custom screening solutions and accelerate your research.

✔ Target identification for novel drug discovery
✔ Drug repurposing opportunities for existing therapies
✔ Pathway and biomarker analysis for precision oncology